
<html lang="en"     class="pb-page"  data-request-id="a19aa6a6-23ea-4c2e-809c-32858b817815"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.1c00506;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma" /></meta><meta name="dc.Creator" content="David E.  Uehling" /></meta><meta name="dc.Creator" content="Babu  Joseph" /></meta><meta name="dc.Creator" content="Kim Chan  Chung" /></meta><meta name="dc.Creator" content="Andrew X.  Zhang" /></meta><meta name="dc.Creator" content="Spencer  Ler" /></meta><meta name="dc.Creator" content="Michael A.  Prakesch" /></meta><meta name="dc.Creator" content="Gennady  Poda" /></meta><meta name="dc.Creator" content="Julie  Grouleff" /></meta><meta name="dc.Creator" content="Ahmed  Aman" /></meta><meta name="dc.Creator" content="Taira  Kiyota" /></meta><meta name="dc.Creator" content="Chungyee  Leung-Hagesteijn" /></meta><meta name="dc.Creator" content="John David  Konda" /></meta><meta name="dc.Creator" content="Richard  Marcellus" /></meta><meta name="dc.Creator" content="Carly  Griffin" /></meta><meta name="dc.Creator" content="Ratheesh  Subramaniam" /></meta><meta name="dc.Creator" content="Ayome  Abibi" /></meta><meta name="dc.Creator" content="Craig A.  Strathdee" /></meta><meta name="dc.Creator" content="Methvin B.  Isaac" /></meta><meta name="dc.Creator" content="Rima  Al-awar" /></meta><meta name="dc.Creator" content="Rodger E.  Tiedemann" /></meta><meta name="dc.Description" content="Both previous and additional genetic knockdown studies reported herein implicate G protein-coupled receptor kinase 6 (GRK6) as a critical kinase required for the survival of multiple myeloma (MM) c..." /></meta><meta name="Description" content="Both previous and additional genetic knockdown studies reported herein implicate G protein-coupled receptor kinase 6 (GRK6) as a critical kinase required for the survival of multiple myeloma (MM) c..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 22, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00506" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00506" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00506" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00506" /></link>
        
    
    

<title>Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00506" /></meta><meta property="og:title" content="Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0019.jpeg" /></meta><meta property="og:description" content="Both previous and additional genetic knockdown studies reported herein implicate G protein-coupled receptor kinase 6 (GRK6) as a critical kinase required for the survival of multiple myeloma (MM) cells. Therefore, we sought to develop a small molecule GRK6 inhibitor as an MM therapeutic. From a focused library of known kinase inhibitors, we identified two hits with moderate biochemical potencies against GRK6. From these hits, we developed potent (IC50 &lt; 10 nM) analogues with selectivity against off-target kinases. Further optimization led to the discovery of an analogue (18) with an IC50 value of 6 nM against GRK6 and selectivity against a panel of 85 kinases. Compound 18 has potent cellular target engagement and antiproliferative activity against MM cells and is synergistic with bortezomib. In summary, we demonstrate that targeting GRK6 with small molecule inhibitors represents a promising approach for MM and identify 18 as a novel, potent, and selective GRK6 inhibitor." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00506"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00506">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00506&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00506&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00506&amp;href=/doi/10.1021/acs.jmedchem.1c00506" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00282" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00608" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">David E. Uehling</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David E. Uehling</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e48085928d80ca91818c888d8a83a48b8d8796ca8b8aca8785"><span class="__cf_email__" data-cfemail="83e7e2f5eae7adf6e6ebefeaede4c3eceae0f1adecedade0e2">[email protected]</span></a>. Phone: +1 (647) 259-4237.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+E.++Uehling">David E. Uehling</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9748-0500" title="Orcid link">https://orcid.org/0000-0002-9748-0500</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Babu Joseph</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Babu Joseph</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Babu++Joseph">Babu Joseph</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kim Chan Chung</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kim Chan Chung</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Princess Margaret Cancer Centre, Toronto Medical Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kim+Chan++Chung">Kim Chan Chung</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew X. Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew X. Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+X.++Zhang">Andrew X. Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Spencer Ler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Spencer Ler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Spencer++Ler">Spencer Ler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael A. Prakesch</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael A. Prakesch</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+A.++Prakesch">Michael A. Prakesch</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gennady Poda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gennady Poda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div><div class="loa-info-affiliations-info">Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gennady++Poda">Gennady Poda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Julie Grouleff</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julie Grouleff</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julie++Grouleff">Julie Grouleff</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ahmed Aman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ahmed Aman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div><div class="loa-info-affiliations-info">Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ahmed++Aman">Ahmed Aman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Taira Kiyota</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Taira Kiyota</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Taira++Kiyota">Taira Kiyota</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chungyee Leung-Hagesteijn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chungyee Leung-Hagesteijn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Princess Margaret Cancer Centre, Toronto Medical Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chungyee++Leung-Hagesteijn">Chungyee Leung-Hagesteijn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John David Konda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John David Konda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Princess Margaret Cancer Centre, Toronto Medical Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+David++Konda">John David Konda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Marcellus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Marcellus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Marcellus">Richard Marcellus</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carly Griffin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carly Griffin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carly++Griffin">Carly Griffin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ratheesh Subramaniam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ratheesh Subramaniam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ratheesh++Subramaniam">Ratheesh Subramaniam</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ayome Abibi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ayome Abibi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ayome++Abibi">Ayome Abibi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Craig A. Strathdee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Craig A. Strathdee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Craig+A.++Strathdee">Craig A. Strathdee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Methvin B. Isaac</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Methvin B. Isaac</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Methvin+B.++Isaac">Methvin B. Isaac</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rima Al-awar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rima Al-awar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</div><div class="loa-info-affiliations-info">Department of Pharmacology and Toxicology, University of Toronto, Medical Sciences Building, 1 King’s College Circle, Toronto, Ontario M5S 1A8, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rima++Al-awar">Rima Al-awar</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4185-055X" title="Orcid link">https://orcid.org/0000-0002-4185-055X</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Rodger E. Tiedemann</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rodger E. Tiedemann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Princess Margaret Cancer Centre, Toronto Medical Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#7f2d101b181a0d512b161a1b1a121e11113f0a1711511c1e"><span class="__cf_email__" data-cfemail="c290ada6a5a7b0ec96aba7a6a7afa3acac82b7aaaceca1a3">[email protected]</span></a>. Phone: +1 (416) 634-8769.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rodger+E.++Tiedemann">Rodger E. Tiedemann</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00506&amp;href=/doi/10.1021%2Facs.jmedchem.1c00506" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 22, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 March 2021</li><li><span class="item_label"><b>Published</b> online</span>22 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00506" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00506</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDavid%2BE.%2BUehling%252C%2BBabu%2BJoseph%252C%2BKim%2BChan%2BChung%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c00506%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BCharacterization%2Bof%2B4-Aminoquinazolines%2Bas%2BPotent%2BInhibitors%2Bof%2Bthe%2BG%2BProtein-Coupled%2BReceptor%2BKinase%2B6%2B%2528GRK6%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BMultiple%2BMyeloma%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D19%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/editorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ec-1612971054143.svg" alt="ACS Editors’ Choice" /></img><span>ACS Editors’ Choice</span></a></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00506"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2238</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00506" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;E. Uehling&quot;},{&quot;first_name&quot;:&quot;Babu&quot;,&quot;last_name&quot;:&quot;Joseph&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;Chan Chung&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;X. Zhang&quot;},{&quot;first_name&quot;:&quot;Spencer&quot;,&quot;last_name&quot;:&quot;Ler&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;A. Prakesch&quot;},{&quot;first_name&quot;:&quot;Gennady&quot;,&quot;last_name&quot;:&quot;Poda&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;Grouleff&quot;},{&quot;first_name&quot;:&quot;Ahmed&quot;,&quot;last_name&quot;:&quot;Aman&quot;},{&quot;first_name&quot;:&quot;Taira&quot;,&quot;last_name&quot;:&quot;Kiyota&quot;},{&quot;first_name&quot;:&quot;Chungyee&quot;,&quot;last_name&quot;:&quot;Leung-Hagesteijn&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;David Konda&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Marcellus&quot;},{&quot;first_name&quot;:&quot;Carly&quot;,&quot;last_name&quot;:&quot;Griffin&quot;},{&quot;first_name&quot;:&quot;Ratheesh&quot;,&quot;last_name&quot;:&quot;Subramaniam&quot;},{&quot;first_name&quot;:&quot;Ayome&quot;,&quot;last_name&quot;:&quot;Abibi&quot;},{&quot;first_name&quot;:&quot;Craig&quot;,&quot;last_name&quot;:&quot;A. Strathdee&quot;},{&quot;first_name&quot;:&quot;Methvin&quot;,&quot;last_name&quot;:&quot;B. Isaac&quot;},{&quot;first_name&quot;:&quot;Rima&quot;,&quot;last_name&quot;:&quot;Al-awar&quot;},{&quot;first_name&quot;:&quot;Rodger&quot;,&quot;last_name&quot;:&quot;E. Tiedemann&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00506&quot;},&quot;abstract&quot;:&quot;Both previous and additional genetic knockdown studies reported herein implicate G protein-coupled receptor kinase 6 (GRK6) as a critical kinase required for the survival of multiple myeloma (MM) cells. Therefore, we sought to develop a small molecule GRK6 inhibitor as an MM therapeutic. From a focused library of known kinase inhibitors, we identified two hits with moderate biochemical potencies against GRK6. From these hits, we developed potent (IC50 &lt; 10 nM) analogues with selectivity against off-target kinases. Further optimization led to the discovery of an analogue (18) with an IC50 value of 6 nM against GRK6 and selectivity against a panel of 85 kinases. Compound 18 has potent cellular target engagement and antiproliferative activity against MM cells and is synergistic with bortezomib. In summary, we demonstrate that targeting GRK6 with small molecule inhibitors represents a promising approach for MM and identify 18 as a novel, potent, and selective GRK6 inhibitor.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00506&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00506" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00506&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00506" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00506&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00506" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00506&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00506&amp;href=/doi/10.1021/acs.jmedchem.1c00506" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00506" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00506" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00506%26sid%3Dliteratum%253Aachs%26pmid%3D34291633%26genre%3Darticle%26aulast%3DUehling%26date%3D2021%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BCharacterization%2Bof%2B4-Aminoquinazolines%2Bas%2BPotent%2BInhibitors%2Bof%2Bthe%2BG%2BProtein-Coupled%2BReceptor%2BKinase%2B6%2B%2528GRK6%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BMultiple%2BMyeloma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Both previous and additional genetic knockdown studies reported herein implicate G protein-coupled receptor kinase 6 (GRK6) as a critical kinase required for the survival of multiple myeloma (MM) cells. Therefore, we sought to develop a small molecule GRK6 inhibitor as an MM therapeutic. From a focused library of known kinase inhibitors, we identified two hits with moderate biochemical potencies against GRK6. From these hits, we developed potent (IC<sub>50</sub> < 10 nM) analogues with selectivity against off-target kinases. Further optimization led to the discovery of an analogue (<b>18</b>) with an IC<sub>50</sub> value of 6 nM against GRK6 and selectivity against a panel of 85 kinases. Compound <b>18</b> has potent cellular target engagement and antiproliferative activity against MM cells and is synergistic with bortezomib. In summary, we demonstrate that targeting GRK6 with small molecule inhibitors represents a promising approach for MM and identify <b>18</b> as a novel, potent, and selective GRK6 inhibitor.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote"><h4><span></span>  Note</h4><license-p>Made available for a limited time for personal research and study only <a href="/page/policy/termsofuse.html" class="ext-link">License</a>.</license-p></div><div class="extra-info-sec articleNote"><h4><span></span>  Note</h4><p class="first last">Made available for a limited time for personal research and study only <a href="/page/policy/termsofuse.html" class="ext-link">License</a>.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73500" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73500" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Multiple myeloma (MM) is a malignancy of mature plasma cells that accounts for approximately 1% of cancer and 2% of cancer deaths.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> While existing therapeutic options are efficacious, none are curative and resistance invariably develops. A 5-year survival has been reported at 46.6%.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> For the treatment of MM, thalidomide, and its immunomodulatory derivatives (IMiDs), the small molecule proteasome inhibitors (PIs) and the anti-CD38 antibodies, daratumumab and isatuximab, represent the most active drugs in the clinic today. Thalidomide (<b>1</b>, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) was first used for the treatment of MM in the late 1990s, and discovery of its anti-MM activity led to the rapid development of lenalidomide (<b>2</b>) and pomalidomide (<b>3</b>). All three IMiDs function as adaptor molecules for the cereblon E3 ligase, altering its substrate specificity and inducing the degradation of key protein targets, such as IKF1 and IKF3.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Bortezomib (<b>4</b>), the first in class proteasome inhibitor (PI), was approved by the FDA for MM in 2003. Over the past 15 years, two additional PIs, carfilzomib (<b>5</b>) and ixazomib (<b>6</b>), have also secured FDA approval. The monoclonal antibodies elotuzumab, daratumumab, and isatuximab have demonstrated efficacy in combination with the IMiDs and/or PIs and are in mainstream clinical usage. Although the IMiDs, PIs, and these monoclonal antibodies represent the mainstay of the MM treatment, several other drugs with distinct mechanisms have FDA approval for the treatment of MM, including the pan-HDAC inhibitor panobinostat (<b>7</b>), the XPO1 inhibitor selinexor, and the antibody–drug conjugate, belantamab mafodotin. A number of additional antibodies and immune cell engaging biologics are also in development.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Initial GRK6 hits and quinazoline lead analogue <b>10a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="cht1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Representative FDA-Approved Small Molecule Drugs for Multiple Myeloma</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite this impressive progress, a cure for MM has remained elusive and newer treatments continue to be sought. Inhibition of vital kinase(s) can induce differentiation and apoptosis in human cancer.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4−7)</a> Moreover, kinases are among the most druggable of protein targets.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> Kinase inhibitors have proven successful in the treatment of a variety of solid cancers;<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10−13)</a> however, their most notable successes have been against hematological malignancies<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> including chronic myeloid leukemia,<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Ph-positive acute lymphoblastic lymphoma,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> chronic lymphocytic leukemia, and indolent B cell lymphoproliferative disorders. On the other hand, clinically effective small molecule kinase inhibitors for multiple myeloma (MM) have not yet been identified.</div><div class="NLM_p">Because kinases represent a druggable but understudied target class in the context of MM, Tiedemann and colleagues conducted genome-wide small interfering RNA (siRNA) lethality studies in MM cells to identify critical kinase targets. While most MM survival kinases were not tumor-specific, the G protein-coupled receptor kinase GRK6 was selectively vulnerable in MM plasma cells.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> At the same time, human WHIM syndrome, a genetic condition characterized by plasma cell deficiency and hypogammaglobulinemia (as well as a neutrophil migration defect),<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> was found to arise from mutations of the GRK6 phosphorylation site on CXCR4.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> These dual studies therefore implicate GRK6 as playing an important role in plasma cell survival. Moreover, as GRK6 knockout mice are viable,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> these data suggest that GRK6 may represent an effective drug target for plasma cell disorders such as MM.</div><div class="NLM_p">GRK6, along with other G protein-coupled receptor (GPCR) kinases (GRK), belongs to the AGC protein kinase family. GRKs are best known for their ability to interact with conformationally activated GPCRs and phosphorylate cytoplasmic Ser/Thr residues, triggering a cascade of events that includes (i) recruitment of an arrestin molecule to the GPCR, (ii) uncoupling of the GPCR from heterotrimeric G proteins, (iii) receptor internalization, and (iv) activation of G protein-independent signal transduction pathways, including ERK1/2 and SRC pathways.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> GRK family members are subdivided into three groups by sequence homology, including visual GRKs (GRK1 and GRK7), the β-adrenergic receptor kinase subfamily (GRK2/GRK3), and the GRK4 subfamily (GRK4, GRK5, and GRK6). GRKs share certain characteristics but are distinct enzymes with specific regulatory properties. While GRK2, 3, and 5 are ubiquitously expressed in mammalian tissues, GRK1, 4, and 7 are primarily confined to specific organs. GRK1 and 7 are expressed in retinal rods and cones, respectively, and GRK4 is present in the testis. The distribution of GRK6 includes leukocytes<a onclick="showRef(event, 'ref21 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref23">(21,23)</a> and the brain.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> GRK6 is post-translationally palmitoylated, leading to constitutive membrane-associated localization.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The GPCR targets of GRK6 have been reported to include CXCR4,<a onclick="showRef(event, 'ref20 ref26'); return false;" href="javascript:void(0);" class="ref ref20 ref26">(20,26)</a> CCR7,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Wnt receptor LRP6,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> bradykinin receptor BDKRB2,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> leukotriene B-4 receptor, LTB4R,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and the smoothened (smo)-hedgehog(Hh)-Gli axis.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Phosphorylation of GPCR by GRK6 causes recruitment of β-arrestin-2 and secondary signaling via ERK,<a onclick="showRef(event, 'ref20 ref27'); return false;" href="javascript:void(0);" class="ref ref20 ref27">(20,27)</a> SRC, and perhaps other pathways. Interestingly, there are three splicing variants of GRK6 containing differences in the C-terminus that impact their membrane localization characteristics. While GRK6A contains a palmitoylation site and undergoes reversible post-translational modification to induce plasma membrane localization,<a onclick="showRef(event, 'ref25 ref32'); return false;" href="javascript:void(0);" class="ref ref25 ref32">(25,32)</a> GRK6B and GRK6C splice variants lack this site.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p last">Due to growing appreciation of the therapeutic potential of targeting the GRK family for the treatment of various diseases, over the past several years there have been a number of reports of small molecule inhibitors of GRK family members. In particular, because of the relevance of GRK2 and GRK5 in cardiovascular diseases, several publications have described the discovery of either GRK2,<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33−35)</a> GRK5,<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> or dual GRK2,5 inhibitors.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> However, despite significant progress in our understanding of the structural features of the GRK protein class in binding to small molecules,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> there are no publications specifically focusing on GRK6 inhibitors, and only a few  ligands of GRK6 such as the adenosine analogue sangivamycin and the nonhydrolyzable analogue of adenylyl-imidodiphosphate (AMP-PNP) have been described.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Given the strong rationale for targeting GRK6 in MM highlighted above, we therefore sought to identify GRK6 inhibitors through a de novo approach.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20421" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20421" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Target Confirmation Studies and Identification of Quinazoline Hit Series</h3><div class="NLM_p">Prior to initiating a discovery campaign for a small molecule GRK6 kinase inhibitor, we first validated the essentiality of GRK6 for MM cell survival by silencing GRK6 in both MM and non-MM cells using both shRNA and CRISPR techniques (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Sections S1–S3</a>). Mirroring earlier siRNA studies, shRNA-induced knockdown of GRK6 in the MM cell lines KMS11, RPMI-8226, and OCI-MY5 caused a profound decline in viable cells while having minimal impact on the growth and viability of non-MM HeLa or MiaPaca carcinoma cells (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Section S1</a>). In CRISPR studies, similar effects were observed for two distinct guide RNA target sequences, with KMS11 MM cells undergoing extensive apoptosis following GRK6 knockout, while the viability of HEK293 control cells was unaffected (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Sections S2 and S3</a>). Importantly, whereas endogenous GRK6 knockdown caused KMS11 cell death, this loss of viability could be rescued by re-expression of an shRNA-resistant GRK6 but was not rescued by expression of the shRNA-resistant GRK6A–K215R mutant, which lacks kinase activity<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Section S4</a>). Thus, the essentiality of GRK6 in MM maps to its kinase domain and, together with the observation that GRK6 knockout mice are healthy, suggests that small molecule inhibition of GRK6 kinase activity may represent a viable therapeutic strategy in MM.</div><div class="NLM_p">To identify hits amenable to further optimization against GRK6, we conducted a biochemical screening campaign against a focused set of 480 nonproprietary kinase inhibitors. This kinase inhibitor collection is composed of a number of clinically investigated or marketed agents, as well as preclinical compounds identified from the patent and primary literature. In addition to representing diverse chemical scaffolds, this set of compounds was designed to include inhibitors that target a number of kinases from all major branches of the kinome and was envisioned to be useful in terms of providing starting points for both new drug discovery campaigns and phenotypic screening investigations.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a></div><div class="NLM_p">To efficiently triage compounds of interest within the kinase library, the percent inhibition against full-length recombinant human GRK6 was first determined using a standard radiometric assay at a single concentration. Despite the fact that this library is inherently biased toward kinase inhibition, we were surprised to find that only 13/480 compounds demonstrated greater than 50% inhibition at 1 μM against GRK6. Two of the most active compounds were <b>8</b>, an IRE-1 inhibitor identified from the patent literature<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> that showed a 95% inhibition, and AZ960<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (<b>9</b>), a JAK inhibitor showing a 79% inhibition at 1 μM. Follow-up IC<sub>50</sub> determination of <b>8</b> and <b>9</b> showed that they had IC<sub>50</sub> values of 230 and 450 nM, respectively, against GRK6 (ATP at its GRK6 <i>K</i><sub>m</sub> of 45 μM). A common aminopyridine substructure in <b>8</b> and <b>9</b> suggested the possibility of a scaffold-merging approach to develop more potent analogues. In fact, by combining the quinazoline substructure of <b>8</b> with the <i>p</i>-fluorobenzylic substituent of <b>9</b>, we were able to identify a sub-100 nM inhibitor of GRK6 (<b>10a</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). This derivative served as a lead for further optimization studies.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Model of <b>10a</b> bound to the GRK6 active site. (A) Two-dimensional (2D) protein–ligand interaction diagram as depicted by MolSoft ICM using 4.5 Å as a hydrophobic interaction distance cutoff. (B) <b>10a</b> docked with Glide in the homology model of GRK6. The aminopyrazole of <b>10a</b> forms two strong H-bonds with the backbone NH of M266 and the backbone carbonyl of T264, while the 3-ethyl forms favorable van der Waals interactions with the gatekeeper residue L263. One more H-bond is formed between NH of quinazoline-2-amine and side chain of D270. The chiral methyl of the benzylic substituent binds toward the Gly-rich loop and V200 side chain, stabilizing the position of the 4-fluoro-benzylic substituent. The catalytic Lys K215 forms a salt bridge with E234 from the αC-helix. Only residues within 5 Å from the ligand are shown for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Chemistry</h3><div class="NLM_p">Analogues were prepared by a sequence shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> starting from commercially available 2,4-dichloroquinazoline starting materials (<b>A</b>). Treatment of an appropriately substituted 2,4-dichloroquinazoline with an aminopyrazole or other electron-rich amino-substituted heterocycles leads to regioselective addition of the amino-heterocyclic nucleophile at the 4-position to afford the corresponding 4-amino-2-chloroquinazoline intermediate (<b>B</b>), which was then subjected to heating in the presence of the desired amine in an alcoholic solvent to supply the final 2,4-diaminoquinazoline targets <b>10</b>–<b>22</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 4-Aminopyrazole-2-aminoalkyl Quinazoline Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Investigations to Optimize GRK6 Potency and Selectivity</h3><div class="NLM_p">We first explored the impact of various substitutions on the A-ring of the quinazoline scaffold on the GRK6 activity. Given the encouraging potency of <b>10a</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), for our initial investigations, we chose to hold the ethylaminopyrazole group at the 4-position constant and restrict modifications of the 2-position to a limited set of benzylic and homobenzylic substituents. As can be seen in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, while substitution with halogen or methoxy on the A-ring was generally tolerated, there was a preference for substitution at the 5-position relative to 6- or 7-substitution, the latter being particularly detrimental for the GRK6 activity. For further optimization, we therefore chose to focus only on the synthesis of derivatives with substitution at the 5-position of the A-ring.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. GRK6 Kinase Inhibition Data for A-Ring-Substituted Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0012.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were conducted at Eurofins (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Information</a>).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last"><i>N</i> = 2; error values are standard deviation. All other values are <i>n</i> = 1.</p></div></div><div></div></div><div class="NLM_p">To help guide our SAR studies to optimize the potency of the hit series, we sought to obtain structural information on the binding mode of our hit compounds. Unfortunately, despite extensive efforts, we were unsuccessful in solving a cocrystal structure of GRK6 and a compound within our series. Therefore, in the absence of this, we instead developed a binding model hypothesis for our series bound to the ATP active site of GRK6 that was based on the known crystal structure of GRK6 bound to sangivamycin (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NYN">3NYN</a> resolved at 2.72 Å). Through docking of our compounds in the site bound by sangivamycin, it appears that the likely binding mode of our compounds is within the ATP active site in the manner shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. The incorporation of a critical hinge-binding interaction of the aminopyrazole as part of the binding mode was based on the precedent from crystal structures of other aminopyrazole-containing kinase inhibitors bound, for example, to Janus kinase 2 (JAK2)<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> or tropomyosin receptor kinase A (TrkA).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Consistent with this hypothesis was the observation that attempts to significantly modify the structure of the aminopyrazole led to dramatic reductions in activity (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Interestingly, the modest activity of the amino-imidazole-containing analogue <b>13</b> against GRK6 was not unanticipated based on the tolerance of JAK2 for this group in a distinct series of analogues.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Impact of Pyrazole Modifications on the GRK6 Activity</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0013.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0014.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> were conducted at Eurofins (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Information</a>).</p></div></div><div></div></div><div class="NLM_p">The lack of significant steric constraints in the proposed binding mode in the GRK6 pocket surrounding the C-2 benzylic amine suggested opportunities to further increase potency through engagement in additional hydrophobic interactions. We therefore conducted a systematic exploration of the impact of the amino substituent at C-2. In this exercise, we held the 5-substituent constant as either H or F and employed the 2-ethylaminopyrazole hinge-binding unit. This investigation revealed several key findings (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). First, benzylic or homobenzylic groups were strongly preferred over aliphatic groups (e.g., <b>10a</b>, <b>10b</b> and <b>10g</b>, <b>10n</b> vs. <b>10z</b> and <b>10aa</b>). Second, a chiral (<i>S</i>)-methyl substituent was strongly preferred over (<i>R</i>)-methyl (<b>10a</b> vs <b>10p</b>) or the corresponding group without a chiral methyl (<b>10a</b> vs <b>10o</b>). Third, while substitution of pyridyl (e.g., <b>10v</b>) in place of phenyl was well tolerated, the more electron-deficient pyrimidine (<b>10x</b>) was less active, indicating a preference for electron-rich aromatic rings. Finally, while substitution at the <i>para</i> position was well tolerated in the benzyl aromatic ring, <i>meta</i> substitution decreased activity (<b>10a</b> vs <b>10q</b>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Impact of C-2 Amine Modifications on GRK6 Kinase Inhibition Data<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> for A-Ring-Substituted Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0015.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0016.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> were conducted at Eurofins (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Information</a>).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last"><i>N</i> = 2; error values are the standard deviation. All other values are <i>n</i> = 1.</p></div></div><div></div></div><div class="NLM_p">Although we were encouraged by the GRK6 potency of several of these compounds, the structures of the initial hit compounds in the <b>10</b> series suggested that they might also possess significant off-target activities. In particular, given that our series contains an aminopyrazole group common to many potent Aurora kinase inhibitors,<a onclick="showRef(event, 'ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52 ref53">(50−53)</a> we chose to counterscreen selected analogues against Aurora A, particularly since inhibition of this kinase might prove to be a liability in a chronic dosing setting and would be undesirable. As anticipated, several of the examples with potent GRK6 activity (<b>10n</b>, <b>10u</b>, <b>10v</b>) also displayed significant Aurora A activity (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Indeed, Aurora A appeared to be generally even more tolerant to diverse modifications to the amine substituent than GRK6 itself (e.g., <b>10b, 10x</b>). To develop analogues with improved selectivity against Aurora A, we decided to explore potential differences in the active site of GRK6 relative to Aurora A. While both kinases appeared to have similarities in the area of their pockets neighboring the C-2 substituent, we noticed a substantial difference between the hinge region of GRK6 and Aurora A. According to our model, the C-5-substituent points toward Leu265 and Asn267 in the hinge region of GRK6 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a). On the other hand, the corresponding residues in Aurora A are Tyr212 and Pro214 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b). Inspection of known crystal structures of GRK6 and Aurora A revealed that these residue differences account for the fact that there is a larger subpocket for the C-5-substituent to occupy in GRK6 than in Aurora A. Additionally, the conformational flexibility of proline is restricted, which, in turn, limits the possibility of ligand-induced conformational changes in this portion of the Aurora A binding site.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Model of <b>18</b> bound to GRK6 and Aurora A active sites. Both proteins are depicted by the Connolly surface color-coded by the calculated electrostatic potential (semitransparent). The top part of the proteins, the Gly-rich loop, is clipped for clarity. (A) <b>18</b> docked with Glide (Schrodinger, Inc.) using the SP scoring function in the homology model of the GRK6 active site. The methoxy group of 5-methoxyquinazoline binds in a pocket formed by L265, N267, and L192 (L192 clipped together with the Gly-rich loop for clarity) forming favorable van der Waals interactions. (B) <b>18</b> oriented in Aurora A after the binding sites of GRK6 and Aurora A were overlapped. The OMe-group clearly protrudes the Connolly surface of Aurora A, thus making steric clashes with the Y212 side chain (depicted by dotted red).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The above modeling observations lead us to hypothesize that the bulky substituents at the C-5-position might afford selectivity against Aurora A. Therefore, in a final effort to optimize this series, we applied our learnings from the data shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and the molecular docking considerations described above into the design of a set of 4-aminoethyl pyrazole quinazolines containing a 5-methoxy group. For this exercise, in addition to screening against Aurora A, we also counterscreened against IGF-1R, which we had found to be potently inhibited by some examples (e.g. <b>10v</b>, <b>10w</b>, IGF-1R IC<sub>50</sub> = 19, 32 nM, respectively). Notably, incorporation of the 5-methoxy group in their design led to compounds that were not only potent against GRK6 but were also highly selective against both Aurora A and IGF-1R (examples <b>10i</b> and <b>15</b>–<b>20</b>; <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Replacement of the 5-methoxy group with methyl also afforded compounds that were both potent and selective with respect to IGF-1R, though they showed a slight drop in selectivity against Aurora A.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. GRK6, Aurora A, and IGF-1R Activity<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> of 5-Methyl and 5-Methoxyquinazolines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0017.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0018.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> were conducted at Eurofins (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Information</a>).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last"><i>N</i> = 5; error values are standard deviation.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last"><i>N</i> = 3; error values are standard deviation.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last"><i>N</i> = 2; error values are standard deviation. All other values are <i>n</i> = 1.</p></div></div><div></div></div><div class="NLM_p">Given the excellent potency and selectivity of analogues <b>15</b>, <b>16</b>, and <b>18</b> against Aurora A and IGF-1R, we then evaluated their selectivity against a broader panel of 85 kinases. Although <b>15</b> showed inhibition of at least 14 of these kinases at levels of >50% at 1 μM, both <b>16</b> and <b>18</b> exhibited significantly greater overall selectivity profiles (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Table S3 and Supporting Section S5</a>). In particular, among the 85 kinases evaluated, <b>18</b> was found to inhibit only focal adhesion kinase (FAK), zipper-interacting protein kinase (ZIPK), TrkA, and checkpoint kinase 2 (CHK2) at levels > 50%. Moreover, follow-up IC<sub>50</sub> values (220 ± 150, 720 ± 49, 2000 ± 1500, and 820 ± 520 nM, respectively) demonstrated around or above 30-fold selectivity for GRK6 versus these targets. Despite the fact that the original hit <b>9</b> in our kinase library was a potent inhibitor of JAK kinases, <b>18</b> showed no significant inhibition (IC<sub>50</sub> > 10 μM) against JAK2. Finally, to identify other potential kinase off-targets of <b>18</b>, we investigated the profiles of two compounds known in the literature to inhibit GRK6 and whose full kinase profile had been characterized.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In addition to those kinases against which <b>18</b> had already been tested, this interrogation identified eight kinases that had high potential to be off-targets based on the inhibitory profiles of these GRK6 inhibitors. However, among these, only one kinase (LTK) showed >50% inhibition by <b>18</b> at 1 μM (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Table S4 and Supporting Section S5</a>).</div><div class="NLM_p">Having demonstrated a favorable selectivity profile against a range of kinases of various families, we then evaluated the intra-GRK family selectivity of the lead compounds. As can be seen in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, compounds <b>15</b>, <b>16</b>, and <b>18</b> all exhibited a pattern of high selectivity against GRK2 and 3, a modest selectivity against GRK1 and 4, and a limited to no selectivity against GRK5 and 7, respectively. The high selectivity against GRK2 and 3 might be predicted by the relatively low sequence identity of their kinase domains to GRK6 (51.0 and 50.6%, respectively; <a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Section S6</a>). As it has been shown that kinase selectivity is not necessarily dictated by homology in the ATP binding site,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> the lack of selectivity against GRK1 and 7 is notable given that the homology of their kinase domains to GRK6 is only modestly greater at 58.2 and 55.1%. Although the gatekeeper residues differ between GRK6 (L263) and GRK7 (M78), the remaining residues within 5 Å of the ATP site are identical except T264 in GRK6 versus S79 in GRK7, where the side chains point away from the ligand. Similarly, GRK6 and GRK1 ATP site residues have the same gatekeeper residues (L263 in GRK6 and L261 in GRK1) and other ATP binding site residues, except T264 in GRK6 versus D272 in GRK1 and E315 in GRK6 versus A321 in GRK1, residues with side chains that point away from the ligand. It is interesting that moderate selectivity against GRK4 could be achieved by varying the aniline substituent that binds in the phosphate region under the Gly-rich loop (compare compounds <b>15</b> and <b>18</b>: (<i>S</i>)-1-(5-fluoropyridin-2-yl)ethan-1-amine versus (4-chloro-2-methoxyphenyl)methanamine). While compound <b>15</b> is more selective for GRK4, compound <b>18</b> is highly selective against Aurora A. Given the high sequence identity between GRK6 and GRK4 and 5 (78.7 and 77.9% for the kinase domain, correspondingly) and other family members (sequence identity between 50 and 60%), engineering a compound with a high GRK6 subtype selectivity within this series may prove to be challenging. That said, it is unclear what therapeutic liabilities or benefits might result from the observed cross-GRK inhibitory profiles in an in vivo setting. For example, while GRK5 has been shown to have potential as a target for prostate cancer,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> it has also been shown that germline ablation of GRK2, 5, and 6 induced embryonic lethality,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> whereas mice with cardiac loss of any two of the GRK isoforms -2, -5, or -6 were developmentally normal.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. GRK6 Family IC<sub>50</sub> Values for Compounds <b>15</b>, <b>16</b>, and <b>18</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center" char="±">GRK isoform IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left">number</th><th class="colsep0 rowsep0" align="center" char="±">1</th><th class="colsep0 rowsep0" align="center">2</th><th class="colsep0 rowsep0" align="center">3</th><th class="colsep0 rowsep0" align="center" char="±">4</th><th class="colsep0 rowsep0" align="center" char="±">5</th><th class="colsep0 rowsep0" align="center" char="±">6</th><th class="colsep0 rowsep0" align="center" char="±">7</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">190 ± 12</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="char" char="±">97 ± 7.5</td><td class="colsep0 rowsep0" align="char" char="±">26 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">450 ± 160</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="char" char="±">190 ± 70</td><td class="colsep0 rowsep0" align="char" char="±">51 ± 4.5</td><td class="colsep0 rowsep0" align="char" char="±">33 ± 18</td><td class="colsep0 rowsep0" align="char" char="±">36 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">52 ± 3</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">12 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 0.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> were conducted at the Reaction Biology Corporation (data generated for GRK6 are within 2–3-fold of values obtained at Eurofins, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. See the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last"><i>N</i> = 2; error values are standard deviation.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last"><i>N</i> = 4; error values are standard deviation.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Cellular GRK6 Profiling of Lead Quinazoline Compounds</h3><div class="NLM_p">Given their interesting biochemical profiles, we next sought to examine the activity of key compounds within cells to further guide the development of biologically active molecules. We first examined target engagement of intracellular GRK6 using a cellular thermal shift assay (CETSA) employing FLAG-GRK6-expressing KMS11 MM cells and anti-FLAG immunoblots. In cells, thermal denaturation assays of this type can detect differences between compounds in their cell permeability and in their capacity to bind and stabilize their protein target. At least eight potent compounds were studied by CETSA. Notably, seven of these analogues demonstrated significant intracellular GRK6 binding at 5 μM and induced protection of cell-based GRK6 from thermal denaturation (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Section S7</a>). The high success rate of in-cell GRK6 binding by these compounds likely reflects their development from scaffolds that have been shown for other targets to have good cellular penetration.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In fact, three of the more promising analogues of this series were assessed in Caco-2 permeability assays and, as anticipated, exhibited either medium or high permeability with limited to moderate efflux (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Section S8</a>).</div><div class="NLM_p">To better quantify the relative abilities of the compounds to bind intracellular GRK6, we also performed isothermal drug response (ITDR) assays with the seven cell-penetrating compounds identified by CETSA. While appreciable engagement of cell-based GRK6 by four of the compounds dropped off at concentrations of 1 μM and below, compounds <b>18</b>, <b>20</b>, and <b>22</b> showed intracellular GRK6 binding in the nanomolar range, with compound <b>18</b> showing the most promising cell-based GRK6 engagement with an IC<sub>50</sub> value of 30 nM (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Isothermal drug response (ITDR) assays, showing in-cell GRK6 binding by lead compounds as a function of concentration. KMS11–FLAG-GRK6 cells were incubated with compounds at the specified concentrations for 2.5 h and were then washed, lysed with NP40, and heated for 10 min at 51 or 52 °C (as shown) to induce denaturation of unbound FLAG-GRK6. Following this, soluble nondenatured GRK6, which had been protected from thermal denaturation by compound binding, was quantified by gel electrophoresis and anti-FLAG immunoblot. For comparison, the total cellular FLAG-GRK6 was determined from aliquots that were left unexposed to compounds or thermal denaturation (column 0*).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In-Cell GRK6 Binding (IC<sub>50</sub> Values and Half-Life) for Compounds <b>15</b>–<b>18</b>, <b>20</b>, and <b>22</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">number</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM) intracellular GRK6 binding (ITDR)</th><th class="colsep0 rowsep0" align="center">half-life (h) Intracellular GRK6 binding (thermal protection) after compound washout</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">2000</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">2000</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">610</td><td class="colsep0 rowsep0" align="left"><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">170</td><td class="colsep0 rowsep0" align="left">2</td></tr></tbody></table></div></div><div class="NLM_p">Cellular GRK6 binding IC<sub>50</sub> values in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> were determined from ITDR assays conducted in KMS11 cells as described in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and analyzed by immunoblot densitometry scanning. The IC<sub>50</sub> was calculated as the concentration at which 50% of total cellular GRK6 (measured without thermal denaturation) was protected from denaturation by compound binding. The approximate half-life of GRK6 occupancy by a compound in cells was determined as described in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, following cell-based target saturation and compound washout and was calculated as the time until 50% GRK6 occupancy in cells.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In-cell GRK6 occupancy by compounds <b>18</b>, <b>20</b>, or <b>22</b>, as a function of time. KMS11–FLAG-GRK6 cells were preincubated with a compound at 5 μM for 2.5 h at 37 °C to achieve loading and were then divided. An aliquot of cells was washed to remove the unbound compound (time = 0) and was then further incubated at 37 °C, while a second aliquot of cells was continuously incubated with the  compound. Following the specified intervals, cells were assayed for thermally protected bound GRK6, or total GRK6, by incubation at either 52 °C or room temperature, respectively (for 10 min) followed by gel electrophoresis and anti-FLAG immunoblot, as described for CETSA and ITDR studies. The half-life of cellular GRK6 occupancy was calculated as the time following drug washout required for GRK6 occupancy to fall to 50%. The fraction of GRK6 occupancy was determined as the amount of GRK6 experiencing thermal protection at 52 °C relative to the total cellular GRK6, measured at each time point from lysate aliquots processed at 23 °C and not subjected to thermal denaturation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We next sought to determine the duration of cell-based GRK6 occupancy by compounds <b>18</b>, <b>20</b>, and <b>22</b>. In this experiment, KMS11 cells were preincubated with the compounds at 5 μM for 2.5 h to saturate the GRK6 target. The cells were then divided into aliquots, with one aliquot washed to remove the unbound compound. The time course of cell-based GRK6 occupancy was then monitored by periodic isothermal denaturation assays (at 52 °C) to assess the rate of complex dissolution and emergence of unbound GRK6 (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). From these studies, GRK6 occupancy by <b>18</b> was found to be strongly sustained with a half-life of approximately 24 h after free drug washout. In contrast, the half-life occupancy of GRK6 by compound <b>22</b> was found to be considerably shorter. The binding of <b>20</b> to cell-based GRK6 was difficult to detect when a thermal stress of 52 °C rather than 51 °C was employed, suggesting that its affinity for GRK6 is less than either <b>18</b> or <b>20</b>. Furthermore, despite this lower affinity, continuous treatment of cells with <b>20</b> for 48–72 h caused a drop-off in the total FLAG-GRK6 abundance (at 23 °C) consistent with cell toxicity; this toxicity was likely due to off-target effects as this compound has considerably less selectivity than <b>18</b> or <b>22</b> for GRK6 versus other critical kinases (only 15–30-fold for IGF-1R and Aurora A; <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), which may have been biologically significant at 5 μM. Overall, these studies further demonstrate that among the compounds examined, <b>18</b> has the most potent cellular GRK6 occupancy.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Antiproliferative Activity of <b>18</b></h3><div class="NLM_p">On the basis of the genetic validation of GRK6 knockdown on the proliferative cellular phenotype of MM and demonstration of high cellular occupancy at 0.5 μM, we next sought to assess the antiproliferative activity of <b>18</b> on MM cells. Seven MM cell lines, including two KMS11 variants, were treated with <b>18</b> at increasing concentrations up to 25 μM and the effects on cellular viability were examined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay following 3 or 6 days of exposure. Following 3 days of treatment, <b>18</b> inhibited MM cells with IC<sub>50</sub> values of 1–1.1 μM for the KMS11 variants and approximately 1.9–3.0 μM for the other 4 MM cell lines (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Furthermore, when MM cells were exposed to <b>18</b> for 6 days, the IC<sub>50</sub> was reduced to approximately 340–460 nM, consistent with the notion that the maximal efficacy against MM cells may require chronic suppression of GRK6 kinase activity. Indeed, in our genetic GRK6 knockdown studies, cell viability was assayed on day 8 following shRNA induction (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Section S1</a>), and on day 8 or day 11 following CRISPR (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Sections S2 and S3</a>), well after GRK6 activity was suppressed, as preliminary studies demonstrated latency in MM cell death following GRK6 silencing. Notably, the fact that GRK6 knockout is well tolerated in mice suggests that such prolonged inhibition should be well tolerated.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antiproliferative activity of compound <b>18</b> versus MM cells. MM cell lines, including two engineered KMS11 variants expressing either the empty vector pWPI or overexpressing GRK6A from pWPI, were exposed to compound 18 at titrated concentrations under standard cell culture conditions at 37 °C for 3 days or 6 days. For the 6 day incubation, cells were replenished with fresh media and compound on day 3. Viability was assessed by the MTT assay. Results are the mean of replicates (n = 3) ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Antiproliferative IC<sub>50</sub> Values versus MM Cell Lines of Compound <b>18</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cells</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM) day 3</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM) day 6</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KMS11</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KMS11–pWPI</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="left">0.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KMS11–pWPI–FLAG-GRK6A</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="left">0.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RPMI-8226</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="left">0.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LP1</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KMS18</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="left">0.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MM1R</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div></div><div class="NLM_p">Antiproliferation IC<sub>50</sub> values for compound <b>18</b> versus MM cells were determined by MTT assays, performed after 3 or 6 days of exposure, as described in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. Results are the mean of replicates (<i>n</i> = 3) ± SEM. ND, not determined.</div><div class="NLM_p">Having demonstrated that compound <b>18</b> has an antiproliferative activity against MM cells, we next sought to examine whether it might combine favorably with existing MM drugs such as the proteasome inhibitor, bortezomib. To study this, KMS11, KMS18, and RPMI-8226 MM cells were individually incubated with either compound <b>18</b> alone (at 125–8000 nM), or the proteasome inhibitor bortezomib (at 0.5–64 nM), or with both drugs, for 96 h and the effects on viability were assessed by the MTT assay (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Importantly, when used in combination, these drugs demonstrated a striking synergistic inhibition of all three MM cell lines, across a broad range of concentrations (including IC<sub>50</sub>–IC<sub>95</sub>), which significantly exceeded the inhibition that would be expected from independent “additive” effects. Thus, in addition to exerting a direct cytotoxic effect on MM cells, inhibition of GRK6 using agents such as compound <b>18</b> can also synergistically enhance the activity of existing MM therapeutics such as bortezomib.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound  <b>18</b> and the proteasome inhibitor bortezomib induce synergistic killing of MM cells. KMS11, KMS18, and RPMI-8226 MM cells were treated with bortezomib or compound <b>18</b> separately and with both drugs combined across a range of concentrations. Viability was assessed by the MTT assay at 96 h. The combined effect of the two drugs is compared with their individual potencies. (A) Isobologram plots for the drug combinations at IC<sub>50</sub> or IC<sub>75</sub>, showing the predicted dose–response assuming Loewe additivity (dotted line) and the observed effect of the drug combination (in red). (B) Demonstration of synergy by Bliss independence at IC<sub>90</sub>–IC<sub>95</sub>. Concentrations of bortezomib and <b>18</b> that individually produced only 25–50% MM cell inhibition combined to produce 88–95% inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87452" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87452" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Due to the intriguing biology, structural features, and therapeutic potential of the GRK kinases, the pharmacological targeting of this family of enzymes has attracted increasing interest from both academic and pharmaceutical research groups. While GRK2 and GRK5 have received the most attention in terms of small molecule inhibitors, only limited efforts to target GRK6 have been disclosed. Motivated by target validation using si- and shRNA studies that have shown a striking dependency of the growth of MM cells on GRK6, we undertook an effort to identify potent inhibitors of GRK6 that could be useful not only as tool compounds to further elucidate GRK6 biology but also as leads for the development of drugs to treat MM. By screening a library of known kinase inhibitors in GRK6 biochemical assays, we identified two inhibitors (compounds <b>8</b> and <b>9</b>) of modest potency. By combining key structural features of these two hits, we then discovered the first sub-100 nM inhibitor of GRK6 (compound <b>10a</b>). Despite having poor selectivity with respect to Aurora A and IGF-1R, installing a methyl or methoxy group at the 5-position resulted in a set of compounds with low nM potency against GRK6 and high selectivity against Aurora A, IGF-1R, and a panel of other kinase targets. Furthermore, these compounds showed excellent cellular target engagement of GRK6, particularly compounds <b>18</b>, <b>20</b>, and <b>22</b>.</div><div class="NLM_p last">In addition to their potent biochemical activity, several of the analogues showed high levels of intracellular target engagement and, in the case of compound <b>18</b>, sustained target binding and robust antiproliferative activity. Because these compounds have varying degrees of inhibitory activity at other GRK family members such as GRK5, it is unclear if GRK6 inhibition is solely responsible for their cellular effects. Nonetheless, the genetic discovery of GRK6 from kinome screening as a selective vulnerability in MM plasma cells, combined with our additional target validation studies and demonstration of cellular GRK6 engagement by lead compounds, strongly suggests that GRK6 is their primary antiproliferative target in MM cells. Furthermore, this conclusion is supported by the observation that loss of a single GRK6 interaction with CXCR4 causes human WHIM syndrome,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> characterized by hypogammaglobulinemia secondary to plasma cell deficiency. In addition to causing direct inhibition of MM plasma cells, GRK6 inhibition by <b>18</b> also demonstrated striking synergism with bortezomib, a standard of care in MM. As genetic loss of GRK6 is well tolerated in mice, these results support the potential of GRK6 inhibition as a therapeutic strategy for MM. Unfortunately, despite having high permeability and acceptable stability in microsomes, preliminary data showed that representative compounds such as <b>18</b> had poor bioavailability (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">Supporting Section S9</a>), which may limit their in vivo utility. Nevertheless, the biochemical and cellular activity of these compounds, their low molecular weight, and drug-like scaffold suggest opportunities for further optimization to maximize their therapeutic potential in MM and other diseases where GRK6 has been implicated.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56480" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56480" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry</h3><div class="NLM_p">All reagents were purchased from commercial vendors and used without further purification. Volatiles were removed under reduced pressure by rotary evaporation or using the V-10 solvent evaporator system from Biotage. Very high boiling point (6000 rpm, 0 mbar, 56 °C), mixed volatile (7000 rpm, 30 mbar, 36 °C), and volatile (6000 rpm, 30 mbar, 36 °C) methods were used to evaporate solvents. The yields given refer to chromatographically purified and spectroscopically pure compounds, unless stated otherwise. Compounds were purified using a Biotage Isolera One system by normal phase chromatography using Biotage SNAP KP-Sil or Sfär Silica D columns (part no. FSKO-1107/FSRD-0445) or by reverse-phase chromatography using Biotage SNAP KP-C18-HS or Sfär C18 D columns (part no. FSLO-1118/FSUD-040). If additional purification was required, compounds were purified by solid-phase extraction (SPE) using Biotage Isolute Flash SCX-2 cation-exchange cartridges (part nos. 532–0050-C and 456–0200-D). Products were washed with two cartridge volumes of MeOH and eluted with a solution of MeOH and NH<sub>4</sub>OH (9:1 v/v). Preparative chromatography was carried out using a Waters 2767 injector with a collector attached to PDA UV–vis and SQD mass detectors. An XSelect CSH Prep C18 5 μmOBD 19 mm × 100 mm (part no. 186005421) or an Xselect CSH Prep C18 5 μm 10 mm × 100 mm (part no. 186005415) column was used for purification. Final compounds were dried using the Labconco Benchtop Free-ZoneTM Freeze-Dry System (4.5 L model). <sup>1</sup>H NMRs were recorded on a Bruker Avance-III 500 MHz spectrometer at an ambient temperature. Residual protons of CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, and CD<sub>3</sub>OD solvents were used as internal references. Spectral data are reported as follows: chemical shift (δ in ppm), multiplicity (br, broad; s, singlet; d, doublet; dd, doublet of doublets; m, multiplet), coupling constants (<i>J</i> in Hz), and proton integration. Compound purity was determined by UV absorbance at 254 nm during tandem liquid chromatography/mass spectrometry (LC-MS) using a Waters Acquity separation module. All final compounds had a purity of ≥95% as determined using this method. Low-resolution mass spectrometry was conducted in the positive ion mode using a Waters Acquity SQD mass spectrometer (electrospray ionization source) fitted with a PDA detector. Mobile phase A consisted of 0.1% formic acid in water, while mobile phase B consisted of 0.1% formic acid in acetonitrile. One of three types of columns was used; column 1: Acquity UPLC CSH C18 (2.1 mm × 50 mm, 130 Å, 1.7 μm, part no. 186005296); column 2: Acquity UPLC BEH C8 (2.1 mm × 50 mm, 130 Å, 1.7 μm, part no. 186002877); or column 3: Acquity UPLC HSS T3 (2.1 mm × 50 mm, 100 Å, 1.8 μm, part no. 186003538). For columns 1 and 2, the gradient went from 90 to 5% mobile phase A over 1.8 min, maintained at 5% for 0.5 min, and then increased to 90% over 0.2 min for a total run time of 3 min. For column 3, the gradient went from 98 to 5% mobile phase A over 1.8 min, maintained at 5% for 0.5 min, and then increased to 98% over 0.2 min for a total run time of 3 min. The flow rate was 0.4 mL/min throughout both runs. All columns were used with the temperature maintained at 25 °C. High-resolution mass spectrometry was conducted using a Waters Synapt G2-S quadrupole-time-of-flight (Q-TOF) hybrid mass spectrometer system coupled with an Acquity ultraperformance liquid chromatography (UPLC) I-Class system. Chromatographic separations were carried out on an Acquity UPLC HSS T3 (2.1 mm × 100 mm, 100 Å, 1.8 μm, part no. 186003539). The mobile phases were 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). Leucine enkephalin was used as the lock-mass. MassLynx 4.1 was used for data analysis.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> General Procedure for the Synthesis of Intermediates B-1–B-11: 2-Chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-1</b>)</h4><div class="NLM_p last">A solution of 2,4-dichloroquinazoline (260 mg, 1.3 mmol), 3-ethyl-1<i>H</i>-pyrazol-5-amine (149 mg, 1.03 mmol), and triethylamine (0.68 mL, 3.92 mmol) in ethanol (5 mL) was stirred overnight at room temperature. The precipitate was filtered, the filter cake was washed with 0.5 mL ethanol, and then dried under high vacuum to yield the product (304 mg, 81%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.35 (bs, 1H), 10.80 (bs, 1H), 8.66 (d, <i>J</i> = 7.9, 1H), 7.83–7.87 (m, 1H), 7.56–7.70 (m, 2H), 6.60 (d, <i>J</i> = 1.7, 1H), 2.66 (q, <i>J</i> = 7.6, 2H), 1.24 (t, <i>J</i> = 7.6, 3H). LC-MS: <i>m</i>/<i>z</i> 274.14 (M + 1)<sup>+</sup>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-Chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-7-fluoroquinazolin-4-amine (<b>B-2</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2,4-dichloro-7-fluoroquinazoline (250 mg, 1.15 mmol) and 3-ethyl-1<i>H</i>-pyrazol-5-amine (131 mg, 1.18 mmol) using a procedure analogous to that described for the synthesis of <b>B-1</b> to afford the product (335 mg, 95%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.36 (bs, 1H), 10.88 (bs, 1H), 8.66 (d, <i>J</i> = 7.9, 1H), 7.76 (dd, <i>J</i> = 8.8, 5.9, 1H), 7.47–7.52 (m, 2H), 6.58 (d, <i>J</i> = 1.9, 1H), 2.66 (q, <i>J</i> = 7.6, 2H), 1.24 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 291.1 (M + 1)<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 2,7-Dichloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-3</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2,4,7-trichloroquinazoline (250 mg, 1.07 mmol) and 3-ethyl-1<i>H</i>-pyrazol-5-amine (122 mg, 1.10 mmol) using a procedure analogous to that described for the synthesis of <b>B-1</b> to afford the product (304 mg, 88%) as a white solid. δ 12.38 (s, 1H), 10.95 (s, 1H), 8.70 (d, <i>J</i> = 8.9, 1H), 7.77 (d, <i>J</i> = 2.1, 1H), 7.58–7.64 (m, 1H), 6.59 (d, <i>J</i> = 1.9, 1H), 2.66 (q, <i>J</i> = 7.6, 2H), 1.23 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 309.25 (M + 1)<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-Chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-6-fluoroquinazolin-4-amine (<b>B-4</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2,4-dichloro-6-fluoroquinazoline (250 mg, 1.15 mmol) and 3-ethyl-1<i>H</i>-pyrazol-5-amine (131 mg, 1.18 mmol) using the procedure analogous to that described for the synthesis of <b>B-1</b> to provide the product (264 mg, 75%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.37 (bs, 1H), 10.89 (bs, 1H), 8.76 (dd, <i>J</i> = 8.8, 5.9, 1H), 7.76 (dd, <i>J</i> = 8.8, 5.9, 1H), 7.47–7.52 (m, 2H), 6.58 (d, <i>J</i> = 1.9, 1H), 2.67 (q, <i>J</i> = 7.6, 2H), 1.24 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 293.17 (M + 1)<sup>+</sup>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2-Chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-6-methoxyquinazolin-4-amine (<b>B-5</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2,4-dichloro-6-methoxyquinazoline (250 mg, 1.09 mmol) and 3-ethyl-1<i>H</i>-pyrazol-5-amine (124 mg, 1.12 mmol) using the procedure analogous to that described for the synthesis of <b>B-1</b> to afford the product (254 mg, 73%) as a white solid. δ 12.32 (bs, 1H), 10.75 (bs, 1H), 8.10 (d, <i>J</i> = 2.6, 1H), 7.62 (d, <i>J</i> = 9.1, 1H), 7.47 (dd, <i>J</i> = 9.1, 2.6, 1H), 6.64 (d, <i>J</i> = 1.7, 1H), 3.91 (s, 3H), 2.67 (q, <i>J</i> = 7.6, 2H), 1.24 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 305.37 (M + 1)<sup>+</sup>.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-Chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoroquinazolin-4-amine (<b>B-6</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2,4-dichloro-5-fluoroquinazoline (250 mg, 1.15 mmol) and 3-ethyl-1<i>H</i>-pyrazol-5-amine (131 mg, 1.18 mmol) using the procedure analogous to that described for the synthesis of <b>B-1</b> to give the product as a white solid (260 mg, 74%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.43 (bs, 1H), 9.30 (d, <i>J</i> = 14.4, 1H), 8.87 (dd, <i>J</i> = 14.4, 8.2, 1H), 7.56 (d, <i>J</i> = 8.3, 1H), 7.46 (dd, <i>J</i> = 12.3, 8.3, 1H), 6.57 (bs, 1H), 2.66 (q, <i>J</i> = 7.7, 2H), 1.23 (t, <i>J</i> = 7.5, 3H). LC-MS <i>m</i>/<i>z</i> 293.29 (M + 1)<sup>+</sup>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-Chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methoxyquinazolin-4-amine (<b>B-7</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2,4-dichloro-5-methoxyquinazoline (250 mg, 1.09 mmol) and 3-ethyl-1<i>H</i>-pyrazol-5-amine (124 mg, 1.12 mmol) using the procedure analogous to that described for the synthesis of <b>B-1</b> to afford the product (265 mg, 76%) as a pale pink solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.29 (bs, 1H), 7.79 (t, <i>J</i> = 8.3, 1H), 7.28 (d, <i>J</i> = 8.3, 1H), 7.18 (d, <i>J</i> = 8.1, 1H), 6.61 (bs, 1H), 4.12 (s, 3H), 2.65 (q, <i>J</i> = 7.6, 2H), 1.23 (t, <i>J</i> = 7.5, 3H). LC-MS <i>m</i>/<i>z</i> 305.43 (M + 1)<sup>+</sup>.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-Chloro-<i>N</i>-(1-ethyl-1<i>H</i>-imidazol-4-yl)-5-fluoroquinazolin-4-amine <b>(B-8</b>)</h4><div class="NLM_p last">The title compound was synthesized in a manner similar to that described in <b>B-1</b> using 2,4-dichloro-5-fluoroquinazoline (150 mg, 0.69 mmol) and 1-ethyl-1<i>H</i>-imidazol-4-amine<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (96 mg, 0.86 mmol) and stirring at room temperature for 2 h. Following workup, the product (117 mg, 58%) was collected by suction filtration and drying provided a pale peach-colored solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (d, <i>J</i> = 13.5, 1H), 7.85 (dd, <i>J</i> = 13.5, 8.1, 1H), 7.63 (bs, 1H), 7.54 (m, 2H), 7.45 (dd, <i>J</i> = 12.2, 8.2, 1H), 4.06 (q, <i>J</i> = 7.3, 2H), 2.65 (q, <i>J</i> = 7.6, 2H), 1.38 (t, <i>J</i> = 7.3, 3H). LC-MS <i>m</i>/<i>z</i> 293.8 (M + 1)<sup>+</sup>.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-Chloro-5-fluoro-<i>N</i>-(1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-9</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2,4-dichloro-5-fluoroquinazoline (70 mg, 0.323 mmol) and 1<i>H</i>-pyrazol-3-amine (107 mg, 1.29 mmol) using the procedure analogous to that described for the synthesis of <b>B-1</b> to give the product (56 mg, 66%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.29 (bs, 1H), 7.79 (t, <i>J</i> = 8.3, 1H), 7.28 (d, <i>J</i> = 8.3, 1H), 7.18 (d, <i>J</i> = 8.1, 1H), 6.61 (bs, 1H), 4.12 (s, 3H), 2.65 (q, <i>J</i> = 7.6, 2H), 1.23 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 264.12 (M + 1)<sup>+</sup>.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(2-Chloro-5-fluoroquinazolin-4-yl)isoxazol-5-amine (<b>B-10</b>)</h4><div class="NLM_p last">The title compound was prepared by dissolving 2,4-dichloro-5-fluoroquinazoline (50 mg, 0.230 mmol) in 3-aminoisoxazole (387 mg, 4.61 mmol) and stirring at room temperature for 45 min. After taking the mixture up in a small amount of DMF, the product was purified by flash chromatography and isolated as a white solid (37 mg, 58%). LC-MS <i>m</i>/<i>z</i> 265.08 (M + 1)<sup>+</sup>.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-Chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methylquinazolin-4-amine (<b>B-11</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2,4-dichloro-5-methylquinazoline (300 mg, 1.41 mmol) and 5-ethyl-1<i>H</i>-pyrazol-3-amine (235 mg, 2.11 mmol) using a procedure analogous to that described for the synthesis of <b>B-1</b>. The product (234 g, 58%) was collected as a bright yellow precipitate by suction filtration and drying <i>in vacuo</i>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.37 (bs, 1H), 9.12 (bs, 1H), 7.71 (t, <i>J</i> = 7.6, 1H), 7.53 (d, <i>J</i> = 8.2, 1H), 7.39 (d, <i>J</i> = 7.6, 1H), 6.58 (bs, 1 H), 2.97 (s, 3H), 2.66 (q, <i>J</i> = 7.6, 2H), 1.23 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 287.9 (M + 1)<sup>+</sup>.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> General Procedure for the Syntheses of Compounds 10–22: Synthesis of (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>2-(1-(4-fluorophenyl)ethyl)quinazoline-2,4-diamine (<b>10a</b>)</h4><div class="NLM_p last">A mixture of 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-1</b>) (50 mg, 0.183 mmol) and (<i>S</i>)-1-(4-fluorophenyl)ethanamine (54 mg, 0.384 mmol) in butan-1-ol (0.7 mL) was heated in an oil bath or a microwave reactor at 80–200 °C for 1–2 h. The reaction mixture was concentrated to dryness and purified by column chromatography (0–5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to yield the product as a white solid (21 mg, 29%). <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.14 (d, <i>J</i> = 8.0, 1H), 7.68 (t, <i>J</i> = 6.8, 1H), 7.39–7.52 (m, 3H), 7.28 (d, <i>J</i> = 6.6, 1H), 7.07 (d, <i>J</i> = 8.8, 1H), 7.04 (d, <i>J</i> = 8.8, 1H), 6.29 (s, 1H), 5.28 (q, <i>J</i> = 6.9, 1H), 2.71 (q, <i>J</i> = 7.6, 2H), 1.60 (d, <i>J</i> = 6.9, 3H), 1.31 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 377.21 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>2-(4-fluorophenethyl)quinazoline-2,4-diamine (<b>10b</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-1</b>) (40 mg, 0.146 mmol) and 4-fluorophenethylamine (42 mg, 0.307 mmol) using the procedure analogous to that described for the synthesis of <b>10a</b> to provide the product (15 mg, 26%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.08 (d, <i>J</i> = 8.1, 1H), 7.62 (t, <i>J</i> = 7.6, 1H), 7.37–7.54 (m, 1H), 7.28 (m, 2H), 7.18 (t, <i>J</i> = 7.6, 1H), 7.00 (d, <i>J</i> = 8.8, 1H), 7.02 (d, <i>J</i> = 8.8, 1H), 7.00 (d, <i>J</i> = 8.8, 1H), 6.63 (bs, 1H), 3.70 (t, <i>J</i> = 7.3, 2H), 2.90–3.06 (m, 2H), 2.63–2.78 (m, 2H), 1.28 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 377.02 (M + 1)<sup>+</sup>. HPLC purity > 90%.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-7-fluoro-<i>N</i>2-(4-fluorophenethyl)quinazoline-2,4-diamine (<b>10c</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-7-fluoroquinazolin-4-amine (<b>B-2</b>) (32 mg, 0.137 mmol) and 4-fluorophenethylamine (40 mg, 0.288 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (24 mg, 42%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.14 (dd, <i>J</i> = 9.1, 6.1, 1H), 7.20–7.40 (m, 2H), 6.91–7.18 (m, 4H), 5.87–6.73 (m, 1H), 3.68 (t, <i>J</i> = 6.8, 2H), 2.89–3.01 (m, 2H), 2.61–2.79 (m, 2H), 1.28 (t, <i>J</i> = 7.3, 3H). LC-MS <i>m</i>/<i>z</i> 395.37 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 7-Chloro-<i>N</i>4-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>2-(4-fluorophenethyl)quinazoline-2,4-diamine (<b>10d</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2,7-dichloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-3</b>) (40 mg, 0.130 mmol) and 4-fluorophenethylamine (37.9 mg, 0.273 mmol) using the procedure analogous to that described for the synthesis of <b>10a</b> to afford the product (31 mg, 55%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.05 (d, 1 H, <i>J</i> = 8.8, 1 H), 7.34–7.57 (m, 1H), 7.20–7.34 (m, 2H), 7.14 (d, <i>J</i> = 8.4, 1H), 7.01 (d, <i>J</i> = 8.8, 1H), 7.00 (d, <i>J</i> = 8.8, 1H), 5.87–6.70 (m, 1H), 3.68 (t, <i>J</i> = 7.3, 2H), 2.93 (bs, 2 H), 2.62–2.76 (m, 2H), 1.27 (t, <i>J</i> = 7.3, 3H). LC-MS <i>m</i>/<i>z</i> 412.14 (M + H)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-6-fluoro-<i>N</i>2-(4-fluorophenethyl)quinazoline-2,4-diamine (<b>10e</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-6-fluoroquinazolin-4-amine (<b>B-4</b>) (40 mg, 0.137 mmol) and 4-fluorophenethylamine (40.1 mg, 0.288 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to afford the product (35 mg, 62%) as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.82–7.98 (m, 1H), 7.40–7.57 (m, 2H), 7.21–7.36 (m, 2H), 6.93–7.02 (m, 2H), 5.82–6.74 (m, 1H), 3.68 (t, <i>J</i> = 7.2, 2H), 2.85–3.05 (m, 2H), 2.57–2.79 (m, 2H), 1.28 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 395.30 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>2-(4-fluorophenethyl)-6-methoxyquinazoline-2,4-diamine (<b>10f</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-6-methoxyquinazolin-4-amine (<b>B-5</b>) (40 mg, 0.132 mmol) and 4-fluorophenethylamine (38.5 mg, 0.277 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (32 mg, 57%) as a pale yellow solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.87 (bs, 1H), 7.40–7.60 (m, 2H), 7.16–7.36 (m, 2H), 7.03 (d, <i>J</i> = 8.8, 1H), 7.01 (d, <i>J</i> = 8.8, 1H), 6.56 (bs, 1H), 3.96 (s, 3H), 3.75 (t, <i>J</i> = 7.4, 2H), 2.88–3.08 (m, 2H), 2.73 (t, <i>J</i> = 7.6, 2H), 1.22–1.38 (m, 3H). LC-MS <i>m</i>/<i>z</i> 407.32 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoro-<i>N</i>2-(4-fluorophenethyl)quinazoline-2,4-diamine (<b>10g</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-N-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoroquinazolin-4-amine (<b>B-6</b>) (40 mg, 0.137 mmol) and 4-fluorophenethylamine (40.1 mg, 0.288 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to afford the product (44 mg, 77%) as a pale yellow solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.51–7.64 (m, 1H), 7.17–7.36 (m, 3H), 6.97–7.07 (m, 2H), 6.85–6.96 (m, 1H), 6.65–6.85 (m, 1H), 3.72 (br t, <i>J</i> = 7.3 Hz, 2H), 2.96 (t, <i>J</i> = 7.6, 2H), 2.69 (q, <i>J</i> = 7.6, 2H), 1.22–1.33 (m, 3H). LC-MS <i>m</i>/<i>z</i> 395.24 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoro-<i>N</i>2-phenethylquinazoline-2,4-diamine (<b>10h</b>)</h4><div class="NLM_p last">The title compound was from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoroquinazolin-4-amine (<b>B-6</b>) (40 mg, 0.137 mmol) and 2-phenylethylamine (19.9 mg, 0.165 mmol) using the procedure analogous to that described for the synthesis of <b>10a</b> to afford the product (28 mg, 52%) as a white powder. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.54 (dd, <i>J</i> = 15.4, 14.9, 1H), 7.30–7.18 (m, 6H), 6.89 (dd, <i>J</i> = 13.0, 7.9, 1H), 6.78 (bs, 1H), 3.72 (t, <i>J</i> = 7.1, 2H), 2.97 (t, <i>J</i> = 7.8, 2H), 2.67 (q, <i>J</i> = 7.6, 2H), 1.26 (t, <i>J</i> = 7.8, 3H). LC-MS <i>m</i>/<i>z</i> = 377.92 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>4-(5-Ethyl-1<i>H</i>-pyrazol-3-yl)-5-methoxy-<i>N</i>2-phenethylquinazoline-2,4-diamine (<b>10i</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(5-ethyl-1<i>H</i>-pyrazol-3-yl)-5-methoxyquinazolin-4-amine (<b>B-7</b>) (50 mg, 0.165 mmol) and 2-phenylethylamine (46 mg, 0.379 mmol) using the procedure analogous to that described for the synthesis of <b>10a</b> to afford the product (49 mg, 73%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.09 (bs, 1H), 9.92 (bs, 1H), 7.44 (d, <i>J</i> = 8.0, 1H), 7.25–7.36 (m, 4H), 7.19–7.24 (m, 1H), 6.83–7.01 (m, 2H), 6.64–6.74 (m, 1H), 4.02 (m, 3H), 3.53–3.65 (m, 2H), 2.84–2.96 (m, 2H), 2.54–2.66 (m, 2H), 1.22 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 389.98 (M + H)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-7-fluoro-<i>N</i>2-(1-(4-fluorophenyl)ethyl)quinazoline-2,4-diamine (<b>10j</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-7-fluoroquinazolin-4-amine (<b>B-2</b>) (40 mg, 0.137 mmol) and (<i>S</i>)-1-(4-fluorophenyl)ethanamine (40.1 mg, 0.288 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (26 mg, 46%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.11 (dd, <i>J</i> = 9.0, 6.1, 1H), 7.35–7.55 (m, 2H), 6.99–7.10 (m, 3H), 6.91–6.99 (m, 1H), 5.80–6.64 (m, 1H), 5.18–5.38 (m, 1H), 2.61–2.75 (m, 2H), 1.52–1.63 (m, 3H), 1.31 (t, <i>J</i> = 7.5, 3H). LC-MS <i>m</i>/<i>z</i> 394.11 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-6-fluoro-N2-(1-(4-fluorophenyl)ethyl)quinazoline-2,4-diamine (<b>10k</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-6-fluoroquinazolin-4-amine (<b>B-4</b>) (40 mg, 0.137 mmol) and (<i>S</i>)-1-(4-fluorophenyl)ethanamine (40.1 mg, 0.288 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (35 mg, 62%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.85 (dd, <i>J</i> = 9.7, 1.5, 1H), 7.33–7.53 (m, 4H), 6.95–7.12 (m, 2H), 5.89–6.56 (m, 1H), 5.20–5.36 (m, 1H), 2.61–2.81 (m, 2H), 1.56 (d, <i>J</i> = 6.3, 3H), 1.31 (t, <i>J</i> = 7.7, 3H). LC-MS <i>m</i>/<i>z</i> 395.24 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>S</i>)-7-Chloro-<i>N</i>4-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-N2-(1-(4-fluorophenyl)ethyl)quinazoline-2,4-diamine (<b>10l</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2,7-dichloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-3</b>) (40 mg, 0.130 mmol) and (<i>S</i>)-1-(4-fluorophenyl)ethanamine (37.9 mg, 0.273 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (29 mg, 52%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.04 (m, <i>J</i> = 8.8, 1H), 7.33–7.51 (m, 3H), 7.10–7.22 (m, 1H), 6.98–7.09 (m, 2H), 5.88–6.57 (m, 1H), 5.22–5.38 (m, 1H), 2.59–2.84 (m, 2H), 1.57 (d, <i>J</i> = 6.5, 3H), 1.31 (t, <i>J</i> = 7.5, 3H). LC-MS <i>m</i>/<i>z</i> 412.26 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>2-(1-(4-fluorophenyl)ethyl)-6-methoxyquinazoline-2,4-diamine (<b>10m</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-6-methoxyquinazolin-4-amine (<b>B-5</b>) (40 mg, 0.132 mmol) and (<i>S</i>)-1-(4-fluorophenyl)ethanamine (38.5 mg, 0.277 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (37 mg, 66%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.56 (s, 1H), 7.43–7.49 (m, 2H), 7.40 (d, <i>J</i> = 9.3 Hz, 1H), 7.30–7.38 (m, 1H), 7.00–7.12 (m, 2H), 6.12–6.40 (m, 1H), 5.21–5.32 (m, 1H), 3.95 (s, 3H), 2.69–2.79 (m, 2H), 1.55–1.65 (d, <i>J</i> = 6.9, 3H), 1.32 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 407.32 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoro-<i>N</i>2-(1-(4-fluorophenyl)ethyl)quinazoline-2,4-diamine (<b>10n</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoroquinazolin-4-amine (<b>B-6</b>) (40 mg, 0.137 mmol) and (<i>S</i>)-1-(4-fluorophenyl)ethanamine (40.1 mg, 0.288 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (28 mg, 49%) as a cream-colored solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.54 (dd, <i>J</i> = 14.9, 8.2, 1H), 7.43–7.46 (m, 2H), 7.21 (d, <i>J</i> = 8.5, 1H), 7.02 (m, 2H), 6.85–6.89 (m, 1H), 5.30 (q, <i>J</i> = 6.8, 2H), 2.70 (bs, 2H), 1.58 (d, <i>J</i> = 7.0, 3H), 1.32 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 395.24 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>2-(4-fluorobenzyl)quinazoline-2,4-diamine (<b>10o</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-1</b>) (50 mg, 0.183 mmol) and (4-fluorophenyl)methanamine (48 mg, 0.384 mmol) using the procedure analogous to that described for the synthesis of <b>10a</b> to afford the product (20 mg, 29%) as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.08 (d, <i>J</i> = 8.2, 1H), 7.58–7.70 (m, 1H), 7.36–7.53 (m, 3H), 7.15–7.26 (m, 1 H), 7.00–7.11 (m, 2H), 5.74–6.64 (m, 1H), 4.86 (s, 2 H), 2.63 (d, <i>J</i> = 7.2, 2H), 1.26 (t, <i>J</i> = 7.2, 3H). LC-MS <i>m</i>/<i>z</i> 363.23 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>R</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>2-(1-(4-fluorophenyl)ethyl)quinazoline-2,4-diamine (<b>10p</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-1</b>) (40 mg, 0.146 mmol) and (<i>R</i>)-1-(4-fluorophenyl)ethanamine (42.7 mg, 0.307 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to afford the product (46 mg, 79%) as a beige solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.11 (d, <i>J</i> = 8.1, 1H), 7.61–7.72 (m, 1H), 7.41–7.49 (m, 3H), 7.23–7.31 (m, 1H), 7.05 (d, <i>J</i> = 8.8, 1H), 7.04 (d, <i>J</i> = 8.8, 1H), 5.86–6.46 (bs, 1H), 5.24–5.36 (m, 1H), 2.69 (d, <i>J</i> = 7.7, 2H), 1.59 (d, <i>J</i> = 7.0, 3H), 1.31 (t, <i>J</i> = 7.7, 3H). LC-MS <i>m</i>/<i>z</i> 377.21 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>2-(1-(3-fluorophenyl)ethyl)quinazoline-2,4-diamine (<b>10q</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-1</b>) (40 mg, 0.146 mmol) and (<i>S</i>)-1-(3-fluorophenyl)ethanamine (42.7 mg, 0.307 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to afford the product (22 mg, 38%) as a beige solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.27 (d, <i>J</i> = 8.2, 1H), 7.81 (m, 1H), 7.52 (d, <i>J</i> = 8.3, 1H), 7.42–7.49 (m, 1H), 7.35–7.41 (m, 1H), 7.20–7.28 (m, 1H), 7.11–7.19 (m, 1H), 6.96–7.05 (m, 1H), 6.31 (bs, 1H), 5.30 (q, <i>J</i> = 6.6, 1H), 2.74 (q, <i>J</i> = 7.6, 2H), 1.65 (d, <i>J</i> = 6.6, 3H), 1.33 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 377.27 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>2-(1-(4-methoxyphenyl)ethyl)quinazoline-2, 4-diamine (<b>10r</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-1</b>) (40 mg, 0.146 mmol) and (<i>S</i>)-1-(4-methoxyphenyl)ethanamine (46.4 mg, 0.307 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (33 mg, 55%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.05 (d, <i>J</i> = 8.1, 1H), 7.54–7.66 (m, 1H), 7.29–7.47 (m, 3H), 7.14–7.24 (m, 1H), 6.82 (d, <i>J</i> = 6.4, 2H), 5.82–6.58 (m, 1H), 5.24 (q, <i>J</i> = 6.5, 1H), 3.77 (s, 3H), 2.70 (d, <i>J</i> = 7.6, 2H), 1.56 (d, <i>J</i> = 6.5, 3H), 1.31 (br t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 389.18 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>S</i>)-<i>N</i>2-(1-(4-Chlorophenyl)ethyl)-<i>N</i>4-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazoline-2,4-diamine (<b>10s</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-1</b>) (40 mg, 0.146 mmol) and (<i>S</i>)-1-(4-chlorophenyl)ethanamine (47.8 mg, 0.307 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (12 mg, 55%) as a cream-colored solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.08 (dd, <i>J</i> = 10.7, 0.7, 1H), 7.62 (t, <i>J</i> = 7.5, 1H), 7.39–7.45 (m, 3H), 7.27–7.35 (m, 2H), 7.21–7.23 (m, 1H), 6.2 (bs, 1H), 5.26 (q, <i>J</i> = 6.9, 1H), 2.71 (d, <i>J</i> = 7.6, 1H), 2.68 (d, <i>J</i> = 7.6, 1H), 1.58 (d, <i>J</i> = 6.9, 3H), 1.31 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 392.94 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>2-(1-(4-Chlorophenyl)cyclopropyl)-<i>N</i>4-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazoline-2,4-diamine <b>(10t</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-1</b>) (40 mg, 0.146 mmol) and 1-(4-chlorophenyl)cyclopropanamine hydrochloride (74.6 mg, 0.365 mmol) using the procedure analogous to that described for the synthesis of <b>10a</b> to give the product (22 mg, 51%) as a beige solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.17–8.40 (m, 1H), 7.70–7.85 (m, 1H), 7.47–7.67 (m, 1H), 7.36–7.47 (m, 1H), 7.22–7.34 (m, 4H), 5.93–6.80 (m, 1H), 2.52–2.79 (m, 2H), 1.68–1.70 (m, 1H), 1.43–1.60 (m, 4H), 1.16–1.35 (m, 3H). LC-MS <i>m</i>/<i>z</i> 406.19 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoro-<i>N</i>2-(1-(p-tolyl)ethyl)quinazoline-2,4-diamine (<b>10u</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoroquinazolin-4-amine (<b>B-6</b>) (40 mg, 0.137 mmol) and (<i>S</i>)-1-(p-tolyl)ethanamine (38.9 mg, 0.288 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (35 mg, 62%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.55 (dd, <i>J</i> = 14.9, 8.1, 1H), 7.3 (d, <i>J</i> = 7.9, 2H), 7.22 (m, 1H), 7.15 (d, <i>J</i> = 8., 2H), 6.84–6.93 (m, 1H), 6.60 (bs, 1H), 5.29 (q, <i>J</i> = 6.5, 1H), 2.72 (q, <i>J</i> = 7.6, 2H), 2.32 (s, 3H), 1.58 (d, <i>J</i> = 6.5, 3H), 1.32 (t, <i>J</i> = 7.6 Hz, 3H). LC-MS <i>m</i>/<i>z</i> 391.42 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoro-<i>N</i>2-(1-(5-fluoropyridin-2-yl)ethyl)quinazoline-2,4-diamine (<b>10v</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoroquinazolin-4-amine (<b>B-6</b>) (40 mg, 0.137 mmol) and (<i>S</i>)-1-(5-fluoropyridin-2-yl)ethanamine hydrochloride (55.7 mg, 0.315 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (6 mg, 11%) as a beige solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.42 (s, 1H), 7.47–7.60 (m, 3H), 7.19 (d, <i>J</i> = 8.5, 1H), 6.78–6.94 (m, 1 H), 6.5 (bs, 1 H), 5.33 (q, <i>J</i> = 7.0, 1H), 2.71 (dd, <i>J</i> = 7.6, 6.9, 2H), 1.61 (d, <i>J</i> = 6.9, 3H), 1.33 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 396.37 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>S</i>)-6-(1-((4-((3-Ethyl-1<i>H</i>-pyrazol-5-yl)amino)-5-fluoroquinazolin-2-yl)amino)ethyl)nicotinonitrile (<b>10w</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoroquinazolin-4-amine (<b>B-6</b>) (40 mg, 0.137 mmol) and (<i>S</i>)-6-(1-aminoethyl)nicotinonitrile hydrochloride (57.9 mg, 0.315 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (11 mg, 18%) as a beige solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.90 (d, <i>J</i> = 1.4, 1H), 8.04–8.14 (m, 1H), 7.63–7.72 (m, 1H), 7.49–7.61 (m, 1H), 7.13–7.27 (m, 1H), 6.86–6.95 (m, 1H), 5.85–6.63 (m, 1H), 5.37 (q, <i>J</i> = 7.2 Hz, 1H), 2.69–2.77 (m, 2H), 1.65 (d, <i>J</i> = 7.1, 3H), 1.35 (t, <i>J</i> = 7.2, 3H). LC-MS <i>m</i>/<i>z</i> 403.38 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoro-<i>N</i>2-(1-(5-fluoropyrimidin-2-yl)ethyl)quinazoline-2,4-diamine (<b>10x</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoroquinazolin-4-amine (<b>B-6</b>) (40 mg, 0.137 mmol) and (<i>S</i>)-1-(5-fluoropyrimidin-2-yl)ethanamine hydrochloride (56 mg, 0.315 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (31 mg, 54% yield) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.73 (d, <i>J</i> = 12.7, 2H), 7.50–7.66 (m, 1H), 7.20 (d, <i>J</i> = 8.5, 1H), 6.87–6.98 (m, 1H), 6.60 (bs, 1 H), 5.49 (q, <i>J</i> = 7.7, 1H,), 2.70–2.86 (m, 2 H), 1.66 (m, <i>J</i> = 7.0, 3H), 1.37 (t, <i>J</i> = 7.7, 3H). LC-MS <i>m</i>/<i>z</i> 397.37 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>2-(4-Chloro-2-methoxybenzyl)-<i>N</i>4-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazoline-2,4-diamine (<b>10y</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-1</b>) (30 mg, 0.110 mmol) and (4-chloro-2-methoxyphenyl)methanamine (37.6 mg, 0.219 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (22 mg, 47%) as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.06 (d, <i>J</i> = 8.1, 1H), 7.59 (t, <i>J</i> = 7.5, 1H), 7.41 (bs, 1H), 7.05–7.23 (m, 2H), 6.99 (s, 1H), 6.72–6.85 (m, 1H), 5.74–6.45 (m, 1H), 4.61 (s, 2H), 3.89 (s, 3H), 2.62 (q, <i>J</i> = 7.5, 2H), 1.23 (t, <i>J</i> = 7.5, 3H). LC-MS <i>m</i>/<i>z</i> 410.86 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>S</i>)-<i>N</i>2-(1-Cyclohexylethyl)-<i>N</i>4-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazoline-2,4-diamine (<b>10z</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)quinazolin-4-amine (<b>B-1</b>) (40 mg, 0.146 mmol) and (<i>S</i>)-(+)-1-cyclohexylethylamine (39.0 mg, 0.307 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (16 mg, 29%) as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.05 (d, <i>J</i> = 8.1, 1H), 7.59 (t, <i>J</i> = 7.2, 1H), 7.41 (bs, 1H), 7.15–7.21 (m, 1H), 6.64 (bs, 1H), 3.95–4.15 (m, 1H), 2.61–2.80 (m, 2H), 1.78–1.94 (m, 4H), 1.67–1.72 (m, 1H), 1.51–1.58 (m, 1H), 1.21–1.35 (m, 9H), 1.04–1.18 (m, 2H). LC-MS <i>m</i>/<i>z</i> 364.98 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoro-<i>N</i>2-(2-morpholinoethyl)quinazoline-2,4-diamine (<b>10aa</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-fluoroquinazolin-4-amine (<b>B-6</b>) (40 mg, 0.137 mmol) and 4-(2-aminoethyl)morpholine (44.6 mg, 0.343 mmol) using a procedure analogous to that described for the synthesis of <b>8a</b> to give the product (28 mg, 50%) as a white powder. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.99–12.37 (m, 1H), 8.70 (bs, 1H), 7.50 (dd, <i>J</i> = 15.0, 8.0, 1H), 7.07–7.24 (m, 1H), 6.94–7.05 (m, 1H), 6.85–6.93 (m, 1H), 6.37–6.84 (m, 1H), 3.56–3.59 (m, 4H), 3.47–3.52 (m, 2H), 3.35–3.37 (m, 2H), 2.61 (q, <i>J</i> = 7.6, 2H), 2.38–2.44 (m, 4H), 1.23 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 386.28 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 5-Fluoro-<i>N</i>2-phenethyl-<i>N</i>4-(1<i>H</i>-pyrazol-3-yl)quinazoline-2,4-diamine (<b>11</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2-chloro-5-fluoro-<i>N</i>-(1<i>H</i>-pyrazol-3-yl)quinazolin-4-amine (<b>B-9</b>) (25 mg, 0.095 mmol) and 2-phenylethylamine (230 mg, 1.90 mmol) using the procedure analogous to that described for the synthesis of <b>10a</b> to give the product (23 mg, 66%). <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.27–8.32 (m, 1H), 7.45–7.61 (m, 2H), 7.18 (br d,, <i>J</i> = 7.0, 4H), 7.06–7.11 (m, 1H), 6.70 (br d, <i>J</i> = 5.5 Hz, 2H), 3.72 (t, <i>J</i> = 7.3, 2H), 2.95 (t, <i>J</i> = 7.3, 2H). LC-MS <i>m</i>/<i>z</i> 349.21 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 5-Fluoro-<i>N</i>4-(isoxazol-5-yl)-<i>N</i>2-phenethylquinazoline-2,4-diamine (<b>12</b>)</h4><div class="NLM_p last">The title compound was synthesized by stirring <i>N</i>-(2-chloro-5-fluoroquinazolin-4-yl)isoxazol-5-amine (<b>B-10</b>) (25 mg, 0.094 mmol) in 2-phenylethylamine (1.0 g, 8.25 mmol) at room temperature to give, after purifying the crude product using silica gel chromatography, the product (15 mg, 42%) as a fluffy white powder. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.46–8.53 (m, 1H), 7.45–7.52 (m, 1H), 7.21–7.30 (m, 1H), 7.16–7.20 (m, 5H), 7.04–7.10 (m, 1H), 6.90 (dd, <i>J</i> = 12.8, 7.9, 1H), 3.70 (t, <i>J</i> = 7.3, 2H), 2.95 (t, <i>J</i> = 7.3, 2H). LC-MS <i>m</i>/<i>z</i> 350.81 (M + 1)<sup>+</sup>. HPLC purity 92%.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (<i>S</i>)-<i>N</i>4-(1-Ethyl-1<i>H</i>-imidazol-4-yl)-5-fluoro-<i>N</i>2-(1-(5-fluoropyridin-2-yl)ethyl)quinazoline-2,4-diamine (<b>13</b>)</h4><div class="NLM_p last">The title compound was synthesized by the reaction between 2-chloro-<i>N</i>-(1-ethyl-1<i>H</i>-imidazol-4-yl)-5-fluoroquinazolin-4-amine (<b>B-8</b>) (25 mg, 0.086 mmol) and (1<i>S</i>)-1-(5-fluoro(2-pyridyl))ethylamine hydrochloride (22.7 mg, 0.129 mmol) using the procedure analogous to that described for the synthesis of <b>10a</b> to give the product (14 mg, 38% yield) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.44 (bs, 1H), 7.45–7.60 (m, 5H), 7.17 (d, <i>J</i> = 8.5, 1H), 6.85 (dd, <i>J</i> = 12.6, 4.6, 1H), 5.34 (q, <i>J</i> = 7.3, 1H), 4.06–4.08 (m, 2H), 1.61 (d, <i>J</i> = 7.0, 3H), 1.50 (t, <i>J</i> = 7.3, 3H). LC-MS <i>m</i>/<i>z</i> 396.19 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (<i>S</i>)-<i>N</i>4-(6-Ethoxypyridin-3-yl)-5-fluoro-<i>N</i>2-(1-(5-fluoropyridin-2-yl)ethyl)quinazoline-2,4-diamine (<b>14</b>)</h4><div class="NLM_p last">A solution of 2,4-dichloroquinazoline (35 mg, 0.161 mmol), 2-ethoxy-5-aminopyridine (22.3 mg, 0.161 mmol), and <i>N,N</i>-diisopropylethylamine (62.5 mg, 0.484 mmol) in ethanol (2 mL) was stirred for 2 h at room temperature prior to heating at 80 °C for 15 min. The reaction mixture was concentrated to afford the crude intermediate, which was taken up in n-butanol (1 mL) with (<i>S</i>)-1-(5-fluoro(2-pyridyl))ethylamine hydrochloride (28.5 mg, 0.161 mmol) and heated overnight at 120 °C. The reaction mixture was concentrated to dryness and purified by column chromatography to yield the title compound as a white solid (36 mg, 50% over two steps). <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.35 (d, <i>J</i> = 2.8, 1H), 7.96–8.33 (m, 1H), 7.59–7.94 (m, 1H), 7.45–7.58 (m, 2H), 7.21–7.44 (m, 1H), 7.15–7.20 (m, 1 H), 6.83–6.91 (m, 1 H), 6.77 (m, <i>J</i> = 8.8, 1H), 4.95–5.24 (m, 1H), 4.35 (q, <i>J</i> = 7.1, 2H), 1.50 (bs, 3H), 1.42 (t, <i>J</i> = 7.1, 3H). LC-MS <i>m</i>/<i>z</i> 423.06 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>2-(1-(5-fluoropyridin-2-yl)ethyl)-5-methoxyquinazoline-2,4-diamine (<b>15</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methoxyquinazolin-4-amine (<b>B-7</b>) (100 mg, 0.329 mmol) and (<i>S</i>)-1-(5-fluoropyridin-2-yl)ethanamine (87 mg, 0.494 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to afford the crude product. Purification of the crude material by silica gel chromatography eluting with DCM containing 0–5% MeOH gave, after concentration of fractions containing the product, a pale green solid. This residue was triturated with DCM/Et<sub>2</sub>O and washed with Et<sub>2</sub>O to afford, after drying <i>in vacuo</i>, 39 mg of the product as a white solid. The impure fractions from the chromatography and mother liquor of the trituration were combined, concentrated, and subjected to purification using prep HPLC eluting with acetonitrile/ammonium bicarbonate to afford, after concentrating fractions containing the product, another 24.5 mg of product (total yield 63.5 mg, 47%) as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.42 (s, 1H), 7.43–7.57 (m, 3H), 6.96 (d, <i>J</i> = 8.4, 1H), 6.71 (d, <i>J</i> = 8.0, 1H), 6.2–6.8 (m, 1H), 5.32 (q, <i>J</i> = 7.0, 1H), 4.07 (s, 3H), 2.69 (m, <i>J</i> = 7.6, 2H), 1.60 (d, <i>J</i> = 7.0, 3H), 1.28 (t, <i>J</i> = 7.6, 3H). LC-MS <i>m</i>/<i>z</i> 407.89 (M + 1)<sup>+</sup>. HPLC purity 92%.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>N</i>4-(5-Ethyl-1<i>H</i>-pyrazol-3-yl)-<i>N</i>2-((5-fluoropyridin-2-yl)methyl)-5-methoxyquinazoline-2,4-diamine (<b>16</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methoxyquinazolin-4-amine (<b>B-7</b>) (60 mg, 0.198 mmol) and (5-fluoropyridin-2-yl)methanamine (29.9 mg, 0.237 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to afford, after purification by silica gel chromatography (eluting with DCM containing 0–5% MeOH), concentrating fractions showing the relevant material, and triturating the resulting residue with DCM/Et<sub>2</sub>O, the product (50.5 mg, 62%) as a beige solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.45 (d, <i>J</i> = 2.7, 1H), 7.36–7.49 (m, 3H), 7.04 (d, <i>J</i> = 8.4, 1H), 6.84 (d, <i>J</i> = 8.1, 1H), 6.60–6.71 (m, 1H), 5.86–6.55 (m, 1H), 4.69 (s, 2H), 4.00 (s, 3H), 2.64 (q, <i>J</i> = 7.6, 2H), 1.13 (br t, <i>J</i> = 7.0 Hz, 3H). LC-MS <i>m</i>/<i>z</i> 394.1 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>N</i>2-(4-Chlorobenzyl)-<i>N</i>4-(5-ethyl-1<i>H</i>-pyrazol-3-yl)-5-methoxyquinazoline-2,4-diamine (<b>17</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methoxyquinazolin-4-amine (<b>B-7</b>) (100 mg, 0.329 mmol) and 4-chlorobenzylamine (58.3 mg, 0.412 mmol) using the procedure analogous to that described for the synthesis of <b>10a</b>. The crude product was purified by silica gel chromatography eluting with DCM containing 0–5% MeOH to afford, after concentration the fractions containing product and triturating the residue with DCM/Et<sub>2</sub>O, the desired product as an off-white solid (66 mg, 47%). <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.71 (t, <i>J</i> = 8.0, 1H), 7.22–7.32 (m, 4H), 6.95–7.04 (m, 1H), 6.86–6.94 (m, 1H), 6.40 (bs, 1H), 4.60–4.70 (m, 2H), 4.17 (s, 3H), 2.60 (q, <i>J</i> = 7.2, 2H), 1.18 (m, 3H). LC-MS <i>m</i>/<i>z</i> 409.1 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>N</i>2-(4-Chloro-2-methoxybenzyl)-<i>N</i>4-(5-ethyl-1<i>H</i>-pyrazol-3-yl)-5-methoxyquinazoline-2,4-diamine (<b>18</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methoxyquinazolin-4-amine (<b>B-7</b>) (80 mg, 0.263 mmol) and (4-chloro-2-methoxyphenyl)methanamine (67.8 mg, 0.395 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b>. The crude product was subjected to purification by silica gel chromatography, eluting with DCM containing 0–5% MeOH. Combining and concentrating the fractions with the product, followed by trituration of the residue with DCM/Et<sub>2</sub>O, afforded the product (76.8 mg, 63%) as a pale yellow solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.77 (t, <i>J</i> = 8.3, 1H), 7.09–7.21 (m, 1H), 6.87–6.95 (m, 2H), 6.75–6.83 (m, 1H), 6.40 (bs, 1H), 5.93–6.52 (m, 1H), 4.43–4.61 (m, 2H), 4.21 (bs, 3H), 3.93 (bs, 3H), 2.58 (q, <i>J</i> = 7.1, 2H), 1.06–1.19 (t, <i>J</i> = 7.1, 3H). LC-MS <i>m</i>/<i>z</i> 440.89 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (<i>S</i>)-<i>N</i>2-(1-(5-Chloropyridin-2-yl)ethyl)-<i>N</i>4-(5-ethyl-1<i>H</i>-pyrazol-3-yl)-5-methoxyquinazoline-2,4-diamine (<b>19</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methoxyquinazolin-4-amine (<b>B-7</b>) (25 mg, 0.082 mmol) and (<i>S</i>)-1-(5-chloropyridin-2-yl)ethanamine dihydrochloride (23.6 mg, 0.103 mmol) using a procedure analogous to that described for the synthesis of <b>10a</b> to give the product (10 mg, 26% yield) as an off-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.52 (d, <i>J</i> = 2.2, 1H), 7.76 (d, <i>J</i> = 2.4, 1H), 7.49 (d, <i>J</i> = 7.6, 1H), 7.47 (d, <i>J</i> = 7.2, 1H), 6.97 (d, <i>J</i> = 8.4, 1H), 6.71 (1, <i>J</i> = 8.0, 1H), 5.29 (q, <i>J</i> = 7.0, 1H), 4.08 (s, 3H), 2.69 (q, <i>J</i> = 7.3, 2H), 1.60 (d, <i>J</i> = 7.0, 3H), 1.31 (t, <i>J</i> = 7.3, 3H). LC-MS <i>m</i>/<i>z</i> 424.27 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (<i>S</i>)-<i>N</i>4-(3-Ethyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>2-(1-(5-fluoropyridin-2-yl)ethyl)-5-methylquinazoline-2,4-diamine (<b>20</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methylquinazolin-4-amine (<b>B-11</b>) (30.4 mg, 0.106 mmol) and (<i>S</i>)-1-(5-fluoropyridin-2-yl)ethanamine hydrochloride (24.5 mg, 0.139 mmol) using the procedure analogous to that described for the synthesis of <b>10a</b> to give the product (15 mg, 35%) as a chalk-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.33–8.50 (m, 1H), 7.45–7.56 (m, 2H), 7.36–7.45 (m, 1H), 7.15–7.31 (m, 1H), 6.92–7.06 (m, 1H), 5.82–6.61 (m, 1H), 5.22–5.37 (m, 1H), 2.86–2.96 (m, 3H), 2.65–2.75 (m, 2H), 1.56–1.63 (m, 3H), 1.27–1.37 (m, 3H). LC-MS <i>m</i>/<i>z</i> 392.36 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>N</i>2-(4-Chlorobenzyl)-<i>N</i>4-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methylquinazoline-2,4-diamine (<b>21</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methylquinazolin-4-amine (<b>B-11</b>) (30.4 mg, 0.106 mmol) and (4-chlorophenyl)methanamine (20.9 mg, 0.148 mmol) using the procedure analogous to that described for the synthesis of <b>10a</b> to give the product (26 mg, 62%) as a cream-colored solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.79 (s, 1H), 7.52 (br. s., 1H), 7.37–7.26 (m, 5H), 7.10 (br. s., 1H), 4.69 (br. s., 2H), 2.94 (br. s., 3H), 2.66–2.58 (m, 2H), 1.19 (t, <i>J</i> = 6.9, 3H). LC-MS <i>m</i>/<i>z</i> 393.37 (M + 1)<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>2-(4-Chloro-2-methoxybenzyl)-<i>N</i>4-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methylquinazoline-2,4-diamine (<b>22</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-chloro-<i>N</i>-(3-ethyl-1<i>H</i>-pyrazol-5-yl)-5-methylquinazolin-4-amine (<b>B-11</b>) (30.4 mg, 0.106 mmol) and (4-chloro-2-methoxyphenyl)methanamine (25.4 mg, 0.148 mmol) using the procedure analogous to that described for the synthesis of <b>8a</b> to give the product (15 mg, 33%) as a chalk-white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 12.07 (bs, 1H), 8.48 (bs, 1H), 7.30–7.45 (m, 6H), 7.14–7.16 (d, <i>J</i> = 8.0, 1H), 6.89 (d, <i>J</i> = 6.8, 1H), 4.56 (s, 3 H), 3.88–3.92 (m, 3H), 2.92–2.98 (m, 3H), 2.62 (q, <i>J</i> = 7.4, 2H), 1.19 (t, <i>J</i> = 7.4, 3H). LC-MS <i>m</i>/<i>z</i> 423.1 (M + 1)<sup>+</sup>. HPLC purity > 95%.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Biochemical Assays</h3><div class="NLM_p last">GRK6 assays were conducted using the kinase profiler service of Eurofins Pharma Discovery Services U.K. Limited, according to the following modified protocol: the enzyme was incubated with the test compound in 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2 mg/mL casein, 10 mM magnesium acetate, and γ-[33P]-ATP. The final concentration of ATP was 45 μM (this was the <i>K</i><sub>m</sub> value determined by Eurofins), with the reaction initiated by the addition of the Mg/ATP mix. A radiolabeled ATP spike was used, and reactions were allowed to progress for 80 min at room temperature. Enzyme concentrations were fixed at 2.5 nM for the 80 min incubation. The activity of GRK6(h) was determined at nine concentrations of the compound with semilog dilutions from 10 μM. All data points were performed in duplicate with DMSO and acid blank controls. The reaction was stopped by the addition of phosphoric acid to a concentration of 0.5%. An aliquot of the reaction was then spotted onto a P30 filtermat and washed four times for 4 min in 0.425% phosphoric acid and once in methanol prior to drying and scintillation counting. Results were calculated in relation to controls containing DMSO only in place of the test compound. GRK5 and GRK7 assays were conducted at Eurofins using the kinase profiler assay. GRK5 (h) was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 2 mg/mL casein, 10 mM Mg acetate, and [γ-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The final concentration of ATP was 15 μM, and the reaction was initiated by the addition of the Mg ATP mix. After incubation for 40 min at room temperature, the reaction was stopped by the addition of 3% phosphoric acid solution. Ten microliters of the reaction was then spotted onto a P30 filtermat and washed three times for 5 min in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting. With the exception of GRK1, 2, 3, and 4, all other kinase assays were conducted at Eurofins used similar protocols and were developed from protocols similar to that developed previously.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> GRK assays were carried out by Reaction Biology Corporation at their respective [<i>K</i><sub>m</sub>] of ATP.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> FLAG-GRK6 Cells</h3><div class="NLM_p last">The production of KMS11 MM cells expressing FLAG-tagged GRK6A from the vector pWPI was previously described.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Immunoblotting Protocol</h3><div class="NLM_p last">Cells were washed in an ice-cold phosphate-buffered saline and lysed in NP40 lysis buffer. Extracts were centrifuged and quantified by bicinchoninic acid assay (Pierce), and 10 μg/lane was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). GAPDH loading controls were assessed for each gel. Proteins were transferred to a poly(vinylidene fluoride) membrane and probed with an anti-FLAG primary antibody (M2; Sigma-Aldrich). A secondary horse antimouse (Cell Signaling Technology) horseradish peroxidase-conjugated antibody was used at a dilution of 1:10 000, and the signal was detected using Amersham ECL Western Blotting Detection Reagents (GE Healthcare).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Cellular Thermal Shift Assay (CETSA)</h3><div class="NLM_p last">The CETSA protocol was based on that reported by Molina et al.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Aliquots of viable cells (10<sup>6</sup>) were incubated in 3 mL culture media with or without a 5 μM test compound for 2.5 h at 37 °C, 5% CO<sub>2</sub>. Cells were then resuspended in PBS, divided into aliquots in PCR tubes, pelleted by centrifugation, and resuspended in a 20 μL kinase buffer (25 mM Tris–HCl (pH 7.5), 5 mM β-glycerophosphate, 2 mM dithiothreitol (DTT), 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, 10 mM MgCl<sub>2</sub>, trace DNAse). Paired aliquots with or without compounds were exposed to discrete temperatures comprising a thermal gradient over the range of 39–56 °C using a thermocycler for 10 min. NP40 buffer (10 μL) was added, and the samples were further incubated at room temperature for 10 min. Following this, the aliquots were transferred to 1.5 mL Eppendorf tubes and centrifuged at 18 000<i>g</i> for 10 min. Supernatants were collected and assessed by SDS-PAGE and immunoblot.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Isothermal Dose–Response (ITDR) Protocol</h3><div class="NLM_p last">Viable cells were washed in PBS, divided into aliquots in PCR tubes, and were then treated with a test compound across a range of concentrations for 2.5 h at 37 °C, 5% CO<sub>2</sub>. Cells were then centrifuged briefly and resuspended in a 20 μL kinase buffer. A control sample was retained at room temperature. The remaining samples were subjected to a thermal exposure of 51 or 52 °C (as specified in the text) for 10 min in a thermocycler. Samples were then lysed, clarified, and analyzed by SDS-PAGE and immunoblot as described for the CETSA experiments.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Modified ITDR Protocol for Persistence of GRK6 Target Occupancy by Compound</h3><div class="NLM_p last">Cells (2 × 10<sup>6</sup>) in culture media were incubated with compounds <b>18</b>, <b>20</b>, or <b>22</b> at 5 μM for 2.5 h at 37 °C to achieve target loading and were then divided. Following this, the time was set to zero. One aliquot of cells was washed to remove the unbound compound and was then resuspended in culture media and further incubated at 37 °C, while the remaining aliquot of cells was incubated continuously with the compound. At the time intervals specified in the text and figures, the cells were removed from the culture and assayed for thermally protected bound GRK6 or total GRK6 by incubation at either 52 °C or room temperature, respectively, for 10 min, followed by gel electrophoresis and anti-FLAG immunoblot as described for CETSA and ITDR studies.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Compound Cell Viability Assays</h3><div class="NLM_p last">Compound <b>18</b> stock solution was prepared in 5% DMSO, 20% PEG 400, 75% (H20/10%-Tween 80 solution), and titrated in cell culture media. The dose–response of MM cells was assessed in triplicate using KMS11, KMS18, LP1, MM1R, and RPMI-8226 cell lines and derivatives KMS11–pWPI–FLAG-GRK6A and KMS11–pWPI cells, which overexpressed FLAG-GRK6A or contained an empty vector. Cells were incubated with a compound at 37 °C for 72 or 144 h, and viability was assessed by the MTT assay (Sigma-Aldrich) following the manufacturer’s instructions. For the 144 h exposure, cells were replenished with fresh media and compound on day 3.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Drug Combination Assay</h3><div class="NLM_p last">MM cells were treated with titrated bortezomib or compound <b>18</b> separately and with both drugs together in a 9 × 9 combinatorial matrix on a 96-well plate. Viability was assessed by the MTT assay at 96 h. To assess for synergy or antagonism, the observed activities of drug combinations were compared to expected additivity using Loewe (IC<sub>50</sub>, IC<sub>75</sub>) and Bliss independence methods (IC<sub>90</sub>–IC<sub>95</sub>).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> GRK6 Homology Model</h3><div class="NLM_p last">A homology model of GRK6 was built based on the structure of GRK6 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NYN">3NYN</a>, 2.72 Å) solved with sangivamycin for several early-stage analogues (not included in the manuscript) and subsequently refined with compound <b>15</b> (GRK6 IC<sub>50</sub> 7.2 nM). For the development of the homology model, we adjusted the side-chain conformations for both catalytic D329 and K215. The catalytic D329 was placed in the most neutral position, while the catalytic K215 was reoriented to form a salt bridge with the E234 from the αC-helix and energy-minimized while keeping positional constraints for the rest of the protein with compound <b>15</b> present at the ATP site, known as one of the active forms of the kinase. The phenylalanine residue F197 located at the very tip of the Gly-rich loop was kept in the outside position to create more room for potentially bulky substituents that could bind under the Gly-rich loop. PDB coordinates of compound <b>15</b> modeled in GRK6 are provided.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Molecular Modeling of GRK6 Inhibitors</h3><div class="NLM_p last">Docking of GRK6 inhibitors was carried out with a homology model of GRK6 built as described above using the Schrödinger Drug Discovery suite using the Glide SP scoring (<a href="https://www.schrodinger.com/glide" class="extLink">https://www.schrodinger.com/glide</a>). The protein was prepared using the Protein Prep procedure using the EPA to define the binding site. An inner docking box size of 10 Å × 10 Å × 10 Å was used. Missing side chains were filled in using PRIME, structural water orientations were sampled, protonation states of ionizable side chains were assigned with PropKa to pH 7, and only hydrogens were minimized using OPLS3. Two key H-bonds were set up as restraints (backbone NH of M266 and backbone carbonyl of T264) to anchor the pyrazole group to the hinge region of GRK6 and to prevent it from binding elsewhere. The ligands were prepared for docking using LIGPREP. The ligands were ionized to pH 7 ± 1 and energy-minimized using OPLS3. The docking was done using the Glide SP scoring. In most cases, one best-scored docking pose was used. When necessary, 10 docking poses were saved out of 500 that were chosen for the postdocking minimization. The docking poses were ranked by the emodel score and compared with the Glide SP score. The docking poses were visualized and inspected using MolSoft ICM (<a href="http://www.molsoft.com/icm_pro.html" class="extLink">http://www.molsoft.com/icm_pro.html</a>). For convenience, the Glide docking service was implemented on the BIOVIA Pipeline Pilot Web Port (<a href="https://www.3ds.com/products-services/biovia/products/data-science/pipeline-pilot/" class="extLink">https://www.3ds.com/products-services/biovia/products/data-science/pipeline-pilot/</a>) and made accessible to medicinal chemists on the project.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00506" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28251" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28251" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00506?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00506</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">GRK6_Cpd10i_3NYN_Model_2p72 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">GRK6_Cpd18_3NYN_Model_2p72 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_003.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">GRK6 shRNA knockdown, CRISPR knockout studies and GRK6 kinase rescue studies; cellular thermal shift assay (CETSA) employing FLAG-GRK6-expressing KMS11 MM cells and anti-FLAG immunoblots for GRK6 compounds studied; mouse liver microsome and Caco-2 permeability data for <b>16</b>–<b>18</b> and PK data for compound <b>18</b>; and analytical data for select compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_001.pdb">jm1c00506_si_001.pdb (702.76 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_002.pdb">jm1c00506_si_002.pdb (703.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_003.csv">jm1c00506_si_003.csv (3.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf">jm1c00506_si_004.pdf (1.61 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00506" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07212" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07212" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David E. Uehling</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9748-0500" title="Orcid link">https://orcid.org/0000-0002-9748-0500</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ed898c9b8489c39888858184838aad82848e9fc38283c38e8c"><span class="__cf_email__" data-cfemail="620603140b064c17070a0e0b0c05220d0b01104c0d0c4c0103">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rodger E. Tiedemann</span> - <span class="hlFld-Affiliation affiliation">Princess
Margaret Cancer Centre, Toronto Medical
Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5c0e33383b392e720835393839313d32321c293432723f3d"><span class="__cf_email__" data-cfemail="e3b18c87848691cdb78a8687868e828d8da3968b8dcd8082">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Babu Joseph</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim Chan Chung</span> - <span class="hlFld-Affiliation affiliation">Princess
Margaret Cancer Centre, Toronto Medical
Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew X. Zhang</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span>Present Address:
                        Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Boston, Massachusetts, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Spencer Ler</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael A. Prakesch</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gennady Poda</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Leslie
Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie Grouleff</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ahmed Aman</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Leslie
Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taira Kiyota</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chungyee Leung-Hagesteijn</span> - <span class="hlFld-Affiliation affiliation">Princess
Margaret Cancer Centre, Toronto Medical
Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John David Konda</span> - <span class="hlFld-Affiliation affiliation">Princess
Margaret Cancer Centre, Toronto Medical
Discovery Tower, 101 College Street, Room 12-306, Toronto, Ontario M5G 1L7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Marcellus</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carly Griffin</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ratheesh Subramaniam</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ayome Abibi</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Craig A. Strathdee</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span>Present Address:
                        Oncorus, Inc., 50 Hampshire Street Suite 401, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Methvin B. Isaac</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rima Al-awar</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Ontario Institute for
Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Toxicology, University
of Toronto, Medical Sciences
Building, 1 King’s College Circle, Toronto, Ontario M5S 1A8, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4185-055X" title="Orcid link">https://orcid.org/0000-0002-4185-055X</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Compounds were designed and their syntheses were devised by D.E.U., B.J., M.B.I., A.Z., and S.L. Compounds were synthesized by B.J., A.Z., S.L., and D.E.U. Initial assay development work and in vitro kinase screening data were generated by A.A. M.P. was responsible for kinase library curation and GRK6 biochemical screening. Caco-2, microsomal stability, and PPB studies were conducted by T.K. G.P. and J.G. conducted homology modeling studies and docking analyses and generated the Oracle database, where compound data were stored. K.C., C.L-H., C.G., and R. S. conducted cellular studies involving target dependency, and target engagement and antiproliferative studies. J.D.K. conducted synergy studies with compound 18 and bortezomib. D.E.U, R.E.T., R.M., A.A., C.A.S., M.B.I., and R.A. were involved in experimental design, interpretation of data, and monitoring project progress. R.E.T. first identified the target in the context of MM and obtained external funding. The first draft of the manuscript was written by D.E.U. and R.E.T., with section contributions by G.P., B.J., and A.A. Additional edits were made by T.K., B.J., M.B.I., M.P., R.A., and A.Z. All authors approved the final manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e4992-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84103" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84103" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to acknowledge funding from the Canadian Institutes of Health Research (CIHR, Operating Grant MOP-119377) to Tiedemann (PI) and Al-awar (co-investigator) and the Ontario government for financial support of this work.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AMP-PNP</td><td class="NLM_def"><p class="first last">adenylyl-imidodiphosphate</p></td></tr><tr><td class="NLM_term">CHK2</td><td class="NLM_def"><p class="first last">checkpoint kinase 2</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">GRK</td><td class="NLM_def"><p class="first last">G protein-coupled receptor kinase</p></td></tr><tr><td class="NLM_term">IGF-1R</td><td class="NLM_def"><p class="first last">insuline-like growth factor 1 receptor</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">LTK</td><td class="NLM_def"><p class="first last">leukocyte receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">MoPS</td><td class="NLM_def"><p class="first last">3-morpholinopropane-1-sulfonic acid</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">TrkA</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase A</p></td></tr><tr><td class="NLM_term">ZIPK</td><td class="NLM_def"><p class="first last">zipper-interacting protein kinase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27084" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27084" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 61 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naymagon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Hay, M.</span></span> <span> </span><span class="NLM_article-title">Novel agents in the treatment of multiple myeloma: a review about the future</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">52</span> <span class="refDoi"> DOI: 10.1186/s13045-016-0282-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1186%2Fs13045-016-0282-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=27363832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGktr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&author=L.+Naymagonauthor=M.+Abdul-Hay&title=Novel+agents+in+the+treatment+of+multiple+myeloma%3A+a+review+about+the+future&doi=10.1186%2Fs13045-016-0282-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Novel agents in the treatment of multiple myeloma: a review about the future</span></div><div class="casAuthors">Naymagon, Leonard; Abdul-Hay, Maher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52/1-52/20</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating clin. features such as anemia, lytic bone lesions, hypercalcemia, and renal disease.  An enhanced understanding of MM disease mechanisms has led to new more targeted treatments.  There is now a plethora of treatments available for MM.  In this review article, our aim is to discuss many of the novel agents that are being studied or have recently been approved for the treatment of MM.  These agents include the following: immunomodulators (pomalidomide), proteasome inhibitors (carfilzomib, marizomib, ixazomib, oprozomib), alkylating agents (bendamustine), AKT inhibitors (afuresertib), BTK inhibitors (ibrutinib), CDK inhibitors (dinaciclib), histone deacetylase inhibitors (panobinostat, rocilinostat, vorinostat), IL-6 inhibitors (siltuximab), kinesin spindle protein inhibitors (filanesib), monoclonal antibodies (daratumumab, elotuzumab, indatuximab, SAR650984), and phosphoinositide 3-kinase (PI3K) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMUyMzVHsBtLVg90H21EOLACvtfcHk0lhV0vRiXXbaSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGktr7F&md5=5a45e84d62cab3225d1f5fd819ead845</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0282-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0282-1%26sid%3Dliteratum%253Aachs%26aulast%3DNaymagon%26aufirst%3DL.%26aulast%3DAbdul-Hay%26aufirst%3DM.%26atitle%3DNovel%2520agents%2520in%2520the%2520treatment%2520of%2520multiple%2520myeloma%253A%2520a%2520review%2520about%2520the%2520future%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26doi%3D10.1186%2Fs13045-016-0282-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kronke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svinkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarlo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1126/science.1244851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1126%2Fscience.1244851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=24292625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=301-305&author=J.+Kronkeauthor=N.+D.+Udeshiauthor=A.+Narlaauthor=P.+Graumanauthor=S.+N.+Hurstauthor=M.+McConkeyauthor=T.+Svinkinaauthor=D.+Hecklauthor=E.+Comerauthor=X.+Liauthor=C.+Ciarloauthor=E.+Hartmanauthor=N.+Munshiauthor=M.+Schenoneauthor=S.+L.+Schreiberauthor=S.+A.+Carrauthor=B.+L.+Ebert&title=Lenalidomide+causes+selective+degradation+of+IKZF1+and+IKZF3+in+multiple+myeloma+cells&doi=10.1126%2Fscience.1244851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</span></div><div class="casAuthors">Kronke Jan; Udeshi Namrata D; Narla Anupama; Grauman Peter; Hurst Slater N; McConkey Marie; Svinkina Tanya; Heckl Dirk; Comer Eamon; Li Xiaoyu; Ciarlo Christie; Hartman Emily; Munshi Nikhil; Schenone Monica; Schreiber Stuart L; Carr Steven A; Ebert Benjamin L</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">301-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown.  Using quantitative proteomics, we found that lenalidomide causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.  IKZF1 and IKZF3 are essential transcription factors in multiple myeloma.  A single amino acid substitution of IKZF3 conferred resistance to lenalidomide-induced degradation and rescued lenalidomide-induced inhibition of cell growth.  Similarly, we found that lenalidomide-induced interleukin-2 production in T cells is due to depletion of IKZF1 and IKZF3.  These findings reveal a previously unknown mechanism of action for a therapeutic agent: alteration of the activity of an E3 ubiquitin ligase, leading to selective degradation of specific targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiiGR0Yx7nuYFEOhA_Im3cfW6udTcc2ebGAp6v5QC6srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D&md5=8cae3e554399308493aa38f0d05ed610</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244851%26sid%3Dliteratum%253Aachs%26aulast%3DKronke%26aufirst%3DJ.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DNarla%26aufirst%3DA.%26aulast%3DGrauman%26aufirst%3DP.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DMcConkey%26aufirst%3DM.%26aulast%3DSvinkina%26aufirst%3DT.%26aulast%3DHeckl%26aufirst%3DD.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCiarlo%26aufirst%3DC.%26aulast%3DHartman%26aufirst%3DE.%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DSchenone%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520causes%2520selective%2520degradation%2520of%2520IKZF1%2520and%2520IKZF3%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D301%26epage%3D305%26doi%3D10.1126%2Fscience.1244851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naniong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaelin, W. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1126/science.1244917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1126%2Fscience.1244917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=24292623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=305-309&author=G.+Luauthor=R.+E.+Middletonauthor=H.+Sunauthor=M.+Naniongauthor=C.+J.+Ottauthor=C.+S.+Mitsiadesauthor=K.+K.+Wongauthor=J.+E.+Bradnerauthor=W.+G.+Kaelin&title=The+myeloma+drug+lenalidomide+promotes+the+cereblon-dependent+destruction+of+ikaros+proteins&doi=10.1126%2Fscience.1244917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins</span></div><div class="casAuthors">Lu, Gang; Middleton, Richard E.; Sun, Huahang; Naniong, MarkVic; Ott, Christopher J.; Mitsiades, Constantine S.; Wong, Kwok-Kin; Bradner, James E.; Kaelin, William G., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">305-309</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Thalidomide-like drugs such as lenalidomide are clin. important treatments for multiple myeloma and show promise for other B cell malignancies.  The biochem. mechanisms underlying their antitumor activity are unknown.  Thalidomide was recently shown to bind to, and inhibit, the cereblon ubiquitin ligase.  Cereblon loss in zebrafish causes fin defects reminiscent of the limb defects seen in children exposed to thalidomide in utero.  Here we show that lenalidomide-bound cereblon acquires the ability to target for proteasomal degrdn. two specific B cell transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3).  Anal. of myeloma cell lines revealed that loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect, suggesting that the antitumor and teratogenic activities of thalidomide-like drugs are dissociable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0froz4Kipu7Vg90H21EOLACvtfcHk0ljC4DfuiSXZjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D&md5=a9df5bbde0f676b92b1bec48fdbbb502</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244917%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DG.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DNaniong%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26atitle%3DThe%2520myeloma%2520drug%2520lenalidomide%2520promotes%2520the%2520cereblon-dependent%2520destruction%2520of%2520ikaros%2520proteins%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D305%26epage%3D309%26doi%3D10.1126%2Fscience.1244917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, H. N.</span></span> <span> </span><span class="NLM_article-title">The multiple myeloma drug pipeline-2018: a review of small molecules and their therapeutic targets</span>. <i>Clin. Lymphoma, Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2018.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.clml.2018.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=30001985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FnsFygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=611-627&author=H.+N.+Abramson&title=The+multiple+myeloma+drug+pipeline-2018%3A+a+review+of+small+molecules+and+their+therapeutic+targets&doi=10.1016%2Fj.clml.2018.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets</span></div><div class="casAuthors">Abramson Hanley N</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma, myeloma & leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">611-627</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of multiple myeloma (MM), a neoplasm of plasma cells, formerly dependent on alkylating drugs, corticosteroids, and autologous stem cell transplantation, has changed dramatically in the past 20 years because 3 new classes of small molecule drugs (arbitrarily defined as having a molecular weight of < 900 kDa)-immunomodulators, proteasome inhibitors, and histone deacetylase blockers-have been introduced for the disease.  Therapeutic options for MM expanded further in 2015 when 2 new monoclonal antibodies (daratumumab and elotuzumab) were approved by the Food and Drug Administration for MM.  Although MM remains incurable, the cumulative effect of these advances has resulted in a near-doubling of the 5-year survival rate since the late 1980s.  Despite these advances, therapy for MM continues to pose substantial challenges because resistance to therapy frequently develops, and relapse and recurrence are all too common.  The present review focused on the pipeline for new small molecules in various stages of development and their associated cellular targets.  In addition to newer versions of alkylators, immunomodulators, proteasome inhibitors, and histone deacetylase inhibitors, the present review considered the prospects for adding new classes of small molecules to the MM armamentarium, which offer the potential for oral efficacy, relative simplicity of preparation, and prospects for improvement in the cost-to-benefit ratio.  Included are agents that affect myeloma epigenetics and the ubiquitination-proteasome system and the unfolded protein response, apoptotic mechanisms, chromosomal abnormalities, nuclear protein transport, and various kinases involved in cellular signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS29pXs7jYk7MSzjBFCN0BJfW6udTcc2ebrtbus-fA64bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FnsFygsw%253D%253D&md5=3ead649460f6be413b2f7e82b659a8bf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2018.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2018.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DAbramson%26aufirst%3DH.%2BN.%26atitle%3DThe%2520multiple%2520myeloma%2520drug%2520pipeline-2018%253A%2520a%2520review%2520of%2520small%2520molecules%2520and%2520their%2520therapeutic%2520targets%26jtitle%3DClin.%2520Lymphoma%252C%2520Myeloma%2520Leuk.%26date%3D2018%26volume%3D18%26spage%3D611%26epage%3D627%26doi%3D10.1016%2Fj.clml.2018.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydon, N. B.</span></span> <span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nm0596-561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Fnm0596-561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=8616716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&author=B.+J.+Drukerauthor=S.+Tamuraauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=S.+Fanningauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells&doi=10.1038%2Fnm0596-561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span></div><div class="casAuthors">Druker, Brian J.; Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Shane; Zimmermann, Jurg; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">The Bcr-Abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease.  A compd., designed to inhibit the Abl protein tyrosine kinase (CGP 57148), was evaluated for its effects on cells contg. the Bcr-Abl fusion protein.  Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compd.  In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the no. of Bcr-Abl colonies formed but no inhibition of normal colony formation.  This compd. may be useful in the treatment of Bcr-Abl-pos. leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzXj-25AHOrVg90H21EOLACvtfcHk0ljC4DfuiSXZjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D&md5=1dc111cc883a1ed29964ae2c88c88cb9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnm0596-561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0596-561%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnm0596-561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lugo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendergast, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase activity and transformation potency of bcr-abl oncogene products</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">1079</span>– <span class="NLM_lpage">1082</span>, <span class="refDoi"> DOI: 10.1126/science.2408149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1126%2Fscience.2408149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=2408149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADyaK3cXhslensbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1990&pages=1079-1082&author=T.+Lugoauthor=A.+Pendergastauthor=A.+Mullerauthor=O.+Witte&title=Tyrosine+kinase+activity+and+transformation+potency+of+bcr-abl+oncogene+products&doi=10.1126%2Fscience.2408149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase activity and transformation potency of bcr-abl oncogene products</span></div><div class="casAuthors">Lugo, Tracy G.; Pendergast, Ann Marie; Muller, Alexander J.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">4946</span>),
    <span class="NLM_cas:pages">1079-82</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Oncogenic activation of the proto-oncogene c-abl in human leukemias occurs as a result of the addn. of exons from the gene bcr and truncation of the first abl exon.  Anal. of tyrosine kinase activity and quant. measurement of transformation potency in a single-step assay indicate that variation in bcr exon contribution results in a functional difference between p210bcr-abl and p185bcr-abl proteins.  Thus, foreign upstream sequences are important in the deregulation of the kinase activity of the abl product, and the extent of deregulation correlates with the pathol. effects of the bcr-abl proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor_5g1b7WQRLVg90H21EOLACvtfcHk0ljC4DfuiSXZjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhslensbg%253D&md5=6dedfdc01020bc7f0ad1013e394e9648</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.2408149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2408149%26sid%3Dliteratum%253Aachs%26aulast%3DLugo%26aufirst%3DT.%26aulast%3DPendergast%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DA.%26aulast%3DWitte%26aufirst%3DO.%26atitle%3DTyrosine%2520kinase%2520activity%2520and%2520transformation%2520potency%2520of%2520bcr-abl%2520oncogene%2520products%26jtitle%3DScience%26date%3D1990%26volume%3D247%26spage%3D1079%26epage%3D1082%26doi%3D10.1126%2Fscience.2408149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(03)01137-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2FS1470-2045%2803%2901137-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12850190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1alu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=397-406&author=S.+S.+Sridharauthor=L.+Seymourauthor=F.+A.+Shepherd&title=Inhibitors+of+epidermal-growth-factor+receptors%3A+a+review+of+clinical+research+with+a+focus+on+non-small-cell+lung+cancer&doi=10.1016%2FS1470-2045%2803%2901137-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer</span></div><div class="casAuthors">Sridhar, Srikala S.; Seymour, Lesley; Shepherd, Frances A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">397-406</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite aggressive surgical and chemotherapeutic interventions, non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death in men and women with overall cure rates of less than 15%.  Recent advances in our understanding of cellular signaling and its crit. role in tumorigenesis has led to the development of novel therapies which may offer new hope.  In particular, the epidermal growth-factor receptor superfamily is an attractive therapeutic target because it is commonly overexpressed in malignant disease, regulates many vital cellular processes, and seems to be a neg. prognostic indicator.  Several selective inhibitors of this family of receptors are currently being evaluated in several cancers including NSCLC.  In this review we examine current preclin. and clin. evidence on monoclonal antibodies (cetuximab, ABX-EGF, EMD72000, MAb ICR62, h-R3, MDX-447, MDX-H210, trastuzumab, and 2C4), immunoconjugates (Y10, Ua30:2, Mab806), anti-EGF vaccine (YMB2000), and tyrosine kinase inhibitors (gefitinib, erlotinib, CI1033, GW572016, EKB 569, PKI166, PD158780, and TAK 165).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkpYr5VybYiLVg90H21EOLACvtfcHk0lj82cAmRsp3lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1alu78%253D&md5=780268a27f84dadb63c4f270ab2625c3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2803%2901137-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252803%252901137-9%26sid%3Dliteratum%253Aachs%26aulast%3DSridhar%26aufirst%3DS.%2BS.%26aulast%3DSeymour%26aufirst%3DL.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DInhibitors%2520of%2520epidermal-growth-factor%2520receptors%253A%2520a%2520review%2520of%2520clinical%2520research%2520with%2520a%2520focus%2520on%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2003%26volume%3D4%26spage%3D397%26epage%3D406%26doi%3D10.1016%2FS1470-2045%2803%2901137-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Protein kinases - the major drug targets of the twenty-first century?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1038/nrd773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Fnrd773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12120282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=309-315&author=P.+Cohen&title=Protein+kinases+-+the+major+drug+targets+of+the+twenty-first+century%3F&doi=10.1038%2Fnrd773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: Protein kinases - the major drug targets of the twenty-first century?</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-315</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of disease.  A growing interest in developing orally active protein-kinase inhibitors has recently culminated in the approval of the first of these drugs for clin. use.  Protein kinases have now become the second most important group of drug targets, after G-protein-coupled receptors.  Here, I give a personal view of some of the most important advances that have shaped this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRd_GqiGAWaLVg90H21EOLACvtfcHk0lj82cAmRsp3lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D&md5=67d2fbc11a55b5980ee0692f7bc13cc9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd773%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DProtein%2520kinases%2520-%2520the%2520major%2520drug%2520targets%2520of%2520the%2520twenty-first%2520century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D309%26epage%3D315%26doi%3D10.1038%2Fnrd773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melnikova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, J.</span></span> <span> </span><span class="NLM_article-title">Targeting protein kinases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1038/nrd1600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Fnrd1600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=15645605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVarsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=993-994&author=I.+Melnikovaauthor=J.+Golden&title=Targeting+protein+kinases&doi=10.1038%2Fnrd1600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">From the analyst's couch: Targeting protein kinases</span></div><div class="casAuthors">Melnikova, Irena; Golden, James</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">993-994</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxKgb6vOzrkbVg90H21EOLACvtfcHk0lj82cAmRsp3lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVarsLvJ&md5=fd1f562792d3c286191a55538bf86e5e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd1600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1600%26sid%3Dliteratum%253Aachs%26aulast%3DMelnikova%26aufirst%3DI.%26aulast%3DGolden%26aufirst%3DJ.%26atitle%3DTargeting%2520protein%2520kinases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D993%26epage%3D994%26doi%3D10.1038%2Fnrd1600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Gefitinib - a novel targeted approach to treating cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">956</span>– <span class="NLM_lpage">965</span>, <span class="refDoi"> DOI: 10.1038/nrc1506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Fnrc1506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=15573117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVarsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=956-965&author=R.+S.+Herbstauthor=M.+Fukuokaauthor=J.+Baselga&title=Gefitinib+-+a+novel+targeted+approach+to+treating+cancer&doi=10.1038%2Fnrc1506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: Gefitinib - a novel targeted approach to treating cancer</span></div><div class="casAuthors">Herbst, Roy S.; Fukuoka, Masahiro; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">956-965</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential anticancer target, the EGFR inhibitor gefitinib (Iressa; AstraZeneca) has been approved for the treatment of patients with advanced non-small-cell lung cancer in many countries.  Studies have indicated its potential for treating patients with other types of solid tumors.  Investigation of gefitinib has not only increased our knowledge about the biol. of EGFR signaling, but is contributing to our evolving understanding of which tumors are EGFR dependent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V2qzLg_-rrVg90H21EOLACvtfcHk0ljXVVso1Cshow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVarsLjJ&md5=03a6c08b947bc3e0ca59e1b92fa8d214</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc1506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1506%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DFukuoka%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DGefitinib%2520-%2520a%2520novel%2520targeted%2520approach%2520to%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D956%26epage%3D965%26doi%3D10.1038%2Fnrc1506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues Pereira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciuleanu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thongprasert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maoleekoonpiroj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smylie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kooten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dediu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezjak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santabarbara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span> <span> </span><span class="NLM_article-title">The National Cancer Institute of Canada Clinical Trials Group, erlotinib in previously treated non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa050753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&author=F.+A.+Shepherdauthor=J.+Rodrigues+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+van+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjakauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=The+National+Cancer+Institute+of+Canada+Clinical+Trials+Group%2C+erlotinib+in+previously+treated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa050753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0ljXVVso1Cshow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DRodrigues%2BPereira%26aufirst%3DJ.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3Dvan%2BKooten%26aufirst%3DM.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjak%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DThe%2520National%2520Cancer%2520Institute%2520of%2520Canada%2520Clinical%2520Trials%2520Group%252C%2520erlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D123%26epage%3D132%26doi%3D10.1056%2FNEJMoa050753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallegos Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Chevalier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oulid-Aissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span> <span> </span><span class="NLM_article-title">Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">6049</span>– <span class="NLM_lpage">6055</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-0260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1158%2F1078-0432.CCR-06-0260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=17062680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6049-6055&author=G.+Giacconeauthor=M.+Gallegos+Ruizauthor=T.+Le+Chevalierauthor=N.+Thatcherauthor=E.+Smitauthor=J.+A.+Rodriguezauthor=P.+Janneauthor=D.+Oulid-Aissaauthor=J.-C.+Soria&title=Erlotinib+for+frontline+treatment+of+advanced+non-small+cell+lung+cancer%3A+a+phase+II+study&doi=10.1158%2F1078-0432.CCR-06-0260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study</span></div><div class="casAuthors">Giaccone, Giuseppe; Gallegos Ruiz, Marielle; Le Chevalier, Thierry; Thatcher, Nick; Smit, Egbert; Rodriguez, Jose Antonio; Janne, Pasi; Oulid-Aissa, Dalila; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20, Pt. 1</span>),
    <span class="NLM_cas:pages">6049-6055</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Erlotinib has proven activity in pretreated patients with advanced non-small cell lung cancer (NSCLC).  We evaluated erlotinib in the front-line treatment of advanced NSCLC and assessed biol. predictors of outcome.  Exptl. Design: In this phase II study, chemotherapy-naive patients with stage IIIB/IV NSCLC received oral erlotinib (150 mg/d) until disease progression or unacceptable toxicity occurred.  Tumor response was assessed every 6 wk, and samples were analyzed for potential mol. markers of treatment response and survival.  The primary end point was the proportion of patients without disease progression after 6 wk of treatment.  Results: Fifty-three patients were eligible.  The overall rate of nonprogression at 6 wk was 52.8% (28 of 53 patients).  Tumor response rate was 22.7%, with 1 complete response, 11 partial responses, and 16 cases of stable disease.  Responses were seen across most patient clin. characteristics.  The median duration of tumor response was 333 days; median overall survival was 391 days; and median time to disease progression was 84 days.  Erlotinib was well tolerated, the main treatment-related adverse events being mild-to-moderate rash and diarrhea.  Histol. material for biol. studies was available in 29 cases.  Four of five responders and one patient with stable disease had a classic epidermal growth factor receptor tyrosine kinase mutation.  Two progressing patients exhibited epidermal growth factor receptor point mutations (one with T790M mutation), and K-ras mutations were detected in 10 nonresponders.  Conclusions: Erlotinib shows significant antitumor activity in the first-line treatment of advanced NSCLC and may be a viable alternative to chemotherapy.  Patient selection cannot easily be based on clin. or biol. variables.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU7JRZAYUK8rVg90H21EOLACvtfcHk0ljXVVso1Cshow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbjF&md5=f4ae1f677dc52dc4f73b00d916afb8f1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0260%26sid%3Dliteratum%253Aachs%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DGallegos%2BRuiz%26aufirst%3DM.%26aulast%3DLe%2BChevalier%26aufirst%3DT.%26aulast%3DThatcher%26aufirst%3DN.%26aulast%3DSmit%26aufirst%3DE.%26aulast%3DRodriguez%26aufirst%3DJ.%2BA.%26aulast%3DJanne%26aufirst%3DP.%26aulast%3DOulid-Aissa%26aufirst%3DD.%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DErlotinib%2520for%2520frontline%2520treatment%2520of%2520advanced%2520non-small%2520cell%2520lung%2520cancer%253A%2520a%2520phase%2520II%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6049%26epage%3D6055%26doi%3D10.1158%2F1078-0432.CCR-06-0260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kannaiyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review of protein kinase inhibitors for cancer therapy</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1080/14737140.2018.1527688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1080%2F14737140.2018.1527688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=30259761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOqs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=1249-1270&author=R.+Kannaiyanauthor=D.+Mahadevan&title=A+comprehensive+review+of+protein+kinase+inhibitors+for+cancer+therapy&doi=10.1080%2F14737140.2018.1527688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of protein kinase inhibitors for cancer therapy</span></div><div class="casAuthors">Kannaiyan, Radhamani; Mahadevan, Daruka</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1249-1270</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are involved in various cellular functions.  About 2% of the human genome encodes for protein kinases.  Dysregulation of protein kinases is implicated in various processes of carcinogenesis.  The advent of protein kinase inhibitors in cancer therapy has led to a paradigm shift in cancer therapy.  Several protein kinase inhibitors have been approved by FDA in the last few decades.  This article provides a review of the FDA approved protein kinase inhibitors as of Dec. 2017 for the well-known oncogenic protein kinases.  A list of FDA approved protein kinase inhibitors and their FDA approved clin. indications were cataloged.  The role of the resp. oncogenic protein kinases in carcinogenesis and cancer progression and the relevant landmark clin. trials of resp. protein kinase inhibitors leading up to the FDA approval were PubMed searched and discussed.  Further understanding of the mol. origin of various cancers would help identify new targets.  Use of biomarker profiling might select the patient population that would benefit better from kinase inhibitors.  Clin. trials should be designed to identify the appropriate sequence of the available kinase inhibitors.  It would prove to be useful to test these drugs in the adjuvant setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUeLoNJcZUGLVg90H21EOLACvtfcHk0liYO4wg-HGJ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOqs7nK&md5=853138e6be969ecb6d137356bf5d2fd3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F14737140.2018.1527688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2018.1527688%26sid%3Dliteratum%253Aachs%26aulast%3DKannaiyan%26aufirst%3DR.%26aulast%3DMahadevan%26aufirst%3DD.%26atitle%3DA%2520comprehensive%2520review%2520of%2520protein%2520kinase%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2018%26volume%3D18%26spage%3D1249%26epage%3D1270%26doi%3D10.1080%2F14737140.2018.1527688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrenbacher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartwright, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hainsworth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffing, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmgren, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyfe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabbinavar, F.</span></span> <span> </span><span class="NLM_article-title">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">2335</span>– <span class="NLM_lpage">2342</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa032691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1056%2FNEJMoa032691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=15175435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2335-2342&author=H.+Hurwitzauthor=L.+Fehrenbacherauthor=W.+Novotnyauthor=T.+Cartwrightauthor=J.+Hainsworthauthor=W.+Heimauthor=J.+Berlinauthor=A.+Baronauthor=S.+Griffingauthor=E.+Holmgrenauthor=N.+Ferraraauthor=G.+Fyfeauthor=B.+Rogersauthor=R.+Rossauthor=F.+Kabbinavar&title=Bevacizumab+plus+irinotecan%2C+fluorouracil%2C+and+leucovorin+for+metastatic+colorectal+cancer&doi=10.1056%2FNEJMoa032691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Fehrenbacher, Louis; Novotny, William; Cartwright, Thomas; Hainsworth, John; Heim, William; Berlin, Jordan; Baron, Ari; Griffing, Susan; Holmgren, Eric; Ferrara, Napoleone; Fyfe, Gwen; Rogers, Beth; Ross, Robert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2335-2342</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclin. and clin. activity against metastatic colorectal cancer, particularly in combination with chemotherapy.  Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kg of body wt. every two weeks) and 411 to receive IFL plus placebo.  The primary end point was overall survival.  Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life.  The median duration of survival was 20.3 mo in the group given IFL plus bevacizumab, as compared with 15.6 mo in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001).  The median duration of progression-free survival was 10.6 mo in the group given IFL plus bevacizumab, as compared with 6.2 mo in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 % and 34.8 % (P = 0.004).  The median duration of the response was 10.4 mo in the group given IFL plus bevacizumab, as compared with 7.1 mo in the group given IFL plus placebo (hazard ratio for progression, 0.62; P = 0.001).  Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 % vs. 2.3 %) but was easily managed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5r6uP5oxZU7Vg90H21EOLACvtfcHk0liYO4wg-HGJ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D&md5=6a1289cdbf1501f121eb0482e5a1f536</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032691%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DCartwright%26aufirst%3DT.%26aulast%3DHainsworth%26aufirst%3DJ.%26aulast%3DHeim%26aufirst%3DW.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DGriffing%26aufirst%3DS.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520plus%2520irinotecan%252C%2520fluorouracil%252C%2520and%2520leucovorin%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2335%26epage%3D2342%26doi%3D10.1056%2FNEJMoa032691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabbinavar, F.</span></span> <span> </span><span class="NLM_article-title">Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer</span>. <i>Oncology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1159/000088480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1159%2F000088480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=16301832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1aqsrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2005&pages=17-24&author=H.+Hurwitzauthor=F.+Kabbinavar&title=Bevacizumab+combined+with+standard+fluoropyrimidine-based+chemotherapy+regimens+to+treat+colorectal+cancer&doi=10.1159%2F000088480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab Combined with Standard Fluoropyrimidine-Based Chemotherapy Regimens to Treat Colorectal Cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">17-24</span>CODEN:
                <span class="NLM_cas:coden">ONCOBS</span>;
        ISSN:<span class="NLM_cas:issn">0030-2414</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">For several decades, 5-fluorouracil (5-FU) with or without leucovorin defined the std. of care for the treatment of metastatic colorectal cancer (CRC).  The addn. of other chemotherapy regimens to 5-FU has improved survival, but often at the expense of increased toxicity.  Recent advances in our understanding of the mol. basis of CRC have led to the prodn. of novel targeted agents, such as bevacizumab (Avastin).  Bevacizumab is currently approved for the first-line treatment of metastatic CRC and is currently being tested in combination with std. therapies for a range of indications.  Phase II/III trials have demonstrated that the addn. of bevacizumab to 5-FU-based first-line chemotherapy improves survival, progression-free survival and response rate compared with chemotherapy alone.  Combination therapy does not appear to exacerbate side effects known to be assocd. with the chemotherapy regimen.  The most common side effects attributable to bevacizumab therapy include hypertension, proteinuria and bleeding.  Although uncommon, gastrointestinal perforation and arterial thromobembolic events are the most serious side effects reported to date.  Bevacizumab is currently being evaluated in combination with oxaliplatin (Eloxatin)-based therapies and preliminary data are encouraging.  Ongoing trials of bevacizumab in combination with std. first-line chemotherapy regimens will evaluate bevacizumab's potential in a range of cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtw2uXR6TcfLVg90H21EOLACvtfcHk0liYO4wg-HGJ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1aqsrbO&md5=e8a759ad940dd0c7d848e3e7ff66bccb</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1159%2F000088480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000088480%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520combined%2520with%2520standard%2520fluoropyrimidine-based%2520chemotherapy%2520regimens%2520to%2520treat%2520colorectal%2520cancer%26jtitle%3DOncology%26date%3D2005%26volume%3D69%26spage%3D17%26epage%3D24%26doi%3D10.1159%2F000088480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resta, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydon, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno-Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1037</span>, <span class="refDoi"> DOI: 10.1056/NEJM200104053441401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1056%2FNEJM200104053441401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=11287972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFGnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1031-1037&author=B.+J.+Drukerauthor=M.+Talpazauthor=D.+J.+Restaauthor=B.+Pengauthor=E.+Buchdungerauthor=J.+M.+Fordauthor=N.+B.+Lydonauthor=H.+Kantarjianauthor=R.+Capdevilleauthor=S.+Ohno-Jonesauthor=C.+L.+Sawyers&title=Efficacy+and+safety+of+a+specific+inhibitor+of+the+BCR-ABL+tyrosine+kinase+in+chronic+myeloid+leukemia&doi=10.1056%2FNEJM200104053441401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia</span></div><div class="casAuthors">Druker, Brian J.; Talpaz, Moshe; Resta, Debra J.; Peng, Bin; Buchdunger, Elisabeth; Ford, John M.; Lydon, Nicholas B.; Kantarjian, Hagop; Capdeville, Renaud; Ohno-Jones, Sayuri; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1031-1037</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML).  Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML.  Methods: We conducted a phase 1, dose-escalating trial of STI571 (formerly known as CGP 57148B), a specific inhibitor of the BCR-ABL tyrosine kinase.  STI571 was administered orally to 83 patients with CML in the chronic phase in whom treatment with interferon alpha had failed.  Patients were successively assigned to 1 of 14 doses ranging from 25 to 1000 mg per day.  Results: Adverse effects of STI571 were minimal; the most common were nausea, myalgias, edema, and diarrhea.  A maximal tolerated dose was not identified.  Complete hematol. responses were obsd. in 53 of 54 patients treated with daily doses of 300 mg or more and typically occurred in the first four weeks of therapy.  Of the 54 patients treated with doses of 300 mg or more, cytogenetic responses occurred in 29, including 17 (31 percent of the 54 patients who received this dose) with major responses (0 to 35 percent of cells in metaphase pos. for the Philadelphia chromosome); 7 of these patients had complete cytogenetic remissions.  Conclusion: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alpha had failed.  Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific mol. abnormality present in a human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrprbDzKoC0ubVg90H21EOLACvtfcHk0liYO4wg-HGJ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFGnu70%253D&md5=1554407678838243a753aa056ffd4f7c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441401%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DResta%26aufirst%3DD.%2BJ.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DOhno-Jones%26aufirst%3DS.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520a%2520specific%2520inhibitor%2520of%2520the%2520BCR-ABL%2520tyrosine%2520kinase%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1031%26epage%3D1037%26doi%3D10.1056%2FNEJM200104053441401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicaise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleickardt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwood-Chirchir, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decillis, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">2531</span>– <span class="NLM_lpage">2541</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa055229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1056%2FNEJMoa055229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=16775234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD28Xlslyisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=2531-2541&author=M.+Talpazauthor=N.+P.+Shahauthor=H.+Kantarjianauthor=N.+Donatoauthor=J.+Nicollauthor=R.+Paquetteauthor=J.+Cortesauthor=S.+O%E2%80%99Brienauthor=C.+Nicaiseauthor=E.+Bleickardtauthor=M.+A.+Blackwood-Chirchirauthor=V.+Iyerauthor=T.-T.+Chenauthor=F.+Huangauthor=A.+P.+Decillisauthor=C.+L.+Sawyers&title=Dasatinib+in+imatinib-resistant+philadelphia+chromosome-positive+leukemias&doi=10.1056%2FNEJMoa055229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias</span></div><div class="casAuthors">Talpaz, Moshe; Shah, Neil P.; Kantarjian, Hagop; Donato, Nicholas; Nicoll, John; Paquette, Ron; Cortes, Jorge; O'Brien, Susan; Nicaise, Claude; Bleickardt, Eric; Blackwood-Chirchir, M. Anne; Iyer, Vishwanath; Chen, Tai-Tsang; Huang, Fei; Decillis, Arthur P.; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2531-2541</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-pos. (Ph-pos.) leukemias, but relapse occurs, mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutations.  We evaluated dasatinib, a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations, in patients with chronic myelogenous leukemia (CML) or Ph-pos. acute lymphoblastic leukemia (ALL).  Patients with various phases of CML or with Ph-pos. ALL who could not tolerate or were resistant to imatinib were enrolled in a phase 1 dose-escalation study.  Dasatinib (15 to 240 mg per day) was administered orally in four-week treatment cycles, once or twice daily.  A complete hematol. response was achieved in 37 of 40 patients with chronic-phase CML, and major hematol. responses were seen in 31 of 44 patients with accelerated-phase CML, CML with blast crisis, or Ph-pos. ALL.  In these two phases, the rates of major cytogenetic response were 45% and 25%, resp.  Responses were maintained in 95% of patients with chronic-phase disease and in 82% of patients with accelerated-phase disease, with a median follow-up more than 12 mo and 5 mo, resp.  Nearly all patients with lymphoid blast crisis and Ph-pos. ALL had a relapse within six months.  Responses occurred among all BCR-ABL genotypes, with the exception of the T315I mutation, which confers resistance to both dasatinib and imatinib in vitro.  Myelosuppression was common but not dose-limiting.  Dasatinib induces hematol. and cytogenetic responses in patients with CML or Ph-pos. ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov no., NCT00064233.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIX_T8oTKTw7Vg90H21EOLACvtfcHk0ljx5g3r1IpFeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xlslyisb0%253D&md5=0bef963bce785b8b2a19b548905e2543</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa055229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa055229%26sid%3Dliteratum%253Aachs%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DDonato%26aufirst%3DN.%26aulast%3DNicoll%26aufirst%3DJ.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DNicaise%26aufirst%3DC.%26aulast%3DBleickardt%26aufirst%3DE.%26aulast%3DBlackwood-Chirchir%26aufirst%3DM.%2BA.%26aulast%3DIyer%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DT.-T.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DDecillis%26aufirst%3DA.%2BP.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DDasatinib%2520in%2520imatinib-resistant%2520philadelphia%2520chromosome-positive%2520leukemias%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D2531%26epage%3D2541%26doi%3D10.1056%2FNEJMoa055229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiedemann, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Que, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azorsa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braggio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsagel, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousses, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span> <span> </span><span class="NLM_article-title">Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1594</span>– <span class="NLM_lpage">1604</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-09-243980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1182%2Fblood-2009-09-243980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=19996089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtV2gtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=1594-1604&author=R.+E.+Tiedemannauthor=Y.+X.+Zhuauthor=J.+Schmidtauthor=H.+Yinauthor=C.+X.+Shiauthor=Q.+Queauthor=G.+Basuauthor=D.+Azorsaauthor=L.+M.+Perkinsauthor=E.+Braggioauthor=R.+Fonsecaauthor=P.+L.+Bergsagelauthor=S.+Moussesauthor=A.+K.+Stewart&title=Kinome-wide+RNAi+studies+in+human+multiple+myeloma+identify+vulnerable+kinase+targets%2C+including+a+lymphoid-restricted+kinase%2C+GRK6&doi=10.1182%2Fblood-2009-09-243980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6</span></div><div class="casAuthors">Tiedemann, Rodger E.; Zhu, Yuan Xiao; Schmidt, Jessica; Yin, Hongwei; Shi, Chang-Xin; Que, Qiang; Basu, Gargi; Azorsa, David; Perkins, Louise M.; Braggio, Esteban; Fonseca, Rafael; Bergsagel, P. Leif; Mousses, Spyro; Stewart, A. Keith</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1594-1604</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A paucity of validated kinase targets in human multiple myeloma has delayed clin. deployment of kinase inhibitors in treatment strategies.  The authors therefore conducted a kinome-wide small interfering RNA (siRNA) lethality study in myeloma tumor lines bearing common t(4;14), t(14;16), and t(11;14) translocations to identify critically vulnerable kinases in myeloma tumor cells without regard to preconceived mechanistic notions.  Fifteen kinases were repeatedly vulnerable in myeloma cells, including AKT1, AK3L1, AURKA, AURKB, CDC2L1, CDK5R2, FES, FLT4, GAK, GRK6, HK1, PKN1, PLK1, SMG1, and TNK2.  Whereas several kinases (PLK1, HK1) were equally vulnerable in epithelial cells, others and particularly G protein-coupled receptor kinase, GRK6, appeared selectively vulnerable in myeloma.  GRK6 inhibition was lethal to 6 of 7 myeloma tumor lines but was tolerated in 7 of 7 human cell lines.  GRK6 exhibits lymphoid-restricted expression, and from coimmunopptn. studies the authors demonstrate that expression in myeloma cells is regulated via direct assocn. with the heat shock protein 90 (HSP90) chaperone.  GRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation assocd. with redn. in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells.  As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWyCueT3_UmrVg90H21EOLACvtfcHk0ljx5g3r1IpFeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtV2gtLo%253D&md5=2572ab7ed80ff48d250507e0db16b88e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-09-243980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-09-243980%26sid%3Dliteratum%253Aachs%26aulast%3DTiedemann%26aufirst%3DR.%2BE.%26aulast%3DZhu%26aufirst%3DY.%2BX.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DC.%2BX.%26aulast%3DQue%26aufirst%3DQ.%26aulast%3DBasu%26aufirst%3DG.%26aulast%3DAzorsa%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DL.%2BM.%26aulast%3DBraggio%26aufirst%3DE.%26aulast%3DFonseca%26aufirst%3DR.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26aulast%3DMousses%26aufirst%3DS.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26atitle%3DKinome-wide%2520RNAi%2520studies%2520in%2520human%2520multiple%2520myeloma%2520identify%2520vulnerable%2520kinase%2520targets%252C%2520including%2520a%2520lymphoid-restricted%2520kinase%252C%2520GRK6%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D1594%26epage%3D1604%26doi%3D10.1182%2Fblood-2009-09-243980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mentzer, W. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, R. B.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baehner, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, D. G.</span></span> <span> </span><span class="NLM_article-title">An unusual form of chronic neutropenia in a father and daughter with hypogammaglobulinaemia</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.1977.tb00654.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1111%2Fj.1365-2141.1977.tb00654.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=889707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A280%3ADyaE2s3kt1Wjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1977&pages=313-322&author=W.+C.+Mentzerauthor=R.+B.+Johnstonauthor=R.+L.+Baehnerauthor=D.+G.+Nathan&title=An+unusual+form+of+chronic+neutropenia+in+a+father+and+daughter+with+hypogammaglobulinaemia&doi=10.1111%2Fj.1365-2141.1977.tb00654.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">An unusual form of chronic neutropenia in a father and daughter with hypogammaglobulinaemia</span></div><div class="casAuthors">Mentzer W C Jr; Johnston R B Jr; Baehner R L; Nathan D G</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">313-22</span>
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    </div><div class="casAbstract">Chronic neutropenia, with an abundance of mature neutrophils in the bone marrow, was discovered in a father and daughter who also had common variable hypogammaglobulinaemia.  Under the stress of infection or following the administration of typhoid vaccine, release of neutrophils from the marrow was enhanced sufficiently to abolish neutropenia temporarily.  Although their morphology was abnormal, the function of neutrophils in vitro was normal.  Thus, the increased susceptibility to infection that characterized these patients appeared to be due primarily to their defect in humoral immunity rather than their neutropenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMFVws0TwWk7HHuJhbyicZfW6udTcc2ebmuDs7bWg_sbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2s3kt1Wjsg%253D%253D&md5=0bfd726a0f911eebc638d894d45719b6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.1977.tb00654.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.1977.tb00654.x%26sid%3Dliteratum%253Aachs%26aulast%3DMentzer%26aufirst%3DW.%2BC.%26aulast%3DJohnston%26aufirst%3DR.%2BB.%26aulast%3DBaehner%26aufirst%3DR.%2BL.%26aulast%3DNathan%26aufirst%3DD.%2BG.%26atitle%3DAn%2520unusual%2520form%2520of%2520chronic%2520neutropenia%2520in%2520a%2520father%2520and%2520daughter%2520with%2520hypogammaglobulinaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D1977%26volume%3D36%26spage%3D313%26epage%3D322%26doi%3D10.1111%2Fj.1365-2141.1977.tb00654.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segarra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasperini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosato, G.</span></span> <span> </span><span class="NLM_article-title">Impaired recruitment of GRK6 and beta-arrestin 2 causes delayed internalization and desensitization of a WHIM syndrome-associated CXCR4 mutant receptor</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e8102</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0008102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1371%2Fjournal.pone.0008102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=19956569" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&author=P.+J.+McCormickauthor=M.+Segarraauthor=P.+Gasperiniauthor=A.+V.+Gulinoauthor=G.+Tosato&title=Impaired+recruitment+of+GRK6+and+beta-arrestin+2+causes+delayed+internalization+and+desensitization+of+a+WHIM+syndrome-associated+CXCR4+mutant+receptor&doi=10.1371%2Fjournal.pone.0008102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0008102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0008102%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26aulast%3DSegarra%26aufirst%3DM.%26aulast%3DGasperini%26aufirst%3DP.%26aulast%3DGulino%26aufirst%3DA.%2BV.%26aulast%3DTosato%26aufirst%3DG.%26atitle%3DImpaired%2520recruitment%2520of%2520GRK6%2520and%2520beta-arrestin%25202%2520causes%2520delayed%2520internalization%2520and%2520desensitization%2520of%2520a%2520WHIM%2520syndrome-associated%2520CXCR4%2520mutant%2520receptor%26jtitle%3DPLoS%2520One%26date%3D2009%26volume%3D4%26doi%3D10.1371%2Fjournal.pone.0008102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fong, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premont, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.-R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. D.</span></span> <span> </span><span class="NLM_article-title">Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">7478</span>– <span class="NLM_lpage">7483</span>, <span class="refDoi"> DOI: 10.1073/pnas.112198299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1073%2Fpnas.112198299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12032308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlCktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=7478-7483&author=A.+M.+Fongauthor=R.+T.+Premontauthor=R.+M.+Richardsonauthor=Y.-R.+A.+Yuauthor=R.+J.+Lefkowitzauthor=D.+D.+Patel&title=Defective+lymphocyte+chemotaxis+in+beta-arrestin2-+and+GRK6-deficient+mice&doi=10.1073%2Fpnas.112198299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Defective lymphocyte chemotaxis in β-arrestin2- and GRK6-deficient mice</span></div><div class="casAuthors">Fong, Alan M.; Premont, Richard T.; Richardson, Ricardo M.; Yu, Yen-Rei A.; Lefkowitz, Robert J.; Patel, Dhavalkumar D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7478-7483</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lymphocyte chemotaxis is a complex process by which cells move within tissues and across barriers such as vascular endothelium and is usually stimulated by chemokines such as stromal cell-derived factor-1 (CXCL12) acting via G protein-coupled receptors.  Because members of this receptor family are regulated ("desensitized") by G protein-coupled receptor kinase (GRK)-mediated receptor phosphorylation and β-arrestin binding, the authors examd. signaling and chemotactic responses in splenocytes derived from knockout mice deficient in various β-arrestins and GRKs, with the expectation that these responses might be enhanced.  Knockouts of β-arrestin2, GRK5, and GRK6 were examd. because all three proteins are expressed at high levels in purified mouse CD3+ T and B220+ B splenocytes.  CXCL12 stimulation of membrane GTPase activity was unaffected in splenocytes derived from GRK5-deficient mice but was increased in splenocytes from the β-arrestin2- and GRK6-deficient animals.  Surprisingly, however, both T and B cells from β-arrestin2-deficient animals and T cells from GRK6-deficient animals were strikingly impaired in their ability to respond to CXCL12 both in Transwell migration assays and in transendothelial migration assays.  Chemotactic responses of lymphocytes from GRK5-deficient mice were unaffected.  Thus, these results indicate that β-arrestin2 and GRK6 actually play pos. regulatory roles in mediating the chemotactic responses of T and B lymphocytes to CXCL12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwhhtdtSuoY7Vg90H21EOLACvtfcHk0lhsm2DdiTgQow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlCktbc%253D&md5=f474e5f1e7e59a9a13055cbfdee4263e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.112198299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.112198299%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DA.%2BM.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26aulast%3DRichardson%26aufirst%3DR.%2BM.%26aulast%3DYu%26aufirst%3DY.-R.%2BA.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DPatel%26aufirst%3DD.%2BD.%26atitle%3DDefective%2520lymphocyte%2520chemotaxis%2520in%2520beta-arrestin2-%2520and%2520GRK6-deficient%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2002%26volume%3D99%26spage%3D7478%26epage%3D7483%26doi%3D10.1073%2Fpnas.112198299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushegian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, V. V.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptor kinases: more than just kinases and not only for GPCRs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2011.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.pharmthera.2011.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=21903131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Ciur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2012&pages=40-69&author=E.+V.+Gurevichauthor=J.+J.+Tesmerauthor=A.+Mushegianauthor=V.+V.+Gurevich&title=G+protein-coupled+receptor+kinases%3A+more+than+just+kinases+and+not+only+for+GPCRs&doi=10.1016%2Fj.pharmthera.2011.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptor kinases: More than just kinases and not only for GPCRs</span></div><div class="casAuthors">Gurevich, Eugenia V.; Tesmer, John J. G.; Mushegian, Arcady; Gurevich, Vsevolod V.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-69</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptor (GPCR) kinases (GRKs) are best known for their role in homologous desensitization of GPCRs.  GRKs phosphorylate activated receptors and promote high affinity binding of arrestins, which precludes G protein coupling.  GRKs have a multidomain structure, with the kinase domain inserted into a loop of a regulator of G protein signaling homol. domain.  Unlike many other kinases, GRKs do not need to be phosphorylated in their activation loop to achieve an activated state.  Instead, they are directly activated by docking with active GPCRs.  In this manner they are able to selectively phosphorylate Ser/Thr residues on only the activated form of the receptor, unlike related kinases such as protein kinase A.  GRKs also phosphorylate a variety of non-GPCR substrates and regulate several signaling pathways via direct interactions with other proteins in a phosphorylation-independent manner.  Multiple GRK subtypes are present in virtually every animal cell, with the highest expression levels found in neurons, with their extensive and complex signal regulation.  Insufficient or excessive GRK activity was implicated in a variety of human disorders, ranging from heart failure to depression to Parkinson's disease.  As key regulators of GPCR-dependent and -independent signaling pathways, GRKs are emerging drug targets and promising mol. tools for therapy.  Targeted modulation of expression and/or of activity of several GRK isoforms for therapeutic purposes was recently validated in cardiac disorders and Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru2us2UKmea7Vg90H21EOLACvtfcHk0lh_o1zBljYI1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Ciur%252FE&md5=3f132767c5dfe390c8e2a3b643d68ca3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DGurevich%26aufirst%3DE.%2BV.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26aulast%3DMushegian%26aufirst%3DA.%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26atitle%3DG%2520protein-coupled%2520receptor%2520kinases%253A%2520more%2520than%2520just%2520kinases%2520and%2520not%2520only%2520for%2520GPCRs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2012%26volume%3D133%26spage%3D40%26epage%3D69%26doi%3D10.1016%2Fj.pharmthera.2011.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moepps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vatter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frodl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waechter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixkens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameister, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gierschik, P.</span></span> <span> </span><span class="NLM_article-title">Alternative splicing produces transcripts encoding four variants of mouse G-protein-coupled receptor kinase 6</span>. <i>Genomics</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1006/geno.1999.5901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1006%2Fgeno.1999.5901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10486211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVWqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1999&pages=199-209&author=B.+Moeppsauthor=P.+Vatterauthor=R.+Frodlauthor=F.+Waechterauthor=C.+Dixkensauthor=H.+Hameisterauthor=P.+Gierschik&title=Alternative+splicing+produces+transcripts+encoding+four+variants+of+mouse+G-protein-coupled+receptor+kinase+6&doi=10.1006%2Fgeno.1999.5901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Alternative splicing produces transcripts encoding four variants of mouse G-protein-coupled receptor kinase 6</span></div><div class="casAuthors">Moepps, Barbara; Vatter, Petra; Frodl, Reinhard; Waechter, Fabian; Dixkens, Christa; Hameister, Horst; Gierschik, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Genomics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-209</span>CODEN:
                <span class="NLM_cas:coden">GNMCEP</span>;
        ISSN:<span class="NLM_cas:issn">0888-7543</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A family of protein kinases, termed G-protein-coupled receptor kinases (GRK1-6), is known to phosphorylate agonist-occupied G-protein-coupled receptors.  We have identified mRNAs encoding four distinct mouse GRK6 isoforms (mGRK6), designated mGRK6-A through mGRK6-D.  Mouse GRK6-B and mGRK6-C diverge from the known human GRK6 (577 residues) at residue 560 and are 13 residues longer and 16 residues shorter, resp., than human GRK6, while mGRK6-A very likely represents the mouse equiv. of human GRK6.  Mouse GRK6-D is identical to the other mGRK6 variants in the amino-terminal region, but comprises only 59 of the 263 amino acids of the putative catalytical domain.  As mGRK6-D retains the region involved in interacting with activated receptors, but most likely lacks catalytic activity, this variant might represent a naturally occurring inhibitor of other GRKs.  Anal. of the genomic organization of mGRK6 gene revealed that the four mRNAs are generated by alternative RNA splicing from a single approx. 14.5-kb gene, made up of at least 17 exons and located on mouse chromosome 13.  Similar to human GRK6, mGRK6-A contains three cysteine residues within its carboxyl-terminal region known to serve as substrates for palmitoylation.  Mouse GRK6-B lacks these palmitoylation sites, but carries a basic carboxyl-terminus contg. consensus sequences for phosphorylation by protein kinases C and cAMP/cGMP-dependent protein kinases.  Mouse GRK6-C displays none of these motifs.  Thus, mGRK6-A, mGRK6-B, and mGRK6-C are predicted to differ in terms of their regulation by carboxyl-terminal posttranslational modification.  Anal. of mRNA expression revealed that the four mGRK6 mRNAs are differentially expressed in mouse tissues, suggesting that the four mGRK6 isoforms are involved in regulating tissue- or cell type-specific functions in vivo.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzU7UCKjiUvLVg90H21EOLACvtfcHk0lh_o1zBljYI1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVWqsbk%253D&md5=a01bba28361727397d8e91238a3464b1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1006%2Fgeno.1999.5901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fgeno.1999.5901%26sid%3Dliteratum%253Aachs%26aulast%3DMoepps%26aufirst%3DB.%26aulast%3DVatter%26aufirst%3DP.%26aulast%3DFrodl%26aufirst%3DR.%26aulast%3DWaechter%26aufirst%3DF.%26aulast%3DDixkens%26aufirst%3DC.%26aulast%3DHameister%26aufirst%3DH.%26aulast%3DGierschik%26aufirst%3DP.%26atitle%3DAlternative%2520splicing%2520produces%2520transcripts%2520encoding%2520four%2520variants%2520of%2520mouse%2520G-protein-coupled%2520receptor%2520kinase%25206%26jtitle%3DGenomics%26date%3D1999%26volume%3D60%26spage%3D199%26epage%3D209%26doi%3D10.1006%2Fgeno.1999.5901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotnikova, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laakso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premont, R. T.</span></span> <span> </span><span class="NLM_article-title">Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1016/S0896-6273(03)00192-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2FS0896-6273%2803%2900192-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12718862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslOktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=291-303&author=R.+R.+Gainetdinovauthor=L.+M.+Bohnauthor=T.+D.+Sotnikovaauthor=M.+Cyrauthor=A.+Laaksoauthor=A.+D.+Macraeauthor=G.+E.+Torresauthor=K.+M.+Kimauthor=R.+J.+Lefkowitzauthor=M.+G.+Caronauthor=R.+T.+Premont&title=Dopaminergic+supersensitivity+in+G+protein-coupled+receptor+kinase+6-deficient+mice&doi=10.1016%2FS0896-6273%2803%2900192-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice</span></div><div class="casAuthors">Gainetdinov, Raul R.; Bohn, Laura M.; Sotnikova, Tatyana D.; Cyr, Michel; Laakso, Aki; Macrae, Alexander D.; Torres, Gonzalo E.; Kim, Kyeong-Man; Lefkowitz, Robert J.; Caron, Marc G.; Premont, Richard T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">291-303</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Brain dopaminergic transmission is a crit. component in numerous vital functions, and its dysfunction is involved in several disorders, including addiction and Parkinson's disease.  Responses to dopamine are mediated via G protein-coupled dopamine receptors (D1-D5).  Desensitization of G protein-coupled receptors is mediated via phosphorylation by members of the family of G protein-coupled receptor kinases (GRK1-GRK7).  Here we show that GRK6-deficient mice are supersensitive to the locomotor-stimulating effect of psychostimulants, including cocaine and amphetamine.  In addn., these mice demonstrate an enhanced coupling of striatal D2-like dopamine receptors to G proteins and augmented locomotor response to direct dopamine agonists both in intact and in dopamine-depleted animals.  The present study indicates that postsynaptic D2-like dopamine receptors are physiol. targets for GRK6 and suggests that this regulatory mechanism contributes to central dopaminergic supersensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr--gIoM0vWlbVg90H21EOLACvtfcHk0lh_o1zBljYI1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslOktLc%253D&md5=237a0357b09c8d7f3ba909462b2a4699</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2803%2900192-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252803%252900192-2%26sid%3Dliteratum%253Aachs%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DSotnikova%26aufirst%3DT.%2BD.%26aulast%3DCyr%26aufirst%3DM.%26aulast%3DLaakso%26aufirst%3DA.%26aulast%3DMacrae%26aufirst%3DA.%2BD.%26aulast%3DTorres%26aufirst%3DG.%2BE.%26aulast%3DKim%26aufirst%3DK.%2BM.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26atitle%3DDopaminergic%2520supersensitivity%2520in%2520G%2520protein-coupled%2520receptor%2520kinase%25206-deficient%2520mice%26jtitle%3DNeuron%26date%3D2003%26volume%3D38%26spage%3D291%26epage%3D303%26doi%3D10.1016%2FS0896-6273%2803%2900192-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premont, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, J.</span></span> <span> </span><span class="NLM_article-title">Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid modification diversity in the GRK family</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">27791</span>– <span class="NLM_lpage">27794</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)46852-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2FS0021-9258%2818%2946852-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=7961702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADyaK2cXmsV2ntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=27791-27794&author=R.+H.+Stoffelauthor=R.+R.+Randallauthor=R.+T.+Premontauthor=R.+J.+Lefkowitzauthor=J.+Inglese&title=Palmitoylation+of+G+protein-coupled+receptor+kinase%2C+GRK6.+Lipid+modification+diversity+in+the+GRK+family&doi=10.1016%2FS0021-9258%2818%2946852-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid modification diversity in the GRK family</span></div><div class="casAuthors">Stoffel, Robert H.; Randall, Richard R.; Premont, Richard T.; Lefkowitz, Robert J.; Inglese, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">27791-4</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Gene GRK6 receptor kinase, a 66-kDa serine/threonine protein kinase, is a recently identified member of the G protein-coupled receptor kinase (GRK) family.  GRKs are involved in the phosphorylation of 7-transmembrane receptors, a process mediating desensitization of signal transduction.  An important feature of these enzymes is their membrane-assocd. nature, which for some members is stimulus-dependent.  The structural basis for this membrane assocn. previously has been shown in different members of the GRK family to include isoprenylation, G protein βγ-binding domains, and basic regions to provide electrostatic interactions with phospholipids.  Here, evidence is provided that another mechanism includes fatty acid acylation.  GRK6, but not other GRKs tested, incorporated 3H after incubation with [3H]palmitate in Sf9 and in COS-7 cells overexpressing the kinase.  The incorporated radioactivity was released from the protein by neutral hydroxylamine, indicating the presence of a thioester bond and was confirmed as palmitic acid by HPLC anal.  Site-directed mutagenesis defined the region of palmitate attachment as a cluster of 3 cysteines (Cys-561, Cys-562, and Cys-565) in the C-terminal domain of the kinase, consistent with the location of the membrane targeting domains of GRKs 1, 2, 3, and 5.  Palmitoylation of GRK6 appears essential for membrane assocn., since palmitoylated kinase was found only in the membrane fraction.  This lipid modification provides a structural basis for potential regulation of the subcellular distribution of GRK6 through acylation/deacylation cycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7QuLcwiAKFrVg90H21EOLACvtfcHk0lh_o1zBljYI1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsV2ntb4%253D&md5=9e9e8296a37eb3286ccfa0e8d70487a1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2946852-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252946852-4%26sid%3Dliteratum%253Aachs%26aulast%3DStoffel%26aufirst%3DR.%2BH.%26aulast%3DRandall%26aufirst%3DR.%2BR.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DInglese%26aufirst%3DJ.%26atitle%3DPalmitoylation%2520of%2520G%2520protein-coupled%2520receptor%2520kinase%252C%2520GRK6.%2520Lipid%2520modification%2520diversity%2520in%2520the%2520GRK%2520family%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D27791%26epage%3D27794%26doi%3D10.1016%2FS0021-9258%2818%2946852-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vroon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heijnen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raatgever, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touw, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploemacher, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premont, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavelaars, A.</span></span> <span> </span><span class="NLM_article-title">GRK6 deficiency is associated with enhanced CXCR4-mediated neutrophil chemotaxis in vitro and impaired responsiveness to G-CSF in vivo</span>. <i>J. Leukoc. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1189/jlb.0703320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1189%2Fjlb.0703320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=14704365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2004&pages=698-704&author=A.+Vroonauthor=C.+J.+Heijnenauthor=R.+Raatgeverauthor=I.+P.+Touwauthor=R.+E.+Ploemacherauthor=R.+T.+Premontauthor=A.+Kavelaars&title=GRK6+deficiency+is+associated+with+enhanced+CXCR4-mediated+neutrophil+chemotaxis+in+vitro+and+impaired+responsiveness+to+G-CSF+in+vivo&doi=10.1189%2Fjlb.0703320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">GRK6 deficiency is associated with enhanced CXCR4-mediated neutrophil chemotaxis in vitro and impaired responsiveness to G-CSF in vivo</span></div><div class="casAuthors">Vroon, Anne; Heijnen, Cobi J.; Raatgever, Roel; Touw, Ivo P.; Ploemacher, Rob E.; Premont, Richard T.; Kavelaars, Annemieke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">698-704</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">The stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor 4 (CXCR4) signaling pathway is thought to play an important role in the induction of neutrophil mobilization from the bone marrow in response to granulocyte-colony stimulating factor (G-CSF) treatment.  CXCR4 belongs to the family of G protein-coupled receptors.  Multiple members of this receptor family are desensitized by agonist-induced G protein-coupled receptor kinase (GRK)-mediated phosphorylation.  Here, the authors demonstrate that in vitro SDF-1-induced chemotaxis of bone marrow-derived neutrophils from GRK6-deficient mice is significantly enhanced and that desensitization of the calcium response to SDF-1 is impaired in GRK6-/- neutrophils.  CXCR4 activation by SDF-1 provides a key retention signal for hematopoietic cells in the bone marrow.  It is interesting that the authors obsd. that in the absence of GRK6, the G-CSF-induced increase in circulating neutrophils is profoundly impaired.  Three days after injection of pegylated-G-CSF, significantly lower nos. of circulating neutrophils were obsd. in GRK6-/- as compared with wild-type (WT) mice.  In addn., early/acute neutrophil mobilization in response to G-CSF (3 h after treatment) was also impaired in GRK6-/- mice.  However, blood neutrophil levels in untreated GRK6-/- and WT mice were not different.  Moreover, the percentage of neutrophils in the bone marrow after G-CSF treatment was increased to the same extent in WT and GRK6-/- mice, indicating that neutrophil prodn. is normal in the absence of GRK6.  However, the increased chemotactic sensitivity of GRK6-/- neutrophils to SDF-1 was retained after G-CSF treatment.  In view of these data, the authors suggest that the impaired G-CSF-induced neutrophil mobilization in the absence of GRK6 may be a result of enhanced CXCR4-mediated retention of PMN in the bone marrow.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhQ_hTHtYCILVg90H21EOLACvtfcHk0lhc9u8SMipk7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFyrtr4%253D&md5=3167d60a87917a409e8f4f52bb61d40e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0703320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0703320%26sid%3Dliteratum%253Aachs%26aulast%3DVroon%26aufirst%3DA.%26aulast%3DHeijnen%26aufirst%3DC.%2BJ.%26aulast%3DRaatgever%26aufirst%3DR.%26aulast%3DTouw%26aufirst%3DI.%2BP.%26aulast%3DPloemacher%26aufirst%3DR.%2BE.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26aulast%3DKavelaars%26aufirst%3DA.%26atitle%3DGRK6%2520deficiency%2520is%2520associated%2520with%2520enhanced%2520CXCR4-mediated%2520neutrophil%2520chemotaxis%2520in%2520vitro%2520and%2520impaired%2520responsiveness%2520to%2520G-CSF%2520in%2520vivo%26jtitle%3DJ.%2520Leukoc.%2520Biol.%26date%3D2004%26volume%3D75%26spage%3D698%26epage%3D704%26doi%3D10.1189%2Fjlb.0703320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zidar, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">9649</span>– <span class="NLM_lpage">9654</span>, <span class="refDoi"> DOI: 10.1073/pnas.0904361106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1073%2Fpnas.0904361106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=19497875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=9649-9654&author=D.+A.+Zidarauthor=J.+D.+Violinauthor=E.+J.+Whalenauthor=R.+J.+Lefkowitz&title=Selective+engagement+of+G+protein+coupled+receptor+kinases+%28GRKs%29+encodes+distinct+functions+of+biased+ligands&doi=10.1073%2Fpnas.0904361106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands</span></div><div class="casAuthors">Zidar, David A.; Violin, Jonathan D.; Whalen, Erin J.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9649-9654, S9649/1-S9649/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">CCL19 and CCL21 are endogenous agonists for the seven-transmembrane receptor CCR7.  They are equally active in promoting G protein stimulation and chemotaxis.  Yet, the authors find that they result in striking differences in activation of the G protein-coupled receptor kinase (GRK)/β-arrestin system.  CCL19 leads to robust CCR7 phosphorylation and β-arrestin2 recruitment catalyzed by both GRK3 and GRK6 whereas CCL21 activates GRK6 alone.  This differential GRK activation leads to distinct functional consequences.  Although each ligand leads to β-arrestin2 recruitment, only CCL19 leads to redistribution of β-arrestin2-GFP into endocytic vesicles and classical receptor desensitization.  In contrast, these agonists are both capable of signaling through GRK6 and β-arrestin2 to ERK kinases.  Thus, this mechanism for "ligand bias" whereby endogenous agonists activate different GRK isoforms leads to functionally distinct pools of β-arrestin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVIg9KXFgIIrVg90H21EOLACvtfcHk0lhc9u8SMipk7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCqurc%253D&md5=d94e0d529075db86d94261833c9a4c8a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904361106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904361106%26sid%3Dliteratum%253Aachs%26aulast%3DZidar%26aufirst%3DD.%2BA.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DSelective%2520engagement%2520of%2520G%2520protein%2520coupled%2520receptor%2520kinases%2520%2528GRKs%2529%2520encodes%2520distinct%2520functions%2520of%2520biased%2520ligands%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D9649%26epage%3D9654%26doi%3D10.1073%2Fpnas.0904361106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premont, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span> <span> </span><span class="NLM_article-title">G Protein-coupled receptor kinases phosphorylate LRP6 in the Wnt pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">35040</span>– <span class="NLM_lpage">35048</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.047456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fjbc.M109.047456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=19801552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFWitbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=35040-35048&author=M.+Chenauthor=M.+Philippauthor=J.+Wangauthor=R.+T.+Premontauthor=T.+R.+Garrisonauthor=M.+G.+Caronauthor=R.+J.+Lefkowitzauthor=W.+Chen&title=G+Protein-coupled+receptor+kinases+phosphorylate+LRP6+in+the+Wnt+pathway&doi=10.1074%2Fjbc.M109.047456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">G Protein-coupled Receptor Kinases Phosphorylate LRP6 in the Wnt Pathway</span></div><div class="casAuthors">Chen, Min-Yong; Philipp, Melanie; Wang, Jiang-Bo; Premont, Richard T.; Garrison, Tiffany R.; Caron, Marc G.; Lefkowitz, Robert J.; Chen, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">35040-35048</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Wnt ligands conduct their functions in canonical Wnt signaling by binding to 2 receptors, the single transmembrane low d. lipoprotein receptor-related proteins 5 and 6 (LRP5/6) and 7 transmembrane (7TM) Frizzled receptors.  Subsequently, phosphorylation of serine/threonine residues within 5 repeating signature PPPSP motifs on LRP6 is responsible for LRP6 activation.  GSK3β, a cytosolic kinase for phosphorylation of a downstream effector β-catenin, was proposed to participate in such LRP6 phosphorylation.  Here, we report a new class of membrane-assocd. kinases for LRP6 phosphorylation.  G protein-coupled receptor kinases 5 and 6 (GRK5/6), traditionally known to phosphorylate and desensitize 7TM G protein-coupled receptors, directly phosphorylate the PPPSP motifs on single transmembrane LRP6 and regulate Wnt/LRP6 signaling.  GRK5/6-induced LRP6 activation is inhibited by the LRP6 antagonist Dickkopf.  Depletion of GRK5 markedly reduces Wnt3A-stimulated LRP6 phosphorylation in cells.  In zebrafish, functional knock-down of GRK5 results in reduced Wnt signaling, analogous to LRP6 knock-down, as assessed by decreased abundance of β-catenin and lowered expression of the Wnt target genes cdx4, vent, and axin2.  Expression of GRK5 rescues the diminished β-catenin and axin2 response caused by GRK5 depletion.  Thus, our findings identify GRK5/6 as novel kinases for the single transmembrane receptor LRP6 during Wnt signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_FM4K81kUkrVg90H21EOLACvtfcHk0lhc9u8SMipk7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFWitbzI&md5=d578d432df8b1123c4208a84b778fdd9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.047456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.047456%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPhilipp%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26aulast%3DGarrison%26aufirst%3DT.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DChen%26aufirst%3DW.%26atitle%3DG%2520Protein-coupled%2520receptor%2520kinases%2520phosphorylate%2520LRP6%2520in%2520the%2520Wnt%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D35040%26epage%3D35048%26doi%3D10.1074%2Fjbc.M109.047456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernstedt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhenc-Gelas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Esterl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikic, I.</span></span> <span> </span><span class="NLM_article-title">Determination of bradykinin B2 receptor in vivo phosphorylation sites and their role in receptor function</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">40431</span>– <span class="NLM_lpage">40440</span>, <span class="refDoi"> DOI: 10.1074/jbc.M107024200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fjbc.M107024200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=11517230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A280%3ADC%252BD3MrnsVOnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=40431-40440&author=A.+Blaukatauthor=A.+Pizardauthor=A.+Breitauthor=C.+Wernstedtauthor=F.+Alhenc-Gelasauthor=W.+Muller-Esterlauthor=I.+Dikic&title=Determination+of+bradykinin+B2+receptor+in+vivo+phosphorylation+sites+and+their+role+in+receptor+function&doi=10.1074%2Fjbc.M107024200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of bradykinin B2 receptor in vivo phosphorylation sites and their role in receptor function</span></div><div class="casAuthors">Blaukat A; Pizard A; Breit A; Wernstedt C; Alhenc-Gelas F; Muller-Esterl W; Dikic I</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">40431-40</span>
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Reversible phosphorylation plays important roles in G protein-coupled receptor signaling, desensitization, and endocytosis, yet the precise location and role of in vivo phosphorylation sites is unknown for most receptors.  Using metabolic 32P labeling and phosphopeptide sequencing we provide a complete phosphorylation map of the human bradykinin B2 receptor in its native cellular environment.  We identified three serine residues, Ser(339), Ser(346), and Ser(348), at the C-terminal tail as principal phosphorylation sites.  Constitutive phosphorylation occurs at Ser(348), while ligand-induced phosphorylation is found at Ser(339) and Ser(346)/Ser(348) that could be executed by several G protein-coupled receptor kinases.  In addition, we found a protein kinase C-dependent phosphorylation of Ser(346) that was mutually exclusive with the basal phosphorylation at Ser(348) and therefore may be implicated in differential regulation of B2 receptor activation.  Functional analysis of receptor mutants revealed that a low phosphorylation stoichiometry is sufficient to initiate receptor sequestration while a clustered phosphorylation around Ser(346) is necessary for desensitization of the B2 receptor-induced phospholipase C activation.  This was further supported by the specifically reduced Ser(346)/Ser(348) phosphorylation observed upon stimulation with a nondesensitizing B2 receptor agonist.  The differential usage of clustered phosphoacceptor sites points to distinct roles of multiple kinases in controlling G protein-coupled receptor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4SZXITJek86qcneEtCi92fW6udTcc2eYorvYULD2ynLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MrnsVOnug%253D%253D&md5=b3307ee5eebc2f62af94f43590b35084</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M107024200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M107024200%26sid%3Dliteratum%253Aachs%26aulast%3DBlaukat%26aufirst%3DA.%26aulast%3DPizard%26aufirst%3DA.%26aulast%3DBreit%26aufirst%3DA.%26aulast%3DWernstedt%26aufirst%3DC.%26aulast%3DAlhenc-Gelas%26aufirst%3DF.%26aulast%3DMuller-Esterl%26aufirst%3DW.%26aulast%3DDikic%26aufirst%3DI.%26atitle%3DDetermination%2520of%2520bradykinin%2520B2%2520receptor%2520in%2520vivo%2520phosphorylation%2520sites%2520and%2520their%2520role%2520in%2520receptor%2520function%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D40431%26epage%3D40440%26doi%3D10.1074%2Fjbc.M107024200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaudreau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gouill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rola-Pleszczynski, M.</span></span> <span> </span><span class="NLM_article-title">Threonine 308 within a putative casein kinase 2 site of the cytoplasmic tail of leukotriene B(4) receptor (BLT1) is crucial for ligand-induced, G-protein-coupled receptor-specific kinase 6-mediated desensitization</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">31567</span>– <span class="NLM_lpage">31576</span>, <span class="refDoi"> DOI: 10.1074/jbc.M202723200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fjbc.M202723200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12077128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslOqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=31567-31576&author=R.+Gaudreauauthor=C.+Le+Gouillauthor=M.+H.+Venneauthor=J.+Stankovaauthor=M.+Rola-Pleszczynski&title=Threonine+308+within+a+putative+casein+kinase+2+site+of+the+cytoplasmic+tail+of+leukotriene+B%284%29+receptor+%28BLT1%29+is+crucial+for+ligand-induced%2C+G-protein-coupled+receptor-specific+kinase+6-mediated+desensitization&doi=10.1074%2Fjbc.M202723200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Threonine 308 within a putative casein kinase 2 site of the cytoplasmic tail of leukotriene B4 receptor (BLT1) is crucial for ligand-induced, G-protein-coupled receptor-specific kinase 6-mediated desensitization</span></div><div class="casAuthors">Gaudreau, Remi; Le Gouill, Christian; Venne, Marie-Helene; Stankova, Jana; Rola-Pleszczynski, Marek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">31567-31576</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Desensitization of G-protein-coupled receptors may involve phosphorylation of serine and threonine residues.  The leukotriene B4 (LTB4) receptor (BLT1) contains 14 intracellular serines and threonines, 8 of which are part of consensus target sequences for protein kinase C (PKC) or casein kinase 2.  In this study, we investigated the importance of PKC and GPCR-specific kinase (GRK) phosphorylation in BLT1 desensitization.  Pretreatment of BLT1-transfected COS-7 cells with PKC activators caused a decrease of LTB4-induced inositol phosphate (IP) accumulation.  This redn. was prevented with the PKC inhibitor, staurosporine, and not obsd. in cells expressing a BLT1 deletion mutant (G291stop) lacking the cytoplasmic tail.  Moreover LTB4-induced IP accumulation was significantly inhibited by overexpression of GRK2, GRK5, and esp. GRK6, in cells expressing wild type BLT1 but not in those expressing G291stop.  GRK6-mediated desensitization correlated with increased phosphorylation of BLT1.  The G319stop truncated BLT1 mutant displayed functional characteristics comparable with wild type BLT1 in terms of desensitization by GRK6, but not by PKC.  Substitution of Thr308 within a putative casein kinase 2 site to proline or alanine in the full-length BLT1 receptor prevented most of GRK6-mediated inhibition of LTB4-induced IP prodn. but only partially affected LTB4-induced BLT1 phosphorylation.  Our findings thus suggest that Thr308 is a major residue involved in GRK6-mediated desensitization of BLT1 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp83IiGE24e6bVg90H21EOLACvtfcHk0lj6ISqxV0Z-RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslOqtr8%253D&md5=bc618ba374285a03d9245032f2000f53</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M202723200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M202723200%26sid%3Dliteratum%253Aachs%26aulast%3DGaudreau%26aufirst%3DR.%26aulast%3DLe%2BGouill%26aufirst%3DC.%26aulast%3DVenne%26aufirst%3DM.%2BH.%26aulast%3DStankova%26aufirst%3DJ.%26aulast%3DRola-Pleszczynski%26aufirst%3DM.%26atitle%3DThreonine%2520308%2520within%2520a%2520putative%2520casein%2520kinase%25202%2520site%2520of%2520the%2520cytoplasmic%2520tail%2520of%2520leukotriene%2520B%25284%2529%2520receptor%2520%2528BLT1%2529%2520is%2520crucial%2520for%2520ligand-induced%252C%2520G-protein-coupled%2520receptor-specific%2520kinase%25206-mediated%2520desensitization%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D31567%26epage%3D31576%26doi%3D10.1074%2Fjbc.M202723200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matkovich, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorn, G. W.</span></span> <span> </span><span class="NLM_article-title">2nd, G-protein receptor kinases 2, 5 and 6 redundantly modulate smoothened-GATA transcriptional crosstalk in fetal mouse hearts</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2018.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.yjmcc.2018.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=29969579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yitb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2018&pages=60-68&author=A.+Francoauthor=L.+Zhangauthor=S.+J.+Matkovichauthor=A.+Kovacsauthor=G.+W.+Dorn&title=2nd%2C+G-protein+receptor+kinases+2%2C+5+and+6+redundantly+modulate+smoothened-GATA+transcriptional+crosstalk+in+fetal+mouse+hearts&doi=10.1016%2Fj.yjmcc.2018.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">G-protein receptor kinases 2, 5 and 6 redundantly modulate Smoothened-GATA transcriptional crosstalk in fetal mouse hearts</span></div><div class="casAuthors">Franco, Antoinetta; Zhang, Lihong; Matkovich, Scot J.; Kovacs, Attila; Dorn, Gerald W., II</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-68</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G protein receptor kinases (GRKs) regulate adult hearts by modulating inotropic, chronotropic and hypertrophic signaling of 7-transmembrane spanning neurohormone receptors.  GRK-mediated desensitization and downregulation of β-adrenergic receptors has been implicated in adult heart failure; GRKs are therefore a promising therapeutic target.  However, germ-line (but not cardiomyocyte-specific) GRK2 deletion provoked lethal fetal heart defects, suggesting an unexplained role for GRKs in heart development.  Here we undertook to better understand the consequences of GRK deficiency on fetal heart development by creating mice and cultured murine embryonic fibroblasts (MEFs) having floxed GRK2 and GRK5 alleles on the GRK6 null background; simultaneous conditional deletion of these 3 GRK genes was achieved using Nkx2-5 Cre or adenoviral Cre, resp.  Phenotypes were related to GRK-modulated gene expression using whole-transcriptome RNA sequencing, RT-qPCR, and luciferase reporter assays.  In cultured MEFs the atypical 7-transmembrane spanning protein and GRK2 substrate Smoothened (Smo) stimulated Gli-mediated transcriptional activity, which was interrupted by deleting GRK2/5/6.  Mice with Nkx2-5 Cre mediated GRK2/5/6 ablation died between E15.5 and E16.5, whereas mice expressing any one of these 3 GRKs (i.e. GRK2/5, GRK2/6 or GRK5/6 deleted) were developmentally normal.  GRK2/5/6 triple null mice at E14.5 exhibited left and right heart blood intermixing through single atrioventricular valves or large membranous ventricular septal defects.  Hedgehog and GATA pathway gene expression promoted by Smo/Gli was suppressed in GRK2/5/6 deficient fetal hearts and MEFs.  These data indicate that GRK2, GRK5 and GRK6 redundantly modulate Smo-GATA crosstalk in fetal mouse hearts, orchestrating transcriptional pathways previously linked to clin. and exptl. atrioventricular canal defects.  GRK modulation of Smo reflects convergence of conventional neurohormonal signaling and transcriptional regulation pathways, comprising an unanticipated mechanism for spatiotemporal orchestration of developmental gene expression in the heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA94lConk9orVg90H21EOLACvtfcHk0lj6ISqxV0Z-RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yitb7O&md5=c1443b33adf482cde39735739be86282</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2018.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2018.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DFranco%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DMatkovich%26aufirst%3DS.%2BJ.%26aulast%3DKovacs%26aufirst%3DA.%26aulast%3DDorn%26aufirst%3DG.%2BW.%26atitle%3D2nd%252C%2520G-protein%2520receptor%2520kinases%25202%252C%25205%2520and%25206%2520redundantly%2520modulate%2520smoothened-GATA%2520transcriptional%2520crosstalk%2520in%2520fetal%2520mouse%2520hearts%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2018%26volume%3D121%26spage%3D60%26epage%3D68%26doi%3D10.1016%2Fj.yjmcc.2018.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benovic, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedegaertner, P. B.</span></span> <span> </span><span class="NLM_article-title">Plasma membrane and nuclear localization of G protein coupled receptor kinase 6A</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2960</span>– <span class="NLM_lpage">2969</span>, <span class="refDoi"> DOI: 10.1091/mbc.e07-01-0013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1091%2Fmbc.e07-01-0013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=17538017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFalu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=2960-2969&author=X.+Jiangauthor=J.+L.+Benovicauthor=P.+B.+Wedegaertner&title=Plasma+membrane+and+nuclear+localization+of+G+protein+coupled+receptor+kinase+6A&doi=10.1091%2Fmbc.e07-01-0013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma membrane and nuclear localization of G protein-coupled receptor kinase 6A</span></div><div class="casAuthors">Jiang, Xiaoshan; Benovic, Jeffrey L.; Wedegaertner, Philip B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2960-2969</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">G protein-coupled receptor (GPCR) kinases (GRKs) specifically phosphorylate agonist-occupied GPCRs at the inner surface of the plasma membrane (PM), leading to receptor desensitization.  Here we show that the C-terminal 30 amino acids of GRK6A contain multiple elements that either promote or inhibit PM localization.  Disruption of palmitoylation by individual mutation of Cys 561, 562, or 565 or treatment of cells with 2-bromopalmitate shifts GRK6A from the PM to both the cytoplasm and nucleus.  Likewise, disruption of the hydrophobic nature of a predicted amphipathic helix by mutation of two leucines to alanines at positions 551 and 552 causes a loss of PM localization.  Moreover, acidic amino acids in the C-terminus appear to neg. regulate PM localization; mutational replacement of several acidic residues with neutral or basic residues rescues PM localization of a palmitoylation-defective GRK6A.  Last, we characterize the novel nuclear localization, showing that nuclear export of nonpalmitoylated GRK6A is sensitive to leptomycin B and that GRK6A contains a potential nuclear localization signal.  These results suggest that the C-terminus of GRK6A contains a novel electrostatic palmitoyl switch in which acidic residues weaken the membrane-binding strength of the amphipathic helix, thus allowing changes in palmitoylation to regulate PM vs. cytoplasmic/nuclear localization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgJDTxg5zCj7Vg90H21EOLACvtfcHk0ljkDZXmg2wv2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFalu70%253D&md5=2c0ce25753c3121ae6f06f8661d3e0e0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e07-01-0013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e07-01-0013%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DBenovic%26aufirst%3DJ.%2BL.%26aulast%3DWedegaertner%26aufirst%3DP.%2BB.%26atitle%3DPlasma%2520membrane%2520and%2520nuclear%2520localization%2520of%2520G%2520protein%2520coupled%2520receptor%2520kinase%25206A%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2007%26volume%3D18%26spage%3D2960%26epage%3D2969%26doi%3D10.1091%2Fmbc.e07-01-0013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aramaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of the highly selective and potent G-protein-coupled receptor kinase 2 (GRK2) inhibitor for the potential treatment of heart failure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6942</span>– <span class="NLM_lpage">6990</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6942-6990&author=T.+Okawaauthor=Y.+Aramakiauthor=M.+Yamamotoauthor=T.+Kobayashiauthor=S.+Fukumotoauthor=Y.+Toyodaauthor=T.+Hentaauthor=A.+Hataauthor=S.+Ikedaauthor=M.+Kanekoauthor=I.+D.+Hoffmanauthor=B.+C.+Sangauthor=H.+Zouauthor=T.+Kawamoto&title=Design%2C+synthesis%2C+and+evaluation+of+the+highly+selective+and+potent+G-protein-coupled+receptor+kinase+2+%28GRK2%29+inhibitor+for+the+potential+treatment+of+heart+failure&doi=10.1021%2Facs.jmedchem.7b00443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure</span></div><div class="casAuthors">Okawa, Tomohiro; Aramaki, Yoshio; Yamamoto, Mitsuo; Kobayashi, Toshitake; Fukumoto, Shoji; Toyoda, Yukio; Henta, Tsutomu; Hata, Akito; Ikeda, Shota; Kaneko, Manami; Hoffman, Isaac D.; Sang, Bi-Ching; Zou, Hua; Kawamoto, Tetsuji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6942-6990</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies.  Hydrazone deriv. and 1,2,4-triazole deriv. were identified as hit compds. by HTS.  New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole deriv. with an N-benzylcarboxamide moiety with highly potent activity towards GRK2, and selectivity over other kinases.  In terms of subtype selectivity, these compds. showed enough selectivity against GRK1, 5, 6, 7 with almost equipotent inhibition to GRK3.  The medicinal chem. efforts led to the discovery of I (GRK2 IC50 = 18 nM) which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol.  Therefore, I appears to be a novel class of therapeutic for heart failure treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrov4sgtujNFbVg90H21EOLACvtfcHk0ljkDZXmg2wv2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbjF&md5=6077a12ddcbd4454ccfc4d55c65c5a61</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00443%26sid%3Dliteratum%253Aachs%26aulast%3DOkawa%26aufirst%3DT.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukumoto%26aufirst%3DS.%26aulast%3DToyoda%26aufirst%3DY.%26aulast%3DHenta%26aufirst%3DT.%26aulast%3DHata%26aufirst%3DA.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DI.%2BD.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DKawamoto%26aufirst%3DT.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520the%2520highly%2520selective%2520and%2520potent%2520G-protein-coupled%2520receptor%2520kinase%25202%2520%2528GRK2%2529%2520inhibitor%2520for%2520the%2520potential%2520treatment%2520of%2520heart%2520failure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6942%26epage%3D6990%26doi%3D10.1021%2Facs.jmedchem.7b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkle, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuprun, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1830</span>– <span class="NLM_lpage">1839</span>, <span class="refDoi"> DOI: 10.1021/cb3003013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb3003013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1830-1839&author=D.+M.+Thalauthor=K.+T.+Homanauthor=J.+Chenauthor=E.+K.+Wuauthor=P.+M.+Hinkleauthor=Z.+M.+Huangauthor=J.+K.+Chuprunauthor=J.+Songauthor=E.+Gaoauthor=J.+Y.+Cheungauthor=L.+A.+Sklarauthor=W.+J.+Kochauthor=J.+J.+Tesmer&title=Paroxetine+is+a+direct+inhibitor+of+g+protein-coupled+receptor+kinase+2+and+increases+myocardial+contractility&doi=10.1021%2Fcb3003013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxetine Is a Direct Inhibitor of G Protein-Coupled Receptor Kinase 2 and Increases Myocardial Contractility</span></div><div class="casAuthors">Thal, David M.; Homan, Kristoff T.; Chen, Jun; Wu, Emily K.; Hinkle, Patricia M.; Huang, Z. Maggie; Chuprun, J. Kurt; Song, Jianliang; Gao, Erhe; Cheung, Joseph Y.; Sklar, Larry A.; Koch, Walter J.; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1830-1839</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G protein-coupled receptor kinase 2 (GRK2) is a well-established therapeutic target for the treatment of heart failure.  Herein we identify the selective serotonin reuptake inhibitor (SSRI) paroxetine as a selective inhibitor of GRK2 activity both in vitro and in living cells.  In the crystal structure of the GRK2·paroxetine-Gβγ complex, paroxetine binds in the active site of GRK2 and stabilizes the kinase domain in a novel conformation in which a unique regulatory loop forms part of the ligand binding site.  Isolated cardiomyocytes show increased isoproterenol-induced shortening and contraction amplitude in the presence of paroxetine, and pretreatment of mice with paroxetine before isoproterenol significantly increases left ventricular inotropic reserve in vivo with no significant effect on heart rate.  Neither is obsd. in the presence of the SSRI fluoxetine.  Our structural and functional results validate a widely available drug as a selective chem. probe for GRK2 and represent a starting point for the rational design of more potent and specific GRK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaoH2b0cTO5rVg90H21EOLACvtfcHk0ljkDZXmg2wv2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOntLfI&md5=08df20fa41a8b3241640db5de557a001</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fcb3003013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb3003013%26sid%3Dliteratum%253Aachs%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DHoman%26aufirst%3DK.%2BT.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DE.%2BK.%26aulast%3DHinkle%26aufirst%3DP.%2BM.%26aulast%3DHuang%26aufirst%3DZ.%2BM.%26aulast%3DChuprun%26aufirst%3DJ.%2BK.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DE.%26aulast%3DCheung%26aufirst%3DJ.%2BY.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DParoxetine%2520is%2520a%2520direct%2520inhibitor%2520of%2520g%2520protein-coupled%2520receptor%2520kinase%25202%2520and%2520increases%2520myocardial%2520contractility%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1830%26epage%3D1839%26doi%3D10.1021%2Fcb3003013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldschmidt, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Rodriguez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cato, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waninger-Saroni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larimore, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannavo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhoff, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. D.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis, and biological evaluation of highly selective and potent G protein-coupled receptor kinase 2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3793</span>– <span class="NLM_lpage">3807</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b02000</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b02000" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVOgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3793-3807&author=H.+V.+Waldschmidtauthor=K.+T.+Homanauthor=O.+Cruz-Rodriguezauthor=M.+C.+Catoauthor=J.+Waninger-Saroniauthor=K.+M.+Larimoreauthor=A.+Cannavoauthor=J.+Songauthor=J.+Y.+Cheungauthor=P.+D.+Kirchhoffauthor=W.+J.+Kochauthor=J.+J.+Tesmerauthor=S.+D.+Larsen&title=Structure-based+design%2C+synthesis%2C+and+biological+evaluation+of+highly+selective+and+potent+G+protein-coupled+receptor+kinase+2+inhibitors&doi=10.1021%2Facs.jmedchem.5b02000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors</span></div><div class="casAuthors">Waldschmidt, Helen V.; Homan, Kristoff T.; Cruz-Rodriguez, Osvaldo; Cato, Marilyn C.; Waninger-Saroni, Jessica; Larimore, Kelly L.; Cannavo, Alessandro; Song, Jianliang; Cheung, Joseph Y.; Kirchhoff, Paul D.; Koch, Walter J.; Tesmer, John J. G.; Larsen, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3793-3807</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are central to many physiol. processes.  Regulation of this superfamily of receptors is controlled by GPCR kinases (GRKs), some of which have been implicated in heart failure.  GSK180736A, developed as a Rho-assocd. coiled-coil kinase 1 (ROCK1) inhibitor, was identified as an inhibitor of GRK2 and co-crystd. in the active site.  Guided by its binding pose overlaid with the binding pose of a known potent GRK2 inhibitor, Takeda103A, a library of hybrid inhibitors was developed.  This campaign produced several compds. possessing high potency and selectivity for GRK2 over other GRK subfamilies, PKA, and ROCK1.  The most selective compd., 12n (I) (CCG-224406), had an IC50 for GRK2 of 130 nM, >700-fold selectivity over other GRK subfamilies, and no detectable inhibition of ROCK1.  Four of the new inhibitors were crystd. with GRK2 to give mol. insights into the binding and kinase selectivity of this class of inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzeEC4l5djErVg90H21EOLACvtfcHk0lhEtMcv_iZFqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVOgtL8%253D&md5=149b7722909617a88d439ae3d90338a4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b02000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b02000%26sid%3Dliteratum%253Aachs%26aulast%3DWaldschmidt%26aufirst%3DH.%2BV.%26aulast%3DHoman%26aufirst%3DK.%2BT.%26aulast%3DCruz-Rodriguez%26aufirst%3DO.%26aulast%3DCato%26aufirst%3DM.%2BC.%26aulast%3DWaninger-Saroni%26aufirst%3DJ.%26aulast%3DLarimore%26aufirst%3DK.%2BM.%26aulast%3DCannavo%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DJ.%2BY.%26aulast%3DKirchhoff%26aufirst%3DP.%2BD.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26aulast%3DLarsen%26aufirst%3DS.%2BD.%26atitle%3DStructure-based%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520highly%2520selective%2520and%2520potent%2520G%2520protein-coupled%2520receptor%2520kinase%25202%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3793%26epage%3D3807%26doi%3D10.1021%2Facs.jmedchem.5b02000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldschmidt, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannavo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of G protein-coupled receptor kinase 5 in complex with a rationally designed inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">20649</span>– <span class="NLM_lpage">20659</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.647370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fjbc.M115.647370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=26032411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOrtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=20649-20659&author=K.+T.+Homanauthor=H.+V.+Waldschmidtauthor=A.+Glukhovaauthor=A.+Cannavoauthor=J.+Songauthor=J.+Y.+Cheungauthor=W.+J.+Kochauthor=S.+D.+Larsenauthor=J.+J.+Tesmer&title=Crystal+structure+of+G+protein-coupled+receptor+kinase+5+in+complex+with+a+rationally+designed+inhibitor&doi=10.1074%2Fjbc.M115.647370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of G Protein-coupled Receptor Kinase 5 in Complex with a Rationally Designed Inhibitor</span></div><div class="casAuthors">Homan, Kristoff T.; Waldschmidt, Helen V.; Glukhova, Alisa; Cannavo, Alessandro; Song, Jianliang; Cheung, Joseph Y.; Koch, Walter J.; Larsen, Scott D.; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">20649-20659</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">G protein-coupled receptor kinases (GRKs) regulate cell signaling by initiating the desensitization of active G protein-coupled receptors.  The two most widely expressed GRKs (GRK2 and GRK5) play a role in cardiovascular disease and thus represent important targets for the development of novel therapeutic drugs.  In the course of a GRK2 structure-based drug design campaign, one inhibitor (CCG215022) exhibited nanomolar IC50 values against both GRK2 and GRK5 and good selectivity against other closely related kinases such as GRK1 and PKA.  Treatment of murine cardiomyocytes with CCG215022 resulted in significantly increased contractility at 20-fold lower concns. than paroxetine, an inhibitor with more modest selectivity for GRK2.  A 2.4 Å crystal structure of the GRK5·CCG215022 complex was detd. and revealed that the inhibitor binds in the active site similarly to its parent compd. GSK180736A.  As designed, its 2-pyridylmethyl amide side chain occupies the hydrophobic subsite of the active site where it forms three addnl. hydrogen bonds, including one with the catalytic lysine.  The overall conformation of the GRK5 kinase domain is similar to that of a previously detd. structure of GRK6 in what is proposed to be its active state, but the C-terminal region of the enzyme adopts a distinct conformation.  The kinetic properties of site-directed mutants in this region are consistent with the hypothesis that this novel C-terminal structure is representative of the membrane-bound conformation of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCa90PSxbJr7Vg90H21EOLACvtfcHk0lhEtMcv_iZFqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOrtrfP&md5=1cd56381cfc8d5ec1265cc6672b94946</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.647370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.647370%26sid%3Dliteratum%253Aachs%26aulast%3DHoman%26aufirst%3DK.%2BT.%26aulast%3DWaldschmidt%26aufirst%3DH.%2BV.%26aulast%3DGlukhova%26aufirst%3DA.%26aulast%3DCannavo%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DJ.%2BY.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DLarsen%26aufirst%3DS.%2BD.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520G%2520protein-coupled%2520receptor%2520kinase%25205%2520in%2520complex%2520with%2520a%2520rationally%2520designed%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D20649%26epage%3D20659%26doi%3D10.1074%2Fjbc.M115.647370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannavo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">16937</span>– <span class="NLM_lpage">16949</span>, <span class="refDoi"> DOI: 10.3390/molecules191016937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.3390%2Fmolecules191016937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=25340299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCisr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=16937-16949&author=K.+T.+Homanauthor=E.+Wuauthor=A.+Cannavoauthor=W.+J.+Kochauthor=J.+J.+Tesmer&title=Identification+and+characterization+of+amlexanox+as+a+G+protein-coupled+receptor+kinase+5+inhibitor&doi=10.3390%2Fmolecules191016937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor</span></div><div class="casAuthors">Homan, Kristoff T.; Wu, Emily; Cannavo, Alessandro; Koch, Walter J.; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">16937-16949, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">G protein-coupled receptor kinases (GRKs) have been implicated in human diseases ranging from heart failure to diabetes.  Previous studies have identified several compds. that selectively inhibit GRK2, such as paroxetine and balanol.  Far fewer selective inhibitors have been reported for GRK5, a target for the treatment of cardiac hypertrophy, and the mechanism of action of reported compds. is unknown.  To identify novel scaffolds that selectively inhibit GRK5, a differential scanning fluorometry screen was used to probe a library of 4480 compds.  The best hit was amlexanox, an FDA-approved anti-inflammatory, anti-allergic immunomodulator.  The crystal structure of amlexanox in complex with GRK1 demonstrates that its tricyclic arom. ring system forms ATP-like interactions with the hinge of the kinase domain, which is likely similar to how this drug binds to IκB kinase ε (IKKε), another kinase known to be inhibited by this compd.  Amlexanox was also able to inhibit myocyte enhancer factor 2 transcriptional activity in neonatal rat ventricular myocytes in a manner consistent with GRK5 inhibition.  The GRK1 amlexanox structure thus serves as a springboard for the rational design of inhibitors with improved potency and selectivity for GRK5 and IKKε.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyXvoGyufJ4LVg90H21EOLACvtfcHk0lgZgjcBtPFcuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCisr3L&md5=5a7c8d455e1fa7b596c816f9126f1b9f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3390%2Fmolecules191016937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules191016937%26sid%3Dliteratum%253Aachs%26aulast%3DHoman%26aufirst%3DK.%2BT.%26aulast%3DWu%26aufirst%3DE.%26aulast%3DCannavo%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520amlexanox%2520as%2520a%2520G%2520protein-coupled%2520receptor%2520kinase%25205%2520inhibitor%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26spage%3D16937%26epage%3D16949%26doi%3D10.3390%2Fmolecules191016937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowlands, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avramova, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. D.</span></span> <span> </span><span class="NLM_article-title">Generation of highly selective, potent, and covalent G protein-coupled receptor kinase 5 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01522</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01522" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtVOmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=566-585&author=R.+A.+Rowlandsauthor=Q.+Chenauthor=R.+A.+Bouleyauthor=L.+V.+Avramovaauthor=J.+J.+G.+Tesmerauthor=A.+D.+White&title=Generation+of+highly+selective%2C+potent%2C+and+covalent+G+protein-coupled+receptor+kinase+5+inhibitors&doi=10.1021%2Facs.jmedchem.0c01522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of Highly Selective, Potent, and Covalent G Protein-Coupled Receptor Kinase 5 Inhibitors</span></div><div class="casAuthors">Rowlands, Rachel A.; Chen, Qiuyan; Bouley, Renee A.; Avramova, Larisa V.; Tesmer, John J. G.; White, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">566-585</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ability of G protein-coupled receptor (GPCR) kinases (GRKs) to regulate the desensitization of GPCRs has made GRK2 and GRK5 attractive targets for treating diseases such as heart failure and cancer.  Previously, our work showed that Cys474, a GRK5 subfamily-specific residue located on a flexible loop adjacent to the active site, can be used as a covalent handle to achieve selective inhibition of GRK5 over GRK2 subfamily members.  However, the potency of the most selective inhibitors remained modest.  Herein, we describe a successful campaign to adapt an indolinone scaffold with covalent warheads, resulting in a series of 2-haloacetyl-contg. compds. that react quickly and exhibit three orders of magnitude selectivity for GRK5 over GRK2 and low nanomolar potency.  They however retain a similar selectivity profile across the kinome as the core scaffold, which was based on Sunitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS1bZaUeDZrrVg90H21EOLACvtfcHk0lgZgjcBtPFcuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtVOmsw%253D%253D&md5=31d279aaa80a89992610d878cf5f0917</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01522%26sid%3Dliteratum%253Aachs%26aulast%3DRowlands%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DBouley%26aufirst%3DR.%2BA.%26aulast%3DAvramova%26aufirst%3DL.%2BV.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%2BG.%26aulast%3DWhite%26aufirst%3DA.%2BD.%26atitle%3DGeneration%2520of%2520highly%2520selective%252C%2520potent%252C%2520and%2520covalent%2520G%2520protein-coupled%2520receptor%2520kinase%25205%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D566%26epage%3D585%26doi%3D10.1021%2Facs.jmedchem.0c01522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, K. S.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6711</span>– <span class="NLM_lpage">6716</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.10.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.bmcl.2013.10.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=24210504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=6711-6716&author=S.+Y.+Choauthor=B.+H.+Leeauthor=H.+Jungauthor=C.+S.+Yunauthor=J.+D.+Haauthor=H.+R.+Kimauthor=C.+H.+Chaeauthor=J.+H.+Leeauthor=H.+W.+Seoauthor=K.+S.+Oh&title=Design+and+synthesis+of+novel+3-%28benzo%5Bd%5Doxazol-2-yl%29-5-%281-%28piperidin-4-yl%29-1H-pyrazol-4-yl%29pyridin-2-amine+derivatives+as+selective+G-protein-coupled+receptor+kinase-2+and+-5+inhibitors&doi=10.1016%2Fj.bmcl.2013.10.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors</span></div><div class="casAuthors">Cho, Sung Yun; Lee, Byung Ho; Jung, Heejung; Yun, Chang Soo; Ha, Jae Du; Kim, Hyoung Rae; Chae, Chong Hak; Lee, Jeong Hyun; Seo, Ho Won; Oh, Kwang-Seok</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6711-6716</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G-protein-coupled receptor kinase (GRK)-2 and -5 are emerging therapeutic targets for the treatment of cardiovascular disease.  In the efforts to discover novel small mols. to inhibit GRK-2 and -5, a class of compd. based on 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine was identified as a novel hit by high throughput screening campaign.  Structural modification of parent benzoxazole scaffolds by introducing substituents on Ph displayed potent inhibitory activities toward GRK-2 and -5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk9cUk_aJBEbVg90H21EOLACvtfcHk0lgZgjcBtPFcuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCrurvL&md5=5bc20ccc08b2831fce29fd7aa60a6b22</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.10.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.10.036%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DJung%26aufirst%3DH.%26aulast%3DYun%26aufirst%3DC.%2BS.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DChae%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DSeo%26aufirst%3DH.%2BW.%26aulast%3DOh%26aufirst%3DK.%2BS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%25203-%2528benzo%255Bd%255Doxazol-2-yl%2529-5-%25281-%2528piperidin-4-yl%2529-1H-pyrazol-4-yl%2529pyridin-2-amine%2520derivatives%2520as%2520selective%2520G-protein-coupled%2520receptor%2520kinase-2%2520and%2520-5%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D6711%26epage%3D6716%26doi%3D10.1016%2Fj.bmcl.2013.10.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for small molecule inhibition of G protein-coupled receptor kinases</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1021/cb5003976</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5003976" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOjtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=246-256&author=K.+T.+Homanauthor=J.+J.+Tesmer&title=Molecular+basis+for+small+molecule+inhibition+of+G+protein-coupled+receptor+kinases&doi=10.1021%2Fcb5003976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for small molecule inhibition of G protein-coupled receptor kinases</span></div><div class="casAuthors">Homan, Kristoff T.; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">246-256</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Small mols. that inhibit the protein kinase A, G, and C (AGC) family of serine/threonine kinases can exert profound effects on cell homeostasis and thereby regulate fundamental processes such as heart rate, blood pressure, and metab., but there is not yet a clin. approved drug in the United States selective for a member of this family.  One subfamily of AGC kinases, the G protein-coupled receptor (GPCR) kinases (GRKs), initiates the desensitization of active GPCRs.  Of these, GRK2 has been directly implicated in the progression of heart failure.  Thus, there is great interest in the identification of GRK2-specific chem. probes that can be further developed into therapeutics.  Here, the authors compare crystal structures of small mol. inhibitors in complex with GRK2 to those of highly selective compds. in complex with Rho-assocd. coiled-coil contg. kinase 1 (ROCK1), a closely related AGC kinase.  This anal. suggests that reduced H-bond formation with the hinge of the kinase domain, occupation of the hydrophobic subsite, and, consequently, higher buried surface area are key drivers of potency and selectivity among GRK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw1BX1Q5uXt7Vg90H21EOLACvtfcHk0ljdpBMyCEWH8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOjtL3E&md5=c80248ae417a2d94f3d7bd788273b696</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fcb5003976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5003976%26sid%3Dliteratum%253Aachs%26aulast%3DHoman%26aufirst%3DK.%2BT.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520basis%2520for%2520small%2520molecule%2520inhibition%2520of%2520G%2520protein-coupled%2520receptor%2520kinases%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D246%26epage%3D256%26doi%3D10.1021%2Fcb5003976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boguth, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for activation of G protein-coupled receptor kinases</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3249</span>– <span class="NLM_lpage">3259</span>, <span class="refDoi"> DOI: 10.1038/emboj.2010.206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Femboj.2010.206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=20729810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGgtb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=3249-3259&author=C.+A.+Boguthauthor=P.+Singhauthor=C.+C.+Huangauthor=J.+J.+Tesmer&title=Molecular+basis+for+activation+of+G+protein-coupled+receptor+kinases&doi=10.1038%2Femboj.2010.206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for activation of G protein-coupled receptor kinases</span></div><div class="casAuthors">Boguth, Cassandra A.; Singh, Puja; Huang, Chih-chin; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3249-3259</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptor (GPCR) kinases (GRKs) selectively recognize and are allosterically regulated by activated GPCRs, but the mol. basis for this interaction is not understood.  Herein, we report crystal structures of GRK6 in which regions known to be crit. for receptor phosphorylation have coalesced to stabilize the kinase domain in a closed state and to form a likely receptor docking site.  The crux of this docking site is an extended N-terminal helix that bridges the large and small lobes of the kinase domain and lies adjacent to a basic surface of the protein proposed to bind anionic phospholipids.  Mutation of exposed, hydrophobic residues in the N-terminal helix selectively inhibits receptor, but not peptide phosphorylation, suggesting that these residues interact directly with GPCRs.  Our structural and biochem. results thus provide an explanation for how receptor recognition, phospholipid binding, and kinase activation are intimately coupled in GRKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxCitsTX_fhbVg90H21EOLACvtfcHk0ljdpBMyCEWH8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGgtb%252FE&md5=15d6df48fad121f18286e4ac1db6edef</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Femboj.2010.206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2010.206%26sid%3Dliteratum%253Aachs%26aulast%3DBoguth%26aufirst%3DC.%2BA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520basis%2520for%2520activation%2520of%2520G%2520protein-coupled%2520receptor%2520kinases%26jtitle%3DEMBO%2520J.%26date%3D2010%26volume%3D29%26spage%3D3249%26epage%3D3259%26doi%3D10.1038%2Femboj.2010.206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-Tannoudji, J.</span></span> <span> </span><span class="NLM_article-title">Endogenous G protein-coupled receptor kinase 6 triggers homologous beta-adrenergic receptor desensitization in primary uterine smooth muscle cells</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">3058</span>– <span class="NLM_lpage">3066</span>, <span class="refDoi"> DOI: 10.1210/en.2002-0138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1210%2Fen.2002-0138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12810562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvF2kt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2003&pages=3058-3066&author=V.+Simonauthor=M.+T.+Robinauthor=C.+Legrandauthor=J.+Cohen-Tannoudji&title=Endogenous+G+protein-coupled+receptor+kinase+6+triggers+homologous+beta-adrenergic+receptor+desensitization+in+primary+uterine+smooth+muscle+cells&doi=10.1210%2Fen.2002-0138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous G protein-coupled receptor kinase 6 triggers homologous β-adrenergic receptor desensitization in primary uterine smooth muscle cells</span></div><div class="casAuthors">Simon, Violaine; Robin, Marie-Therese; Legrand, Chantal; Cohen-Tannoudji, Joelle</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3058-3066</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">The authors previously reported that G protein-coupled receptor kinase (GRK) may contribute to β-adrenergic receptor (β-AR) uncoupling occurring just before parturition in rat uterine muscle (myometrium).  To identify the GRK involved, the authors set up in this study a primary cell culture retaining the morphol. and functional characteristics of myometrial tissue as well as the in vivo pattern of GRK expression (GRK2, GRK5, and GRK6).  In this model, homologous β-AR desensitization was assessed by an approx. 60% decrease in cAMP prodn. to a subsequent challenge with the β-agonist, isoproterenol.  Desensitization was reduced by 36% with a GRK inhibitor, heparin, and by 31% with a protein kinase A inhibitor, H89.  Using antibodies known to specifically inhibit either GRK2/3 or GRK4-6 families, the authors demonstrated that only the GRK4-6 family mediated β-AR desensitization.  To discriminate between endogenous GRK5 and GRK6, the authors attempted to inhibit their action by introducing, into myometrial cells, kinase-dead dominant-neg. mutants (K215RGRK5 and K215RGRK6).  Expression of K215RGRK6 increased by approx. 70% the cAMP response to isoproterenol without effect on forskolin stimulation.  Conversely, expression of K215RGRK5 or K220RGRK2 had no effect on β-adrenergic signaling.  These results strongly suggest that endogenous GRK6 mediate homologous β-AR desensitization in myometrial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrBkh4Jtgz7Vg90H21EOLACvtfcHk0ljdpBMyCEWH8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvF2kt7c%253D&md5=5c48e302b216b8ecc30b4e7fed9709db</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1210%2Fen.2002-0138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2002-0138%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DV.%26aulast%3DRobin%26aufirst%3DM.%2BT.%26aulast%3DLegrand%26aufirst%3DC.%26aulast%3DCohen-Tannoudji%26aufirst%3DJ.%26atitle%3DEndogenous%2520G%2520protein-coupled%2520receptor%2520kinase%25206%2520triggers%2520homologous%2520beta-adrenergic%2520receptor%2520desensitization%2520in%2520primary%2520uterine%2520smooth%2520muscle%2520cells%26jtitle%3DEndocrinology%26date%3D2003%26volume%3D144%26spage%3D3058%26epage%3D3066%26doi%3D10.1210%2Fen.2002-0138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grinshtein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujitani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakesch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrana, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span> <span> </span><span class="NLM_article-title">Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1385</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1158%2F0008-5472.CAN-10-2484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=21303981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFSjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1385-1395&author=N.+Grinshteinauthor=A.+Dattiauthor=M.+Fujitaniauthor=D.+Uehlingauthor=M.+Prakeschauthor=M.+Isaacauthor=M.+S.+Irwinauthor=J.+L.+Wranaauthor=R.+Al-Awarauthor=D.+R.+Kaplan&title=Small+molecule+kinase+inhibitor+screen+identifies+polo-like+kinase+1+as+a+target+for+neuroblastoma+tumor-initiating+cells&doi=10.1158%2F0008-5472.CAN-10-2484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Kinase Inhibitor Screen Identifies Polo-Like Kinase 1 as a Target for Neuroblastoma Tumor-Initiating Cells</span></div><div class="casAuthors">Grinshtein, Natalie; Datti, Alessandro; Fujitani, Mayumi; Uehling, David; Prakesch, Michael; Isaac, Methvin; Irwin, Meredith S.; Wrana, Jeffrey L.; Al-Awar, Rima; Kaplan, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1385-1395</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Neuroblastoma (NB) is an often fatal pediatric tumor of neural crest origin.  We previously isolated NB tumor-initiating cells (NB TIC) from bone marrow metastases that resemble cancer stem cells and form metastatic NB in immunodeficient animals with as few as ten cells.  To identify signaling pathways important for the survival and self-renewal of NB TICs and potential therapeutic targets, we screened a small mol. library of 143 protein kinase inhibitors, including 33 in clin. trials.  Cytostatic or cytotoxic drugs were identified that targeted PI3K (phosphoinositide 3-kinase)/Akt, PKC (protein kinase C), Aurora, ErbB2, Trk, and Polo-like kinase 1 (PLK1).  Treatment with PLK1 siRNA or low nanomolar concns. of BI 2536 or BI 6727, PLK1 inhibitors in clin. trials for adult malignancies, were cytotoxic to TICs whereas only micromolar concns. of the inhibitors were cytotoxic for normal pediatric neural stem cells.  Furthermore, BI 2536 significantly inhibited TIC tumor growth in a therapeutic xenograft model, both as a single agent and in combination with irinotecan, an active agent for relapsed NB.  Our findings identify candidate kinases that regulate TIC growth and survival and suggest that PLK1 inhibitors are an attractive candidate therapy for metastatic NB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Lun2JYBAvrVg90H21EOLACvtfcHk0ljdpBMyCEWH8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFSjsbo%253D&md5=4b44c2950ae96e2b405727fc4489cadd</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2484%26sid%3Dliteratum%253Aachs%26aulast%3DGrinshtein%26aufirst%3DN.%26aulast%3DDatti%26aufirst%3DA.%26aulast%3DFujitani%26aufirst%3DM.%26aulast%3DUehling%26aufirst%3DD.%26aulast%3DPrakesch%26aufirst%3DM.%26aulast%3DIsaac%26aufirst%3DM.%26aulast%3DIrwin%26aufirst%3DM.%2BS.%26aulast%3DWrana%26aufirst%3DJ.%2BL.%26aulast%3DAl-Awar%26aufirst%3DR.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26atitle%3DSmall%2520molecule%2520kinase%2520inhibitor%2520screen%2520identifies%2520polo-like%2520kinase%25201%2520as%2520a%2520target%2520for%2520neuroblastoma%2520tumor-initiating%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1385%26epage%3D1395%26doi%3D10.1158%2F0008-5472.CAN-10-2484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trzcińska-Daneluti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fladd, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakesch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotin, D.</span></span> <span> </span><span class="NLM_article-title">Use of kinase inhibitors to correct DeltaF508-CFTR function</span>. <i>Mol. Cell. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1074/mcp.M111.016626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fmcp.M111.016626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=22700489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlOjsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=745-757&author=A.+M.+Trzci%C5%84ska-Danelutiauthor=L.+Nguyenauthor=C.+Jiangauthor=C.+Fladdauthor=D.+Uehlingauthor=M.+Prakeschauthor=R.+Al-awarauthor=D.+Rotin&title=Use+of+kinase+inhibitors+to+correct+DeltaF508-CFTR+function&doi=10.1074%2Fmcp.M111.016626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Use of kinase inhibitors to correct ΔF508-CFTR function</span></div><div class="casAuthors">Trzcinska-Daneluti, Agata M.; Nguyen, Leo; Jiang, Chong; Fladd, Christopher; Uehling, David; Prakesch, Michael; Al-Awar, Rima; Rotin, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Proteomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">745-757</span>CODEN:
                <span class="NLM_cas:coden">MCPOBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-9484</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The most common mutation in cystic fibrosis (CF) is a deletion of Phe at position 508 (ΔF508-CFTR).  ΔF508-CFTR is a trafficking mutant that is retained in the ER, unable to reach the plasma membrane.  To identify compds. and drugs that rescue this trafficking defect, we screened a kinase inhibitor library enriched for small mols. already in the clinic or in clin. trials for the treatment of cancer and inflammation, using our recently developed high-content screen technol.  The top hits of the screen were further validated by (1) biochem. anal. to demonstrate the presence of mature (Band C) ΔF508-CFTR, (2) flow cytometry to reveal the presence of ΔF508-CFTR at the cell surface, (3) short-circuit current (Isc) anal. in Ussing chambers to show restoration of function of the rescued ΔF508-CFTR in epithelial MDCK cells stably expressing this mutant (including EC50 detns.), and importantly (4) Isc anal. of Human Bronchial Epithelial (HBE) cells harvested from homozygote ΔF508-CFTR transplant patients.  Interestingly, several inhibitors of receptor Tyr kinases (RTKs), such as SU5402 and SU6668 (which target FGFRs, VEGFR, and PDGFR) exhibited strong rescue of ΔF508-CFTR, as did several inhibitors of the Ras/Raf/MEK/ERK or p38 pathways (e.g. (5Z)-7-oxozeaenol).  Prominent rescue was also obsd. by inhibitors of GSK-3β (e.g. GSK-3β Inhibitor II and Kenpaullone).  These results identify several kinase inhibitors that can rescue ΔF508-CFTR to various degrees, and suggest that use of compds. or drugs already in the clinic or in clin. trials for other diseases can expedite delivery of treatment for CF patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFSVfvmQVRoLVg90H21EOLACvtfcHk0liK4YahNnXAPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlOjsLzJ&md5=399260492c4c3ed07a06764878075be2</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1074%2Fmcp.M111.016626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fmcp.M111.016626%26sid%3Dliteratum%253Aachs%26aulast%3DTrzci%25C5%2584ska-Daneluti%26aufirst%3DA.%2BM.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DFladd%26aufirst%3DC.%26aulast%3DUehling%26aufirst%3DD.%26aulast%3DPrakesch%26aufirst%3DM.%26aulast%3DAl-awar%26aufirst%3DR.%26aulast%3DRotin%26aufirst%3DD.%26atitle%3DUse%2520of%2520kinase%2520inhibitors%2520to%2520correct%2520DeltaF508-CFTR%2520function%26jtitle%3DMol.%2520Cell.%2520Proteomics%26date%3D2012%26volume%3D11%26spage%3D745%26epage%3D757%26doi%3D10.1074%2Fmcp.M111.016626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexei, W. P. K.</span>; <span class="NLM_string-name">Shokat, K. M.</span>; <span class="NLM_string-name">Zhang, C.</span>; <span class="NLM_string-name">Finer-More, J.</span>; <span class="NLM_string-name">Stroud, R.</span>; <span class="NLM_string-name">Egea, P.</span>; <span class="NLM_string-name">Korostelev, A.</span>; <span class="NLM_string-name">Dar, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrazolyl-Substituted Pyrimidine-2,4-diamine Derivatives as Ire1, Src and Abl Modulators</span>. <span class="NLM_patent">WO2010031056</span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=W.+P.+K.+Alexei&author=K.+M.+Shokat&author=C.+Zhang&author=J.+Finer-More&author=R.+Stroud&author=P.+Egea&author=A.+Korostelev&author=A.+Dar&title=Preparation+of+Pyrazolyl-Substituted+Pyrimidine-2%2C4-diamine+Derivatives+as+Ire1%2C+Src+and+Abl+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlexei%26aufirst%3DW.%2BP.%2BK.%26atitle%3DPreparation%2520of%2520Pyrazolyl-Substituted%2520Pyrimidine-2%252C4-diamine%2520Derivatives%2520as%2520Ire1%252C%2520Src%2520and%2520Abl%2520Modulators%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furihata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">AZ960, a novel jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3386</span>– <span class="NLM_lpage">3395</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1158%2F1535-7163.MCT-10-0416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=21159615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=3386-3395&author=J.+Yangauthor=T.+Ikezoeauthor=C.+Nishiokaauthor=M.+Furihataauthor=A.+Yokoyama&title=AZ960%2C+a+novel+jak2+inhibitor%2C+induces+growth+arrest+and+apoptosis+in+adult+T-cell+leukemia+cells&doi=10.1158%2F1535-7163.MCT-10-0416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">AZ960, a Novel Jak2 Inhibitor, Induces Growth Arrest and Apoptosis in Adult T-Cell Leukemia Cells</span></div><div class="casAuthors">Yang, Jing; Ikezoe, Takayuki; Nishioka, Chie; Furihata, Mutsuo; Yokoyama, Akihito</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3386-3395</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive disease in which the Jak2/Stat5 pathway is constitutively activated.  This study found that AZ960, a novel inhibitor of Jak2 kinase, effectively induced growth arrest and apoptosis of human T-cell lymphotropic virus type 1, HTLV-1-infected T cells (MT-1 and MT-2) in parallel with downregulation of the phosphorylated forms of Jak2 and Bcl-2 family proteins including Bcl-2 and Mcl-1.  Interestingly, AZ960 increased levels of Bcl-xL in MT-1 and MT-2 cells in assocn. with accumulation of cAMP response element-binding protein bound to the Bcl-xL promoter as measured by chromatin immunopptn. assay.  Importantly, genetic inhibition of Bcl-xL by a small interfering RNA potentiated antiproliferative effects of AZ960 in MT-1 cells.  Taken together, Jak2 is an attractive mol. target for treatment of ATL.  Concomitant blockade of Jak2 and Bcl-xL may be a promising treatment strategy for this lethal disease.  Mol Cancer Ther; 9(12); 3386-95.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5A7ZSZ5lKF7Vg90H21EOLACvtfcHk0liK4YahNnXAPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsLvK&md5=6c4899e4340922287a44ec3a888e9b24</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0416%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DFurihata%26aufirst%3DM.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DAZ960%252C%2520a%2520novel%2520jak2%2520inhibitor%252C%2520induces%2520growth%2520arrest%2520and%2520apoptosis%2520in%2520adult%2520T-cell%2520leukemia%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D3386%26epage%3D3395%26doi%3D10.1158%2F1535-7163.MCT-10-0416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrace, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel jak2-stat pathway inhibitors with extended residence time on target</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3105</span>– <span class="NLM_lpage">3110</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.bmcl.2013.02.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=23562594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltlOhtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3105-3110&author=H.+Guanauthor=M.+L.+Lambauthor=B.+Pengauthor=S.+Huangauthor=N.+Degraceauthor=J.+Readauthor=S.+Hussainauthor=J.+Wuauthor=C.+Rivardauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=M.+Zindaauthor=S.+Ioannidis&title=Discovery+of+novel+jak2-stat+pathway+inhibitors+with+extended+residence+time+on+target&doi=10.1016%2Fj.bmcl.2013.02.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target</span></div><div class="casAuthors">Guan, Huiping; Lamb, Michelle L.; Peng, Bo; Huang, Shan; DeGrace, Nancy; Read, Jon; Hussain, Syeed; Wu, Jiaquan; Rivard, Caroline; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Ye, Minwei; Zinda, Michael; Ioannidis, Stephanos</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3105-3110</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of the activating mutation V617F in the JH2 domain of Jak2 and the modulation of oncogenic Stat3 by Jak2 inhibitors have spurred a great interest in the inhibition of the Jak2/Stat pathway in oncol.  In this Letter, the authors communicate the discovery of novel inhibitors of the Jak2/Stat5 axis, the N-(1H-pyrazol-3-yl)pyrimidin-2-amino derivs.  The rationale, synthesis and biol. evaluation of these derivs. are reported.  Two lead analogs from this series, (I) and (II), displayed prolonged residence time on Jak2, at enzymic level.  Although (I) and (II) exhibited moderate selectivity in a selected kinase panel, the authors chose to test these inhibitors in vivo as a consequence to their long residence time.  However, extended inhibition of Jak2 due to the long residence time, in the form of inhibiting phosphorylation of downstream Stat5, was not recapitulated in an in vivo setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEqzh5WfofE7Vg90H21EOLACvtfcHk0liK4YahNnXAPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltlOhtrk%253D&md5=dee4662399d073c0d1a5f8dddcd9682a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.111%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DDegrace%26aufirst%3DN.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520novel%2520jak2-stat%2520pathway%2520inhibitors%2520with%2520extended%2520residence%2520time%2520on%2520target%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3105%26epage%3D3110%26doi%3D10.1016%2Fj.bmcl.2013.02.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard
Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-methyl-1H-imidazole derivatives as potent jak2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1021/jm401546n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401546n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=144-158&author=Q.+Suauthor=S.+Ioannidisauthor=C.+Chuaquiauthor=L.+Almeidaauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Blockauthor=T.+Howardauthor=S.+Huangauthor=D.+Huszarauthor=J.+A.+Readauthor=C.+Rivard%0ACostaauthor=J.+Shiauthor=M.+Suauthor=M.+Yeauthor=M.+Zinda&title=Discovery+of+1-methyl-1H-imidazole+derivatives+as+potent+jak2+inhibitors&doi=10.1021%2Fjm401546n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors</span></div><div class="casAuthors">Su, Qibin; Ioannidis, Stephanos; Chuaqui, Claudio; Almeida, Lynsie; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Block, Michael; Howard, Tina; Huang, Shan; Huszar, Dennis; Read, Jon A.; Rivard Costa, Caroline; Shi, Jie; Su, Mei; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure based design, synthesis, and biol. evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described.  Using the C-ring fragment from our first clin. candidate AZD1480 (I), optimization of the series led to the discovery of compd. II, a potent, orally bioavailable Jak2 inhibitor.  Compd. II displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells.  Compd. II demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczgU5RpFv1bVg90H21EOLACvtfcHk0ljnd5_5JxK7pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL&md5=88c57119ec77d084a91a1123fd9dea86</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm401546n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401546n%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DBlock%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DRivard%2BCosta%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25201-methyl-1H-imidazole%2520derivatives%2520as%2520potent%2520jak2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D144%26epage%3D158%26doi%3D10.1021%2Fjm401546n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjogren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of disubstituted imidazo[4,5-b]pyridines and purines as potent trkA inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">709</span>, <span class="refDoi"> DOI: 10.1021/ml300074j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300074j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2isbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=705-709&author=T.+Wangauthor=M.+L.+Lambauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=Y.+Hanauthor=E.+Hoffmannauthor=S.+Ioannidisauthor=J.+A.+Joseyauthor=Z.+Y.+Liuauthor=P.+D.+Lyneauthor=T.+MacIntyreauthor=P.+J.+Mohrauthor=C.+A.+Omerauthor=T.+Sjogrenauthor=K.+Thressauthor=B.+Wangauthor=H.+Wangauthor=D.+Yuauthor=H.+J.+Zhang&title=Discovery+of+disubstituted+imidazo%5B4%2C5-b%5Dpyridines+and+purines+as+potent+trkA+inhibitors&doi=10.1021%2Fml300074j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors</span></div><div class="casAuthors">Wang, Tao; Lamb, Michelle L.; Block, Michael H.; Davies, Audrey Molina; Han, Yongxin; Hoffmann, Ethan; Ioannidis, Stephanos; Josey, John A.; Liu, Zhong-Ying; Lyne, Paul D.; MacIntyre, Terry; Mohr, Peter J.; Omer, Charles A.; Sjogren, Tove; Thress, Kenneth; Wang, Bin; Wang, Haiyun; Yu, Dingwei; Zhang, Hai-Jun</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">705-709</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trk receptor tyrosine kinases have been implicated in cancer and pain.  A crystal structure of TrkA with AZ-23 (1a) was obtained, and scaffold hopping resulted in two 5/6-bicyclic series comprising either imidazo[4,5-b]pyridines or purines.  Further optimization of these two fusion series led to compds. with subnanomolar potencies against TrkA kinase in cellular assays.  Antitumor effects in a TrkA-driven mouse allograft model were demonstrated with compds. 2d and 3a.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8S857L3CJC7Vg90H21EOLACvtfcHk0ljnd5_5JxK7pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2isbzK&md5=fc0e518c0f71276ad4cb416270844931</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fml300074j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300074j%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DZ.%2BY.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DMacIntyre%26aufirst%3DT.%26aulast%3DMohr%26aufirst%3DP.%2BJ.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DSjogren%26aufirst%3DT.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26atitle%3DDiscovery%2520of%2520disubstituted%2520imidazo%255B4%252C5-b%255Dpyridines%2520and%2520purines%2520as%2520potent%2520trkA%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D705%26epage%3D709%26doi%3D10.1021%2Fml300074j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikegami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomozane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morioka, M.</span></span> <span> </span><span class="NLM_article-title">3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective aurora A kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4709</span>– <span class="NLM_lpage">4711</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.04.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.bmcl.2010.04.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=20573509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4709-4711&author=R.+Andoauthor=H.+Ikegamiauthor=M.+Sakiyamaauthor=S.+Ooikeauthor=M.+Hayashiauthor=Y.+Fujinoauthor=D.+Abeauthor=H.+Nakamuraauthor=T.+Mishinaauthor=H.+Katoauthor=Y.+Iwaseauthor=H.+Tomozaneauthor=M.+Morioka&title=3-Cyano-6-%285-methyl-3-pyrazoloamino%29pyridines%3A+selective+aurora+A+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2010.04.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: Selective Aurora A kinase inhibitors</span></div><div class="casAuthors">Ando, Ryoichi; Ikegami, Hiroshi; Sakiyama, Makoto; Ooike, Shinsuke; Hayashi, Masayuki; Fujino, Yasuhiro; Abe, Daisuke; Nakamura, Hideo; Mishina, Tadashi; Kato, Harutoshi; Iwase, Yumiko; Tomozane, Hideo; Morioka, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4709-4711</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new class of Aurora A kinase inhibitor was created by transforming 4-(5-methyl-3-pyrazoloamino)pyrimidine moiety of VX-680 to 3-cyano-6-(5-methyl-3-pyrazoloamino)pyridine.  Compd. 6 exhibited a potent Aurora A kinase inhibitory activity, excellent selectivity to Aurora B kinase and other 60 kinases, good cell permeability and good PK profile.  Therefore compd. 6 was effective in antitumor mice model at a dose of 30 mg/kg po qd without decrease of body wt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPZJZo36mNM7Vg90H21EOLACvtfcHk0lgrM_WosRwlfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSrsrg%253D&md5=762fd01810b8ee23cfc90aae99defd78</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.04.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.04.119%26sid%3Dliteratum%253Aachs%26aulast%3DAndo%26aufirst%3DR.%26aulast%3DIkegami%26aufirst%3DH.%26aulast%3DSakiyama%26aufirst%3DM.%26aulast%3DOoike%26aufirst%3DS.%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DFujino%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DMishina%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DIwase%26aufirst%3DY.%26aulast%3DTomozane%26aufirst%3DH.%26aulast%3DMorioka%26aufirst%3DM.%26atitle%3D3-Cyano-6-%25285-methyl-3-pyrazoloamino%2529pyridines%253A%2520selective%2520aurora%2520A%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4709%26epage%3D4711%26doi%3D10.1016%2Fj.bmcl.2010.04.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebbington, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajose-Adeogun, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hercend, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diu-Hercend, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. M.</span></span> <span> </span><span class="NLM_article-title">VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1038/nm1003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Fnm1003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=14981513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=262-267&author=E.+A.+Harringtonauthor=D.+Bebbingtonauthor=J.+Mooreauthor=R.+K.+Rasmussenauthor=A.+O.+Ajose-Adeogunauthor=T.+Nakayamaauthor=J.+A.+Grahamauthor=C.+Demurauthor=T.+Hercendauthor=A.+Diu-Hercendauthor=M.+Suauthor=J.+M.+Golecauthor=K.+M.+Miller&title=VX-680%2C+a+potent+and+selective+small-molecule+inhibitor+of+the+aurora+kinases%2C+suppresses+tumor+growth+in+vivo&doi=10.1038%2Fnm1003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span></div><div class="casAuthors">Harrington, Elizabeth A.; Bebbington, David; Moore, Jeff; Rasmussen, Richele K.; Ajose-Adeogun, Abi O.; Nakayama, Tomoko; Graham, Joanne A.; Demur, Cecile; Hercend, Thierry; Diu-Hercend, Anita; Su, Michael; Golec, Julian M. C.; Miller, Karen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-267</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis.  Aberrant expression and activity of these kinases occur in a wide range of human tumors, and lead to aneuploidy and tumorigenesis.  Here we report the discovery of a highly potent and selective small-mol. inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types.  This compd. causes profound inhibition of tumor growth in a variety of in vivo xenograft models, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses.  Our data indicate that Aurora kinase inhibition provides a new approach for the treatment of multiple human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgm1YUgqkWLVg90H21EOLACvtfcHk0lgrM_WosRwlfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D&md5=954ba274e280d8d08a7f2e331011432d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnm1003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1003%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DBebbington%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DJ.%26aulast%3DRasmussen%26aufirst%3DR.%2BK.%26aulast%3DAjose-Adeogun%26aufirst%3DA.%2BO.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DJ.%2BA.%26aulast%3DDemur%26aufirst%3DC.%26aulast%3DHercend%26aufirst%3DT.%26aulast%3DDiu-Hercend%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26atitle%3DVX-680%252C%2520a%2520potent%2520and%2520selective%2520small-molecule%2520inhibitor%2520of%2520the%2520aurora%2520kinases%252C%2520suppresses%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D262%26epage%3D267%26doi%3D10.1038%2Fnm1003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinn, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollok, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crean, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvannasankha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abonour, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farag, S. S.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.2010.08248.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1111%2Fj.1365-2141.2010.08248.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=20560971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOntrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2010&pages=313-325&author=X.+Wangauthor=A.+L.+Sinnauthor=K.+Pollokauthor=G.+Sanduskyauthor=S.+Zhangauthor=L.+Chenauthor=J.+Liangauthor=C.+D.+Creanauthor=A.+Suvannasankhaauthor=R.+Abonourauthor=C.+Sidorauthor=M.+R.+Brayauthor=S.+S.+Farag&title=Preclinical+activity+of+a+novel+multiple+tyrosine+kinase+and+aurora+kinase+inhibitor%2C+ENMD-2076%2C+against+multiple+myeloma&doi=10.1111%2Fj.1365-2141.2010.08248.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma</span></div><div class="casAuthors">Wang, Xiaojing; Sinn, Anthony L.; Pollok, Karen; Sandusky, George; Zhang, Shuhong; Chen, Li; Liang, Jing; Crean, Colin D.; Suvannasankha, Attaya; Abonour, Rafat; Sidor, Carolyn; Bray, Mark R.; Farag, Sherif S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">313-325</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">ENMD-2076 is a novel, orally-active mol. that has been shown to have significant activity against aurora and multiple receptor tyrosine kinases.  We investigated the activity of ENMD-2076 against multiple myeloma (MM) cells in vitro and in vivo.  ENMD-2076 showed significant cytotoxicity against MM cell lines and primary cells, with minimal cytotoxicity to haematopoietic progenitors.  ENMD-2076 inhibited the phosphoinositide 3-kinase/AKT pathway and downregulated survivin and X-linked inhibitor of apoptosis as early as 6 h after treatment.  With longer treatment (24-48 h), ENMD-2076 also inhibited aurora A and B kinases, and induced G2/M cell cycle arrest.  In non-obese diabetic/severe combined immunodeficient mice implanted with H929 human plasmacytoma xenografts, oral treatment with ENMD-2076 (50, 100, 200 mg/kg per day) resulted in a dose-dependent inhibition of tumor growth.  Immunohistochem. staining of excised tumors showed significant redn. in phospho-Histone 3 (pH3), Ki-67, and angiogenesis, and also a significant increase in cleaved caspase-3 at all dose levels compared to tumors from vehicle-treated mice.  In addn., a significant redn. in p-FGFR3 was obsd. on Western blot.  ENMD-2076 shows significant activity against MM cells in vitro and in vivo, and acts on several pathways important for myeloma cell growth and survival.  These results provide preclin. rationale for clin. investigation of ENMD-2076 in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCdi2TPYK9NrVg90H21EOLACvtfcHk0lgrM_WosRwlfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOntrjN&md5=a351edddc67aab8043c055e4e54b606f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08248.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08248.x%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSinn%26aufirst%3DA.%2BL.%26aulast%3DPollok%26aufirst%3DK.%26aulast%3DSandusky%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DCrean%26aufirst%3DC.%2BD.%26aulast%3DSuvannasankha%26aufirst%3DA.%26aulast%3DAbonour%26aufirst%3DR.%26aulast%3DSidor%26aufirst%3DC.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DFarag%26aufirst%3DS.%2BS.%26atitle%3DPreclinical%2520activity%2520of%2520a%2520novel%2520multiple%2520tyrosine%2520kinase%2520and%2520aurora%2520kinase%2520inhibitor%252C%2520ENMD-2076%252C%2520against%2520multiple%2520myeloma%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2010%26volume%3D150%26spage%3D313%26epage%3D325%26doi%3D10.1111%2Fj.1365-2141.2010.08248.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandobashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togitani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2034</span>– <span class="NLM_lpage">2040</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-02-073700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1182%2Fblood-2007-02-073700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=17495131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2034-2040&author=J.+Yangauthor=T.+Ikezoeauthor=C.+Nishiokaauthor=T.+Tasakaauthor=A.+Taniguchiauthor=Y.+Kuwayamaauthor=N.+Komatsuauthor=K.+Bandobashiauthor=K.+Togitaniauthor=H.+P.+Koefflerauthor=H.+Taguchiauthor=A.+Yokoyama&title=AZD1152%2C+a+novel+and+selective+aurora+B+kinase+inhibitor%2C+induces+growth+arrest%2C+apoptosis%2C+and+sensitization+for+tubulin+depolymerizing+agent+or+topoisomerase+II+inhibitor+in+human+acute+leukemia+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2007-02-073700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo</span></div><div class="casAuthors">Yang, Jing; Ikezoe, Takayuki; Nishioka, Chie; Tasaka, Taizo; Taniguchi, Ayuko; Kuwayama, Yoshio; Komatsu, Naoki; Bandobashi, Kentaro; Togitani, Kazuto; Koeffler, H. Phillip; Taguchi, Hirokuni; Yokoyama, Akihito</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2034-2040</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Aurora kinases play an important role in chromosome alignment, segregation, and cytokinesis during mitosis.  We have recently shown that hematopoietic malignant cells including those from acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) aberrantly expressed Aurora A and B kinases, and ZM447439, a potent inhibitor of Aurora kinases, effectively induced growth arrest and apoptosis of a variety of leukemia cells.  The present study explored the effect of AZD1152, a highly selective inhibitor of Aurora B kinase, on various types of human leukemia cells.  AZD1152 inhibited the proliferation of AML lines (HL-60, NB4, MOLM13), ALL line (PALL-2), biphenotypic leukemia (MV4-11), acute eosinophilic leukemia (EOL-1), and the blast crisis of chronic myeloid leukemia K562 cells with an IC50 ranging from 3 nM to 40 nM, as measured by thymidine uptake on day 2 of culture.  These cells had 4N/8N DNA content followed by apoptosis, as measured by cell-cycle anal. and annexin V staining, resp.  Of note, AZD1152 synergistically enhanced the antiproliferative activity of vincristine, a tubulin depolymg. agent, and daunorubicin, a topoisomerase II inhibitor, against the MOLM13 and PALL-2 cells in vitro.  Furthermore, AZD1152 potentiated the action of vincristine and daunorubicin in a MOLM13 murine xenograft model.  Taken together, AZD1152 is a promising new agent for treatment of individuals with leukemia.  The combined administration of AZD1152 and conventional chemotherapeutic agent to patients with leukemia warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3zl3doZGXmbVg90H21EOLACvtfcHk0lgHkYVM41i1eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbnJ&md5=3d094eb4953d1e516a91cc922906ee5c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-02-073700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-02-073700%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DTasaka%26aufirst%3DT.%26aulast%3DTaniguchi%26aufirst%3DA.%26aulast%3DKuwayama%26aufirst%3DY.%26aulast%3DKomatsu%26aufirst%3DN.%26aulast%3DBandobashi%26aufirst%3DK.%26aulast%3DTogitani%26aufirst%3DK.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DTaguchi%26aufirst%3DH.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DAZD1152%252C%2520a%2520novel%2520and%2520selective%2520aurora%2520B%2520kinase%2520inhibitor%252C%2520induces%2520growth%2520arrest%252C%2520apoptosis%252C%2520and%2520sensitization%2520for%2520tubulin%2520depolymerizing%2520agent%2520or%2520topoisomerase%2520II%2520inhibitor%2520in%2520human%2520acute%2520leukemia%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2034%26epage%3D2040%26doi%3D10.1182%2Fblood-2007-02-073700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeow, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1124/mol.111.071522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1124%2Fmol.111.071522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=21596927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1yqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=294-303&author=D.+M.+Thalauthor=R.+Y.+Yeowauthor=C.+Schoenauauthor=J.+Huberauthor=J.+J.+Tesmer&title=Molecular+mechanism+of+selectivity+among+G+protein-coupled+receptor+kinase+2+inhibitors&doi=10.1124%2Fmol.111.071522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors</span></div><div class="casAuthors">Thal, David M.; Yeow, Raymond Y.; Schoenau, Christian; Huber, Jochen; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">294-303</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are key regulators of cell physiol. and control processes ranging from glucose homeostasis to contractility of the heart.  A major mechanism for the desensitization of activated GPCRs is their phosphorylation by GPCR kinases (GRKs).  Overexpression of GRK2 is strongly linked to heart failure, and GRK2 has long been considered a pharmaceutical target for the treatment of cardiovascular disease.  Several lead compds. developed by Takeda Pharmaceuticals show high selectivity for GRK2 and therapeutic potential for the treatment of heart failure.  To understand how these drugs achieve their selectivity, we detd. crystal structures of the bovine GRK2-Gβγ complex in the presence of two of these inhibitors.  Comparison with the apoGRK2-Gβγ structure demonstrates that the compds. bind in the kinase active site in a manner similar to that of the AGC kinase inhibitor balanol.  Both balanol and the Takeda compds. induce a slight closure of the kinase domain, the degree of which correlates with the potencies of the inhibitors.  Based on our crystal structures and homol. modeling, we identified five amino acids surrounding the inhibitor binding site that we hypothesized could contribute to inhibitor selectivity.  However, our results indicate that these residues are not major determinants of selectivity among GRK subfamilies.  Rather, selectivity is achieved by the stabilization of a unique inactive conformation of the GRK2 kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYlIMlpK9bU7Vg90H21EOLACvtfcHk0lgHkYVM41i1eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1yqsL0%253D&md5=cde68787c0f4f20131ffe88ddbfd9284</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.071522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.071522%26sid%3Dliteratum%253Aachs%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DYeow%26aufirst%3DR.%2BY.%26aulast%3DSchoenau%26aufirst%3DC.%26aulast%3DHuber%26aufirst%3DJ.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520mechanism%2520of%2520selectivity%2520among%2520G%2520protein-coupled%2520receptor%2520kinase%25202%2520inhibitors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D294%26epage%3D303%26doi%3D10.1124%2Fmol.111.071522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coomes, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupay, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daaka, Y.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptor kinase GRK5 phosphorylates moesin and regulates metastasis in prostate cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3489</span>– <span class="NLM_lpage">3500</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-2708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1158%2F0008-5472.CAN-13-2708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=24755472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKlurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3489-3500&author=P.+K.+Chakrabortyauthor=Y.+Zhangauthor=A.+S.+Coomesauthor=W.+J.+Kimauthor=R.+Stupayauthor=L.+D.+Lynchauthor=T.+Atkinsonauthor=J.+I.+Kimauthor=Z.+Nieauthor=Y.+Daaka&title=G+protein-coupled+receptor+kinase+GRK5+phosphorylates+moesin+and+regulates+metastasis+in+prostate+cancer&doi=10.1158%2F0008-5472.CAN-13-2708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">G Protein-Coupled Receptor Kinase GRK5 Phosphorylates Moesin and Regulates Metastasis in Prostate Cancer</span></div><div class="casAuthors">Chakraborty, Prabir Kumar; Zhang, Yushan; Coomes, Alexandra S.; Kim, Wan-Ju; Stupay, Rachel; Lynch, Lauren D.; Atkinson, Tamieka; Kim, Jae I.; Nie, Zhongzhen; Daaka, Yehia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3489-3500</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">G protein-coupled receptor kinases (GRK) regulate diverse cellular functions ranging from metab. to growth and locomotion.  Here, we report an important contributory role for GRK5 in human prostate cancer.  Inhibition of GRK5 kinase activity attenuated the migration and invasion of prostate cancer cells and, concordantly, increased cell attachment and focal adhesion formation.  Mass spectrometric anal. of the phosphoproteome revealed the cytoskeletal-membrane attachment protein moesin as a putative GRK5 substrate.  GRK5 regulated the subcellular distribution of moesin and colocalized with moesin at the cell periphery.  We identified amino acid T66 of moesin as a principal GRK5 phosphorylation site and showed that enforcing the expression of a T66-mutated moesin reduced cell spreading.  In a xenograft model of human prostate cancer, GRK5 silencing reduced tumor growth, invasion, and metastasis.  Taken together, our results established GRK5 as a key contributor to the growth and metastasis of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_qbVyWviPj7Vg90H21EOLACvtfcHk0lgHkYVM41i1eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKlurnM&md5=04ed0215f1c911cf108bed806d5fe879</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-2708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-2708%26sid%3Dliteratum%253Aachs%26aulast%3DChakraborty%26aufirst%3DP.%2BK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCoomes%26aufirst%3DA.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BJ.%26aulast%3DStupay%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DL.%2BD.%26aulast%3DAtkinson%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DJ.%2BI.%26aulast%3DNie%26aufirst%3DZ.%26aulast%3DDaaka%26aufirst%3DY.%26atitle%3DG%2520protein-coupled%2520receptor%2520kinase%2520GRK5%2520phosphorylates%2520moesin%2520and%2520regulates%2520metastasis%2520in%2520prostate%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3489%26epage%3D3500%26doi%3D10.1158%2F0008-5472.CAN-13-2708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulik, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giros, B.</span></span> <span> </span><span class="NLM_article-title">Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">12974</span>– <span class="NLM_lpage">12979</span>, <span class="refDoi"> DOI: 10.1073/pnas.93.23.12974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1073%2Fpnas.93.23.12974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=8917529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADyaK28XmvV2ksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=12974-12979&author=M.+Jaberauthor=W.+J.+Kochauthor=H.+Rockmanauthor=B.+Smithauthor=R.+A.+Bondauthor=K.+K.+Sulikauthor=J.+Rossauthor=R.+J.+Lefkowitzauthor=M.+G.+Caronauthor=B.+Giros&title=Essential+role+of+beta-adrenergic+receptor+kinase+1+in+cardiac+development+and+function&doi=10.1073%2Fpnas.93.23.12974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of β-adrenergic receptor kinase 1 in cardiac development and function</span></div><div class="casAuthors">Jaber, Mohamed; Koch, Walter J.; Rockman, Howard; Smith, Bradley; Bond, Richard A.; Sulik, Kathleen K.; Ross, John, Jr.; Lefkowitz, Robert J.; Caron, Marc G.; Giros, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12974-12979</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The β-adrenergic receptor kinase 1 (βARK1) is a member of the G protein-coupled receptor kinase (GRK) family that mediates the agonist-dependent phosphorylation and desensitization of G protein-coupled receptors.  We have cloned and disrupted the βARK1 gene in mice by homologous recombination.  No homozygote βARK1-/- embryos survive beyond gestational day 15.5.  Prior to gestational day 15.5, βARK1-/- embryos display pronounced hypoplasia of the ventricular myocardium essentially identical to the "thin myocardium syndrome" obsd. upon gene inactivation of several transcription factors (RXRα, N-myc, TEF-1, WT-1).  Lethality in βARK1-/- embryos is likely due to heart failure as they exhibit a >70% decrease in cardiac ejection fraction detd. by direct in utero intravital microscopy.  These results along with the virtual absence of endogenous GRK activity in βARK1-/- embryos demonstrate that βARK1 appears to be the predominant GRK in early embryogenesis and that it plays a functional role in cardiac development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwWiHmr8dR27Vg90H21EOLACvtfcHk0lh0061fBr00Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmvV2ksLk%253D&md5=92fb1cfe44d81638912c35f6240f2473</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.23.12974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.23.12974%26sid%3Dliteratum%253Aachs%26aulast%3DJaber%26aufirst%3DM.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DRockman%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DBond%26aufirst%3DR.%2BA.%26aulast%3DSulik%26aufirst%3DK.%2BK.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DGiros%26aufirst%3DB.%26atitle%3DEssential%2520role%2520of%2520beta-adrenergic%2520receptor%2520kinase%25201%2520in%2520cardiac%2520development%2520and%2520function%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1996%26volume%3D93%26spage%3D12974%26epage%3D12979%26doi%3D10.1073%2Fpnas.93.23.12974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paredes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamonova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sneddon, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarvey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Alphonse, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, P. A.</span></span> <span> </span><span class="NLM_article-title">Parathyroid hormone initiates dynamic NHERF1 phosphorylation cycling and conformational changes that regulate NPT2A-dependent phosphate transport</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">4546</span>– <span class="NLM_lpage">4571</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA119.007421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fjbc.RA119.007421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=30696771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFSmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=4546-4571&author=Q.+Zhangauthor=K.+Xiaoauthor=J.+M.+Paredesauthor=T.+Mamonovaauthor=W.+B.+Sneddonauthor=H.+Liuauthor=D.+Wangauthor=S.+Liauthor=J.+C.+McGarveyauthor=D.+Uehlingauthor=R.+Al-Awarauthor=B.+Josephauthor=F.+Jean-Alphonseauthor=A.+Orteauthor=P.+A.+Friedman&title=Parathyroid+hormone+initiates+dynamic+NHERF1+phosphorylation+cycling+and+conformational+changes+that+regulate+NPT2A-dependent+phosphate+transport&doi=10.1074%2Fjbc.RA119.007421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Parathyroid hormone initiates dynamic NHERF1 phosphorylation cycling and conformational changes that regulate NPT2A-dependent phosphate transport</span></div><div class="casAuthors">Zhang, Qiangmin; iao, Kunhong; Paredes, Jose M.; Mamonova, Tatyana; Sneddon, W. Bruce; Liu, Hongda; Wang, Dawei; Li, Sheng; McGarvey, Jennifer C.; Uehling, David; Al-awar, Rima; Joseph, Babu; Jean-Alphonse, Frederic; Orte, Angel; Friedman, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4546-4571</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Na+-Hα exchanger regulatory factor-1 (NHERF1) is a PDZ protein that scaffolds membrane proteins, including sodium- phosphate co-transport protein 2A (NPT2A) at the plasma membrane.  NHERF1 is a phosphoprotein with 40 Ser and Thr residues.  Here, using tandem MS anal., we characterized the sites of parathyroid hormone (PTH)-induced NHERF1 phosphorylation and identified 10 high-confidence phosphorylation sites.  Ala replacement at Ser46, Ser162, Ser181, Ser269, Ser280, Ser291, Thr293, Ser299, and Ser302 did not affect phosphate uptake, but S290A substitution abolished PTH-dependent phosphate transport.  Unexpectedly, Ser290 was rapidly dephosphorylated and rephosphorylated after PTH stimulation, and we found that protein phosphatase 1α (PP1α), which binds NHERF1 through a conserved VxF/W PP1 motif, dephosphorylates Ser290.  Mutating 257VPF259 eliminated PP1 binding and blunted dephosphorylation.  Tautomycetin blocked PP1 activity and abrogated PTH-sensitive phosphate transport.  Using fluorescence lifetime imaging (FLIM), we obsd. that PTH paradoxically and transiently elevates intracellular phosphate.  Added phosphate blocked PP1α-mediated Ser290 dephosphorylation of recombinant NHERF1.  Hydrogen-deuterium exchange M S revealed that β-sheets in NHERF1's PDZ2 domain display lower deuterium uptake than those in the structurally similar PDZ1, implying that PDZ1 is more cloistered.  Dephosphorylated NHERF1 exhibited faster exchange at C-terminal residues suggesting that NHERF1 dephosphorylation precedes Ser290 rephosphorylation.  Our results show that PP1α and NHERF1 form a holoenzyme and that a multiprotein kinase cascade involving G protein-coupled receptor kinase 6A controls the Ser290 phosphorylation status of NHERF1 and regulates PTH-sensitive, NPT2A-mediated phosphate uptake.  These findings reveal how reversible phosphorylation modifies protein conformation and function and the biochem. mechanisms underlying PTH control of phosphate transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYuqItZcK6N7Vg90H21EOLACvtfcHk0lh0061fBr00Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFSmtb8%253D&md5=caaf208e1a82bc5bd9d569e835525088</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.007421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.007421%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DK.%26aulast%3DParedes%26aufirst%3DJ.%2BM.%26aulast%3DMamonova%26aufirst%3DT.%26aulast%3DSneddon%26aufirst%3DW.%2BB.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMcGarvey%26aufirst%3DJ.%2BC.%26aulast%3DUehling%26aufirst%3DD.%26aulast%3DAl-Awar%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DJean-Alphonse%26aufirst%3DF.%26aulast%3DOrte%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DP.%2BA.%26atitle%3DParathyroid%2520hormone%2520initiates%2520dynamic%2520NHERF1%2520phosphorylation%2520cycling%2520and%2520conformational%2520changes%2520that%2520regulate%2520NPT2A-dependent%2520phosphate%2520transport%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D4546%26epage%3D4571%26doi%3D10.1074%2Fjbc.RA119.007421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R. H.</span>; <span class="NLM_string-name">Michael, J.</span>; <span class="NLM_string-name">Holladay, M. W.</span>; <span class="NLM_string-name">Rowbottom, M. W.</span>; <span class="NLM_string-name">Setti, E.</span></span> <span> </span><span class="NLM_article-title">Quinoline and isoquinoline derivatives for use as jak modulators</span>. U.S. Patent <span class="NLM_patent">US20130296363</span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+H.+Faraoni&author=J.+Michael&author=M.+W.+Holladay&author=M.+W.+Rowbottom&author=E.+Setti&title=Quinoline+and+isoquinoline+derivatives+for+use+as+jak+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFaraoni%26aufirst%3DR.%2BH.%26atitle%3DQuinoline%2520and%2520isoquinoline%2520derivatives%2520for%2520use%2520as%2520jak%2520modulators%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caivano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Specificity and mechanism of action of some commonly used protein kinase inhibitors</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1042/bj3510095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1042%2Fbj3510095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10998351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=95-105&author=S.+P.+Daviesauthor=H.+Reddyauthor=M.+Caivanoauthor=P.+Cohen&title=Specificity+and+mechanism+of+action+of+some+commonly+used+protein+kinase+inhibitors&doi=10.1042%2Fbj3510095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity and mechanism of action of some commonly used protein kinase inhibitors</span></div><div class="casAuthors">Davies, Stephen P.; Reddy, Helen; Caivano, Matilde; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 28 com. available compds. reported to be relatively selective inhibitors of particular serine/threonine-specific protein kinases have been examd. against a large panel of protein kinases.  The compds. KT 5720, Rottlerin and quercetin were found to inhibit many protein kinases, sometimes much more potently than their presumed targets, and conclusions drawn from their use in cell-based expts. are likely to be erroneous.  Ro 318220 and related bisindoylmaleimides, as well as H89, HA1077 and Y 27632, were more selective inhibitors, but still inhibited two or more protein kinases with similar potency.  LY 294002 was found to inhibit casein kinase-2 with similar potency to phosphoinositide (phosphatidylinositol) 3-kinase.  The compds. with the most impressive selectivity profiles were KN62, PD 98059, U0126, PD 184352, rapamycin, wortmannin, SB 203580 and SB 202190.  U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly.  Apart from rapamycin and PD 184352, even the most selective inhibitors affected at least one addnl. protein kinase.  Our results demonstrate that the specificities of protein kinase inhibitors cannot be assessed simply by studying their effect on kinases that are closely related in primary structure.  The authors propose guidelines for the use of protein kinase inhibitors in cell-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCs5LPDkzaGrVg90H21EOLACvtfcHk0lh0061fBr00Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D&md5=e14eb47a52dc43afca7373c276b2d147</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1042%2Fbj3510095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3510095%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DS.%2BP.%26aulast%3DReddy%26aufirst%3DH.%26aulast%3DCaivano%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DSpecificity%2520and%2520mechanism%2520of%2520action%2520of%2520some%2520commonly%2520used%2520protein%2520kinase%2520inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26spage%3D95%26epage%3D105%26doi%3D10.1042%2Fbj3510095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatushchenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreekumar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span> <span> </span><span class="NLM_article-title">Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1126/science.1233606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1126%2Fscience.1233606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=23828940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCgs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2013&pages=84-87&author=D.+M.+Molinaauthor=R.+Jafariauthor=M.+Ignatushchenkoauthor=T.+Sekiauthor=E.+A.+Larssonauthor=C.+Danauthor=L.+Sreekumarauthor=Y.+Caoauthor=P.+Nordlund&title=Monitoring+drug+target+engagement+in+cells+and+tissues+using+the+cellular+thermal+shift+assay&doi=10.1126%2Fscience.1233606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay</span></div><div class="casAuthors">Molina, Daniel Martinez; Jafari, Rozbeh; Ignatushchenko, Marina; Seki, Takahiro; Larsson, E. Andreas; Dan, Chen; Sreekumar, Lekshmy; Cao, Yihai; Nordlund, Paer</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">6141</span>),
    <span class="NLM_cas:pages">84-87</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The efficacy of therapeutics is dependent on a drug binding to its cognate target.  Optimization of target engagement by drugs in cells is often challenging, because drug binding cannot be monitored inside cells.  We have developed a method for evaluating drug binding to target proteins in cells and tissue samples.  This cellular thermal shift assay (CETSA) is based on the biophys. principle of ligand-induced thermal stabilization of target proteins.  Using this assay, we validated drug binding for a set of important clin. targets and monitored processes of drug transport and activation, off-target effects and drug resistance in cancer cell lines, as well as drug distribution in tissues.  CETSA is likely to become a valuable tool for the validation and optimization of drug target engagement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaaWSoozY7ObVg90H21EOLACvtfcHk0lgRvEnZpasJRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCgs7rP&md5=f8ba686ba38b67dbdf366c49eb7375b4</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fscience.1233606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1233606%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DD.%2BM.%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DIgnatushchenko%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DLarsson%26aufirst%3DE.%2BA.%26aulast%3DDan%26aufirst%3DC.%26aulast%3DSreekumar%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DNordlund%26aufirst%3DP.%26atitle%3DMonitoring%2520drug%2520target%2520engagement%2520in%2520cells%2520and%2520tissues%2520using%2520the%2520cellular%2520thermal%2520shift%2520assay%26jtitle%3DScience%26date%3D2013%26volume%3D341%26spage%3D84%26epage%3D87%26doi%3D10.1126%2Fscience.1233606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryall, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. C.</span></span> <span> </span><span class="NLM_article-title">Systems biology approaches for advancing the discovery of effective drug combinations</span>. <i>J. Cheminform.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">7</span> <span class="refDoi"> DOI: 10.1186/s13321-015-0055-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1186%2Fs13321-015-0055-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=25741385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A280%3ADC%252BC2MnhsVyjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&author=K.+A.+Ryallauthor=A.+C.+Tan&title=Systems+biology+approaches+for+advancing+the+discovery+of+effective+drug+combinations&doi=10.1186%2Fs13321-015-0055-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Systems biology approaches for advancing the discovery of effective drug combinations</span></div><div class="casAuthors">Ryall Karen A; Tan Aik Choon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cheminformatics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7</span>
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    </div><div class="casAbstract">Complex diseases like cancer are regulated by large, interconnected networks with many pathways affecting cell proliferation, invasion, and drug resistance.  However, current cancer therapy predominantly relies on the reductionist approach of one gene-one disease.  Combinations of drugs may overcome drug resistance by limiting mutations and induction of escape pathways, but given the enormous number of possible drug combinations, strategies to reduce the search space and prioritize experiments are needed.  In this review, we focus on the use of computational modeling, bioinformatics and high-throughput experimental methods for discovery of drug combinations.  We highlight cutting-edge systems approaches, including large-scale modeling of cell signaling networks, network motif analysis, statistical association-based models, identifying correlations in gene signatures, functional genomics, and high-throughput combination screens.  We also present a list of publicly available data and resources to aid in discovery of drug combinations.  Integration of these systems approaches will enable faster discovery and translation of clinically relevant drug combinations.  Graphical abstractSpectrum of Systems Biology Approaches for Drug Combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh4YpxugecZa_dlEzl_fBafW6udTcc2eb0win5x18C0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnhsVyjtA%253D%253D&md5=fa2572a5a35041ea880f7fb01981b5b4</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1186%2Fs13321-015-0055-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-015-0055-9%26sid%3Dliteratum%253Aachs%26aulast%3DRyall%26aufirst%3DK.%2BA.%26aulast%3DTan%26aufirst%3DA.%2BC.%26atitle%3DSystems%2520biology%2520approaches%2520for%2520advancing%2520the%2520discovery%2520of%2520effective%2520drug%2520combinations%26jtitle%3DJ.%2520Cheminform.%26date%3D2015%26volume%3D7%26doi%3D10.1186%2Fs13321-015-0055-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Initial GRK6 hits and quinazoline lead analogue <b>10a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Representative FDA-Approved Small Molecule Drugs for Multiple Myeloma</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Model of <b>10a</b> bound to the GRK6 active site. (A) Two-dimensional (2D) protein–ligand interaction diagram as depicted by MolSoft ICM using 4.5 Å as a hydrophobic interaction distance cutoff. (B) <b>10a</b> docked with Glide in the homology model of GRK6. The aminopyrazole of <b>10a</b> forms two strong H-bonds with the backbone NH of M266 and the backbone carbonyl of T264, while the 3-ethyl forms favorable van der Waals interactions with the gatekeeper residue L263. One more H-bond is formed between NH of quinazoline-2-amine and side chain of D270. The chiral methyl of the benzylic substituent binds toward the Gly-rich loop and V200 side chain, stabilizing the position of the 4-fluoro-benzylic substituent. The catalytic Lys K215 forms a salt bridge with E234 from the αC-helix. Only residues within 5 Å from the ligand are shown for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 4-Aminopyrazole-2-aminoalkyl Quinazoline Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Model of <b>18</b> bound to GRK6 and Aurora A active sites. Both proteins are depicted by the Connolly surface color-coded by the calculated electrostatic potential (semitransparent). The top part of the proteins, the Gly-rich loop, is clipped for clarity. (A) <b>18</b> docked with Glide (Schrodinger, Inc.) using the SP scoring function in the homology model of the GRK6 active site. The methoxy group of 5-methoxyquinazoline binds in a pocket formed by L265, N267, and L192 (L192 clipped together with the Gly-rich loop for clarity) forming favorable van der Waals interactions. (B) <b>18</b> oriented in Aurora A after the binding sites of GRK6 and Aurora A were overlapped. The OMe-group clearly protrudes the Connolly surface of Aurora A, thus making steric clashes with the Y212 side chain (depicted by dotted red).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Isothermal drug response (ITDR) assays, showing in-cell GRK6 binding by lead compounds as a function of concentration. KMS11–FLAG-GRK6 cells were incubated with compounds at the specified concentrations for 2.5 h and were then washed, lysed with NP40, and heated for 10 min at 51 or 52 °C (as shown) to induce denaturation of unbound FLAG-GRK6. Following this, soluble nondenatured GRK6, which had been protected from thermal denaturation by compound binding, was quantified by gel electrophoresis and anti-FLAG immunoblot. For comparison, the total cellular FLAG-GRK6 was determined from aliquots that were left unexposed to compounds or thermal denaturation (column 0*).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In-cell GRK6 occupancy by compounds <b>18</b>, <b>20</b>, or <b>22</b>, as a function of time. KMS11–FLAG-GRK6 cells were preincubated with a compound at 5 μM for 2.5 h at 37 °C to achieve loading and were then divided. An aliquot of cells was washed to remove the unbound compound (time = 0) and was then further incubated at 37 °C, while a second aliquot of cells was continuously incubated with the  compound. Following the specified intervals, cells were assayed for thermally protected bound GRK6, or total GRK6, by incubation at either 52 °C or room temperature, respectively (for 10 min) followed by gel electrophoresis and anti-FLAG immunoblot, as described for CETSA and ITDR studies. The half-life of cellular GRK6 occupancy was calculated as the time following drug washout required for GRK6 occupancy to fall to 50%. The fraction of GRK6 occupancy was determined as the amount of GRK6 experiencing thermal protection at 52 °C relative to the total cellular GRK6, measured at each time point from lysate aliquots processed at 23 °C and not subjected to thermal denaturation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antiproliferative activity of compound <b>18</b> versus MM cells. MM cell lines, including two engineered KMS11 variants expressing either the empty vector pWPI or overexpressing GRK6A from pWPI, were exposed to compound 18 at titrated concentrations under standard cell culture conditions at 37 °C for 3 days or 6 days. For the 6 day incubation, cells were replenished with fresh media and compound on day 3. Viability was assessed by the MTT assay. Results are the mean of replicates (n = 3) ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/medium/jm1c00506_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound  <b>18</b> and the proteasome inhibitor bortezomib induce synergistic killing of MM cells. KMS11, KMS18, and RPMI-8226 MM cells were treated with bortezomib or compound <b>18</b> separately and with both drugs combined across a range of concentrations. Viability was assessed by the MTT assay at 96 h. The combined effect of the two drugs is compared with their individual potencies. (A) Isobologram plots for the drug combinations at IC<sub>50</sub> or IC<sub>75</sub>, showing the predicted dose–response assuming Loewe additivity (dotted line) and the observed effect of the drug combination (in red). (B) Demonstration of synergy by Bliss independence at IC<sub>90</sub>–IC<sub>95</sub>. Concentrations of bortezomib and <b>18</b> that individually produced only 25–50% MM cell inhibition combined to produce 88–95% inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00506/20210720/images/large/jm1c00506_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00506&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52535" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52535" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 61 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naymagon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Hay, M.</span></span> <span> </span><span class="NLM_article-title">Novel agents in the treatment of multiple myeloma: a review about the future</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">52</span> <span class="refDoi"> DOI: 10.1186/s13045-016-0282-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1186%2Fs13045-016-0282-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=27363832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGktr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&author=L.+Naymagonauthor=M.+Abdul-Hay&title=Novel+agents+in+the+treatment+of+multiple+myeloma%3A+a+review+about+the+future&doi=10.1186%2Fs13045-016-0282-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Novel agents in the treatment of multiple myeloma: a review about the future</span></div><div class="casAuthors">Naymagon, Leonard; Abdul-Hay, Maher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52/1-52/20</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating clin. features such as anemia, lytic bone lesions, hypercalcemia, and renal disease.  An enhanced understanding of MM disease mechanisms has led to new more targeted treatments.  There is now a plethora of treatments available for MM.  In this review article, our aim is to discuss many of the novel agents that are being studied or have recently been approved for the treatment of MM.  These agents include the following: immunomodulators (pomalidomide), proteasome inhibitors (carfilzomib, marizomib, ixazomib, oprozomib), alkylating agents (bendamustine), AKT inhibitors (afuresertib), BTK inhibitors (ibrutinib), CDK inhibitors (dinaciclib), histone deacetylase inhibitors (panobinostat, rocilinostat, vorinostat), IL-6 inhibitors (siltuximab), kinesin spindle protein inhibitors (filanesib), monoclonal antibodies (daratumumab, elotuzumab, indatuximab, SAR650984), and phosphoinositide 3-kinase (PI3K) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMUyMzVHsBtLVg90H21EOLACvtfcHk0lh46prjupD4iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGktr7F&md5=5a45e84d62cab3225d1f5fd819ead845</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0282-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0282-1%26sid%3Dliteratum%253Aachs%26aulast%3DNaymagon%26aufirst%3DL.%26aulast%3DAbdul-Hay%26aufirst%3DM.%26atitle%3DNovel%2520agents%2520in%2520the%2520treatment%2520of%2520multiple%2520myeloma%253A%2520a%2520review%2520about%2520the%2520future%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26doi%3D10.1186%2Fs13045-016-0282-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kronke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svinkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarlo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1126/science.1244851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1126%2Fscience.1244851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=24292625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=301-305&author=J.+Kronkeauthor=N.+D.+Udeshiauthor=A.+Narlaauthor=P.+Graumanauthor=S.+N.+Hurstauthor=M.+McConkeyauthor=T.+Svinkinaauthor=D.+Hecklauthor=E.+Comerauthor=X.+Liauthor=C.+Ciarloauthor=E.+Hartmanauthor=N.+Munshiauthor=M.+Schenoneauthor=S.+L.+Schreiberauthor=S.+A.+Carrauthor=B.+L.+Ebert&title=Lenalidomide+causes+selective+degradation+of+IKZF1+and+IKZF3+in+multiple+myeloma+cells&doi=10.1126%2Fscience.1244851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</span></div><div class="casAuthors">Kronke Jan; Udeshi Namrata D; Narla Anupama; Grauman Peter; Hurst Slater N; McConkey Marie; Svinkina Tanya; Heckl Dirk; Comer Eamon; Li Xiaoyu; Ciarlo Christie; Hartman Emily; Munshi Nikhil; Schenone Monica; Schreiber Stuart L; Carr Steven A; Ebert Benjamin L</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">301-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown.  Using quantitative proteomics, we found that lenalidomide causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.  IKZF1 and IKZF3 are essential transcription factors in multiple myeloma.  A single amino acid substitution of IKZF3 conferred resistance to lenalidomide-induced degradation and rescued lenalidomide-induced inhibition of cell growth.  Similarly, we found that lenalidomide-induced interleukin-2 production in T cells is due to depletion of IKZF1 and IKZF3.  These findings reveal a previously unknown mechanism of action for a therapeutic agent: alteration of the activity of an E3 ubiquitin ligase, leading to selective degradation of specific targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiiGR0Yx7nuYFEOhA_Im3cfW6udTcc2eb7WxrlDdKAJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D&md5=8cae3e554399308493aa38f0d05ed610</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244851%26sid%3Dliteratum%253Aachs%26aulast%3DKronke%26aufirst%3DJ.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DNarla%26aufirst%3DA.%26aulast%3DGrauman%26aufirst%3DP.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DMcConkey%26aufirst%3DM.%26aulast%3DSvinkina%26aufirst%3DT.%26aulast%3DHeckl%26aufirst%3DD.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCiarlo%26aufirst%3DC.%26aulast%3DHartman%26aufirst%3DE.%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DSchenone%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520causes%2520selective%2520degradation%2520of%2520IKZF1%2520and%2520IKZF3%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D301%26epage%3D305%26doi%3D10.1126%2Fscience.1244851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naniong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaelin, W. G.,  Jr.</span></span> <span> </span><span class="NLM_article-title">The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1126/science.1244917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1126%2Fscience.1244917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=24292623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=305-309&author=G.+Luauthor=R.+E.+Middletonauthor=H.+Sunauthor=M.+Naniongauthor=C.+J.+Ottauthor=C.+S.+Mitsiadesauthor=K.+K.+Wongauthor=J.+E.+Bradnerauthor=W.+G.+Kaelin&title=The+myeloma+drug+lenalidomide+promotes+the+cereblon-dependent+destruction+of+ikaros+proteins&doi=10.1126%2Fscience.1244917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins</span></div><div class="casAuthors">Lu, Gang; Middleton, Richard E.; Sun, Huahang; Naniong, MarkVic; Ott, Christopher J.; Mitsiades, Constantine S.; Wong, Kwok-Kin; Bradner, James E.; Kaelin, William G., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">305-309</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Thalidomide-like drugs such as lenalidomide are clin. important treatments for multiple myeloma and show promise for other B cell malignancies.  The biochem. mechanisms underlying their antitumor activity are unknown.  Thalidomide was recently shown to bind to, and inhibit, the cereblon ubiquitin ligase.  Cereblon loss in zebrafish causes fin defects reminiscent of the limb defects seen in children exposed to thalidomide in utero.  Here we show that lenalidomide-bound cereblon acquires the ability to target for proteasomal degrdn. two specific B cell transcription factors, Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3).  Anal. of myeloma cell lines revealed that loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect, suggesting that the antitumor and teratogenic activities of thalidomide-like drugs are dissociable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0froz4Kipu7Vg90H21EOLACvtfcHk0lipS4LzKSNnXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2ktg%253D%253D&md5=a9df5bbde0f676b92b1bec48fdbbb502</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244917%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DG.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DNaniong%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DC.%2BJ.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26atitle%3DThe%2520myeloma%2520drug%2520lenalidomide%2520promotes%2520the%2520cereblon-dependent%2520destruction%2520of%2520ikaros%2520proteins%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D305%26epage%3D309%26doi%3D10.1126%2Fscience.1244917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, H. N.</span></span> <span> </span><span class="NLM_article-title">The multiple myeloma drug pipeline-2018: a review of small molecules and their therapeutic targets</span>. <i>Clin. Lymphoma, Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2018.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.clml.2018.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=30001985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FnsFygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=611-627&author=H.+N.+Abramson&title=The+multiple+myeloma+drug+pipeline-2018%3A+a+review+of+small+molecules+and+their+therapeutic+targets&doi=10.1016%2Fj.clml.2018.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets</span></div><div class="casAuthors">Abramson Hanley N</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma, myeloma & leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">611-627</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of multiple myeloma (MM), a neoplasm of plasma cells, formerly dependent on alkylating drugs, corticosteroids, and autologous stem cell transplantation, has changed dramatically in the past 20 years because 3 new classes of small molecule drugs (arbitrarily defined as having a molecular weight of < 900 kDa)-immunomodulators, proteasome inhibitors, and histone deacetylase blockers-have been introduced for the disease.  Therapeutic options for MM expanded further in 2015 when 2 new monoclonal antibodies (daratumumab and elotuzumab) were approved by the Food and Drug Administration for MM.  Although MM remains incurable, the cumulative effect of these advances has resulted in a near-doubling of the 5-year survival rate since the late 1980s.  Despite these advances, therapy for MM continues to pose substantial challenges because resistance to therapy frequently develops, and relapse and recurrence are all too common.  The present review focused on the pipeline for new small molecules in various stages of development and their associated cellular targets.  In addition to newer versions of alkylators, immunomodulators, proteasome inhibitors, and histone deacetylase inhibitors, the present review considered the prospects for adding new classes of small molecules to the MM armamentarium, which offer the potential for oral efficacy, relative simplicity of preparation, and prospects for improvement in the cost-to-benefit ratio.  Included are agents that affect myeloma epigenetics and the ubiquitination-proteasome system and the unfolded protein response, apoptotic mechanisms, chromosomal abnormalities, nuclear protein transport, and various kinases involved in cellular signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS29pXs7jYk7MSzjBFCN0BJfW6udTcc2eb7WxrlDdKAJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FnsFygsw%253D%253D&md5=3ead649460f6be413b2f7e82b659a8bf</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2018.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2018.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DAbramson%26aufirst%3DH.%2BN.%26atitle%3DThe%2520multiple%2520myeloma%2520drug%2520pipeline-2018%253A%2520a%2520review%2520of%2520small%2520molecules%2520and%2520their%2520therapeutic%2520targets%26jtitle%3DClin.%2520Lymphoma%252C%2520Myeloma%2520Leuk.%26date%3D2018%26volume%3D18%26spage%3D611%26epage%3D627%26doi%3D10.1016%2Fj.clml.2018.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydon, N. B.</span></span> <span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nm0596-561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Fnm0596-561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=8616716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&author=B.+J.+Drukerauthor=S.+Tamuraauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=S.+Fanningauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells&doi=10.1038%2Fnm0596-561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span></div><div class="casAuthors">Druker, Brian J.; Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Shane; Zimmermann, Jurg; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">The Bcr-Abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease.  A compd., designed to inhibit the Abl protein tyrosine kinase (CGP 57148), was evaluated for its effects on cells contg. the Bcr-Abl fusion protein.  Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compd.  In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the no. of Bcr-Abl colonies formed but no inhibition of normal colony formation.  This compd. may be useful in the treatment of Bcr-Abl-pos. leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzXj-25AHOrVg90H21EOLACvtfcHk0ljnInAgcvU05w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D&md5=1dc111cc883a1ed29964ae2c88c88cb9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnm0596-561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0596-561%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnm0596-561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lugo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendergast, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase activity and transformation potency of bcr-abl oncogene products</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>247</i></span>,  <span class="NLM_fpage">1079</span>– <span class="NLM_lpage">1082</span>, <span class="refDoi"> DOI: 10.1126/science.2408149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1126%2Fscience.2408149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=2408149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADyaK3cXhslensbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=247&publication_year=1990&pages=1079-1082&author=T.+Lugoauthor=A.+Pendergastauthor=A.+Mullerauthor=O.+Witte&title=Tyrosine+kinase+activity+and+transformation+potency+of+bcr-abl+oncogene+products&doi=10.1126%2Fscience.2408149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase activity and transformation potency of bcr-abl oncogene products</span></div><div class="casAuthors">Lugo, Tracy G.; Pendergast, Ann Marie; Muller, Alexander J.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">247</span>
        (<span class="NLM_cas:issue">4946</span>),
    <span class="NLM_cas:pages">1079-82</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Oncogenic activation of the proto-oncogene c-abl in human leukemias occurs as a result of the addn. of exons from the gene bcr and truncation of the first abl exon.  Anal. of tyrosine kinase activity and quant. measurement of transformation potency in a single-step assay indicate that variation in bcr exon contribution results in a functional difference between p210bcr-abl and p185bcr-abl proteins.  Thus, foreign upstream sequences are important in the deregulation of the kinase activity of the abl product, and the extent of deregulation correlates with the pathol. effects of the bcr-abl proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor_5g1b7WQRLVg90H21EOLACvtfcHk0ljnInAgcvU05w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhslensbg%253D&md5=6dedfdc01020bc7f0ad1013e394e9648</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.2408149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2408149%26sid%3Dliteratum%253Aachs%26aulast%3DLugo%26aufirst%3DT.%26aulast%3DPendergast%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DA.%26aulast%3DWitte%26aufirst%3DO.%26atitle%3DTyrosine%2520kinase%2520activity%2520and%2520transformation%2520potency%2520of%2520bcr-abl%2520oncogene%2520products%26jtitle%3DScience%26date%3D1990%26volume%3D247%26spage%3D1079%26epage%3D1082%26doi%3D10.1126%2Fscience.2408149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(03)01137-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2FS1470-2045%2803%2901137-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12850190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1alu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=397-406&author=S.+S.+Sridharauthor=L.+Seymourauthor=F.+A.+Shepherd&title=Inhibitors+of+epidermal-growth-factor+receptors%3A+a+review+of+clinical+research+with+a+focus+on+non-small-cell+lung+cancer&doi=10.1016%2FS1470-2045%2803%2901137-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer</span></div><div class="casAuthors">Sridhar, Srikala S.; Seymour, Lesley; Shepherd, Frances A.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">397-406</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite aggressive surgical and chemotherapeutic interventions, non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death in men and women with overall cure rates of less than 15%.  Recent advances in our understanding of cellular signaling and its crit. role in tumorigenesis has led to the development of novel therapies which may offer new hope.  In particular, the epidermal growth-factor receptor superfamily is an attractive therapeutic target because it is commonly overexpressed in malignant disease, regulates many vital cellular processes, and seems to be a neg. prognostic indicator.  Several selective inhibitors of this family of receptors are currently being evaluated in several cancers including NSCLC.  In this review we examine current preclin. and clin. evidence on monoclonal antibodies (cetuximab, ABX-EGF, EMD72000, MAb ICR62, h-R3, MDX-447, MDX-H210, trastuzumab, and 2C4), immunoconjugates (Y10, Ua30:2, Mab806), anti-EGF vaccine (YMB2000), and tyrosine kinase inhibitors (gefitinib, erlotinib, CI1033, GW572016, EKB 569, PKI166, PD158780, and TAK 165).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkpYr5VybYiLVg90H21EOLACvtfcHk0ljnInAgcvU05w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1alu78%253D&md5=780268a27f84dadb63c4f270ab2625c3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2803%2901137-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252803%252901137-9%26sid%3Dliteratum%253Aachs%26aulast%3DSridhar%26aufirst%3DS.%2BS.%26aulast%3DSeymour%26aufirst%3DL.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DInhibitors%2520of%2520epidermal-growth-factor%2520receptors%253A%2520a%2520review%2520of%2520clinical%2520research%2520with%2520a%2520focus%2520on%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2003%26volume%3D4%26spage%3D397%26epage%3D406%26doi%3D10.1016%2FS1470-2045%2803%2901137-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Protein kinases - the major drug targets of the twenty-first century?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1038/nrd773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Fnrd773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12120282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=309-315&author=P.+Cohen&title=Protein+kinases+-+the+major+drug+targets+of+the+twenty-first+century%3F&doi=10.1038%2Fnrd773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: Protein kinases - the major drug targets of the twenty-first century?</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-315</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of disease.  A growing interest in developing orally active protein-kinase inhibitors has recently culminated in the approval of the first of these drugs for clin. use.  Protein kinases have now become the second most important group of drug targets, after G-protein-coupled receptors.  Here, I give a personal view of some of the most important advances that have shaped this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRd_GqiGAWaLVg90H21EOLACvtfcHk0lgL1wxmBeyjZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D&md5=67d2fbc11a55b5980ee0692f7bc13cc9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd773%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DProtein%2520kinases%2520-%2520the%2520major%2520drug%2520targets%2520of%2520the%2520twenty-first%2520century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D309%26epage%3D315%26doi%3D10.1038%2Fnrd773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melnikova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, J.</span></span> <span> </span><span class="NLM_article-title">Targeting protein kinases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1038/nrd1600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Fnrd1600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=15645605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVarsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=993-994&author=I.+Melnikovaauthor=J.+Golden&title=Targeting+protein+kinases&doi=10.1038%2Fnrd1600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">From the analyst's couch: Targeting protein kinases</span></div><div class="casAuthors">Melnikova, Irena; Golden, James</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">993-994</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxKgb6vOzrkbVg90H21EOLACvtfcHk0lgL1wxmBeyjZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVarsLvJ&md5=fd1f562792d3c286191a55538bf86e5e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd1600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1600%26sid%3Dliteratum%253Aachs%26aulast%3DMelnikova%26aufirst%3DI.%26aulast%3DGolden%26aufirst%3DJ.%26atitle%3DTargeting%2520protein%2520kinases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D993%26epage%3D994%26doi%3D10.1038%2Fnrd1600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Gefitinib - a novel targeted approach to treating cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">956</span>– <span class="NLM_lpage">965</span>, <span class="refDoi"> DOI: 10.1038/nrc1506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Fnrc1506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=15573117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVarsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=956-965&author=R.+S.+Herbstauthor=M.+Fukuokaauthor=J.+Baselga&title=Gefitinib+-+a+novel+targeted+approach+to+treating+cancer&doi=10.1038%2Fnrc1506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: Gefitinib - a novel targeted approach to treating cancer</span></div><div class="casAuthors">Herbst, Roy S.; Fukuoka, Masahiro; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">956-965</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential anticancer target, the EGFR inhibitor gefitinib (Iressa; AstraZeneca) has been approved for the treatment of patients with advanced non-small-cell lung cancer in many countries.  Studies have indicated its potential for treating patients with other types of solid tumors.  Investigation of gefitinib has not only increased our knowledge about the biol. of EGFR signaling, but is contributing to our evolving understanding of which tumors are EGFR dependent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V2qzLg_-rrVg90H21EOLACvtfcHk0lgL1wxmBeyjZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVarsLjJ&md5=03a6c08b947bc3e0ca59e1b92fa8d214</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc1506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1506%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DFukuoka%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DGefitinib%2520-%2520a%2520novel%2520targeted%2520approach%2520to%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D956%26epage%3D965%26doi%3D10.1038%2Fnrc1506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues Pereira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciuleanu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thongprasert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maoleekoonpiroj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smylie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kooten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dediu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezjak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santabarbara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span> <span> </span><span class="NLM_article-title">The National Cancer Institute of Canada Clinical Trials Group, erlotinib in previously treated non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa050753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&author=F.+A.+Shepherdauthor=J.+Rodrigues+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+van+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjakauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=The+National+Cancer+Institute+of+Canada+Clinical+Trials+Group%2C+erlotinib+in+previously+treated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa050753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0lgL1wxmBeyjZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DRodrigues%2BPereira%26aufirst%3DJ.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3Dvan%2BKooten%26aufirst%3DM.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjak%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DThe%2520National%2520Cancer%2520Institute%2520of%2520Canada%2520Clinical%2520Trials%2520Group%252C%2520erlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D123%26epage%3D132%26doi%3D10.1056%2FNEJMoa050753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallegos Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Chevalier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oulid-Aissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span> <span> </span><span class="NLM_article-title">Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">6049</span>– <span class="NLM_lpage">6055</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-0260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1158%2F1078-0432.CCR-06-0260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=17062680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6049-6055&author=G.+Giacconeauthor=M.+Gallegos+Ruizauthor=T.+Le+Chevalierauthor=N.+Thatcherauthor=E.+Smitauthor=J.+A.+Rodriguezauthor=P.+Janneauthor=D.+Oulid-Aissaauthor=J.-C.+Soria&title=Erlotinib+for+frontline+treatment+of+advanced+non-small+cell+lung+cancer%3A+a+phase+II+study&doi=10.1158%2F1078-0432.CCR-06-0260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib for Frontline Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study</span></div><div class="casAuthors">Giaccone, Giuseppe; Gallegos Ruiz, Marielle; Le Chevalier, Thierry; Thatcher, Nick; Smit, Egbert; Rodriguez, Jose Antonio; Janne, Pasi; Oulid-Aissa, Dalila; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20, Pt. 1</span>),
    <span class="NLM_cas:pages">6049-6055</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Erlotinib has proven activity in pretreated patients with advanced non-small cell lung cancer (NSCLC).  We evaluated erlotinib in the front-line treatment of advanced NSCLC and assessed biol. predictors of outcome.  Exptl. Design: In this phase II study, chemotherapy-naive patients with stage IIIB/IV NSCLC received oral erlotinib (150 mg/d) until disease progression or unacceptable toxicity occurred.  Tumor response was assessed every 6 wk, and samples were analyzed for potential mol. markers of treatment response and survival.  The primary end point was the proportion of patients without disease progression after 6 wk of treatment.  Results: Fifty-three patients were eligible.  The overall rate of nonprogression at 6 wk was 52.8% (28 of 53 patients).  Tumor response rate was 22.7%, with 1 complete response, 11 partial responses, and 16 cases of stable disease.  Responses were seen across most patient clin. characteristics.  The median duration of tumor response was 333 days; median overall survival was 391 days; and median time to disease progression was 84 days.  Erlotinib was well tolerated, the main treatment-related adverse events being mild-to-moderate rash and diarrhea.  Histol. material for biol. studies was available in 29 cases.  Four of five responders and one patient with stable disease had a classic epidermal growth factor receptor tyrosine kinase mutation.  Two progressing patients exhibited epidermal growth factor receptor point mutations (one with T790M mutation), and K-ras mutations were detected in 10 nonresponders.  Conclusions: Erlotinib shows significant antitumor activity in the first-line treatment of advanced NSCLC and may be a viable alternative to chemotherapy.  Patient selection cannot easily be based on clin. or biol. variables.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU7JRZAYUK8rVg90H21EOLACvtfcHk0lgTtZzaJDNV8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhsbjF&md5=f4ae1f677dc52dc4f73b00d916afb8f1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0260%26sid%3Dliteratum%253Aachs%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DGallegos%2BRuiz%26aufirst%3DM.%26aulast%3DLe%2BChevalier%26aufirst%3DT.%26aulast%3DThatcher%26aufirst%3DN.%26aulast%3DSmit%26aufirst%3DE.%26aulast%3DRodriguez%26aufirst%3DJ.%2BA.%26aulast%3DJanne%26aufirst%3DP.%26aulast%3DOulid-Aissa%26aufirst%3DD.%26aulast%3DSoria%26aufirst%3DJ.-C.%26atitle%3DErlotinib%2520for%2520frontline%2520treatment%2520of%2520advanced%2520non-small%2520cell%2520lung%2520cancer%253A%2520a%2520phase%2520II%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6049%26epage%3D6055%26doi%3D10.1158%2F1078-0432.CCR-06-0260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kannaiyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review of protein kinase inhibitors for cancer therapy</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1080/14737140.2018.1527688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1080%2F14737140.2018.1527688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=30259761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOqs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=1249-1270&author=R.+Kannaiyanauthor=D.+Mahadevan&title=A+comprehensive+review+of+protein+kinase+inhibitors+for+cancer+therapy&doi=10.1080%2F14737140.2018.1527688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of protein kinase inhibitors for cancer therapy</span></div><div class="casAuthors">Kannaiyan, Radhamani; Mahadevan, Daruka</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1249-1270</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are involved in various cellular functions.  About 2% of the human genome encodes for protein kinases.  Dysregulation of protein kinases is implicated in various processes of carcinogenesis.  The advent of protein kinase inhibitors in cancer therapy has led to a paradigm shift in cancer therapy.  Several protein kinase inhibitors have been approved by FDA in the last few decades.  This article provides a review of the FDA approved protein kinase inhibitors as of Dec. 2017 for the well-known oncogenic protein kinases.  A list of FDA approved protein kinase inhibitors and their FDA approved clin. indications were cataloged.  The role of the resp. oncogenic protein kinases in carcinogenesis and cancer progression and the relevant landmark clin. trials of resp. protein kinase inhibitors leading up to the FDA approval were PubMed searched and discussed.  Further understanding of the mol. origin of various cancers would help identify new targets.  Use of biomarker profiling might select the patient population that would benefit better from kinase inhibitors.  Clin. trials should be designed to identify the appropriate sequence of the available kinase inhibitors.  It would prove to be useful to test these drugs in the adjuvant setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUeLoNJcZUGLVg90H21EOLACvtfcHk0lgTtZzaJDNV8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOqs7nK&md5=853138e6be969ecb6d137356bf5d2fd3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F14737140.2018.1527688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2018.1527688%26sid%3Dliteratum%253Aachs%26aulast%3DKannaiyan%26aufirst%3DR.%26aulast%3DMahadevan%26aufirst%3DD.%26atitle%3DA%2520comprehensive%2520review%2520of%2520protein%2520kinase%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2018%26volume%3D18%26spage%3D1249%26epage%3D1270%26doi%3D10.1080%2F14737140.2018.1527688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrenbacher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartwright, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hainsworth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffing, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmgren, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyfe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabbinavar, F.</span></span> <span> </span><span class="NLM_article-title">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">2335</span>– <span class="NLM_lpage">2342</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa032691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1056%2FNEJMoa032691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=15175435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2335-2342&author=H.+Hurwitzauthor=L.+Fehrenbacherauthor=W.+Novotnyauthor=T.+Cartwrightauthor=J.+Hainsworthauthor=W.+Heimauthor=J.+Berlinauthor=A.+Baronauthor=S.+Griffingauthor=E.+Holmgrenauthor=N.+Ferraraauthor=G.+Fyfeauthor=B.+Rogersauthor=R.+Rossauthor=F.+Kabbinavar&title=Bevacizumab+plus+irinotecan%2C+fluorouracil%2C+and+leucovorin+for+metastatic+colorectal+cancer&doi=10.1056%2FNEJMoa032691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Fehrenbacher, Louis; Novotny, William; Cartwright, Thomas; Hainsworth, John; Heim, William; Berlin, Jordan; Baron, Ari; Griffing, Susan; Holmgren, Eric; Ferrara, Napoleone; Fyfe, Gwen; Rogers, Beth; Ross, Robert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2335-2342</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclin. and clin. activity against metastatic colorectal cancer, particularly in combination with chemotherapy.  Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kg of body wt. every two weeks) and 411 to receive IFL plus placebo.  The primary end point was overall survival.  Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life.  The median duration of survival was 20.3 mo in the group given IFL plus bevacizumab, as compared with 15.6 mo in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001).  The median duration of progression-free survival was 10.6 mo in the group given IFL plus bevacizumab, as compared with 6.2 mo in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 % and 34.8 % (P = 0.004).  The median duration of the response was 10.4 mo in the group given IFL plus bevacizumab, as compared with 7.1 mo in the group given IFL plus placebo (hazard ratio for progression, 0.62; P = 0.001).  Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 % vs. 2.3 %) but was easily managed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5r6uP5oxZU7Vg90H21EOLACvtfcHk0lgTtZzaJDNV8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D&md5=6a1289cdbf1501f121eb0482e5a1f536</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032691%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DCartwright%26aufirst%3DT.%26aulast%3DHainsworth%26aufirst%3DJ.%26aulast%3DHeim%26aufirst%3DW.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DGriffing%26aufirst%3DS.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520plus%2520irinotecan%252C%2520fluorouracil%252C%2520and%2520leucovorin%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2335%26epage%3D2342%26doi%3D10.1056%2FNEJMoa032691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabbinavar, F.</span></span> <span> </span><span class="NLM_article-title">Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer</span>. <i>Oncology</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1159/000088480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1159%2F000088480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=16301832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1aqsrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2005&pages=17-24&author=H.+Hurwitzauthor=F.+Kabbinavar&title=Bevacizumab+combined+with+standard+fluoropyrimidine-based+chemotherapy+regimens+to+treat+colorectal+cancer&doi=10.1159%2F000088480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab Combined with Standard Fluoropyrimidine-Based Chemotherapy Regimens to Treat Colorectal Cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">Suppl. 3</span>),
    <span class="NLM_cas:pages">17-24</span>CODEN:
                <span class="NLM_cas:coden">ONCOBS</span>;
        ISSN:<span class="NLM_cas:issn">0030-2414</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">For several decades, 5-fluorouracil (5-FU) with or without leucovorin defined the std. of care for the treatment of metastatic colorectal cancer (CRC).  The addn. of other chemotherapy regimens to 5-FU has improved survival, but often at the expense of increased toxicity.  Recent advances in our understanding of the mol. basis of CRC have led to the prodn. of novel targeted agents, such as bevacizumab (Avastin).  Bevacizumab is currently approved for the first-line treatment of metastatic CRC and is currently being tested in combination with std. therapies for a range of indications.  Phase II/III trials have demonstrated that the addn. of bevacizumab to 5-FU-based first-line chemotherapy improves survival, progression-free survival and response rate compared with chemotherapy alone.  Combination therapy does not appear to exacerbate side effects known to be assocd. with the chemotherapy regimen.  The most common side effects attributable to bevacizumab therapy include hypertension, proteinuria and bleeding.  Although uncommon, gastrointestinal perforation and arterial thromobembolic events are the most serious side effects reported to date.  Bevacizumab is currently being evaluated in combination with oxaliplatin (Eloxatin)-based therapies and preliminary data are encouraging.  Ongoing trials of bevacizumab in combination with std. first-line chemotherapy regimens will evaluate bevacizumab's potential in a range of cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtw2uXR6TcfLVg90H21EOLACvtfcHk0li5htm0YcqHEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1aqsrbO&md5=e8a759ad940dd0c7d848e3e7ff66bccb</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1159%2F000088480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000088480%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520combined%2520with%2520standard%2520fluoropyrimidine-based%2520chemotherapy%2520regimens%2520to%2520treat%2520colorectal%2520cancer%26jtitle%3DOncology%26date%3D2005%26volume%3D69%26spage%3D17%26epage%3D24%26doi%3D10.1159%2F000088480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resta, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydon, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno-Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1037</span>, <span class="refDoi"> DOI: 10.1056/NEJM200104053441401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1056%2FNEJM200104053441401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=11287972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFGnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1031-1037&author=B.+J.+Drukerauthor=M.+Talpazauthor=D.+J.+Restaauthor=B.+Pengauthor=E.+Buchdungerauthor=J.+M.+Fordauthor=N.+B.+Lydonauthor=H.+Kantarjianauthor=R.+Capdevilleauthor=S.+Ohno-Jonesauthor=C.+L.+Sawyers&title=Efficacy+and+safety+of+a+specific+inhibitor+of+the+BCR-ABL+tyrosine+kinase+in+chronic+myeloid+leukemia&doi=10.1056%2FNEJM200104053441401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia</span></div><div class="casAuthors">Druker, Brian J.; Talpaz, Moshe; Resta, Debra J.; Peng, Bin; Buchdunger, Elisabeth; Ford, John M.; Lydon, Nicholas B.; Kantarjian, Hagop; Capdeville, Renaud; Ohno-Jones, Sayuri; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1031-1037</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML).  Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML.  Methods: We conducted a phase 1, dose-escalating trial of STI571 (formerly known as CGP 57148B), a specific inhibitor of the BCR-ABL tyrosine kinase.  STI571 was administered orally to 83 patients with CML in the chronic phase in whom treatment with interferon alpha had failed.  Patients were successively assigned to 1 of 14 doses ranging from 25 to 1000 mg per day.  Results: Adverse effects of STI571 were minimal; the most common were nausea, myalgias, edema, and diarrhea.  A maximal tolerated dose was not identified.  Complete hematol. responses were obsd. in 53 of 54 patients treated with daily doses of 300 mg or more and typically occurred in the first four weeks of therapy.  Of the 54 patients treated with doses of 300 mg or more, cytogenetic responses occurred in 29, including 17 (31 percent of the 54 patients who received this dose) with major responses (0 to 35 percent of cells in metaphase pos. for the Philadelphia chromosome); 7 of these patients had complete cytogenetic remissions.  Conclusion: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alpha had failed.  Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific mol. abnormality present in a human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrprbDzKoC0ubVg90H21EOLACvtfcHk0li5htm0YcqHEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFGnu70%253D&md5=1554407678838243a753aa056ffd4f7c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441401%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DResta%26aufirst%3DD.%2BJ.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DOhno-Jones%26aufirst%3DS.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520a%2520specific%2520inhibitor%2520of%2520the%2520BCR-ABL%2520tyrosine%2520kinase%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1031%26epage%3D1037%26doi%3D10.1056%2FNEJM200104053441401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicaise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleickardt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwood-Chirchir, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decillis, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyers, C. L.</span></span> <span> </span><span class="NLM_article-title">Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">2531</span>– <span class="NLM_lpage">2541</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa055229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1056%2FNEJMoa055229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=16775234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD28Xlslyisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=2531-2541&author=M.+Talpazauthor=N.+P.+Shahauthor=H.+Kantarjianauthor=N.+Donatoauthor=J.+Nicollauthor=R.+Paquetteauthor=J.+Cortesauthor=S.+O%E2%80%99Brienauthor=C.+Nicaiseauthor=E.+Bleickardtauthor=M.+A.+Blackwood-Chirchirauthor=V.+Iyerauthor=T.-T.+Chenauthor=F.+Huangauthor=A.+P.+Decillisauthor=C.+L.+Sawyers&title=Dasatinib+in+imatinib-resistant+philadelphia+chromosome-positive+leukemias&doi=10.1056%2FNEJMoa055229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias</span></div><div class="casAuthors">Talpaz, Moshe; Shah, Neil P.; Kantarjian, Hagop; Donato, Nicholas; Nicoll, John; Paquette, Ron; Cortes, Jorge; O'Brien, Susan; Nicaise, Claude; Bleickardt, Eric; Blackwood-Chirchir, M. Anne; Iyer, Vishwanath; Chen, Tai-Tsang; Huang, Fei; Decillis, Arthur P.; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2531-2541</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-pos. (Ph-pos.) leukemias, but relapse occurs, mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutations.  We evaluated dasatinib, a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations, in patients with chronic myelogenous leukemia (CML) or Ph-pos. acute lymphoblastic leukemia (ALL).  Patients with various phases of CML or with Ph-pos. ALL who could not tolerate or were resistant to imatinib were enrolled in a phase 1 dose-escalation study.  Dasatinib (15 to 240 mg per day) was administered orally in four-week treatment cycles, once or twice daily.  A complete hematol. response was achieved in 37 of 40 patients with chronic-phase CML, and major hematol. responses were seen in 31 of 44 patients with accelerated-phase CML, CML with blast crisis, or Ph-pos. ALL.  In these two phases, the rates of major cytogenetic response were 45% and 25%, resp.  Responses were maintained in 95% of patients with chronic-phase disease and in 82% of patients with accelerated-phase disease, with a median follow-up more than 12 mo and 5 mo, resp.  Nearly all patients with lymphoid blast crisis and Ph-pos. ALL had a relapse within six months.  Responses occurred among all BCR-ABL genotypes, with the exception of the T315I mutation, which confers resistance to both dasatinib and imatinib in vitro.  Myelosuppression was common but not dose-limiting.  Dasatinib induces hematol. and cytogenetic responses in patients with CML or Ph-pos. ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov no., NCT00064233.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIX_T8oTKTw7Vg90H21EOLACvtfcHk0li5htm0YcqHEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xlslyisb0%253D&md5=0bef963bce785b8b2a19b548905e2543</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa055229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa055229%26sid%3Dliteratum%253Aachs%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DDonato%26aufirst%3DN.%26aulast%3DNicoll%26aufirst%3DJ.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DNicaise%26aufirst%3DC.%26aulast%3DBleickardt%26aufirst%3DE.%26aulast%3DBlackwood-Chirchir%26aufirst%3DM.%2BA.%26aulast%3DIyer%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DT.-T.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DDecillis%26aufirst%3DA.%2BP.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DDasatinib%2520in%2520imatinib-resistant%2520philadelphia%2520chromosome-positive%2520leukemias%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D2531%26epage%3D2541%26doi%3D10.1056%2FNEJMoa055229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiedemann, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Que, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azorsa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braggio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsagel, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousses, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span> <span> </span><span class="NLM_article-title">Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1594</span>– <span class="NLM_lpage">1604</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-09-243980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1182%2Fblood-2009-09-243980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=19996089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtV2gtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=1594-1604&author=R.+E.+Tiedemannauthor=Y.+X.+Zhuauthor=J.+Schmidtauthor=H.+Yinauthor=C.+X.+Shiauthor=Q.+Queauthor=G.+Basuauthor=D.+Azorsaauthor=L.+M.+Perkinsauthor=E.+Braggioauthor=R.+Fonsecaauthor=P.+L.+Bergsagelauthor=S.+Moussesauthor=A.+K.+Stewart&title=Kinome-wide+RNAi+studies+in+human+multiple+myeloma+identify+vulnerable+kinase+targets%2C+including+a+lymphoid-restricted+kinase%2C+GRK6&doi=10.1182%2Fblood-2009-09-243980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6</span></div><div class="casAuthors">Tiedemann, Rodger E.; Zhu, Yuan Xiao; Schmidt, Jessica; Yin, Hongwei; Shi, Chang-Xin; Que, Qiang; Basu, Gargi; Azorsa, David; Perkins, Louise M.; Braggio, Esteban; Fonseca, Rafael; Bergsagel, P. Leif; Mousses, Spyro; Stewart, A. Keith</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1594-1604</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A paucity of validated kinase targets in human multiple myeloma has delayed clin. deployment of kinase inhibitors in treatment strategies.  The authors therefore conducted a kinome-wide small interfering RNA (siRNA) lethality study in myeloma tumor lines bearing common t(4;14), t(14;16), and t(11;14) translocations to identify critically vulnerable kinases in myeloma tumor cells without regard to preconceived mechanistic notions.  Fifteen kinases were repeatedly vulnerable in myeloma cells, including AKT1, AK3L1, AURKA, AURKB, CDC2L1, CDK5R2, FES, FLT4, GAK, GRK6, HK1, PKN1, PLK1, SMG1, and TNK2.  Whereas several kinases (PLK1, HK1) were equally vulnerable in epithelial cells, others and particularly G protein-coupled receptor kinase, GRK6, appeared selectively vulnerable in myeloma.  GRK6 inhibition was lethal to 6 of 7 myeloma tumor lines but was tolerated in 7 of 7 human cell lines.  GRK6 exhibits lymphoid-restricted expression, and from coimmunopptn. studies the authors demonstrate that expression in myeloma cells is regulated via direct assocn. with the heat shock protein 90 (HSP90) chaperone.  GRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation assocd. with redn. in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells.  As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWyCueT3_UmrVg90H21EOLACvtfcHk0lgmuHNJH7kh-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtV2gtLo%253D&md5=2572ab7ed80ff48d250507e0db16b88e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-09-243980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-09-243980%26sid%3Dliteratum%253Aachs%26aulast%3DTiedemann%26aufirst%3DR.%2BE.%26aulast%3DZhu%26aufirst%3DY.%2BX.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DC.%2BX.%26aulast%3DQue%26aufirst%3DQ.%26aulast%3DBasu%26aufirst%3DG.%26aulast%3DAzorsa%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DL.%2BM.%26aulast%3DBraggio%26aufirst%3DE.%26aulast%3DFonseca%26aufirst%3DR.%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26aulast%3DMousses%26aufirst%3DS.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26atitle%3DKinome-wide%2520RNAi%2520studies%2520in%2520human%2520multiple%2520myeloma%2520identify%2520vulnerable%2520kinase%2520targets%252C%2520including%2520a%2520lymphoid-restricted%2520kinase%252C%2520GRK6%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D1594%26epage%3D1604%26doi%3D10.1182%2Fblood-2009-09-243980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mentzer, W. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, R. B.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baehner, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, D. G.</span></span> <span> </span><span class="NLM_article-title">An unusual form of chronic neutropenia in a father and daughter with hypogammaglobulinaemia</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.1977.tb00654.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1111%2Fj.1365-2141.1977.tb00654.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=889707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A280%3ADyaE2s3kt1Wjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1977&pages=313-322&author=W.+C.+Mentzerauthor=R.+B.+Johnstonauthor=R.+L.+Baehnerauthor=D.+G.+Nathan&title=An+unusual+form+of+chronic+neutropenia+in+a+father+and+daughter+with+hypogammaglobulinaemia&doi=10.1111%2Fj.1365-2141.1977.tb00654.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">An unusual form of chronic neutropenia in a father and daughter with hypogammaglobulinaemia</span></div><div class="casAuthors">Mentzer W C Jr; Johnston R B Jr; Baehner R L; Nathan D G</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">313-22</span>
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    </div><div class="casAbstract">Chronic neutropenia, with an abundance of mature neutrophils in the bone marrow, was discovered in a father and daughter who also had common variable hypogammaglobulinaemia.  Under the stress of infection or following the administration of typhoid vaccine, release of neutrophils from the marrow was enhanced sufficiently to abolish neutropenia temporarily.  Although their morphology was abnormal, the function of neutrophils in vitro was normal.  Thus, the increased susceptibility to infection that characterized these patients appeared to be due primarily to their defect in humoral immunity rather than their neutropenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMFVws0TwWk7HHuJhbyicZfW6udTcc2eZJ8Xn5OyiJz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2s3kt1Wjsg%253D%253D&md5=0bfd726a0f911eebc638d894d45719b6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.1977.tb00654.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.1977.tb00654.x%26sid%3Dliteratum%253Aachs%26aulast%3DMentzer%26aufirst%3DW.%2BC.%26aulast%3DJohnston%26aufirst%3DR.%2BB.%26aulast%3DBaehner%26aufirst%3DR.%2BL.%26aulast%3DNathan%26aufirst%3DD.%2BG.%26atitle%3DAn%2520unusual%2520form%2520of%2520chronic%2520neutropenia%2520in%2520a%2520father%2520and%2520daughter%2520with%2520hypogammaglobulinaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D1977%26volume%3D36%26spage%3D313%26epage%3D322%26doi%3D10.1111%2Fj.1365-2141.1977.tb00654.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segarra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasperini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulino, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosato, G.</span></span> <span> </span><span class="NLM_article-title">Impaired recruitment of GRK6 and beta-arrestin 2 causes delayed internalization and desensitization of a WHIM syndrome-associated CXCR4 mutant receptor</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e8102</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0008102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1371%2Fjournal.pone.0008102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=19956569" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&author=P.+J.+McCormickauthor=M.+Segarraauthor=P.+Gasperiniauthor=A.+V.+Gulinoauthor=G.+Tosato&title=Impaired+recruitment+of+GRK6+and+beta-arrestin+2+causes+delayed+internalization+and+desensitization+of+a+WHIM+syndrome-associated+CXCR4+mutant+receptor&doi=10.1371%2Fjournal.pone.0008102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0008102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0008102%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26aulast%3DSegarra%26aufirst%3DM.%26aulast%3DGasperini%26aufirst%3DP.%26aulast%3DGulino%26aufirst%3DA.%2BV.%26aulast%3DTosato%26aufirst%3DG.%26atitle%3DImpaired%2520recruitment%2520of%2520GRK6%2520and%2520beta-arrestin%25202%2520causes%2520delayed%2520internalization%2520and%2520desensitization%2520of%2520a%2520WHIM%2520syndrome-associated%2520CXCR4%2520mutant%2520receptor%26jtitle%3DPLoS%2520One%26date%3D2009%26volume%3D4%26doi%3D10.1371%2Fjournal.pone.0008102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fong, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premont, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.-R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. D.</span></span> <span> </span><span class="NLM_article-title">Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">7478</span>– <span class="NLM_lpage">7483</span>, <span class="refDoi"> DOI: 10.1073/pnas.112198299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1073%2Fpnas.112198299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12032308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlCktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=7478-7483&author=A.+M.+Fongauthor=R.+T.+Premontauthor=R.+M.+Richardsonauthor=Y.-R.+A.+Yuauthor=R.+J.+Lefkowitzauthor=D.+D.+Patel&title=Defective+lymphocyte+chemotaxis+in+beta-arrestin2-+and+GRK6-deficient+mice&doi=10.1073%2Fpnas.112198299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Defective lymphocyte chemotaxis in β-arrestin2- and GRK6-deficient mice</span></div><div class="casAuthors">Fong, Alan M.; Premont, Richard T.; Richardson, Ricardo M.; Yu, Yen-Rei A.; Lefkowitz, Robert J.; Patel, Dhavalkumar D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7478-7483</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lymphocyte chemotaxis is a complex process by which cells move within tissues and across barriers such as vascular endothelium and is usually stimulated by chemokines such as stromal cell-derived factor-1 (CXCL12) acting via G protein-coupled receptors.  Because members of this receptor family are regulated ("desensitized") by G protein-coupled receptor kinase (GRK)-mediated receptor phosphorylation and β-arrestin binding, the authors examd. signaling and chemotactic responses in splenocytes derived from knockout mice deficient in various β-arrestins and GRKs, with the expectation that these responses might be enhanced.  Knockouts of β-arrestin2, GRK5, and GRK6 were examd. because all three proteins are expressed at high levels in purified mouse CD3+ T and B220+ B splenocytes.  CXCL12 stimulation of membrane GTPase activity was unaffected in splenocytes derived from GRK5-deficient mice but was increased in splenocytes from the β-arrestin2- and GRK6-deficient animals.  Surprisingly, however, both T and B cells from β-arrestin2-deficient animals and T cells from GRK6-deficient animals were strikingly impaired in their ability to respond to CXCL12 both in Transwell migration assays and in transendothelial migration assays.  Chemotactic responses of lymphocytes from GRK5-deficient mice were unaffected.  Thus, these results indicate that β-arrestin2 and GRK6 actually play pos. regulatory roles in mediating the chemotactic responses of T and B lymphocytes to CXCL12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwhhtdtSuoY7Vg90H21EOLACvtfcHk0lh8SwisXjfkBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlCktbc%253D&md5=f474e5f1e7e59a9a13055cbfdee4263e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.112198299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.112198299%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DA.%2BM.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26aulast%3DRichardson%26aufirst%3DR.%2BM.%26aulast%3DYu%26aufirst%3DY.-R.%2BA.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DPatel%26aufirst%3DD.%2BD.%26atitle%3DDefective%2520lymphocyte%2520chemotaxis%2520in%2520beta-arrestin2-%2520and%2520GRK6-deficient%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2002%26volume%3D99%26spage%3D7478%26epage%3D7483%26doi%3D10.1073%2Fpnas.112198299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushegian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, V. V.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptor kinases: more than just kinases and not only for GPCRs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2011.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.pharmthera.2011.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=21903131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Ciur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2012&pages=40-69&author=E.+V.+Gurevichauthor=J.+J.+Tesmerauthor=A.+Mushegianauthor=V.+V.+Gurevich&title=G+protein-coupled+receptor+kinases%3A+more+than+just+kinases+and+not+only+for+GPCRs&doi=10.1016%2Fj.pharmthera.2011.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptor kinases: More than just kinases and not only for GPCRs</span></div><div class="casAuthors">Gurevich, Eugenia V.; Tesmer, John J. G.; Mushegian, Arcady; Gurevich, Vsevolod V.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-69</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptor (GPCR) kinases (GRKs) are best known for their role in homologous desensitization of GPCRs.  GRKs phosphorylate activated receptors and promote high affinity binding of arrestins, which precludes G protein coupling.  GRKs have a multidomain structure, with the kinase domain inserted into a loop of a regulator of G protein signaling homol. domain.  Unlike many other kinases, GRKs do not need to be phosphorylated in their activation loop to achieve an activated state.  Instead, they are directly activated by docking with active GPCRs.  In this manner they are able to selectively phosphorylate Ser/Thr residues on only the activated form of the receptor, unlike related kinases such as protein kinase A.  GRKs also phosphorylate a variety of non-GPCR substrates and regulate several signaling pathways via direct interactions with other proteins in a phosphorylation-independent manner.  Multiple GRK subtypes are present in virtually every animal cell, with the highest expression levels found in neurons, with their extensive and complex signal regulation.  Insufficient or excessive GRK activity was implicated in a variety of human disorders, ranging from heart failure to depression to Parkinson's disease.  As key regulators of GPCR-dependent and -independent signaling pathways, GRKs are emerging drug targets and promising mol. tools for therapy.  Targeted modulation of expression and/or of activity of several GRK isoforms for therapeutic purposes was recently validated in cardiac disorders and Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru2us2UKmea7Vg90H21EOLACvtfcHk0lh8SwisXjfkBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Ciur%252FE&md5=3f132767c5dfe390c8e2a3b643d68ca3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DGurevich%26aufirst%3DE.%2BV.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26aulast%3DMushegian%26aufirst%3DA.%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26atitle%3DG%2520protein-coupled%2520receptor%2520kinases%253A%2520more%2520than%2520just%2520kinases%2520and%2520not%2520only%2520for%2520GPCRs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2012%26volume%3D133%26spage%3D40%26epage%3D69%26doi%3D10.1016%2Fj.pharmthera.2011.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moepps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vatter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frodl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waechter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixkens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hameister, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gierschik, P.</span></span> <span> </span><span class="NLM_article-title">Alternative splicing produces transcripts encoding four variants of mouse G-protein-coupled receptor kinase 6</span>. <i>Genomics</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1006/geno.1999.5901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1006%2Fgeno.1999.5901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10486211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVWqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1999&pages=199-209&author=B.+Moeppsauthor=P.+Vatterauthor=R.+Frodlauthor=F.+Waechterauthor=C.+Dixkensauthor=H.+Hameisterauthor=P.+Gierschik&title=Alternative+splicing+produces+transcripts+encoding+four+variants+of+mouse+G-protein-coupled+receptor+kinase+6&doi=10.1006%2Fgeno.1999.5901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Alternative splicing produces transcripts encoding four variants of mouse G-protein-coupled receptor kinase 6</span></div><div class="casAuthors">Moepps, Barbara; Vatter, Petra; Frodl, Reinhard; Waechter, Fabian; Dixkens, Christa; Hameister, Horst; Gierschik, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Genomics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-209</span>CODEN:
                <span class="NLM_cas:coden">GNMCEP</span>;
        ISSN:<span class="NLM_cas:issn">0888-7543</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A family of protein kinases, termed G-protein-coupled receptor kinases (GRK1-6), is known to phosphorylate agonist-occupied G-protein-coupled receptors.  We have identified mRNAs encoding four distinct mouse GRK6 isoforms (mGRK6), designated mGRK6-A through mGRK6-D.  Mouse GRK6-B and mGRK6-C diverge from the known human GRK6 (577 residues) at residue 560 and are 13 residues longer and 16 residues shorter, resp., than human GRK6, while mGRK6-A very likely represents the mouse equiv. of human GRK6.  Mouse GRK6-D is identical to the other mGRK6 variants in the amino-terminal region, but comprises only 59 of the 263 amino acids of the putative catalytical domain.  As mGRK6-D retains the region involved in interacting with activated receptors, but most likely lacks catalytic activity, this variant might represent a naturally occurring inhibitor of other GRKs.  Anal. of the genomic organization of mGRK6 gene revealed that the four mRNAs are generated by alternative RNA splicing from a single approx. 14.5-kb gene, made up of at least 17 exons and located on mouse chromosome 13.  Similar to human GRK6, mGRK6-A contains three cysteine residues within its carboxyl-terminal region known to serve as substrates for palmitoylation.  Mouse GRK6-B lacks these palmitoylation sites, but carries a basic carboxyl-terminus contg. consensus sequences for phosphorylation by protein kinases C and cAMP/cGMP-dependent protein kinases.  Mouse GRK6-C displays none of these motifs.  Thus, mGRK6-A, mGRK6-B, and mGRK6-C are predicted to differ in terms of their regulation by carboxyl-terminal posttranslational modification.  Anal. of mRNA expression revealed that the four mGRK6 mRNAs are differentially expressed in mouse tissues, suggesting that the four mGRK6 isoforms are involved in regulating tissue- or cell type-specific functions in vivo.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzU7UCKjiUvLVg90H21EOLACvtfcHk0lh8SwisXjfkBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVWqsbk%253D&md5=a01bba28361727397d8e91238a3464b1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1006%2Fgeno.1999.5901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fgeno.1999.5901%26sid%3Dliteratum%253Aachs%26aulast%3DMoepps%26aufirst%3DB.%26aulast%3DVatter%26aufirst%3DP.%26aulast%3DFrodl%26aufirst%3DR.%26aulast%3DWaechter%26aufirst%3DF.%26aulast%3DDixkens%26aufirst%3DC.%26aulast%3DHameister%26aufirst%3DH.%26aulast%3DGierschik%26aufirst%3DP.%26atitle%3DAlternative%2520splicing%2520produces%2520transcripts%2520encoding%2520four%2520variants%2520of%2520mouse%2520G-protein-coupled%2520receptor%2520kinase%25206%26jtitle%3DGenomics%26date%3D1999%26volume%3D60%26spage%3D199%26epage%3D209%26doi%3D10.1006%2Fgeno.1999.5901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotnikova, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laakso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premont, R. T.</span></span> <span> </span><span class="NLM_article-title">Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1016/S0896-6273(03)00192-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2FS0896-6273%2803%2900192-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12718862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslOktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=291-303&author=R.+R.+Gainetdinovauthor=L.+M.+Bohnauthor=T.+D.+Sotnikovaauthor=M.+Cyrauthor=A.+Laaksoauthor=A.+D.+Macraeauthor=G.+E.+Torresauthor=K.+M.+Kimauthor=R.+J.+Lefkowitzauthor=M.+G.+Caronauthor=R.+T.+Premont&title=Dopaminergic+supersensitivity+in+G+protein-coupled+receptor+kinase+6-deficient+mice&doi=10.1016%2FS0896-6273%2803%2900192-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice</span></div><div class="casAuthors">Gainetdinov, Raul R.; Bohn, Laura M.; Sotnikova, Tatyana D.; Cyr, Michel; Laakso, Aki; Macrae, Alexander D.; Torres, Gonzalo E.; Kim, Kyeong-Man; Lefkowitz, Robert J.; Caron, Marc G.; Premont, Richard T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">291-303</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Brain dopaminergic transmission is a crit. component in numerous vital functions, and its dysfunction is involved in several disorders, including addiction and Parkinson's disease.  Responses to dopamine are mediated via G protein-coupled dopamine receptors (D1-D5).  Desensitization of G protein-coupled receptors is mediated via phosphorylation by members of the family of G protein-coupled receptor kinases (GRK1-GRK7).  Here we show that GRK6-deficient mice are supersensitive to the locomotor-stimulating effect of psychostimulants, including cocaine and amphetamine.  In addn., these mice demonstrate an enhanced coupling of striatal D2-like dopamine receptors to G proteins and augmented locomotor response to direct dopamine agonists both in intact and in dopamine-depleted animals.  The present study indicates that postsynaptic D2-like dopamine receptors are physiol. targets for GRK6 and suggests that this regulatory mechanism contributes to central dopaminergic supersensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr--gIoM0vWlbVg90H21EOLACvtfcHk0lg4iQaK5FmCpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslOktLc%253D&md5=237a0357b09c8d7f3ba909462b2a4699</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2803%2900192-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252803%252900192-2%26sid%3Dliteratum%253Aachs%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DSotnikova%26aufirst%3DT.%2BD.%26aulast%3DCyr%26aufirst%3DM.%26aulast%3DLaakso%26aufirst%3DA.%26aulast%3DMacrae%26aufirst%3DA.%2BD.%26aulast%3DTorres%26aufirst%3DG.%2BE.%26aulast%3DKim%26aufirst%3DK.%2BM.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26atitle%3DDopaminergic%2520supersensitivity%2520in%2520G%2520protein-coupled%2520receptor%2520kinase%25206-deficient%2520mice%26jtitle%3DNeuron%26date%3D2003%26volume%3D38%26spage%3D291%26epage%3D303%26doi%3D10.1016%2FS0896-6273%2803%2900192-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premont, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, J.</span></span> <span> </span><span class="NLM_article-title">Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid modification diversity in the GRK family</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">27791</span>– <span class="NLM_lpage">27794</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)46852-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2FS0021-9258%2818%2946852-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=7961702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADyaK2cXmsV2ntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=27791-27794&author=R.+H.+Stoffelauthor=R.+R.+Randallauthor=R.+T.+Premontauthor=R.+J.+Lefkowitzauthor=J.+Inglese&title=Palmitoylation+of+G+protein-coupled+receptor+kinase%2C+GRK6.+Lipid+modification+diversity+in+the+GRK+family&doi=10.1016%2FS0021-9258%2818%2946852-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid modification diversity in the GRK family</span></div><div class="casAuthors">Stoffel, Robert H.; Randall, Richard R.; Premont, Richard T.; Lefkowitz, Robert J.; Inglese, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">27791-4</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Gene GRK6 receptor kinase, a 66-kDa serine/threonine protein kinase, is a recently identified member of the G protein-coupled receptor kinase (GRK) family.  GRKs are involved in the phosphorylation of 7-transmembrane receptors, a process mediating desensitization of signal transduction.  An important feature of these enzymes is their membrane-assocd. nature, which for some members is stimulus-dependent.  The structural basis for this membrane assocn. previously has been shown in different members of the GRK family to include isoprenylation, G protein βγ-binding domains, and basic regions to provide electrostatic interactions with phospholipids.  Here, evidence is provided that another mechanism includes fatty acid acylation.  GRK6, but not other GRKs tested, incorporated 3H after incubation with [3H]palmitate in Sf9 and in COS-7 cells overexpressing the kinase.  The incorporated radioactivity was released from the protein by neutral hydroxylamine, indicating the presence of a thioester bond and was confirmed as palmitic acid by HPLC anal.  Site-directed mutagenesis defined the region of palmitate attachment as a cluster of 3 cysteines (Cys-561, Cys-562, and Cys-565) in the C-terminal domain of the kinase, consistent with the location of the membrane targeting domains of GRKs 1, 2, 3, and 5.  Palmitoylation of GRK6 appears essential for membrane assocn., since palmitoylated kinase was found only in the membrane fraction.  This lipid modification provides a structural basis for potential regulation of the subcellular distribution of GRK6 through acylation/deacylation cycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7QuLcwiAKFrVg90H21EOLACvtfcHk0lg4iQaK5FmCpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsV2ntb4%253D&md5=9e9e8296a37eb3286ccfa0e8d70487a1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2946852-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252946852-4%26sid%3Dliteratum%253Aachs%26aulast%3DStoffel%26aufirst%3DR.%2BH.%26aulast%3DRandall%26aufirst%3DR.%2BR.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DInglese%26aufirst%3DJ.%26atitle%3DPalmitoylation%2520of%2520G%2520protein-coupled%2520receptor%2520kinase%252C%2520GRK6.%2520Lipid%2520modification%2520diversity%2520in%2520the%2520GRK%2520family%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D27791%26epage%3D27794%26doi%3D10.1016%2FS0021-9258%2818%2946852-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vroon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heijnen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raatgever, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touw, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploemacher, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premont, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavelaars, A.</span></span> <span> </span><span class="NLM_article-title">GRK6 deficiency is associated with enhanced CXCR4-mediated neutrophil chemotaxis in vitro and impaired responsiveness to G-CSF in vivo</span>. <i>J. Leukoc. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1189/jlb.0703320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1189%2Fjlb.0703320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=14704365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2004&pages=698-704&author=A.+Vroonauthor=C.+J.+Heijnenauthor=R.+Raatgeverauthor=I.+P.+Touwauthor=R.+E.+Ploemacherauthor=R.+T.+Premontauthor=A.+Kavelaars&title=GRK6+deficiency+is+associated+with+enhanced+CXCR4-mediated+neutrophil+chemotaxis+in+vitro+and+impaired+responsiveness+to+G-CSF+in+vivo&doi=10.1189%2Fjlb.0703320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">GRK6 deficiency is associated with enhanced CXCR4-mediated neutrophil chemotaxis in vitro and impaired responsiveness to G-CSF in vivo</span></div><div class="casAuthors">Vroon, Anne; Heijnen, Cobi J.; Raatgever, Roel; Touw, Ivo P.; Ploemacher, Rob E.; Premont, Richard T.; Kavelaars, Annemieke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">698-704</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">The stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor 4 (CXCR4) signaling pathway is thought to play an important role in the induction of neutrophil mobilization from the bone marrow in response to granulocyte-colony stimulating factor (G-CSF) treatment.  CXCR4 belongs to the family of G protein-coupled receptors.  Multiple members of this receptor family are desensitized by agonist-induced G protein-coupled receptor kinase (GRK)-mediated phosphorylation.  Here, the authors demonstrate that in vitro SDF-1-induced chemotaxis of bone marrow-derived neutrophils from GRK6-deficient mice is significantly enhanced and that desensitization of the calcium response to SDF-1 is impaired in GRK6-/- neutrophils.  CXCR4 activation by SDF-1 provides a key retention signal for hematopoietic cells in the bone marrow.  It is interesting that the authors obsd. that in the absence of GRK6, the G-CSF-induced increase in circulating neutrophils is profoundly impaired.  Three days after injection of pegylated-G-CSF, significantly lower nos. of circulating neutrophils were obsd. in GRK6-/- as compared with wild-type (WT) mice.  In addn., early/acute neutrophil mobilization in response to G-CSF (3 h after treatment) was also impaired in GRK6-/- mice.  However, blood neutrophil levels in untreated GRK6-/- and WT mice were not different.  Moreover, the percentage of neutrophils in the bone marrow after G-CSF treatment was increased to the same extent in WT and GRK6-/- mice, indicating that neutrophil prodn. is normal in the absence of GRK6.  However, the increased chemotactic sensitivity of GRK6-/- neutrophils to SDF-1 was retained after G-CSF treatment.  In view of these data, the authors suggest that the impaired G-CSF-induced neutrophil mobilization in the absence of GRK6 may be a result of enhanced CXCR4-mediated retention of PMN in the bone marrow.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhQ_hTHtYCILVg90H21EOLACvtfcHk0lg4iQaK5FmCpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFyrtr4%253D&md5=3167d60a87917a409e8f4f52bb61d40e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0703320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0703320%26sid%3Dliteratum%253Aachs%26aulast%3DVroon%26aufirst%3DA.%26aulast%3DHeijnen%26aufirst%3DC.%2BJ.%26aulast%3DRaatgever%26aufirst%3DR.%26aulast%3DTouw%26aufirst%3DI.%2BP.%26aulast%3DPloemacher%26aufirst%3DR.%2BE.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26aulast%3DKavelaars%26aufirst%3DA.%26atitle%3DGRK6%2520deficiency%2520is%2520associated%2520with%2520enhanced%2520CXCR4-mediated%2520neutrophil%2520chemotaxis%2520in%2520vitro%2520and%2520impaired%2520responsiveness%2520to%2520G-CSF%2520in%2520vivo%26jtitle%3DJ.%2520Leukoc.%2520Biol.%26date%3D2004%26volume%3D75%26spage%3D698%26epage%3D704%26doi%3D10.1189%2Fjlb.0703320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zidar, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">9649</span>– <span class="NLM_lpage">9654</span>, <span class="refDoi"> DOI: 10.1073/pnas.0904361106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1073%2Fpnas.0904361106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=19497875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFCqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=9649-9654&author=D.+A.+Zidarauthor=J.+D.+Violinauthor=E.+J.+Whalenauthor=R.+J.+Lefkowitz&title=Selective+engagement+of+G+protein+coupled+receptor+kinases+%28GRKs%29+encodes+distinct+functions+of+biased+ligands&doi=10.1073%2Fpnas.0904361106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands</span></div><div class="casAuthors">Zidar, David A.; Violin, Jonathan D.; Whalen, Erin J.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9649-9654, S9649/1-S9649/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">CCL19 and CCL21 are endogenous agonists for the seven-transmembrane receptor CCR7.  They are equally active in promoting G protein stimulation and chemotaxis.  Yet, the authors find that they result in striking differences in activation of the G protein-coupled receptor kinase (GRK)/β-arrestin system.  CCL19 leads to robust CCR7 phosphorylation and β-arrestin2 recruitment catalyzed by both GRK3 and GRK6 whereas CCL21 activates GRK6 alone.  This differential GRK activation leads to distinct functional consequences.  Although each ligand leads to β-arrestin2 recruitment, only CCL19 leads to redistribution of β-arrestin2-GFP into endocytic vesicles and classical receptor desensitization.  In contrast, these agonists are both capable of signaling through GRK6 and β-arrestin2 to ERK kinases.  Thus, this mechanism for "ligand bias" whereby endogenous agonists activate different GRK isoforms leads to functionally distinct pools of β-arrestin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVIg9KXFgIIrVg90H21EOLACvtfcHk0liQ6pBCViUVXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFCqurc%253D&md5=d94e0d529075db86d94261833c9a4c8a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904361106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904361106%26sid%3Dliteratum%253Aachs%26aulast%3DZidar%26aufirst%3DD.%2BA.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DSelective%2520engagement%2520of%2520G%2520protein%2520coupled%2520receptor%2520kinases%2520%2528GRKs%2529%2520encodes%2520distinct%2520functions%2520of%2520biased%2520ligands%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D9649%26epage%3D9654%26doi%3D10.1073%2Fpnas.0904361106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Premont, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span> <span> </span><span class="NLM_article-title">G Protein-coupled receptor kinases phosphorylate LRP6 in the Wnt pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">35040</span>– <span class="NLM_lpage">35048</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.047456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fjbc.M109.047456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=19801552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFWitbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=35040-35048&author=M.+Chenauthor=M.+Philippauthor=J.+Wangauthor=R.+T.+Premontauthor=T.+R.+Garrisonauthor=M.+G.+Caronauthor=R.+J.+Lefkowitzauthor=W.+Chen&title=G+Protein-coupled+receptor+kinases+phosphorylate+LRP6+in+the+Wnt+pathway&doi=10.1074%2Fjbc.M109.047456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">G Protein-coupled Receptor Kinases Phosphorylate LRP6 in the Wnt Pathway</span></div><div class="casAuthors">Chen, Min-Yong; Philipp, Melanie; Wang, Jiang-Bo; Premont, Richard T.; Garrison, Tiffany R.; Caron, Marc G.; Lefkowitz, Robert J.; Chen, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">35040-35048</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Wnt ligands conduct their functions in canonical Wnt signaling by binding to 2 receptors, the single transmembrane low d. lipoprotein receptor-related proteins 5 and 6 (LRP5/6) and 7 transmembrane (7TM) Frizzled receptors.  Subsequently, phosphorylation of serine/threonine residues within 5 repeating signature PPPSP motifs on LRP6 is responsible for LRP6 activation.  GSK3β, a cytosolic kinase for phosphorylation of a downstream effector β-catenin, was proposed to participate in such LRP6 phosphorylation.  Here, we report a new class of membrane-assocd. kinases for LRP6 phosphorylation.  G protein-coupled receptor kinases 5 and 6 (GRK5/6), traditionally known to phosphorylate and desensitize 7TM G protein-coupled receptors, directly phosphorylate the PPPSP motifs on single transmembrane LRP6 and regulate Wnt/LRP6 signaling.  GRK5/6-induced LRP6 activation is inhibited by the LRP6 antagonist Dickkopf.  Depletion of GRK5 markedly reduces Wnt3A-stimulated LRP6 phosphorylation in cells.  In zebrafish, functional knock-down of GRK5 results in reduced Wnt signaling, analogous to LRP6 knock-down, as assessed by decreased abundance of β-catenin and lowered expression of the Wnt target genes cdx4, vent, and axin2.  Expression of GRK5 rescues the diminished β-catenin and axin2 response caused by GRK5 depletion.  Thus, our findings identify GRK5/6 as novel kinases for the single transmembrane receptor LRP6 during Wnt signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_FM4K81kUkrVg90H21EOLACvtfcHk0liQ6pBCViUVXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFWitbzI&md5=d578d432df8b1123c4208a84b778fdd9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.047456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.047456%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPhilipp%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPremont%26aufirst%3DR.%2BT.%26aulast%3DGarrison%26aufirst%3DT.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DChen%26aufirst%3DW.%26atitle%3DG%2520Protein-coupled%2520receptor%2520kinases%2520phosphorylate%2520LRP6%2520in%2520the%2520Wnt%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D35040%26epage%3D35048%26doi%3D10.1074%2Fjbc.M109.047456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernstedt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhenc-Gelas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Esterl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikic, I.</span></span> <span> </span><span class="NLM_article-title">Determination of bradykinin B2 receptor in vivo phosphorylation sites and their role in receptor function</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">40431</span>– <span class="NLM_lpage">40440</span>, <span class="refDoi"> DOI: 10.1074/jbc.M107024200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fjbc.M107024200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=11517230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A280%3ADC%252BD3MrnsVOnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=40431-40440&author=A.+Blaukatauthor=A.+Pizardauthor=A.+Breitauthor=C.+Wernstedtauthor=F.+Alhenc-Gelasauthor=W.+Muller-Esterlauthor=I.+Dikic&title=Determination+of+bradykinin+B2+receptor+in+vivo+phosphorylation+sites+and+their+role+in+receptor+function&doi=10.1074%2Fjbc.M107024200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of bradykinin B2 receptor in vivo phosphorylation sites and their role in receptor function</span></div><div class="casAuthors">Blaukat A; Pizard A; Breit A; Wernstedt C; Alhenc-Gelas F; Muller-Esterl W; Dikic I</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">40431-40</span>
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Reversible phosphorylation plays important roles in G protein-coupled receptor signaling, desensitization, and endocytosis, yet the precise location and role of in vivo phosphorylation sites is unknown for most receptors.  Using metabolic 32P labeling and phosphopeptide sequencing we provide a complete phosphorylation map of the human bradykinin B2 receptor in its native cellular environment.  We identified three serine residues, Ser(339), Ser(346), and Ser(348), at the C-terminal tail as principal phosphorylation sites.  Constitutive phosphorylation occurs at Ser(348), while ligand-induced phosphorylation is found at Ser(339) and Ser(346)/Ser(348) that could be executed by several G protein-coupled receptor kinases.  In addition, we found a protein kinase C-dependent phosphorylation of Ser(346) that was mutually exclusive with the basal phosphorylation at Ser(348) and therefore may be implicated in differential regulation of B2 receptor activation.  Functional analysis of receptor mutants revealed that a low phosphorylation stoichiometry is sufficient to initiate receptor sequestration while a clustered phosphorylation around Ser(346) is necessary for desensitization of the B2 receptor-induced phospholipase C activation.  This was further supported by the specifically reduced Ser(346)/Ser(348) phosphorylation observed upon stimulation with a nondesensitizing B2 receptor agonist.  The differential usage of clustered phosphoacceptor sites points to distinct roles of multiple kinases in controlling G protein-coupled receptor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4SZXITJek86qcneEtCi92fW6udTcc2eY68-kVVCD5yLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MrnsVOnug%253D%253D&md5=b3307ee5eebc2f62af94f43590b35084</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M107024200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M107024200%26sid%3Dliteratum%253Aachs%26aulast%3DBlaukat%26aufirst%3DA.%26aulast%3DPizard%26aufirst%3DA.%26aulast%3DBreit%26aufirst%3DA.%26aulast%3DWernstedt%26aufirst%3DC.%26aulast%3DAlhenc-Gelas%26aufirst%3DF.%26aulast%3DMuller-Esterl%26aufirst%3DW.%26aulast%3DDikic%26aufirst%3DI.%26atitle%3DDetermination%2520of%2520bradykinin%2520B2%2520receptor%2520in%2520vivo%2520phosphorylation%2520sites%2520and%2520their%2520role%2520in%2520receptor%2520function%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D40431%26epage%3D40440%26doi%3D10.1074%2Fjbc.M107024200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaudreau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gouill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rola-Pleszczynski, M.</span></span> <span> </span><span class="NLM_article-title">Threonine 308 within a putative casein kinase 2 site of the cytoplasmic tail of leukotriene B(4) receptor (BLT1) is crucial for ligand-induced, G-protein-coupled receptor-specific kinase 6-mediated desensitization</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">31567</span>– <span class="NLM_lpage">31576</span>, <span class="refDoi"> DOI: 10.1074/jbc.M202723200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fjbc.M202723200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12077128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslOqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=31567-31576&author=R.+Gaudreauauthor=C.+Le+Gouillauthor=M.+H.+Venneauthor=J.+Stankovaauthor=M.+Rola-Pleszczynski&title=Threonine+308+within+a+putative+casein+kinase+2+site+of+the+cytoplasmic+tail+of+leukotriene+B%284%29+receptor+%28BLT1%29+is+crucial+for+ligand-induced%2C+G-protein-coupled+receptor-specific+kinase+6-mediated+desensitization&doi=10.1074%2Fjbc.M202723200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Threonine 308 within a putative casein kinase 2 site of the cytoplasmic tail of leukotriene B4 receptor (BLT1) is crucial for ligand-induced, G-protein-coupled receptor-specific kinase 6-mediated desensitization</span></div><div class="casAuthors">Gaudreau, Remi; Le Gouill, Christian; Venne, Marie-Helene; Stankova, Jana; Rola-Pleszczynski, Marek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">31567-31576</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Desensitization of G-protein-coupled receptors may involve phosphorylation of serine and threonine residues.  The leukotriene B4 (LTB4) receptor (BLT1) contains 14 intracellular serines and threonines, 8 of which are part of consensus target sequences for protein kinase C (PKC) or casein kinase 2.  In this study, we investigated the importance of PKC and GPCR-specific kinase (GRK) phosphorylation in BLT1 desensitization.  Pretreatment of BLT1-transfected COS-7 cells with PKC activators caused a decrease of LTB4-induced inositol phosphate (IP) accumulation.  This redn. was prevented with the PKC inhibitor, staurosporine, and not obsd. in cells expressing a BLT1 deletion mutant (G291stop) lacking the cytoplasmic tail.  Moreover LTB4-induced IP accumulation was significantly inhibited by overexpression of GRK2, GRK5, and esp. GRK6, in cells expressing wild type BLT1 but not in those expressing G291stop.  GRK6-mediated desensitization correlated with increased phosphorylation of BLT1.  The G319stop truncated BLT1 mutant displayed functional characteristics comparable with wild type BLT1 in terms of desensitization by GRK6, but not by PKC.  Substitution of Thr308 within a putative casein kinase 2 site to proline or alanine in the full-length BLT1 receptor prevented most of GRK6-mediated inhibition of LTB4-induced IP prodn. but only partially affected LTB4-induced BLT1 phosphorylation.  Our findings thus suggest that Thr308 is a major residue involved in GRK6-mediated desensitization of BLT1 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp83IiGE24e6bVg90H21EOLACvtfcHk0liQ6pBCViUVXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslOqtr8%253D&md5=bc618ba374285a03d9245032f2000f53</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M202723200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M202723200%26sid%3Dliteratum%253Aachs%26aulast%3DGaudreau%26aufirst%3DR.%26aulast%3DLe%2BGouill%26aufirst%3DC.%26aulast%3DVenne%26aufirst%3DM.%2BH.%26aulast%3DStankova%26aufirst%3DJ.%26aulast%3DRola-Pleszczynski%26aufirst%3DM.%26atitle%3DThreonine%2520308%2520within%2520a%2520putative%2520casein%2520kinase%25202%2520site%2520of%2520the%2520cytoplasmic%2520tail%2520of%2520leukotriene%2520B%25284%2529%2520receptor%2520%2528BLT1%2529%2520is%2520crucial%2520for%2520ligand-induced%252C%2520G-protein-coupled%2520receptor-specific%2520kinase%25206-mediated%2520desensitization%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D31567%26epage%3D31576%26doi%3D10.1074%2Fjbc.M202723200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matkovich, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorn, G. W.</span></span> <span> </span><span class="NLM_article-title">2nd, G-protein receptor kinases 2, 5 and 6 redundantly modulate smoothened-GATA transcriptional crosstalk in fetal mouse hearts</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2018.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.yjmcc.2018.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=29969579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yitb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2018&pages=60-68&author=A.+Francoauthor=L.+Zhangauthor=S.+J.+Matkovichauthor=A.+Kovacsauthor=G.+W.+Dorn&title=2nd%2C+G-protein+receptor+kinases+2%2C+5+and+6+redundantly+modulate+smoothened-GATA+transcriptional+crosstalk+in+fetal+mouse+hearts&doi=10.1016%2Fj.yjmcc.2018.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">G-protein receptor kinases 2, 5 and 6 redundantly modulate Smoothened-GATA transcriptional crosstalk in fetal mouse hearts</span></div><div class="casAuthors">Franco, Antoinetta; Zhang, Lihong; Matkovich, Scot J.; Kovacs, Attila; Dorn, Gerald W., II</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-68</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G protein receptor kinases (GRKs) regulate adult hearts by modulating inotropic, chronotropic and hypertrophic signaling of 7-transmembrane spanning neurohormone receptors.  GRK-mediated desensitization and downregulation of β-adrenergic receptors has been implicated in adult heart failure; GRKs are therefore a promising therapeutic target.  However, germ-line (but not cardiomyocyte-specific) GRK2 deletion provoked lethal fetal heart defects, suggesting an unexplained role for GRKs in heart development.  Here we undertook to better understand the consequences of GRK deficiency on fetal heart development by creating mice and cultured murine embryonic fibroblasts (MEFs) having floxed GRK2 and GRK5 alleles on the GRK6 null background; simultaneous conditional deletion of these 3 GRK genes was achieved using Nkx2-5 Cre or adenoviral Cre, resp.  Phenotypes were related to GRK-modulated gene expression using whole-transcriptome RNA sequencing, RT-qPCR, and luciferase reporter assays.  In cultured MEFs the atypical 7-transmembrane spanning protein and GRK2 substrate Smoothened (Smo) stimulated Gli-mediated transcriptional activity, which was interrupted by deleting GRK2/5/6.  Mice with Nkx2-5 Cre mediated GRK2/5/6 ablation died between E15.5 and E16.5, whereas mice expressing any one of these 3 GRKs (i.e. GRK2/5, GRK2/6 or GRK5/6 deleted) were developmentally normal.  GRK2/5/6 triple null mice at E14.5 exhibited left and right heart blood intermixing through single atrioventricular valves or large membranous ventricular septal defects.  Hedgehog and GATA pathway gene expression promoted by Smo/Gli was suppressed in GRK2/5/6 deficient fetal hearts and MEFs.  These data indicate that GRK2, GRK5 and GRK6 redundantly modulate Smo-GATA crosstalk in fetal mouse hearts, orchestrating transcriptional pathways previously linked to clin. and exptl. atrioventricular canal defects.  GRK modulation of Smo reflects convergence of conventional neurohormonal signaling and transcriptional regulation pathways, comprising an unanticipated mechanism for spatiotemporal orchestration of developmental gene expression in the heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA94lConk9orVg90H21EOLACvtfcHk0liyhWQ08FAZ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yitb7O&md5=c1443b33adf482cde39735739be86282</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2018.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2018.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DFranco%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DMatkovich%26aufirst%3DS.%2BJ.%26aulast%3DKovacs%26aufirst%3DA.%26aulast%3DDorn%26aufirst%3DG.%2BW.%26atitle%3D2nd%252C%2520G-protein%2520receptor%2520kinases%25202%252C%25205%2520and%25206%2520redundantly%2520modulate%2520smoothened-GATA%2520transcriptional%2520crosstalk%2520in%2520fetal%2520mouse%2520hearts%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2018%26volume%3D121%26spage%3D60%26epage%3D68%26doi%3D10.1016%2Fj.yjmcc.2018.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benovic, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedegaertner, P. B.</span></span> <span> </span><span class="NLM_article-title">Plasma membrane and nuclear localization of G protein coupled receptor kinase 6A</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2960</span>– <span class="NLM_lpage">2969</span>, <span class="refDoi"> DOI: 10.1091/mbc.e07-01-0013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1091%2Fmbc.e07-01-0013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=17538017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFalu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=2960-2969&author=X.+Jiangauthor=J.+L.+Benovicauthor=P.+B.+Wedegaertner&title=Plasma+membrane+and+nuclear+localization+of+G+protein+coupled+receptor+kinase+6A&doi=10.1091%2Fmbc.e07-01-0013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma membrane and nuclear localization of G protein-coupled receptor kinase 6A</span></div><div class="casAuthors">Jiang, Xiaoshan; Benovic, Jeffrey L.; Wedegaertner, Philip B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2960-2969</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">G protein-coupled receptor (GPCR) kinases (GRKs) specifically phosphorylate agonist-occupied GPCRs at the inner surface of the plasma membrane (PM), leading to receptor desensitization.  Here we show that the C-terminal 30 amino acids of GRK6A contain multiple elements that either promote or inhibit PM localization.  Disruption of palmitoylation by individual mutation of Cys 561, 562, or 565 or treatment of cells with 2-bromopalmitate shifts GRK6A from the PM to both the cytoplasm and nucleus.  Likewise, disruption of the hydrophobic nature of a predicted amphipathic helix by mutation of two leucines to alanines at positions 551 and 552 causes a loss of PM localization.  Moreover, acidic amino acids in the C-terminus appear to neg. regulate PM localization; mutational replacement of several acidic residues with neutral or basic residues rescues PM localization of a palmitoylation-defective GRK6A.  Last, we characterize the novel nuclear localization, showing that nuclear export of nonpalmitoylated GRK6A is sensitive to leptomycin B and that GRK6A contains a potential nuclear localization signal.  These results suggest that the C-terminus of GRK6A contains a novel electrostatic palmitoyl switch in which acidic residues weaken the membrane-binding strength of the amphipathic helix, thus allowing changes in palmitoylation to regulate PM vs. cytoplasmic/nuclear localization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgJDTxg5zCj7Vg90H21EOLACvtfcHk0liyhWQ08FAZ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFalu70%253D&md5=2c0ce25753c3121ae6f06f8661d3e0e0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e07-01-0013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e07-01-0013%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DBenovic%26aufirst%3DJ.%2BL.%26aulast%3DWedegaertner%26aufirst%3DP.%2BB.%26atitle%3DPlasma%2520membrane%2520and%2520nuclear%2520localization%2520of%2520G%2520protein%2520coupled%2520receptor%2520kinase%25206A%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2007%26volume%3D18%26spage%3D2960%26epage%3D2969%26doi%3D10.1091%2Fmbc.e07-01-0013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aramaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of the highly selective and potent G-protein-coupled receptor kinase 2 (GRK2) inhibitor for the potential treatment of heart failure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6942</span>– <span class="NLM_lpage">6990</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6942-6990&author=T.+Okawaauthor=Y.+Aramakiauthor=M.+Yamamotoauthor=T.+Kobayashiauthor=S.+Fukumotoauthor=Y.+Toyodaauthor=T.+Hentaauthor=A.+Hataauthor=S.+Ikedaauthor=M.+Kanekoauthor=I.+D.+Hoffmanauthor=B.+C.+Sangauthor=H.+Zouauthor=T.+Kawamoto&title=Design%2C+synthesis%2C+and+evaluation+of+the+highly+selective+and+potent+G-protein-coupled+receptor+kinase+2+%28GRK2%29+inhibitor+for+the+potential+treatment+of+heart+failure&doi=10.1021%2Facs.jmedchem.7b00443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure</span></div><div class="casAuthors">Okawa, Tomohiro; Aramaki, Yoshio; Yamamoto, Mitsuo; Kobayashi, Toshitake; Fukumoto, Shoji; Toyoda, Yukio; Henta, Tsutomu; Hata, Akito; Ikeda, Shota; Kaneko, Manami; Hoffman, Isaac D.; Sang, Bi-Ching; Zou, Hua; Kawamoto, Tetsuji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6942-6990</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies.  Hydrazone deriv. and 1,2,4-triazole deriv. were identified as hit compds. by HTS.  New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole deriv. with an N-benzylcarboxamide moiety with highly potent activity towards GRK2, and selectivity over other kinases.  In terms of subtype selectivity, these compds. showed enough selectivity against GRK1, 5, 6, 7 with almost equipotent inhibition to GRK3.  The medicinal chem. efforts led to the discovery of I (GRK2 IC50 = 18 nM) which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol.  Therefore, I appears to be a novel class of therapeutic for heart failure treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrov4sgtujNFbVg90H21EOLACvtfcHk0liyhWQ08FAZ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbjF&md5=6077a12ddcbd4454ccfc4d55c65c5a61</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00443%26sid%3Dliteratum%253Aachs%26aulast%3DOkawa%26aufirst%3DT.%26aulast%3DAramaki%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukumoto%26aufirst%3DS.%26aulast%3DToyoda%26aufirst%3DY.%26aulast%3DHenta%26aufirst%3DT.%26aulast%3DHata%26aufirst%3DA.%26aulast%3DIkeda%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DI.%2BD.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DKawamoto%26aufirst%3DT.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520the%2520highly%2520selective%2520and%2520potent%2520G-protein-coupled%2520receptor%2520kinase%25202%2520%2528GRK2%2529%2520inhibitor%2520for%2520the%2520potential%2520treatment%2520of%2520heart%2520failure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6942%26epage%3D6990%26doi%3D10.1021%2Facs.jmedchem.7b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkle, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuprun, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1830</span>– <span class="NLM_lpage">1839</span>, <span class="refDoi"> DOI: 10.1021/cb3003013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb3003013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1830-1839&author=D.+M.+Thalauthor=K.+T.+Homanauthor=J.+Chenauthor=E.+K.+Wuauthor=P.+M.+Hinkleauthor=Z.+M.+Huangauthor=J.+K.+Chuprunauthor=J.+Songauthor=E.+Gaoauthor=J.+Y.+Cheungauthor=L.+A.+Sklarauthor=W.+J.+Kochauthor=J.+J.+Tesmer&title=Paroxetine+is+a+direct+inhibitor+of+g+protein-coupled+receptor+kinase+2+and+increases+myocardial+contractility&doi=10.1021%2Fcb3003013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Paroxetine Is a Direct Inhibitor of G Protein-Coupled Receptor Kinase 2 and Increases Myocardial Contractility</span></div><div class="casAuthors">Thal, David M.; Homan, Kristoff T.; Chen, Jun; Wu, Emily K.; Hinkle, Patricia M.; Huang, Z. Maggie; Chuprun, J. Kurt; Song, Jianliang; Gao, Erhe; Cheung, Joseph Y.; Sklar, Larry A.; Koch, Walter J.; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1830-1839</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G protein-coupled receptor kinase 2 (GRK2) is a well-established therapeutic target for the treatment of heart failure.  Herein we identify the selective serotonin reuptake inhibitor (SSRI) paroxetine as a selective inhibitor of GRK2 activity both in vitro and in living cells.  In the crystal structure of the GRK2·paroxetine-Gβγ complex, paroxetine binds in the active site of GRK2 and stabilizes the kinase domain in a novel conformation in which a unique regulatory loop forms part of the ligand binding site.  Isolated cardiomyocytes show increased isoproterenol-induced shortening and contraction amplitude in the presence of paroxetine, and pretreatment of mice with paroxetine before isoproterenol significantly increases left ventricular inotropic reserve in vivo with no significant effect on heart rate.  Neither is obsd. in the presence of the SSRI fluoxetine.  Our structural and functional results validate a widely available drug as a selective chem. probe for GRK2 and represent a starting point for the rational design of more potent and specific GRK2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaoH2b0cTO5rVg90H21EOLACvtfcHk0lh1BkScqF2fww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOntLfI&md5=08df20fa41a8b3241640db5de557a001</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fcb3003013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb3003013%26sid%3Dliteratum%253Aachs%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DHoman%26aufirst%3DK.%2BT.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DE.%2BK.%26aulast%3DHinkle%26aufirst%3DP.%2BM.%26aulast%3DHuang%26aufirst%3DZ.%2BM.%26aulast%3DChuprun%26aufirst%3DJ.%2BK.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DE.%26aulast%3DCheung%26aufirst%3DJ.%2BY.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DParoxetine%2520is%2520a%2520direct%2520inhibitor%2520of%2520g%2520protein-coupled%2520receptor%2520kinase%25202%2520and%2520increases%2520myocardial%2520contractility%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1830%26epage%3D1839%26doi%3D10.1021%2Fcb3003013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldschmidt, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Rodriguez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cato, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waninger-Saroni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larimore, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannavo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhoff, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. D.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis, and biological evaluation of highly selective and potent G protein-coupled receptor kinase 2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3793</span>– <span class="NLM_lpage">3807</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b02000</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b02000" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVOgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3793-3807&author=H.+V.+Waldschmidtauthor=K.+T.+Homanauthor=O.+Cruz-Rodriguezauthor=M.+C.+Catoauthor=J.+Waninger-Saroniauthor=K.+M.+Larimoreauthor=A.+Cannavoauthor=J.+Songauthor=J.+Y.+Cheungauthor=P.+D.+Kirchhoffauthor=W.+J.+Kochauthor=J.+J.+Tesmerauthor=S.+D.+Larsen&title=Structure-based+design%2C+synthesis%2C+and+biological+evaluation+of+highly+selective+and+potent+G+protein-coupled+receptor+kinase+2+inhibitors&doi=10.1021%2Facs.jmedchem.5b02000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors</span></div><div class="casAuthors">Waldschmidt, Helen V.; Homan, Kristoff T.; Cruz-Rodriguez, Osvaldo; Cato, Marilyn C.; Waninger-Saroni, Jessica; Larimore, Kelly L.; Cannavo, Alessandro; Song, Jianliang; Cheung, Joseph Y.; Kirchhoff, Paul D.; Koch, Walter J.; Tesmer, John J. G.; Larsen, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3793-3807</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are central to many physiol. processes.  Regulation of this superfamily of receptors is controlled by GPCR kinases (GRKs), some of which have been implicated in heart failure.  GSK180736A, developed as a Rho-assocd. coiled-coil kinase 1 (ROCK1) inhibitor, was identified as an inhibitor of GRK2 and co-crystd. in the active site.  Guided by its binding pose overlaid with the binding pose of a known potent GRK2 inhibitor, Takeda103A, a library of hybrid inhibitors was developed.  This campaign produced several compds. possessing high potency and selectivity for GRK2 over other GRK subfamilies, PKA, and ROCK1.  The most selective compd., 12n (I) (CCG-224406), had an IC50 for GRK2 of 130 nM, >700-fold selectivity over other GRK subfamilies, and no detectable inhibition of ROCK1.  Four of the new inhibitors were crystd. with GRK2 to give mol. insights into the binding and kinase selectivity of this class of inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzeEC4l5djErVg90H21EOLACvtfcHk0lh1BkScqF2fww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVOgtL8%253D&md5=149b7722909617a88d439ae3d90338a4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b02000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b02000%26sid%3Dliteratum%253Aachs%26aulast%3DWaldschmidt%26aufirst%3DH.%2BV.%26aulast%3DHoman%26aufirst%3DK.%2BT.%26aulast%3DCruz-Rodriguez%26aufirst%3DO.%26aulast%3DCato%26aufirst%3DM.%2BC.%26aulast%3DWaninger-Saroni%26aufirst%3DJ.%26aulast%3DLarimore%26aufirst%3DK.%2BM.%26aulast%3DCannavo%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DJ.%2BY.%26aulast%3DKirchhoff%26aufirst%3DP.%2BD.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26aulast%3DLarsen%26aufirst%3DS.%2BD.%26atitle%3DStructure-based%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520highly%2520selective%2520and%2520potent%2520G%2520protein-coupled%2520receptor%2520kinase%25202%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3793%26epage%3D3807%26doi%3D10.1021%2Facs.jmedchem.5b02000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldschmidt, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannavo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of G protein-coupled receptor kinase 5 in complex with a rationally designed inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">20649</span>– <span class="NLM_lpage">20659</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.647370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fjbc.M115.647370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=26032411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOrtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=20649-20659&author=K.+T.+Homanauthor=H.+V.+Waldschmidtauthor=A.+Glukhovaauthor=A.+Cannavoauthor=J.+Songauthor=J.+Y.+Cheungauthor=W.+J.+Kochauthor=S.+D.+Larsenauthor=J.+J.+Tesmer&title=Crystal+structure+of+G+protein-coupled+receptor+kinase+5+in+complex+with+a+rationally+designed+inhibitor&doi=10.1074%2Fjbc.M115.647370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of G Protein-coupled Receptor Kinase 5 in Complex with a Rationally Designed Inhibitor</span></div><div class="casAuthors">Homan, Kristoff T.; Waldschmidt, Helen V.; Glukhova, Alisa; Cannavo, Alessandro; Song, Jianliang; Cheung, Joseph Y.; Koch, Walter J.; Larsen, Scott D.; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">20649-20659</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">G protein-coupled receptor kinases (GRKs) regulate cell signaling by initiating the desensitization of active G protein-coupled receptors.  The two most widely expressed GRKs (GRK2 and GRK5) play a role in cardiovascular disease and thus represent important targets for the development of novel therapeutic drugs.  In the course of a GRK2 structure-based drug design campaign, one inhibitor (CCG215022) exhibited nanomolar IC50 values against both GRK2 and GRK5 and good selectivity against other closely related kinases such as GRK1 and PKA.  Treatment of murine cardiomyocytes with CCG215022 resulted in significantly increased contractility at 20-fold lower concns. than paroxetine, an inhibitor with more modest selectivity for GRK2.  A 2.4 Å crystal structure of the GRK5·CCG215022 complex was detd. and revealed that the inhibitor binds in the active site similarly to its parent compd. GSK180736A.  As designed, its 2-pyridylmethyl amide side chain occupies the hydrophobic subsite of the active site where it forms three addnl. hydrogen bonds, including one with the catalytic lysine.  The overall conformation of the GRK5 kinase domain is similar to that of a previously detd. structure of GRK6 in what is proposed to be its active state, but the C-terminal region of the enzyme adopts a distinct conformation.  The kinetic properties of site-directed mutants in this region are consistent with the hypothesis that this novel C-terminal structure is representative of the membrane-bound conformation of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCa90PSxbJr7Vg90H21EOLACvtfcHk0lgqMNfZgQrtGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOrtrfP&md5=1cd56381cfc8d5ec1265cc6672b94946</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.647370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.647370%26sid%3Dliteratum%253Aachs%26aulast%3DHoman%26aufirst%3DK.%2BT.%26aulast%3DWaldschmidt%26aufirst%3DH.%2BV.%26aulast%3DGlukhova%26aufirst%3DA.%26aulast%3DCannavo%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DJ.%2BY.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DLarsen%26aufirst%3DS.%2BD.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520G%2520protein-coupled%2520receptor%2520kinase%25205%2520in%2520complex%2520with%2520a%2520rationally%2520designed%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D20649%26epage%3D20659%26doi%3D10.1074%2Fjbc.M115.647370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannavo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">16937</span>– <span class="NLM_lpage">16949</span>, <span class="refDoi"> DOI: 10.3390/molecules191016937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.3390%2Fmolecules191016937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=25340299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCisr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=16937-16949&author=K.+T.+Homanauthor=E.+Wuauthor=A.+Cannavoauthor=W.+J.+Kochauthor=J.+J.+Tesmer&title=Identification+and+characterization+of+amlexanox+as+a+G+protein-coupled+receptor+kinase+5+inhibitor&doi=10.3390%2Fmolecules191016937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor</span></div><div class="casAuthors">Homan, Kristoff T.; Wu, Emily; Cannavo, Alessandro; Koch, Walter J.; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">16937-16949, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">G protein-coupled receptor kinases (GRKs) have been implicated in human diseases ranging from heart failure to diabetes.  Previous studies have identified several compds. that selectively inhibit GRK2, such as paroxetine and balanol.  Far fewer selective inhibitors have been reported for GRK5, a target for the treatment of cardiac hypertrophy, and the mechanism of action of reported compds. is unknown.  To identify novel scaffolds that selectively inhibit GRK5, a differential scanning fluorometry screen was used to probe a library of 4480 compds.  The best hit was amlexanox, an FDA-approved anti-inflammatory, anti-allergic immunomodulator.  The crystal structure of amlexanox in complex with GRK1 demonstrates that its tricyclic arom. ring system forms ATP-like interactions with the hinge of the kinase domain, which is likely similar to how this drug binds to IκB kinase ε (IKKε), another kinase known to be inhibited by this compd.  Amlexanox was also able to inhibit myocyte enhancer factor 2 transcriptional activity in neonatal rat ventricular myocytes in a manner consistent with GRK5 inhibition.  The GRK1 amlexanox structure thus serves as a springboard for the rational design of inhibitors with improved potency and selectivity for GRK5 and IKKε.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyXvoGyufJ4LVg90H21EOLACvtfcHk0lgqMNfZgQrtGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCisr3L&md5=5a7c8d455e1fa7b596c816f9126f1b9f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3390%2Fmolecules191016937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules191016937%26sid%3Dliteratum%253Aachs%26aulast%3DHoman%26aufirst%3DK.%2BT.%26aulast%3DWu%26aufirst%3DE.%26aulast%3DCannavo%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520amlexanox%2520as%2520a%2520G%2520protein-coupled%2520receptor%2520kinase%25205%2520inhibitor%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26spage%3D16937%26epage%3D16949%26doi%3D10.3390%2Fmolecules191016937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowlands, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avramova, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. D.</span></span> <span> </span><span class="NLM_article-title">Generation of highly selective, potent, and covalent G protein-coupled receptor kinase 5 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01522</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01522" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtVOmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=566-585&author=R.+A.+Rowlandsauthor=Q.+Chenauthor=R.+A.+Bouleyauthor=L.+V.+Avramovaauthor=J.+J.+G.+Tesmerauthor=A.+D.+White&title=Generation+of+highly+selective%2C+potent%2C+and+covalent+G+protein-coupled+receptor+kinase+5+inhibitors&doi=10.1021%2Facs.jmedchem.0c01522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of Highly Selective, Potent, and Covalent G Protein-Coupled Receptor Kinase 5 Inhibitors</span></div><div class="casAuthors">Rowlands, Rachel A.; Chen, Qiuyan; Bouley, Renee A.; Avramova, Larisa V.; Tesmer, John J. G.; White, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">566-585</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ability of G protein-coupled receptor (GPCR) kinases (GRKs) to regulate the desensitization of GPCRs has made GRK2 and GRK5 attractive targets for treating diseases such as heart failure and cancer.  Previously, our work showed that Cys474, a GRK5 subfamily-specific residue located on a flexible loop adjacent to the active site, can be used as a covalent handle to achieve selective inhibition of GRK5 over GRK2 subfamily members.  However, the potency of the most selective inhibitors remained modest.  Herein, we describe a successful campaign to adapt an indolinone scaffold with covalent warheads, resulting in a series of 2-haloacetyl-contg. compds. that react quickly and exhibit three orders of magnitude selectivity for GRK5 over GRK2 and low nanomolar potency.  They however retain a similar selectivity profile across the kinome as the core scaffold, which was based on Sunitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS1bZaUeDZrrVg90H21EOLACvtfcHk0lgqMNfZgQrtGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtVOmsw%253D%253D&md5=31d279aaa80a89992610d878cf5f0917</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01522%26sid%3Dliteratum%253Aachs%26aulast%3DRowlands%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DBouley%26aufirst%3DR.%2BA.%26aulast%3DAvramova%26aufirst%3DL.%2BV.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%2BG.%26aulast%3DWhite%26aufirst%3DA.%2BD.%26atitle%3DGeneration%2520of%2520highly%2520selective%252C%2520potent%252C%2520and%2520covalent%2520G%2520protein-coupled%2520receptor%2520kinase%25205%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D566%26epage%3D585%26doi%3D10.1021%2Facs.jmedchem.0c01522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, K. S.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6711</span>– <span class="NLM_lpage">6716</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.10.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.bmcl.2013.10.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=24210504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=6711-6716&author=S.+Y.+Choauthor=B.+H.+Leeauthor=H.+Jungauthor=C.+S.+Yunauthor=J.+D.+Haauthor=H.+R.+Kimauthor=C.+H.+Chaeauthor=J.+H.+Leeauthor=H.+W.+Seoauthor=K.+S.+Oh&title=Design+and+synthesis+of+novel+3-%28benzo%5Bd%5Doxazol-2-yl%29-5-%281-%28piperidin-4-yl%29-1H-pyrazol-4-yl%29pyridin-2-amine+derivatives+as+selective+G-protein-coupled+receptor+kinase-2+and+-5+inhibitors&doi=10.1016%2Fj.bmcl.2013.10.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors</span></div><div class="casAuthors">Cho, Sung Yun; Lee, Byung Ho; Jung, Heejung; Yun, Chang Soo; Ha, Jae Du; Kim, Hyoung Rae; Chae, Chong Hak; Lee, Jeong Hyun; Seo, Ho Won; Oh, Kwang-Seok</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6711-6716</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">G-protein-coupled receptor kinase (GRK)-2 and -5 are emerging therapeutic targets for the treatment of cardiovascular disease.  In the efforts to discover novel small mols. to inhibit GRK-2 and -5, a class of compd. based on 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine was identified as a novel hit by high throughput screening campaign.  Structural modification of parent benzoxazole scaffolds by introducing substituents on Ph displayed potent inhibitory activities toward GRK-2 and -5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk9cUk_aJBEbVg90H21EOLACvtfcHk0lhaobN1BfsZVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCrurvL&md5=5bc20ccc08b2831fce29fd7aa60a6b22</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.10.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.10.036%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DJung%26aufirst%3DH.%26aulast%3DYun%26aufirst%3DC.%2BS.%26aulast%3DHa%26aufirst%3DJ.%2BD.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DChae%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DSeo%26aufirst%3DH.%2BW.%26aulast%3DOh%26aufirst%3DK.%2BS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%25203-%2528benzo%255Bd%255Doxazol-2-yl%2529-5-%25281-%2528piperidin-4-yl%2529-1H-pyrazol-4-yl%2529pyridin-2-amine%2520derivatives%2520as%2520selective%2520G-protein-coupled%2520receptor%2520kinase-2%2520and%2520-5%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D6711%26epage%3D6716%26doi%3D10.1016%2Fj.bmcl.2013.10.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for small molecule inhibition of G protein-coupled receptor kinases</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1021/cb5003976</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5003976" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOjtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=246-256&author=K.+T.+Homanauthor=J.+J.+Tesmer&title=Molecular+basis+for+small+molecule+inhibition+of+G+protein-coupled+receptor+kinases&doi=10.1021%2Fcb5003976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for small molecule inhibition of G protein-coupled receptor kinases</span></div><div class="casAuthors">Homan, Kristoff T.; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">246-256</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Small mols. that inhibit the protein kinase A, G, and C (AGC) family of serine/threonine kinases can exert profound effects on cell homeostasis and thereby regulate fundamental processes such as heart rate, blood pressure, and metab., but there is not yet a clin. approved drug in the United States selective for a member of this family.  One subfamily of AGC kinases, the G protein-coupled receptor (GPCR) kinases (GRKs), initiates the desensitization of active GPCRs.  Of these, GRK2 has been directly implicated in the progression of heart failure.  Thus, there is great interest in the identification of GRK2-specific chem. probes that can be further developed into therapeutics.  Here, the authors compare crystal structures of small mol. inhibitors in complex with GRK2 to those of highly selective compds. in complex with Rho-assocd. coiled-coil contg. kinase 1 (ROCK1), a closely related AGC kinase.  This anal. suggests that reduced H-bond formation with the hinge of the kinase domain, occupation of the hydrophobic subsite, and, consequently, higher buried surface area are key drivers of potency and selectivity among GRK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw1BX1Q5uXt7Vg90H21EOLACvtfcHk0lhaobN1BfsZVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOjtL3E&md5=c80248ae417a2d94f3d7bd788273b696</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fcb5003976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5003976%26sid%3Dliteratum%253Aachs%26aulast%3DHoman%26aufirst%3DK.%2BT.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520basis%2520for%2520small%2520molecule%2520inhibition%2520of%2520G%2520protein-coupled%2520receptor%2520kinases%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D246%26epage%3D256%26doi%3D10.1021%2Fcb5003976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boguth, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Molecular basis for activation of G protein-coupled receptor kinases</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3249</span>– <span class="NLM_lpage">3259</span>, <span class="refDoi"> DOI: 10.1038/emboj.2010.206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Femboj.2010.206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=20729810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGgtb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=3249-3259&author=C.+A.+Boguthauthor=P.+Singhauthor=C.+C.+Huangauthor=J.+J.+Tesmer&title=Molecular+basis+for+activation+of+G+protein-coupled+receptor+kinases&doi=10.1038%2Femboj.2010.206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for activation of G protein-coupled receptor kinases</span></div><div class="casAuthors">Boguth, Cassandra A.; Singh, Puja; Huang, Chih-chin; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3249-3259</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptor (GPCR) kinases (GRKs) selectively recognize and are allosterically regulated by activated GPCRs, but the mol. basis for this interaction is not understood.  Herein, we report crystal structures of GRK6 in which regions known to be crit. for receptor phosphorylation have coalesced to stabilize the kinase domain in a closed state and to form a likely receptor docking site.  The crux of this docking site is an extended N-terminal helix that bridges the large and small lobes of the kinase domain and lies adjacent to a basic surface of the protein proposed to bind anionic phospholipids.  Mutation of exposed, hydrophobic residues in the N-terminal helix selectively inhibits receptor, but not peptide phosphorylation, suggesting that these residues interact directly with GPCRs.  Our structural and biochem. results thus provide an explanation for how receptor recognition, phospholipid binding, and kinase activation are intimately coupled in GRKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxCitsTX_fhbVg90H21EOLACvtfcHk0lhSyFrwzc1s-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGgtb%252FE&md5=15d6df48fad121f18286e4ac1db6edef</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Femboj.2010.206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2010.206%26sid%3Dliteratum%253Aachs%26aulast%3DBoguth%26aufirst%3DC.%2BA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520basis%2520for%2520activation%2520of%2520G%2520protein-coupled%2520receptor%2520kinases%26jtitle%3DEMBO%2520J.%26date%3D2010%26volume%3D29%26spage%3D3249%26epage%3D3259%26doi%3D10.1038%2Femboj.2010.206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-Tannoudji, J.</span></span> <span> </span><span class="NLM_article-title">Endogenous G protein-coupled receptor kinase 6 triggers homologous beta-adrenergic receptor desensitization in primary uterine smooth muscle cells</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">3058</span>– <span class="NLM_lpage">3066</span>, <span class="refDoi"> DOI: 10.1210/en.2002-0138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1210%2Fen.2002-0138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=12810562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvF2kt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2003&pages=3058-3066&author=V.+Simonauthor=M.+T.+Robinauthor=C.+Legrandauthor=J.+Cohen-Tannoudji&title=Endogenous+G+protein-coupled+receptor+kinase+6+triggers+homologous+beta-adrenergic+receptor+desensitization+in+primary+uterine+smooth+muscle+cells&doi=10.1210%2Fen.2002-0138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous G protein-coupled receptor kinase 6 triggers homologous β-adrenergic receptor desensitization in primary uterine smooth muscle cells</span></div><div class="casAuthors">Simon, Violaine; Robin, Marie-Therese; Legrand, Chantal; Cohen-Tannoudji, Joelle</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3058-3066</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">The authors previously reported that G protein-coupled receptor kinase (GRK) may contribute to β-adrenergic receptor (β-AR) uncoupling occurring just before parturition in rat uterine muscle (myometrium).  To identify the GRK involved, the authors set up in this study a primary cell culture retaining the morphol. and functional characteristics of myometrial tissue as well as the in vivo pattern of GRK expression (GRK2, GRK5, and GRK6).  In this model, homologous β-AR desensitization was assessed by an approx. 60% decrease in cAMP prodn. to a subsequent challenge with the β-agonist, isoproterenol.  Desensitization was reduced by 36% with a GRK inhibitor, heparin, and by 31% with a protein kinase A inhibitor, H89.  Using antibodies known to specifically inhibit either GRK2/3 or GRK4-6 families, the authors demonstrated that only the GRK4-6 family mediated β-AR desensitization.  To discriminate between endogenous GRK5 and GRK6, the authors attempted to inhibit their action by introducing, into myometrial cells, kinase-dead dominant-neg. mutants (K215RGRK5 and K215RGRK6).  Expression of K215RGRK6 increased by approx. 70% the cAMP response to isoproterenol without effect on forskolin stimulation.  Conversely, expression of K215RGRK5 or K220RGRK2 had no effect on β-adrenergic signaling.  These results strongly suggest that endogenous GRK6 mediate homologous β-AR desensitization in myometrial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrBkh4Jtgz7Vg90H21EOLACvtfcHk0lhSyFrwzc1s-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvF2kt7c%253D&md5=5c48e302b216b8ecc30b4e7fed9709db</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1210%2Fen.2002-0138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2002-0138%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DV.%26aulast%3DRobin%26aufirst%3DM.%2BT.%26aulast%3DLegrand%26aufirst%3DC.%26aulast%3DCohen-Tannoudji%26aufirst%3DJ.%26atitle%3DEndogenous%2520G%2520protein-coupled%2520receptor%2520kinase%25206%2520triggers%2520homologous%2520beta-adrenergic%2520receptor%2520desensitization%2520in%2520primary%2520uterine%2520smooth%2520muscle%2520cells%26jtitle%3DEndocrinology%26date%3D2003%26volume%3D144%26spage%3D3058%26epage%3D3066%26doi%3D10.1210%2Fen.2002-0138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grinshtein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujitani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakesch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrana, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, D. R.</span></span> <span> </span><span class="NLM_article-title">Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1385</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1158%2F0008-5472.CAN-10-2484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=21303981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFSjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1385-1395&author=N.+Grinshteinauthor=A.+Dattiauthor=M.+Fujitaniauthor=D.+Uehlingauthor=M.+Prakeschauthor=M.+Isaacauthor=M.+S.+Irwinauthor=J.+L.+Wranaauthor=R.+Al-Awarauthor=D.+R.+Kaplan&title=Small+molecule+kinase+inhibitor+screen+identifies+polo-like+kinase+1+as+a+target+for+neuroblastoma+tumor-initiating+cells&doi=10.1158%2F0008-5472.CAN-10-2484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Kinase Inhibitor Screen Identifies Polo-Like Kinase 1 as a Target for Neuroblastoma Tumor-Initiating Cells</span></div><div class="casAuthors">Grinshtein, Natalie; Datti, Alessandro; Fujitani, Mayumi; Uehling, David; Prakesch, Michael; Isaac, Methvin; Irwin, Meredith S.; Wrana, Jeffrey L.; Al-Awar, Rima; Kaplan, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1385-1395</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Neuroblastoma (NB) is an often fatal pediatric tumor of neural crest origin.  We previously isolated NB tumor-initiating cells (NB TIC) from bone marrow metastases that resemble cancer stem cells and form metastatic NB in immunodeficient animals with as few as ten cells.  To identify signaling pathways important for the survival and self-renewal of NB TICs and potential therapeutic targets, we screened a small mol. library of 143 protein kinase inhibitors, including 33 in clin. trials.  Cytostatic or cytotoxic drugs were identified that targeted PI3K (phosphoinositide 3-kinase)/Akt, PKC (protein kinase C), Aurora, ErbB2, Trk, and Polo-like kinase 1 (PLK1).  Treatment with PLK1 siRNA or low nanomolar concns. of BI 2536 or BI 6727, PLK1 inhibitors in clin. trials for adult malignancies, were cytotoxic to TICs whereas only micromolar concns. of the inhibitors were cytotoxic for normal pediatric neural stem cells.  Furthermore, BI 2536 significantly inhibited TIC tumor growth in a therapeutic xenograft model, both as a single agent and in combination with irinotecan, an active agent for relapsed NB.  Our findings identify candidate kinases that regulate TIC growth and survival and suggest that PLK1 inhibitors are an attractive candidate therapy for metastatic NB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Lun2JYBAvrVg90H21EOLACvtfcHk0lhSyFrwzc1s-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFSjsbo%253D&md5=4b44c2950ae96e2b405727fc4489cadd</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2484%26sid%3Dliteratum%253Aachs%26aulast%3DGrinshtein%26aufirst%3DN.%26aulast%3DDatti%26aufirst%3DA.%26aulast%3DFujitani%26aufirst%3DM.%26aulast%3DUehling%26aufirst%3DD.%26aulast%3DPrakesch%26aufirst%3DM.%26aulast%3DIsaac%26aufirst%3DM.%26aulast%3DIrwin%26aufirst%3DM.%2BS.%26aulast%3DWrana%26aufirst%3DJ.%2BL.%26aulast%3DAl-Awar%26aufirst%3DR.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26atitle%3DSmall%2520molecule%2520kinase%2520inhibitor%2520screen%2520identifies%2520polo-like%2520kinase%25201%2520as%2520a%2520target%2520for%2520neuroblastoma%2520tumor-initiating%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D1385%26epage%3D1395%26doi%3D10.1158%2F0008-5472.CAN-10-2484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trzcińska-Daneluti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fladd, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakesch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotin, D.</span></span> <span> </span><span class="NLM_article-title">Use of kinase inhibitors to correct DeltaF508-CFTR function</span>. <i>Mol. Cell. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1074/mcp.M111.016626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fmcp.M111.016626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=22700489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlOjsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=745-757&author=A.+M.+Trzci%C5%84ska-Danelutiauthor=L.+Nguyenauthor=C.+Jiangauthor=C.+Fladdauthor=D.+Uehlingauthor=M.+Prakeschauthor=R.+Al-awarauthor=D.+Rotin&title=Use+of+kinase+inhibitors+to+correct+DeltaF508-CFTR+function&doi=10.1074%2Fmcp.M111.016626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Use of kinase inhibitors to correct ΔF508-CFTR function</span></div><div class="casAuthors">Trzcinska-Daneluti, Agata M.; Nguyen, Leo; Jiang, Chong; Fladd, Christopher; Uehling, David; Prakesch, Michael; Al-Awar, Rima; Rotin, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Proteomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">745-757</span>CODEN:
                <span class="NLM_cas:coden">MCPOBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-9484</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The most common mutation in cystic fibrosis (CF) is a deletion of Phe at position 508 (ΔF508-CFTR).  ΔF508-CFTR is a trafficking mutant that is retained in the ER, unable to reach the plasma membrane.  To identify compds. and drugs that rescue this trafficking defect, we screened a kinase inhibitor library enriched for small mols. already in the clinic or in clin. trials for the treatment of cancer and inflammation, using our recently developed high-content screen technol.  The top hits of the screen were further validated by (1) biochem. anal. to demonstrate the presence of mature (Band C) ΔF508-CFTR, (2) flow cytometry to reveal the presence of ΔF508-CFTR at the cell surface, (3) short-circuit current (Isc) anal. in Ussing chambers to show restoration of function of the rescued ΔF508-CFTR in epithelial MDCK cells stably expressing this mutant (including EC50 detns.), and importantly (4) Isc anal. of Human Bronchial Epithelial (HBE) cells harvested from homozygote ΔF508-CFTR transplant patients.  Interestingly, several inhibitors of receptor Tyr kinases (RTKs), such as SU5402 and SU6668 (which target FGFRs, VEGFR, and PDGFR) exhibited strong rescue of ΔF508-CFTR, as did several inhibitors of the Ras/Raf/MEK/ERK or p38 pathways (e.g. (5Z)-7-oxozeaenol).  Prominent rescue was also obsd. by inhibitors of GSK-3β (e.g. GSK-3β Inhibitor II and Kenpaullone).  These results identify several kinase inhibitors that can rescue ΔF508-CFTR to various degrees, and suggest that use of compds. or drugs already in the clinic or in clin. trials for other diseases can expedite delivery of treatment for CF patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFSVfvmQVRoLVg90H21EOLACvtfcHk0ljoX_iLNOZsEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlOjsLzJ&md5=399260492c4c3ed07a06764878075be2</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1074%2Fmcp.M111.016626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fmcp.M111.016626%26sid%3Dliteratum%253Aachs%26aulast%3DTrzci%25C5%2584ska-Daneluti%26aufirst%3DA.%2BM.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DFladd%26aufirst%3DC.%26aulast%3DUehling%26aufirst%3DD.%26aulast%3DPrakesch%26aufirst%3DM.%26aulast%3DAl-awar%26aufirst%3DR.%26aulast%3DRotin%26aufirst%3DD.%26atitle%3DUse%2520of%2520kinase%2520inhibitors%2520to%2520correct%2520DeltaF508-CFTR%2520function%26jtitle%3DMol.%2520Cell.%2520Proteomics%26date%3D2012%26volume%3D11%26spage%3D745%26epage%3D757%26doi%3D10.1074%2Fmcp.M111.016626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexei, W. P. K.</span>; <span class="NLM_string-name">Shokat, K. M.</span>; <span class="NLM_string-name">Zhang, C.</span>; <span class="NLM_string-name">Finer-More, J.</span>; <span class="NLM_string-name">Stroud, R.</span>; <span class="NLM_string-name">Egea, P.</span>; <span class="NLM_string-name">Korostelev, A.</span>; <span class="NLM_string-name">Dar, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrazolyl-Substituted Pyrimidine-2,4-diamine Derivatives as Ire1, Src and Abl Modulators</span>. <span class="NLM_patent">WO2010031056</span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=W.+P.+K.+Alexei&author=K.+M.+Shokat&author=C.+Zhang&author=J.+Finer-More&author=R.+Stroud&author=P.+Egea&author=A.+Korostelev&author=A.+Dar&title=Preparation+of+Pyrazolyl-Substituted+Pyrimidine-2%2C4-diamine+Derivatives+as+Ire1%2C+Src+and+Abl+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlexei%26aufirst%3DW.%2BP.%2BK.%26atitle%3DPreparation%2520of%2520Pyrazolyl-Substituted%2520Pyrimidine-2%252C4-diamine%2520Derivatives%2520as%2520Ire1%252C%2520Src%2520and%2520Abl%2520Modulators%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furihata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">AZ960, a novel jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3386</span>– <span class="NLM_lpage">3395</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1158%2F1535-7163.MCT-10-0416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=21159615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=3386-3395&author=J.+Yangauthor=T.+Ikezoeauthor=C.+Nishiokaauthor=M.+Furihataauthor=A.+Yokoyama&title=AZ960%2C+a+novel+jak2+inhibitor%2C+induces+growth+arrest+and+apoptosis+in+adult+T-cell+leukemia+cells&doi=10.1158%2F1535-7163.MCT-10-0416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">AZ960, a Novel Jak2 Inhibitor, Induces Growth Arrest and Apoptosis in Adult T-Cell Leukemia Cells</span></div><div class="casAuthors">Yang, Jing; Ikezoe, Takayuki; Nishioka, Chie; Furihata, Mutsuo; Yokoyama, Akihito</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3386-3395</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive disease in which the Jak2/Stat5 pathway is constitutively activated.  This study found that AZ960, a novel inhibitor of Jak2 kinase, effectively induced growth arrest and apoptosis of human T-cell lymphotropic virus type 1, HTLV-1-infected T cells (MT-1 and MT-2) in parallel with downregulation of the phosphorylated forms of Jak2 and Bcl-2 family proteins including Bcl-2 and Mcl-1.  Interestingly, AZ960 increased levels of Bcl-xL in MT-1 and MT-2 cells in assocn. with accumulation of cAMP response element-binding protein bound to the Bcl-xL promoter as measured by chromatin immunopptn. assay.  Importantly, genetic inhibition of Bcl-xL by a small interfering RNA potentiated antiproliferative effects of AZ960 in MT-1 cells.  Taken together, Jak2 is an attractive mol. target for treatment of ATL.  Concomitant blockade of Jak2 and Bcl-xL may be a promising treatment strategy for this lethal disease.  Mol Cancer Ther; 9(12); 3386-95.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5A7ZSZ5lKF7Vg90H21EOLACvtfcHk0ljoX_iLNOZsEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsLvK&md5=6c4899e4340922287a44ec3a888e9b24</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0416%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DFurihata%26aufirst%3DM.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DAZ960%252C%2520a%2520novel%2520jak2%2520inhibitor%252C%2520induces%2520growth%2520arrest%2520and%2520apoptosis%2520in%2520adult%2520T-cell%2520leukemia%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D3386%26epage%3D3395%26doi%3D10.1158%2F1535-7163.MCT-10-0416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrace, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel jak2-stat pathway inhibitors with extended residence time on target</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3105</span>– <span class="NLM_lpage">3110</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.bmcl.2013.02.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=23562594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltlOhtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3105-3110&author=H.+Guanauthor=M.+L.+Lambauthor=B.+Pengauthor=S.+Huangauthor=N.+Degraceauthor=J.+Readauthor=S.+Hussainauthor=J.+Wuauthor=C.+Rivardauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=M.+Zindaauthor=S.+Ioannidis&title=Discovery+of+novel+jak2-stat+pathway+inhibitors+with+extended+residence+time+on+target&doi=10.1016%2Fj.bmcl.2013.02.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target</span></div><div class="casAuthors">Guan, Huiping; Lamb, Michelle L.; Peng, Bo; Huang, Shan; DeGrace, Nancy; Read, Jon; Hussain, Syeed; Wu, Jiaquan; Rivard, Caroline; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Ye, Minwei; Zinda, Michael; Ioannidis, Stephanos</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3105-3110</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of the activating mutation V617F in the JH2 domain of Jak2 and the modulation of oncogenic Stat3 by Jak2 inhibitors have spurred a great interest in the inhibition of the Jak2/Stat pathway in oncol.  In this Letter, the authors communicate the discovery of novel inhibitors of the Jak2/Stat5 axis, the N-(1H-pyrazol-3-yl)pyrimidin-2-amino derivs.  The rationale, synthesis and biol. evaluation of these derivs. are reported.  Two lead analogs from this series, (I) and (II), displayed prolonged residence time on Jak2, at enzymic level.  Although (I) and (II) exhibited moderate selectivity in a selected kinase panel, the authors chose to test these inhibitors in vivo as a consequence to their long residence time.  However, extended inhibition of Jak2 due to the long residence time, in the form of inhibiting phosphorylation of downstream Stat5, was not recapitulated in an in vivo setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEqzh5WfofE7Vg90H21EOLACvtfcHk0ljXW4fpVvBBoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltlOhtrk%253D&md5=dee4662399d073c0d1a5f8dddcd9682a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.111%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DDegrace%26aufirst%3DN.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520novel%2520jak2-stat%2520pathway%2520inhibitors%2520with%2520extended%2520residence%2520time%2520on%2520target%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3105%26epage%3D3110%26doi%3D10.1016%2Fj.bmcl.2013.02.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard
Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-methyl-1H-imidazole derivatives as potent jak2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1021/jm401546n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401546n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=144-158&author=Q.+Suauthor=S.+Ioannidisauthor=C.+Chuaquiauthor=L.+Almeidaauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Blockauthor=T.+Howardauthor=S.+Huangauthor=D.+Huszarauthor=J.+A.+Readauthor=C.+Rivard%0ACostaauthor=J.+Shiauthor=M.+Suauthor=M.+Yeauthor=M.+Zinda&title=Discovery+of+1-methyl-1H-imidazole+derivatives+as+potent+jak2+inhibitors&doi=10.1021%2Fjm401546n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors</span></div><div class="casAuthors">Su, Qibin; Ioannidis, Stephanos; Chuaqui, Claudio; Almeida, Lynsie; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Block, Michael; Howard, Tina; Huang, Shan; Huszar, Dennis; Read, Jon A.; Rivard Costa, Caroline; Shi, Jie; Su, Mei; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure based design, synthesis, and biol. evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described.  Using the C-ring fragment from our first clin. candidate AZD1480 (I), optimization of the series led to the discovery of compd. II, a potent, orally bioavailable Jak2 inhibitor.  Compd. II displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells.  Compd. II demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczgU5RpFv1bVg90H21EOLACvtfcHk0ljXW4fpVvBBoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL&md5=88c57119ec77d084a91a1123fd9dea86</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm401546n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401546n%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DBlock%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DRivard%2BCosta%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25201-methyl-1H-imidazole%2520derivatives%2520as%2520potent%2520jak2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D144%26epage%3D158%26doi%3D10.1021%2Fjm401546n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjogren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of disubstituted imidazo[4,5-b]pyridines and purines as potent trkA inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">709</span>, <span class="refDoi"> DOI: 10.1021/ml300074j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300074j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2isbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=705-709&author=T.+Wangauthor=M.+L.+Lambauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=Y.+Hanauthor=E.+Hoffmannauthor=S.+Ioannidisauthor=J.+A.+Joseyauthor=Z.+Y.+Liuauthor=P.+D.+Lyneauthor=T.+MacIntyreauthor=P.+J.+Mohrauthor=C.+A.+Omerauthor=T.+Sjogrenauthor=K.+Thressauthor=B.+Wangauthor=H.+Wangauthor=D.+Yuauthor=H.+J.+Zhang&title=Discovery+of+disubstituted+imidazo%5B4%2C5-b%5Dpyridines+and+purines+as+potent+trkA+inhibitors&doi=10.1021%2Fml300074j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors</span></div><div class="casAuthors">Wang, Tao; Lamb, Michelle L.; Block, Michael H.; Davies, Audrey Molina; Han, Yongxin; Hoffmann, Ethan; Ioannidis, Stephanos; Josey, John A.; Liu, Zhong-Ying; Lyne, Paul D.; MacIntyre, Terry; Mohr, Peter J.; Omer, Charles A.; Sjogren, Tove; Thress, Kenneth; Wang, Bin; Wang, Haiyun; Yu, Dingwei; Zhang, Hai-Jun</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">705-709</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trk receptor tyrosine kinases have been implicated in cancer and pain.  A crystal structure of TrkA with AZ-23 (1a) was obtained, and scaffold hopping resulted in two 5/6-bicyclic series comprising either imidazo[4,5-b]pyridines or purines.  Further optimization of these two fusion series led to compds. with subnanomolar potencies against TrkA kinase in cellular assays.  Antitumor effects in a TrkA-driven mouse allograft model were demonstrated with compds. 2d and 3a.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8S857L3CJC7Vg90H21EOLACvtfcHk0ljXW4fpVvBBoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2isbzK&md5=fc0e518c0f71276ad4cb416270844931</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fml300074j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300074j%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DZ.%2BY.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DMacIntyre%26aufirst%3DT.%26aulast%3DMohr%26aufirst%3DP.%2BJ.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DSjogren%26aufirst%3DT.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26atitle%3DDiscovery%2520of%2520disubstituted%2520imidazo%255B4%252C5-b%255Dpyridines%2520and%2520purines%2520as%2520potent%2520trkA%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D705%26epage%3D709%26doi%3D10.1021%2Fml300074j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikegami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ooike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomozane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morioka, M.</span></span> <span> </span><span class="NLM_article-title">3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective aurora A kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4709</span>– <span class="NLM_lpage">4711</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.04.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1016%2Fj.bmcl.2010.04.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=20573509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4709-4711&author=R.+Andoauthor=H.+Ikegamiauthor=M.+Sakiyamaauthor=S.+Ooikeauthor=M.+Hayashiauthor=Y.+Fujinoauthor=D.+Abeauthor=H.+Nakamuraauthor=T.+Mishinaauthor=H.+Katoauthor=Y.+Iwaseauthor=H.+Tomozaneauthor=M.+Morioka&title=3-Cyano-6-%285-methyl-3-pyrazoloamino%29pyridines%3A+selective+aurora+A+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2010.04.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: Selective Aurora A kinase inhibitors</span></div><div class="casAuthors">Ando, Ryoichi; Ikegami, Hiroshi; Sakiyama, Makoto; Ooike, Shinsuke; Hayashi, Masayuki; Fujino, Yasuhiro; Abe, Daisuke; Nakamura, Hideo; Mishina, Tadashi; Kato, Harutoshi; Iwase, Yumiko; Tomozane, Hideo; Morioka, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4709-4711</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new class of Aurora A kinase inhibitor was created by transforming 4-(5-methyl-3-pyrazoloamino)pyrimidine moiety of VX-680 to 3-cyano-6-(5-methyl-3-pyrazoloamino)pyridine.  Compd. 6 exhibited a potent Aurora A kinase inhibitory activity, excellent selectivity to Aurora B kinase and other 60 kinases, good cell permeability and good PK profile.  Therefore compd. 6 was effective in antitumor mice model at a dose of 30 mg/kg po qd without decrease of body wt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPZJZo36mNM7Vg90H21EOLACvtfcHk0lgcqAKtUts-IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSrsrg%253D&md5=762fd01810b8ee23cfc90aae99defd78</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.04.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.04.119%26sid%3Dliteratum%253Aachs%26aulast%3DAndo%26aufirst%3DR.%26aulast%3DIkegami%26aufirst%3DH.%26aulast%3DSakiyama%26aufirst%3DM.%26aulast%3DOoike%26aufirst%3DS.%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DFujino%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DMishina%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DIwase%26aufirst%3DY.%26aulast%3DTomozane%26aufirst%3DH.%26aulast%3DMorioka%26aufirst%3DM.%26atitle%3D3-Cyano-6-%25285-methyl-3-pyrazoloamino%2529pyridines%253A%2520selective%2520aurora%2520A%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4709%26epage%3D4711%26doi%3D10.1016%2Fj.bmcl.2010.04.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebbington, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajose-Adeogun, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hercend, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diu-Hercend, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. M.</span></span> <span> </span><span class="NLM_article-title">VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1038/nm1003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1038%2Fnm1003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=14981513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=262-267&author=E.+A.+Harringtonauthor=D.+Bebbingtonauthor=J.+Mooreauthor=R.+K.+Rasmussenauthor=A.+O.+Ajose-Adeogunauthor=T.+Nakayamaauthor=J.+A.+Grahamauthor=C.+Demurauthor=T.+Hercendauthor=A.+Diu-Hercendauthor=M.+Suauthor=J.+M.+Golecauthor=K.+M.+Miller&title=VX-680%2C+a+potent+and+selective+small-molecule+inhibitor+of+the+aurora+kinases%2C+suppresses+tumor+growth+in+vivo&doi=10.1038%2Fnm1003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span></div><div class="casAuthors">Harrington, Elizabeth A.; Bebbington, David; Moore, Jeff; Rasmussen, Richele K.; Ajose-Adeogun, Abi O.; Nakayama, Tomoko; Graham, Joanne A.; Demur, Cecile; Hercend, Thierry; Diu-Hercend, Anita; Su, Michael; Golec, Julian M. C.; Miller, Karen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-267</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis.  Aberrant expression and activity of these kinases occur in a wide range of human tumors, and lead to aneuploidy and tumorigenesis.  Here we report the discovery of a highly potent and selective small-mol. inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types.  This compd. causes profound inhibition of tumor growth in a variety of in vivo xenograft models, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses.  Our data indicate that Aurora kinase inhibition provides a new approach for the treatment of multiple human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgm1YUgqkWLVg90H21EOLACvtfcHk0lgcqAKtUts-IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D&md5=954ba274e280d8d08a7f2e331011432d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnm1003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1003%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DBebbington%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DJ.%26aulast%3DRasmussen%26aufirst%3DR.%2BK.%26aulast%3DAjose-Adeogun%26aufirst%3DA.%2BO.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DJ.%2BA.%26aulast%3DDemur%26aufirst%3DC.%26aulast%3DHercend%26aufirst%3DT.%26aulast%3DDiu-Hercend%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26atitle%3DVX-680%252C%2520a%2520potent%2520and%2520selective%2520small-molecule%2520inhibitor%2520of%2520the%2520aurora%2520kinases%252C%2520suppresses%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D262%26epage%3D267%26doi%3D10.1038%2Fnm1003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinn, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollok, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crean, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvannasankha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abonour, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farag, S. S.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.2010.08248.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1111%2Fj.1365-2141.2010.08248.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=20560971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOntrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2010&pages=313-325&author=X.+Wangauthor=A.+L.+Sinnauthor=K.+Pollokauthor=G.+Sanduskyauthor=S.+Zhangauthor=L.+Chenauthor=J.+Liangauthor=C.+D.+Creanauthor=A.+Suvannasankhaauthor=R.+Abonourauthor=C.+Sidorauthor=M.+R.+Brayauthor=S.+S.+Farag&title=Preclinical+activity+of+a+novel+multiple+tyrosine+kinase+and+aurora+kinase+inhibitor%2C+ENMD-2076%2C+against+multiple+myeloma&doi=10.1111%2Fj.1365-2141.2010.08248.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma</span></div><div class="casAuthors">Wang, Xiaojing; Sinn, Anthony L.; Pollok, Karen; Sandusky, George; Zhang, Shuhong; Chen, Li; Liang, Jing; Crean, Colin D.; Suvannasankha, Attaya; Abonour, Rafat; Sidor, Carolyn; Bray, Mark R.; Farag, Sherif S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">313-325</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">ENMD-2076 is a novel, orally-active mol. that has been shown to have significant activity against aurora and multiple receptor tyrosine kinases.  We investigated the activity of ENMD-2076 against multiple myeloma (MM) cells in vitro and in vivo.  ENMD-2076 showed significant cytotoxicity against MM cell lines and primary cells, with minimal cytotoxicity to haematopoietic progenitors.  ENMD-2076 inhibited the phosphoinositide 3-kinase/AKT pathway and downregulated survivin and X-linked inhibitor of apoptosis as early as 6 h after treatment.  With longer treatment (24-48 h), ENMD-2076 also inhibited aurora A and B kinases, and induced G2/M cell cycle arrest.  In non-obese diabetic/severe combined immunodeficient mice implanted with H929 human plasmacytoma xenografts, oral treatment with ENMD-2076 (50, 100, 200 mg/kg per day) resulted in a dose-dependent inhibition of tumor growth.  Immunohistochem. staining of excised tumors showed significant redn. in phospho-Histone 3 (pH3), Ki-67, and angiogenesis, and also a significant increase in cleaved caspase-3 at all dose levels compared to tumors from vehicle-treated mice.  In addn., a significant redn. in p-FGFR3 was obsd. on Western blot.  ENMD-2076 shows significant activity against MM cells in vitro and in vivo, and acts on several pathways important for myeloma cell growth and survival.  These results provide preclin. rationale for clin. investigation of ENMD-2076 in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCdi2TPYK9NrVg90H21EOLACvtfcHk0lhx_ONn5nkonA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOntrjN&md5=a351edddc67aab8043c055e4e54b606f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08248.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08248.x%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSinn%26aufirst%3DA.%2BL.%26aulast%3DPollok%26aufirst%3DK.%26aulast%3DSandusky%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DCrean%26aufirst%3DC.%2BD.%26aulast%3DSuvannasankha%26aufirst%3DA.%26aulast%3DAbonour%26aufirst%3DR.%26aulast%3DSidor%26aufirst%3DC.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DFarag%26aufirst%3DS.%2BS.%26atitle%3DPreclinical%2520activity%2520of%2520a%2520novel%2520multiple%2520tyrosine%2520kinase%2520and%2520aurora%2520kinase%2520inhibitor%252C%2520ENMD-2076%252C%2520against%2520multiple%2520myeloma%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2010%26volume%3D150%26spage%3D313%26epage%3D325%26doi%3D10.1111%2Fj.1365-2141.2010.08248.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikezoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandobashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togitani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeffler, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, A.</span></span> <span> </span><span class="NLM_article-title">AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2034</span>– <span class="NLM_lpage">2040</span>, <span class="refDoi"> DOI: 10.1182/blood-2007-02-073700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1182%2Fblood-2007-02-073700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=17495131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2034-2040&author=J.+Yangauthor=T.+Ikezoeauthor=C.+Nishiokaauthor=T.+Tasakaauthor=A.+Taniguchiauthor=Y.+Kuwayamaauthor=N.+Komatsuauthor=K.+Bandobashiauthor=K.+Togitaniauthor=H.+P.+Koefflerauthor=H.+Taguchiauthor=A.+Yokoyama&title=AZD1152%2C+a+novel+and+selective+aurora+B+kinase+inhibitor%2C+induces+growth+arrest%2C+apoptosis%2C+and+sensitization+for+tubulin+depolymerizing+agent+or+topoisomerase+II+inhibitor+in+human+acute+leukemia+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood-2007-02-073700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo</span></div><div class="casAuthors">Yang, Jing; Ikezoe, Takayuki; Nishioka, Chie; Tasaka, Taizo; Taniguchi, Ayuko; Kuwayama, Yoshio; Komatsu, Naoki; Bandobashi, Kentaro; Togitani, Kazuto; Koeffler, H. Phillip; Taguchi, Hirokuni; Yokoyama, Akihito</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2034-2040</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Aurora kinases play an important role in chromosome alignment, segregation, and cytokinesis during mitosis.  We have recently shown that hematopoietic malignant cells including those from acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) aberrantly expressed Aurora A and B kinases, and ZM447439, a potent inhibitor of Aurora kinases, effectively induced growth arrest and apoptosis of a variety of leukemia cells.  The present study explored the effect of AZD1152, a highly selective inhibitor of Aurora B kinase, on various types of human leukemia cells.  AZD1152 inhibited the proliferation of AML lines (HL-60, NB4, MOLM13), ALL line (PALL-2), biphenotypic leukemia (MV4-11), acute eosinophilic leukemia (EOL-1), and the blast crisis of chronic myeloid leukemia K562 cells with an IC50 ranging from 3 nM to 40 nM, as measured by thymidine uptake on day 2 of culture.  These cells had 4N/8N DNA content followed by apoptosis, as measured by cell-cycle anal. and annexin V staining, resp.  Of note, AZD1152 synergistically enhanced the antiproliferative activity of vincristine, a tubulin depolymg. agent, and daunorubicin, a topoisomerase II inhibitor, against the MOLM13 and PALL-2 cells in vitro.  Furthermore, AZD1152 potentiated the action of vincristine and daunorubicin in a MOLM13 murine xenograft model.  Taken together, AZD1152 is a promising new agent for treatment of individuals with leukemia.  The combined administration of AZD1152 and conventional chemotherapeutic agent to patients with leukemia warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3zl3doZGXmbVg90H21EOLACvtfcHk0lhx_ONn5nkonA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbnJ&md5=3d094eb4953d1e516a91cc922906ee5c</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-02-073700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-02-073700%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DIkezoe%26aufirst%3DT.%26aulast%3DNishioka%26aufirst%3DC.%26aulast%3DTasaka%26aufirst%3DT.%26aulast%3DTaniguchi%26aufirst%3DA.%26aulast%3DKuwayama%26aufirst%3DY.%26aulast%3DKomatsu%26aufirst%3DN.%26aulast%3DBandobashi%26aufirst%3DK.%26aulast%3DTogitani%26aufirst%3DK.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DTaguchi%26aufirst%3DH.%26aulast%3DYokoyama%26aufirst%3DA.%26atitle%3DAZD1152%252C%2520a%2520novel%2520and%2520selective%2520aurora%2520B%2520kinase%2520inhibitor%252C%2520induces%2520growth%2520arrest%252C%2520apoptosis%252C%2520and%2520sensitization%2520for%2520tubulin%2520depolymerizing%2520agent%2520or%2520topoisomerase%2520II%2520inhibitor%2520in%2520human%2520acute%2520leukemia%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2034%26epage%3D2040%26doi%3D10.1182%2Fblood-2007-02-073700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeow, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesmer, J. J.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1124/mol.111.071522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1124%2Fmol.111.071522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=21596927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1yqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2011&pages=294-303&author=D.+M.+Thalauthor=R.+Y.+Yeowauthor=C.+Schoenauauthor=J.+Huberauthor=J.+J.+Tesmer&title=Molecular+mechanism+of+selectivity+among+G+protein-coupled+receptor+kinase+2+inhibitors&doi=10.1124%2Fmol.111.071522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors</span></div><div class="casAuthors">Thal, David M.; Yeow, Raymond Y.; Schoenau, Christian; Huber, Jochen; Tesmer, John J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">294-303</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are key regulators of cell physiol. and control processes ranging from glucose homeostasis to contractility of the heart.  A major mechanism for the desensitization of activated GPCRs is their phosphorylation by GPCR kinases (GRKs).  Overexpression of GRK2 is strongly linked to heart failure, and GRK2 has long been considered a pharmaceutical target for the treatment of cardiovascular disease.  Several lead compds. developed by Takeda Pharmaceuticals show high selectivity for GRK2 and therapeutic potential for the treatment of heart failure.  To understand how these drugs achieve their selectivity, we detd. crystal structures of the bovine GRK2-Gβγ complex in the presence of two of these inhibitors.  Comparison with the apoGRK2-Gβγ structure demonstrates that the compds. bind in the kinase active site in a manner similar to that of the AGC kinase inhibitor balanol.  Both balanol and the Takeda compds. induce a slight closure of the kinase domain, the degree of which correlates with the potencies of the inhibitors.  Based on our crystal structures and homol. modeling, we identified five amino acids surrounding the inhibitor binding site that we hypothesized could contribute to inhibitor selectivity.  However, our results indicate that these residues are not major determinants of selectivity among GRK subfamilies.  Rather, selectivity is achieved by the stabilization of a unique inactive conformation of the GRK2 kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYlIMlpK9bU7Vg90H21EOLACvtfcHk0lgNGKZb-G_p7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1yqsL0%253D&md5=cde68787c0f4f20131ffe88ddbfd9284</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1124%2Fmol.111.071522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.111.071522%26sid%3Dliteratum%253Aachs%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DYeow%26aufirst%3DR.%2BY.%26aulast%3DSchoenau%26aufirst%3DC.%26aulast%3DHuber%26aufirst%3DJ.%26aulast%3DTesmer%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520mechanism%2520of%2520selectivity%2520among%2520G%2520protein-coupled%2520receptor%2520kinase%25202%2520inhibitors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D80%26spage%3D294%26epage%3D303%26doi%3D10.1124%2Fmol.111.071522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coomes, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupay, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daaka, Y.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptor kinase GRK5 phosphorylates moesin and regulates metastasis in prostate cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3489</span>– <span class="NLM_lpage">3500</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-2708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1158%2F0008-5472.CAN-13-2708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=24755472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKlurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3489-3500&author=P.+K.+Chakrabortyauthor=Y.+Zhangauthor=A.+S.+Coomesauthor=W.+J.+Kimauthor=R.+Stupayauthor=L.+D.+Lynchauthor=T.+Atkinsonauthor=J.+I.+Kimauthor=Z.+Nieauthor=Y.+Daaka&title=G+protein-coupled+receptor+kinase+GRK5+phosphorylates+moesin+and+regulates+metastasis+in+prostate+cancer&doi=10.1158%2F0008-5472.CAN-13-2708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">G Protein-Coupled Receptor Kinase GRK5 Phosphorylates Moesin and Regulates Metastasis in Prostate Cancer</span></div><div class="casAuthors">Chakraborty, Prabir Kumar; Zhang, Yushan; Coomes, Alexandra S.; Kim, Wan-Ju; Stupay, Rachel; Lynch, Lauren D.; Atkinson, Tamieka; Kim, Jae I.; Nie, Zhongzhen; Daaka, Yehia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3489-3500</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">G protein-coupled receptor kinases (GRK) regulate diverse cellular functions ranging from metab. to growth and locomotion.  Here, we report an important contributory role for GRK5 in human prostate cancer.  Inhibition of GRK5 kinase activity attenuated the migration and invasion of prostate cancer cells and, concordantly, increased cell attachment and focal adhesion formation.  Mass spectrometric anal. of the phosphoproteome revealed the cytoskeletal-membrane attachment protein moesin as a putative GRK5 substrate.  GRK5 regulated the subcellular distribution of moesin and colocalized with moesin at the cell periphery.  We identified amino acid T66 of moesin as a principal GRK5 phosphorylation site and showed that enforcing the expression of a T66-mutated moesin reduced cell spreading.  In a xenograft model of human prostate cancer, GRK5 silencing reduced tumor growth, invasion, and metastasis.  Taken together, our results established GRK5 as a key contributor to the growth and metastasis of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_qbVyWviPj7Vg90H21EOLACvtfcHk0lgNGKZb-G_p7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKlurnM&md5=04ed0215f1c911cf108bed806d5fe879</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-2708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-2708%26sid%3Dliteratum%253Aachs%26aulast%3DChakraborty%26aufirst%3DP.%2BK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCoomes%26aufirst%3DA.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BJ.%26aulast%3DStupay%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DL.%2BD.%26aulast%3DAtkinson%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DJ.%2BI.%26aulast%3DNie%26aufirst%3DZ.%26aulast%3DDaaka%26aufirst%3DY.%26atitle%3DG%2520protein-coupled%2520receptor%2520kinase%2520GRK5%2520phosphorylates%2520moesin%2520and%2520regulates%2520metastasis%2520in%2520prostate%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3489%26epage%3D3500%26doi%3D10.1158%2F0008-5472.CAN-13-2708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulik, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giros, B.</span></span> <span> </span><span class="NLM_article-title">Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">12974</span>– <span class="NLM_lpage">12979</span>, <span class="refDoi"> DOI: 10.1073/pnas.93.23.12974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1073%2Fpnas.93.23.12974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=8917529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADyaK28XmvV2ksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=12974-12979&author=M.+Jaberauthor=W.+J.+Kochauthor=H.+Rockmanauthor=B.+Smithauthor=R.+A.+Bondauthor=K.+K.+Sulikauthor=J.+Rossauthor=R.+J.+Lefkowitzauthor=M.+G.+Caronauthor=B.+Giros&title=Essential+role+of+beta-adrenergic+receptor+kinase+1+in+cardiac+development+and+function&doi=10.1073%2Fpnas.93.23.12974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of β-adrenergic receptor kinase 1 in cardiac development and function</span></div><div class="casAuthors">Jaber, Mohamed; Koch, Walter J.; Rockman, Howard; Smith, Bradley; Bond, Richard A.; Sulik, Kathleen K.; Ross, John, Jr.; Lefkowitz, Robert J.; Caron, Marc G.; Giros, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12974-12979</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The β-adrenergic receptor kinase 1 (βARK1) is a member of the G protein-coupled receptor kinase (GRK) family that mediates the agonist-dependent phosphorylation and desensitization of G protein-coupled receptors.  We have cloned and disrupted the βARK1 gene in mice by homologous recombination.  No homozygote βARK1-/- embryos survive beyond gestational day 15.5.  Prior to gestational day 15.5, βARK1-/- embryos display pronounced hypoplasia of the ventricular myocardium essentially identical to the "thin myocardium syndrome" obsd. upon gene inactivation of several transcription factors (RXRα, N-myc, TEF-1, WT-1).  Lethality in βARK1-/- embryos is likely due to heart failure as they exhibit a >70% decrease in cardiac ejection fraction detd. by direct in utero intravital microscopy.  These results along with the virtual absence of endogenous GRK activity in βARK1-/- embryos demonstrate that βARK1 appears to be the predominant GRK in early embryogenesis and that it plays a functional role in cardiac development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwWiHmr8dR27Vg90H21EOLACvtfcHk0lgNGKZb-G_p7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmvV2ksLk%253D&md5=92fb1cfe44d81638912c35f6240f2473</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.23.12974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.23.12974%26sid%3Dliteratum%253Aachs%26aulast%3DJaber%26aufirst%3DM.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DRockman%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DBond%26aufirst%3DR.%2BA.%26aulast%3DSulik%26aufirst%3DK.%2BK.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DGiros%26aufirst%3DB.%26atitle%3DEssential%2520role%2520of%2520beta-adrenergic%2520receptor%2520kinase%25201%2520in%2520cardiac%2520development%2520and%2520function%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1996%26volume%3D93%26spage%3D12974%26epage%3D12979%26doi%3D10.1073%2Fpnas.93.23.12974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paredes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamonova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sneddon, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarvey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Awar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean-Alphonse, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, P. A.</span></span> <span> </span><span class="NLM_article-title">Parathyroid hormone initiates dynamic NHERF1 phosphorylation cycling and conformational changes that regulate NPT2A-dependent phosphate transport</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">4546</span>– <span class="NLM_lpage">4571</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA119.007421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1074%2Fjbc.RA119.007421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=30696771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFSmtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=4546-4571&author=Q.+Zhangauthor=K.+Xiaoauthor=J.+M.+Paredesauthor=T.+Mamonovaauthor=W.+B.+Sneddonauthor=H.+Liuauthor=D.+Wangauthor=S.+Liauthor=J.+C.+McGarveyauthor=D.+Uehlingauthor=R.+Al-Awarauthor=B.+Josephauthor=F.+Jean-Alphonseauthor=A.+Orteauthor=P.+A.+Friedman&title=Parathyroid+hormone+initiates+dynamic+NHERF1+phosphorylation+cycling+and+conformational+changes+that+regulate+NPT2A-dependent+phosphate+transport&doi=10.1074%2Fjbc.RA119.007421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Parathyroid hormone initiates dynamic NHERF1 phosphorylation cycling and conformational changes that regulate NPT2A-dependent phosphate transport</span></div><div class="casAuthors">Zhang, Qiangmin; iao, Kunhong; Paredes, Jose M.; Mamonova, Tatyana; Sneddon, W. Bruce; Liu, Hongda; Wang, Dawei; Li, Sheng; McGarvey, Jennifer C.; Uehling, David; Al-awar, Rima; Joseph, Babu; Jean-Alphonse, Frederic; Orte, Angel; Friedman, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4546-4571</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Na+-Hα exchanger regulatory factor-1 (NHERF1) is a PDZ protein that scaffolds membrane proteins, including sodium- phosphate co-transport protein 2A (NPT2A) at the plasma membrane.  NHERF1 is a phosphoprotein with 40 Ser and Thr residues.  Here, using tandem MS anal., we characterized the sites of parathyroid hormone (PTH)-induced NHERF1 phosphorylation and identified 10 high-confidence phosphorylation sites.  Ala replacement at Ser46, Ser162, Ser181, Ser269, Ser280, Ser291, Thr293, Ser299, and Ser302 did not affect phosphate uptake, but S290A substitution abolished PTH-dependent phosphate transport.  Unexpectedly, Ser290 was rapidly dephosphorylated and rephosphorylated after PTH stimulation, and we found that protein phosphatase 1α (PP1α), which binds NHERF1 through a conserved VxF/W PP1 motif, dephosphorylates Ser290.  Mutating 257VPF259 eliminated PP1 binding and blunted dephosphorylation.  Tautomycetin blocked PP1 activity and abrogated PTH-sensitive phosphate transport.  Using fluorescence lifetime imaging (FLIM), we obsd. that PTH paradoxically and transiently elevates intracellular phosphate.  Added phosphate blocked PP1α-mediated Ser290 dephosphorylation of recombinant NHERF1.  Hydrogen-deuterium exchange M S revealed that β-sheets in NHERF1's PDZ2 domain display lower deuterium uptake than those in the structurally similar PDZ1, implying that PDZ1 is more cloistered.  Dephosphorylated NHERF1 exhibited faster exchange at C-terminal residues suggesting that NHERF1 dephosphorylation precedes Ser290 rephosphorylation.  Our results show that PP1α and NHERF1 form a holoenzyme and that a multiprotein kinase cascade involving G protein-coupled receptor kinase 6A controls the Ser290 phosphorylation status of NHERF1 and regulates PTH-sensitive, NPT2A-mediated phosphate uptake.  These findings reveal how reversible phosphorylation modifies protein conformation and function and the biochem. mechanisms underlying PTH control of phosphate transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYuqItZcK6N7Vg90H21EOLACvtfcHk0lh-lO-HoTkfJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFSmtb8%253D&md5=caaf208e1a82bc5bd9d569e835525088</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.007421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.007421%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DK.%26aulast%3DParedes%26aufirst%3DJ.%2BM.%26aulast%3DMamonova%26aufirst%3DT.%26aulast%3DSneddon%26aufirst%3DW.%2BB.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMcGarvey%26aufirst%3DJ.%2BC.%26aulast%3DUehling%26aufirst%3DD.%26aulast%3DAl-Awar%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DB.%26aulast%3DJean-Alphonse%26aufirst%3DF.%26aulast%3DOrte%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DP.%2BA.%26atitle%3DParathyroid%2520hormone%2520initiates%2520dynamic%2520NHERF1%2520phosphorylation%2520cycling%2520and%2520conformational%2520changes%2520that%2520regulate%2520NPT2A-dependent%2520phosphate%2520transport%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D4546%26epage%3D4571%26doi%3D10.1074%2Fjbc.RA119.007421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R. H.</span>; <span class="NLM_string-name">Michael, J.</span>; <span class="NLM_string-name">Holladay, M. W.</span>; <span class="NLM_string-name">Rowbottom, M. W.</span>; <span class="NLM_string-name">Setti, E.</span></span> <span> </span><span class="NLM_article-title">Quinoline and isoquinoline derivatives for use as jak modulators</span>. U.S. Patent <span class="NLM_patent">US20130296363</span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+H.+Faraoni&author=J.+Michael&author=M.+W.+Holladay&author=M.+W.+Rowbottom&author=E.+Setti&title=Quinoline+and+isoquinoline+derivatives+for+use+as+jak+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFaraoni%26aufirst%3DR.%2BH.%26atitle%3DQuinoline%2520and%2520isoquinoline%2520derivatives%2520for%2520use%2520as%2520jak%2520modulators%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caivano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Specificity and mechanism of action of some commonly used protein kinase inhibitors</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1042/bj3510095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1042%2Fbj3510095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10998351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=95-105&author=S.+P.+Daviesauthor=H.+Reddyauthor=M.+Caivanoauthor=P.+Cohen&title=Specificity+and+mechanism+of+action+of+some+commonly+used+protein+kinase+inhibitors&doi=10.1042%2Fbj3510095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity and mechanism of action of some commonly used protein kinase inhibitors</span></div><div class="casAuthors">Davies, Stephen P.; Reddy, Helen; Caivano, Matilde; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 28 com. available compds. reported to be relatively selective inhibitors of particular serine/threonine-specific protein kinases have been examd. against a large panel of protein kinases.  The compds. KT 5720, Rottlerin and quercetin were found to inhibit many protein kinases, sometimes much more potently than their presumed targets, and conclusions drawn from their use in cell-based expts. are likely to be erroneous.  Ro 318220 and related bisindoylmaleimides, as well as H89, HA1077 and Y 27632, were more selective inhibitors, but still inhibited two or more protein kinases with similar potency.  LY 294002 was found to inhibit casein kinase-2 with similar potency to phosphoinositide (phosphatidylinositol) 3-kinase.  The compds. with the most impressive selectivity profiles were KN62, PD 98059, U0126, PD 184352, rapamycin, wortmannin, SB 203580 and SB 202190.  U0126 and PD 184352, like PD 98059, were found to block the mitogen-activated protein kinase (MAPK) cascade in cell-based assays by preventing the activation of MAPK kinase (MKK1), and not by inhibiting MKK1 activity directly.  Apart from rapamycin and PD 184352, even the most selective inhibitors affected at least one addnl. protein kinase.  Our results demonstrate that the specificities of protein kinase inhibitors cannot be assessed simply by studying their effect on kinases that are closely related in primary structure.  The authors propose guidelines for the use of protein kinase inhibitors in cell-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCs5LPDkzaGrVg90H21EOLACvtfcHk0lh-lO-HoTkfJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnslWltrY%253D&md5=e14eb47a52dc43afca7373c276b2d147</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1042%2Fbj3510095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3510095%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DS.%2BP.%26aulast%3DReddy%26aufirst%3DH.%26aulast%3DCaivano%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DSpecificity%2520and%2520mechanism%2520of%2520action%2520of%2520some%2520commonly%2520used%2520protein%2520kinase%2520inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26spage%3D95%26epage%3D105%26doi%3D10.1042%2Fbj3510095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ignatushchenko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreekumar, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span> <span> </span><span class="NLM_article-title">Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1126/science.1233606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1126%2Fscience.1233606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=23828940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCgs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2013&pages=84-87&author=D.+M.+Molinaauthor=R.+Jafariauthor=M.+Ignatushchenkoauthor=T.+Sekiauthor=E.+A.+Larssonauthor=C.+Danauthor=L.+Sreekumarauthor=Y.+Caoauthor=P.+Nordlund&title=Monitoring+drug+target+engagement+in+cells+and+tissues+using+the+cellular+thermal+shift+assay&doi=10.1126%2Fscience.1233606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay</span></div><div class="casAuthors">Molina, Daniel Martinez; Jafari, Rozbeh; Ignatushchenko, Marina; Seki, Takahiro; Larsson, E. Andreas; Dan, Chen; Sreekumar, Lekshmy; Cao, Yihai; Nordlund, Paer</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">6141</span>),
    <span class="NLM_cas:pages">84-87</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The efficacy of therapeutics is dependent on a drug binding to its cognate target.  Optimization of target engagement by drugs in cells is often challenging, because drug binding cannot be monitored inside cells.  We have developed a method for evaluating drug binding to target proteins in cells and tissue samples.  This cellular thermal shift assay (CETSA) is based on the biophys. principle of ligand-induced thermal stabilization of target proteins.  Using this assay, we validated drug binding for a set of important clin. targets and monitored processes of drug transport and activation, off-target effects and drug resistance in cancer cell lines, as well as drug distribution in tissues.  CETSA is likely to become a valuable tool for the validation and optimization of drug target engagement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaaWSoozY7ObVg90H21EOLACvtfcHk0lj6Nvr5UYhrPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCgs7rP&md5=f8ba686ba38b67dbdf366c49eb7375b4</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fscience.1233606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1233606%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DD.%2BM.%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DIgnatushchenko%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DLarsson%26aufirst%3DE.%2BA.%26aulast%3DDan%26aufirst%3DC.%26aulast%3DSreekumar%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DNordlund%26aufirst%3DP.%26atitle%3DMonitoring%2520drug%2520target%2520engagement%2520in%2520cells%2520and%2520tissues%2520using%2520the%2520cellular%2520thermal%2520shift%2520assay%26jtitle%3DScience%26date%3D2013%26volume%3D341%26spage%3D84%26epage%3D87%26doi%3D10.1126%2Fscience.1233606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryall, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. C.</span></span> <span> </span><span class="NLM_article-title">Systems biology approaches for advancing the discovery of effective drug combinations</span>. <i>J. Cheminform.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">7</span> <span class="refDoi"> DOI: 10.1186/s13321-015-0055-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=10.1186%2Fs13321-015-0055-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=25741385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;key=1%3ACAS%3A280%3ADC%252BC2MnhsVyjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&author=K.+A.+Ryallauthor=A.+C.+Tan&title=Systems+biology+approaches+for+advancing+the+discovery+of+effective+drug+combinations&doi=10.1186%2Fs13321-015-0055-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Systems biology approaches for advancing the discovery of effective drug combinations</span></div><div class="casAuthors">Ryall Karen A; Tan Aik Choon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cheminformatics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7</span>
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    </div><div class="casAbstract">Complex diseases like cancer are regulated by large, interconnected networks with many pathways affecting cell proliferation, invasion, and drug resistance.  However, current cancer therapy predominantly relies on the reductionist approach of one gene-one disease.  Combinations of drugs may overcome drug resistance by limiting mutations and induction of escape pathways, but given the enormous number of possible drug combinations, strategies to reduce the search space and prioritize experiments are needed.  In this review, we focus on the use of computational modeling, bioinformatics and high-throughput experimental methods for discovery of drug combinations.  We highlight cutting-edge systems approaches, including large-scale modeling of cell signaling networks, network motif analysis, statistical association-based models, identifying correlations in gene signatures, functional genomics, and high-throughput combination screens.  We also present a list of publicly available data and resources to aid in discovery of drug combinations.  Integration of these systems approaches will enable faster discovery and translation of clinically relevant drug combinations.  Graphical abstractSpectrum of Systems Biology Approaches for Drug Combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh4YpxugecZa_dlEzl_fBafW6udTcc2eZU2uaTiYooOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnhsVyjtA%253D%253D&md5=fa2572a5a35041ea880f7fb01981b5b4</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1186%2Fs13321-015-0055-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-015-0055-9%26sid%3Dliteratum%253Aachs%26aulast%3DRyall%26aufirst%3DK.%2BA.%26aulast%3DTan%26aufirst%3DA.%2BC.%26atitle%3DSystems%2520biology%2520approaches%2520for%2520advancing%2520the%2520discovery%2520of%2520effective%2520drug%2520combinations%26jtitle%3DJ.%2520Cheminform.%26date%3D2015%26volume%3D7%26doi%3D10.1186%2Fs13321-015-0055-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NYN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3NYN','PDB','3NYN'); return false;">PDB: 3NYN</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i81"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00506">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_45757"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00506?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00506</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">GRK6_Cpd10i_3NYN_Model_2p72 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_001.pdb">PDB</a>)</p></li><li><p class="inline">GRK6_Cpd18_3NYN_Model_2p72 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_003.csv">CSV</a>)</p></li><li><p class="inline">GRK6 shRNA knockdown, CRISPR knockout studies and GRK6 kinase rescue studies; cellular thermal shift assay (CETSA) employing FLAG-GRK6-expressing KMS11 MM cells and anti-FLAG immunoblots for GRK6 compounds studied; mouse liver microsome and Caco-2 permeability data for <b>16</b>–<b>18</b> and PK data for compound <b>18</b>; and analytical data for select compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_001.pdb">jm1c00506_si_001.pdb (702.76 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_002.pdb">jm1c00506_si_002.pdb (703.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_003.csv">jm1c00506_si_003.csv (3.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00506/suppl_file/jm1c00506_si_004.pdf">jm1c00506_si_004.pdf (1.61 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00506&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00506%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00506" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993031bbe33291","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
